0001628280-25-022727.txt : 20250506 0001628280-25-022727.hdr.sgml : 20250506 20250506163441 ACCESSION NUMBER: 0001628280-25-022727 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 103 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAXTER INTERNATIONAL INC CENTRAL INDEX KEY: 0000010456 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 360781620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-04448 FILM NUMBER: 25917827 BUSINESS ADDRESS: STREET 1: ONE BAXTER PARKWAY CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: 2249482000 MAIL ADDRESS: STREET 1: ONE BAXTER PARKWAY CITY: DEERFIELD STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER TRAVENOL LABORATORIES INC DATE OF NAME CHANGE: 19880522 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER LABORATORIES INC DATE OF NAME CHANGE: 19760608 10-Q 1 bax-20250331.htm 10-Q bax-20250331
false2025Q10000010456December 31P1YP1Y91111xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURbax:sitebax:lawsuitbax:complaintbax:de-designationbax:terminatebax:segment00000104562025-01-012025-03-310000010456exch:XCHIbax:CommonStock100PerValueMember2025-01-012025-03-310000010456exch:XNYSbax:CommonStock100PerValueMember2025-01-012025-03-310000010456exch:XNYSbax:GlobalNotes13Due2025Member2025-01-012025-03-310000010456exch:XNYSbax:GlobalNotes13Due2029Member2025-01-012025-03-3100000104562025-04-3000000104562025-03-3100000104562024-12-3100000104562024-01-012024-03-310000010456us-gaap:CommonStockMember2024-12-310000010456us-gaap:TreasuryStockCommonMember2024-12-310000010456us-gaap:AdditionalPaidInCapitalMember2024-12-310000010456us-gaap:RetainedEarningsMember2024-12-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000010456us-gaap:ParentMember2024-12-310000010456us-gaap:NoncontrollingInterestMember2024-12-310000010456us-gaap:RetainedEarningsMember2025-01-012025-03-310000010456us-gaap:ParentMember2025-01-012025-03-310000010456us-gaap:NoncontrollingInterestMember2025-01-012025-03-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:TreasuryStockCommonMember2025-01-012025-03-310000010456us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000010456us-gaap:CommonStockMember2025-03-310000010456us-gaap:TreasuryStockCommonMember2025-03-310000010456us-gaap:AdditionalPaidInCapitalMember2025-03-310000010456us-gaap:RetainedEarningsMember2025-03-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000010456us-gaap:ParentMember2025-03-310000010456us-gaap:NoncontrollingInterestMember2025-03-310000010456us-gaap:CommonStockMember2023-12-310000010456us-gaap:TreasuryStockCommonMember2023-12-310000010456us-gaap:AdditionalPaidInCapitalMember2023-12-310000010456us-gaap:RetainedEarningsMember2023-12-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000010456us-gaap:ParentMember2023-12-310000010456us-gaap:NoncontrollingInterestMember2023-12-3100000104562023-12-310000010456us-gaap:RetainedEarningsMember2024-01-012024-03-310000010456us-gaap:ParentMember2024-01-012024-03-310000010456us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000010456us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000010456us-gaap:CommonStockMember2024-03-310000010456us-gaap:TreasuryStockCommonMember2024-03-310000010456us-gaap:AdditionalPaidInCapitalMember2024-03-310000010456us-gaap:RetainedEarningsMember2024-03-310000010456us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000010456us-gaap:ParentMember2024-03-310000010456us-gaap:NoncontrollingInterestMember2024-03-3100000104562024-03-310000010456us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember2025-01-310000010456us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember2025-01-312025-01-310000010456us-gaap:HurricaneMember2025-01-012025-03-310000010456bax:KidneyCareManufacturingAndSupplyAgreementMember2024-12-312024-12-310000010456bax:KidneyCareTransitionServicesAgreementMember2024-12-312024-12-310000010456us-gaap:IndemnificationGuaranteeMember2025-01-012025-03-310000010456us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember2025-01-012025-03-310000010456us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbax:KidneyCareMember2024-01-012024-03-310000010456us-gaap:SegmentDiscontinuedOperationsMember2024-12-310000010456us-gaap:DiscontinuedOperationsHeldforsaleMemberbax:KidneyCareMember2025-03-310000010456us-gaap:DiscontinuedOperationsHeldforsaleMemberbax:OpelikaAlabamaManufacturingFacilityMember2025-03-310000010456us-gaap:PropertyPlantAndEquipmentMember2025-01-012025-03-310000010456us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-03-310000010456bax:MedicalProductsAndTherapiesMember2024-12-310000010456bax:HealthcareSystemsAndTechnologiesMember2024-12-310000010456bax:PharmaceuticalsMember2024-12-310000010456bax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456bax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456bax:PharmaceuticalsMember2025-01-012025-03-310000010456bax:MedicalProductsAndTherapiesMember2025-03-310000010456bax:HealthcareSystemsAndTechnologiesMember2025-03-310000010456bax:PharmaceuticalsMember2025-03-310000010456us-gaap:CustomerRelationshipsMember2024-12-310000010456bax:DevelopedTechnologyIncludingPatentsMember2024-12-310000010456us-gaap:TradeNamesMember2024-12-310000010456us-gaap:OtherIntangibleAssetsMember2024-12-310000010456us-gaap:TradeNamesMember2024-12-310000010456us-gaap:InProcessResearchAndDevelopmentMember2024-12-310000010456us-gaap:CustomerRelationshipsMember2025-03-310000010456bax:DevelopedTechnologyIncludingPatentsMember2025-03-310000010456us-gaap:TradeNamesMember2025-03-310000010456us-gaap:OtherIntangibleAssetsMember2025-03-310000010456us-gaap:TradeNamesMember2025-03-310000010456us-gaap:InProcessResearchAndDevelopmentMember2025-03-310000010456bax:TermLoanDueTwoThousandAndTwentySixMember2025-02-012025-02-280000010456bax:TermLoanDueTwoThousandAndTwentySixMember2025-03-310000010456bax:SeniorUnsecuredTermLoansMemberbax:BridgeFacilityMember2024-07-170000010456us-gaap:SeniorNotesMember2024-07-170000010456us-gaap:SeniorNotesMembersrt:ScenarioForecastMember2025-01-012025-12-310000010456bax:SeniorUnsecuredTermLoansMemberus-gaap:LineOfCreditMember2024-12-310000010456us-gaap:RevolvingCreditFacilityMember2025-03-310000010456us-gaap:RevolvingCreditFacilityMember2024-12-310000010456us-gaap:RevolvingCreditFacilityMemberus-gaap:CommercialPaperMember2025-03-310000010456us-gaap:CommercialPaperMember2025-01-012025-03-310000010456us-gaap:CommercialPaperMember2024-12-310000010456us-gaap:CommercialPaperMember2025-03-310000010456bax:EnviromentalCleanUpMemberbax:SuperfundSitesMember2025-03-310000010456bax:EnviromentalCleanUpMemberbax:SuperfundSitesMember2024-12-310000010456bax:ExposureToEthyleneOxideMember2020-03-012020-03-310000010456bax:ExposureToEthyleneOxideMember2023-12-312025-03-310000010456bax:ExposureToEthyleneOxideMember2024-07-162024-07-1600000104562024-09-110000010456bax:ExposureToEthyleneOxideMemberus-gaap:SubsequentEventMember2025-04-012025-06-300000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-03-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-03-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-03-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000010456us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:InterestRateContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:InterestRateContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:FairValueHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:FairValueHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000010456us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000010456srt:MinimumMember2025-01-012025-03-310000010456srt:MaximumMember2025-01-012025-03-3100000104562025-04-012025-03-3100000104562026-01-012025-03-3100000104562028-01-012025-03-3100000104562027-01-012025-03-3100000104562029-01-012025-03-310000010456bax:ManufacturingArrangementsMembersrt:MaximumMember2025-01-012025-03-310000010456bax:SoftwareArrangementsMembersrt:MinimumMember2025-01-012025-03-310000010456bax:SoftwareArrangementsMembersrt:MaximumMember2025-01-012025-03-310000010456bax:ConsumableMedicalProductsMembersrt:MinimumMember2025-01-012025-03-310000010456bax:ConsumableMedicalProductsMembersrt:MaximumMember2025-01-012025-03-310000010456bax:ManufacturingArrangementsMember2025-03-310000010456bax:ManufacturingArrangementsMember2024-12-310000010456bax:SoftwareArrangementsMember2025-03-310000010456bax:SoftwareArrangementsMember2024-12-310000010456bax:BundledEquipmentAndConsumableMedicalProductsContractsMember2025-03-310000010456bax:BundledEquipmentAndConsumableMedicalProductsContractsMember2024-12-310000010456us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-03-310000010456us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310000010456us-gaap:OtherNoncurrentAssetsMember2025-03-310000010456us-gaap:OtherNoncurrentAssetsMember2024-12-310000010456bax:AccruedExpensesAndOtherCurrentLiabilitiesMember2025-03-310000010456bax:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-12-310000010456us-gaap:OtherNoncurrentLiabilitiesMember2025-03-310000010456us-gaap:OtherNoncurrentLiabilitiesMember2024-12-310000010456bax:A2021AndPriorYearsMember2025-03-310000010456bax:A2022Member2025-03-310000010456bax:A2023Member2025-03-310000010456bax:A2024Member2025-03-310000010456bax:A2025Member2025-03-310000010456bax:BusinessOptimizationProgramsMember2025-01-012025-03-310000010456bax:BusinessOptimizationProgramsMember2024-01-012024-03-310000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2025-01-012025-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2025-01-012025-03-310000010456us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2025-01-012025-03-310000010456us-gaap:EmployeeSeveranceMember2025-01-012025-03-310000010456us-gaap:CostOfSalesMemberbax:AssetWriteOffsMember2025-01-012025-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:AssetWriteOffsMember2025-01-012025-03-310000010456us-gaap:ResearchAndDevelopmentExpenseMemberbax:AssetWriteOffsMember2025-01-012025-03-310000010456bax:AssetWriteOffsMember2025-01-012025-03-310000010456us-gaap:CostOfSalesMember2025-01-012025-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310000010456us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310000010456us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2024-01-012024-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2024-01-012024-03-310000010456us-gaap:EmployeeSeveranceMember2024-01-012024-03-310000010456us-gaap:CostOfSalesMemberbax:ContractTerminationAndOtherCostsMember2024-01-012024-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMemberbax:ContractTerminationAndOtherCostsMember2024-01-012024-03-310000010456bax:ContractTerminationAndOtherCostsMember2024-01-012024-03-310000010456us-gaap:CostOfSalesMember2024-01-012024-03-310000010456us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000010456us-gaap:EmployeeSeveranceMemberbax:KidneyCareMember2025-01-012025-03-310000010456us-gaap:EmployeeSeveranceMemberbax:NewOperatingModelMember2024-01-012024-03-310000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2024-12-310000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2025-01-012025-03-310000010456bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember2025-03-310000010456us-gaap:PensionPlansDefinedBenefitMember2025-01-012025-03-310000010456us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-01-012025-03-310000010456us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-03-310000010456us-gaap:ForeignExchangeContractMember2025-03-310000010456us-gaap:ForeignExchangeContractMember2024-12-310000010456us-gaap:ForeignExchangeContractMember2025-01-012025-03-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2025-03-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-12-310000010456us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2025-03-310000010456us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2024-12-310000010456us-gaap:FairValueHedgingMember2023-10-310000010456bax:A04SeniorNotesDueMay2024Member2023-10-310000010456bax:A130SeniorNotesDueMay2025Member2017-05-310000010456bax:A13SeniorNotesDueMay2029Member2019-05-310000010456bax:A13SeniorNotesDueMay2029Member2017-05-310000010456bax:A04SeniorNotesDueMay2024Member2019-05-310000010456us-gaap:NetInvestmentHedgingMember2025-03-310000010456us-gaap:DesignatedAsHedgingInstrumentMember2025-03-310000010456us-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000010456us-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-03-310000010456us-gaap:NondesignatedMember2025-03-310000010456us-gaap:NondesignatedMember2024-12-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2025-01-012025-03-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-03-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2025-01-012025-03-310000010456us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-01-012024-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2025-01-012025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2025-01-012025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-03-310000010456us-gaap:FairValueHedgingMember2025-01-012025-03-310000010456us-gaap:FairValueHedgingMember2024-01-012024-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:FairValueHedgingMember2025-01-012025-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:FairValueHedgingMember2024-01-012024-03-310000010456us-gaap:NetInvestmentHedgingMember2025-01-012025-03-310000010456us-gaap:NetInvestmentHedgingMember2024-01-012024-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2025-01-012025-03-310000010456us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-03-310000010456bax:LongTermDebtAndLeaseObligationMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-03-310000010456bax:LongTermDebtAndLeaseObligationCurrentMemberus-gaap:NondesignatedMember2025-03-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-12-310000010456bax:LongTermDebtAndLeaseObligationCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000010456bax:LongTermDebtAndLeaseObligationMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310000010456us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-12-310000010456us-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-03-310000010456us-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-12-310000010456us-gaap:LongTermDebtMember2025-03-310000010456us-gaap:LongTermDebtMember2024-12-310000010456us-gaap:FairValueMeasurementsRecurringMember2025-03-310000010456us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000010456us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000010456us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000010456us-gaap:FairValueMeasurementsRecurringMember2024-12-310000010456us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000010456us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000010456us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000010456us-gaap:FairValueInputsLevel2Member2025-03-310000010456us-gaap:FairValueInputsLevel2Member2024-12-310000010456bax:SeparationRelatedCostsMember2024-12-310000010456us-gaap:AcquisitionRelatedCostsMember2024-12-310000010456bax:AvailableForSaleDebtSecuritiesMember2024-12-310000010456us-gaap:AcquisitionRelatedCostsMember2023-12-310000010456bax:AvailableForSaleDebtSecuritiesMember2023-12-310000010456bax:SeparationRelatedCostsMember2025-01-012025-03-310000010456us-gaap:AcquisitionRelatedCostsMember2025-01-012025-03-310000010456bax:AvailableForSaleDebtSecuritiesMember2025-01-012025-03-310000010456us-gaap:AcquisitionRelatedCostsMember2024-01-012024-03-310000010456bax:AvailableForSaleDebtSecuritiesMember2024-01-012024-03-310000010456bax:SeparationRelatedCostsMember2025-03-310000010456us-gaap:AcquisitionRelatedCostsMember2025-03-310000010456bax:AvailableForSaleDebtSecuritiesMember2025-03-310000010456us-gaap:AcquisitionRelatedCostsMember2024-03-310000010456bax:AvailableForSaleDebtSecuritiesMember2024-03-310000010456us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-03-310000010456us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310000010456us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310000010456us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310000010456us-gaap:OtherAssetsMember2024-12-310000010456us-gaap:OtherAssetsMember2025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:InfusionTherapiesAndTechnologiesMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:AdvancedSurgeryMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:MedicalProductsAndTherapiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:CareAndConnectivitySolutionsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:FrontLineCareMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:HealthcareSystemsAndTechnologiesMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:InjectablesAndAnesthesiaMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalCompoundingMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2025-01-012025-03-310000010456country:USus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:PharmaceuticalsMember2024-01-012024-03-310000010456country:USus-gaap:CorporateNonSegmentMember2025-01-012025-03-310000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2025-01-012025-03-310000010456us-gaap:CorporateNonSegmentMember2025-01-012025-03-310000010456country:USus-gaap:CorporateNonSegmentMember2024-01-012024-03-310000010456us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2024-01-012024-03-310000010456us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000010456country:US2025-01-012025-03-310000010456us-gaap:NonUsMember2025-01-012025-03-310000010456country:US2024-01-012024-03-310000010456us-gaap:NonUsMember2024-01-012024-03-310000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2025-01-012025-03-310000010456bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember2024-01-012024-03-310000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2025-01-012025-03-310000010456bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember2024-01-012024-03-310000010456us-gaap:OperatingSegmentsMemberbax:ReportableSegmentMember2025-01-012025-03-310000010456us-gaap:OperatingSegmentsMemberbax:ReportableSegmentMember2024-01-012024-03-310000010456us-gaap:MaterialReconcilingItemsMemberbax:ReportableSegmentMember2025-01-012025-03-310000010456us-gaap:MaterialReconcilingItemsMemberbax:ReportableSegmentMember2024-01-012024-03-310000010456us-gaap:MaterialReconcilingItemsMember2025-01-012025-03-310000010456us-gaap:MaterialReconcilingItemsMember2024-01-012024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________
FORM 10-Q
_________________________________________________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to            
Commission file number 1-4448
_________________________________________________________________________________
BAXTER INTERNATIONAL INC.
(Exact name of registrant as specified in its charter)
_________________________________________________________________________________
Delaware36-0781620
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
One Baxter Parkway,Deerfield,Illinois60015
(Address of Principal Executive Offices)(Zip Code)
224.948.2000
(Registrant’s telephone number, including area code)
_________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
1.3% Global Notes due 2025BAX 25New York Stock Exchange
1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ☐   No x
The number of shares of the registrant’s Common Stock, par value $1.00 per share, outstanding as of April 30, 2025 was 513,174,623 shares.



BAXTER INTERNATIONAL INC.
FORM 10-Q
For the quarterly period ended March 31, 2025





























PART I. FINANCIAL INFORMATION
Item 1.    Financial Statements
Baxter International Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in millions, except share information)
March 31,
2025		December 31,
2024
Current assets:
Cash and cash equivalents $2,294 1,764 
Accounts receivable, net of allowances of $66 in 2025 and $71 in 2024
1,646 1,679 
Inventories2,170 2,046 
Prepaid expenses and other current assets925 753 
Current assets of discontinued operations— 2,611 
Total current assets7,035 8,853 
Property, plant and equipment, net 2,717 2,870 
Goodwill 5,338 5,275 
Other intangible assets, net 5,081 5,223 
Operating lease right-of-use assets301 306 
Other non-current assets 832 755 
Non-current assets of discontinued operations— 2,500 
Total assets $21,304 $25,782 
Current liabilities:
Short-term debt $11 $2,126 
Current maturities of long-term debt and finance lease obligations651 626 
Accounts payable 963 968 
Accrued expenses and other current liabilities1,856 1,861 
Current liabilities of discontinued operations— 930 
Total current liabilities 3,481 6,511 
Long-term debt and finance lease obligations, less current portion9,412 10,374 
Operating lease liabilities235 243 
Other non-current liabilities 1,122 1,076 
Non-current liabilities of discontinued operations— 554 
Total liabilities 14,250 18,758 
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2025 and 2024
683 683 
Common stock in treasury, at cost, 170,414,885 shares in 2025 and 172,567,636 shares in 2024
(10,937)(11,059)
Additional contributed capital6,309 6,421 
Retained earnings14,968 14,929 
Accumulated other comprehensive loss(3,942)(4,010)
Total Baxter stockholders’ equity7,081 6,964 
Noncontrolling interests(27)60 
Total equity7,054 7,024 
Total liabilities and equity$21,304 $25,782 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

Baxter International Inc.
Condensed Consolidated Statements of Income (Loss) (unaudited)
(in millions, except per share data)
Three months ended
March 31,
20252024
Net sales$2,625 $2,490 
Cost of sales1,764 1,529 
Gross margin861 961 
Selling, general and administrative expenses703 729 
Research and development expenses140 120 
Other operating income, net(40)(3)
Operating income 58 115 
Interest expense, net64 78 
Other (income) expense, net(3)(9)
Income (loss) from continuing operations before income taxes(3)46 
Income tax expense (benefit)(67)40 
Income (loss) from continuing operations64 6 
Income (loss) from discontinued operations, net of tax62 33 
Net income (loss)126 39 
Net income attributable to noncontrolling interests included in continuing operations— — 
Net income attributable to noncontrolling interests included in discontinued operations— 2 
Net income attributable to noncontrolling interests— 2 
Net income (loss) attributable to Baxter stockholders$126 $37 
Income (loss) from continuing operations per common share
Basic$0.13 $0.01 
Diluted$0.13 $0.01 
Income (loss) from discontinued operations per common share
Basic$0.12 $0.06 
Diluted$0.12 $0.06 
Income (loss) per common share
Basic$0.25 $0.07 
Diluted$0.25 $0.07 
Weighted-average number of shares outstanding
Basic512 508 
Diluted514 510 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Baxter International Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)
(in millions)
Three months ended
March 31,
20252024
Income (loss) from continuing operations$64 $6 
Other comprehensive income (loss) from continuing operations, net of tax:
Currency translation adjustments, net of tax expense (benefit) of $6 and $13 for the three months ended March 31, 2025 and 2024, respectively.
(68)(119)
Pension and other postretirement benefits, net of tax expense (benefit) of ($4) and $3 for the three months ended March 31, 2025 and 2024, respectively.
12 4 
Hedging activities, net of tax expense (benefit) of ($1) and $2 for the three months ended March 31, 2025 and 2024, respectively.
(2)8 
Total other comprehensive income (loss) from continuing operations, net of tax(58)(107)
Comprehensive income (loss) from continuing operations6 (101)
Income (loss) from discontinued operations, net of tax62 33 
Other comprehensive income (loss) from discontinued operations
Currency translation adjustments, net of tax expense (benefit) of zero and $(2) for the three months ended March 31, 2025 and 2024, respectively.
137 (65)
Pension and other postretirement benefits, net of tax expense (benefit) of $(3) and zero for the three months ended March 31, 2025 and 2024, respectively.
(11)— 
Total other comprehensive income (loss) from discontinued operations126 (65)
Comprehensive income (loss) from discontinued operations188 (32)
Comprehensive income (loss)194 (133)
Less: Comprehensive income attributable to noncontrolling interests— 2 
Less: Other comprehensive loss attributable to noncontrolling interests— (4)
Comprehensive income (loss) attributable to Baxter stockholders$194 $(131)
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Baxter International Inc.
Condensed Consolidated Statements of Changes in Equity (unaudited)
(in millions)
For the three months ended March 31, 2025
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock shares
in treasury		Common stock in
treasury		Additional contributed capitalRetained earningsAccumulated other comprehensive
loss		Total Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of January 1, 2025683 $683 173 $(11,059)$6,421 $14,929 $(4,010)$6,964 $60 $7,024 
Net income— — — — — 126 — 126 — 126 
Other comprehensive income (loss)— — — — — — (47)(47)— (47)
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation— — — — — — 115 115 — 115 
Stock issued under employee benefit plans and other— — (3)122 (112)— — 10 — 10 
Dividends declared on common stock— — — — — (87)— (87)— (87)
Disposition of noncontrolling interest associated with the Kidney Care separation— — — — — — — — (87)(87)
Balance as of March 31, 2025
683 $683 170 $(10,937)$6,309 $14,968 $(3,942)$7,081 $(27)$7,054 
For the three months ended March 31, 2024
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive lossTotal Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of January 1, 2024683 $683 176 $(11,230)$6,389 $16,114 $(3,554)$8,402 $66 $8,468 
Net income— — — — —37 — 37 2 39 
Other comprehensive income (loss)— — — — — — (168)(168)(4)(172)
Stock issued under employee benefit plans and other— — (2)100 (50)— — 50 — 50 
Dividends declared on common stock— — — — — (148)—(148)— (148)
Change in noncontrolling interests— — — — — — — — (2)(2)
Balance as of March 31, 2024683 $683 174 $(11,130)$6,339 $16,003 $(3,722)$8,173 $62 $8,235 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Baxter International Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)
Three Months Ended March 31,
20252024
Cash flows from operations
Net income (loss)$126 $39 
Less: Income (loss) from discontinued operations, net of tax62 33 
Income (loss) from continuing operations64 6 
Adjustments to reconcile net loss to cash flows from operations:
Depreciation and amortization247 271 
Deferred income taxes(142)(58)
Stock compensation10 17 
Net periodic pension and other postretirement costs(8)(7)
Other long-lived asset impairments22 — 
Other6 5 
Changes in balance sheet items:
Accounts receivable, net26 125 
Inventories(122)(145)
Prepaid expenses and other current assets(24)(4)
Accounts payable 16 119 
Accrued expenses and other current liabilities(143)(240)
Other(51)(22)
Cash flows from operations - continuing operations(99)67 
Cash flows from operations - discontinued operations(94)96 
Cash flows from operations(193)163 
Cash flows from investing activities
Capital expenditures(122)(110)
Other investing activities, net(2)10 
Cash flows from investing activities - continuing operations(124)(100)
Cash flows from investing activities - discontinued operations3,389 (66)
Cash flows from investing activities3,265 (166)
Cash flows from financing activities
Repayments of debt(2,825)(15)
Net decreases in debt with original maturities of three months or less(300)— 
Cash dividends on common stock(87)(147)
Proceeds from stock issued under employee benefit plans10 40 
Other financing activities, net(24)(18)
Cash flows from financing activities(3,226)(140)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations36 (25)
Increase (decrease) in cash, cash equivalents and restricted cash(118)(168)
Cash, cash equivalents and restricted cash at beginning of period (1)
2,414 3,198 
Cash, cash equivalents and restricted cash at end of period (1)
2,296 3,030 
Less cash and cash equivalents of discontinued operations— 200 
Cash, cash equivalents and restricted cash of continuing operations$2,296 $2,830 
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of March 31, 2025, December 31, 2024, and March 31, 2024 (in millions):
March 31, 2025December 31, 2024March 31, 2024
Cash and cash equivalents$2,294 $1,764 $2,826 
Restricted cash included in other non-current assets2 2 4 
Cash and cash equivalents of discontinued operations— 648 200 
Cash, cash equivalents and restricted cash$2,296 $2,414 $3,030 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Baxter International Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1. BASIS OF PRESENTATION
The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).
In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the net after tax proceeds of approximately $3.3 billion, subject to certain post-closing adjustments. The financial position, results of operations and cash flows of our Kidney Care business, including the gain on sale of that business and the related cash proceeds received, are reported as discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations. See Note 2 for additional information.
Hurricane Helene
In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, North Carolina and disrupted operations at that facility. Since then, we have actively worked with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we worked towards resuming our North Cove manufacturing operations. While we continue to increase allocation levels across key impacted product groups, the facility was fully operational by the end of the first quarter of 2025. In the first quarter of 2025, we recorded $98 million of pre-tax net charges related to remediation, air freight and other costs as a result of the damages caused by Hurricane Helene. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three month period ended March 31, 2025.
Risks and Uncertainties
Supply Constraints, Tariffs and Global Economic Conditions
We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which caused the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify
7

additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative of lower cost raw material or component parts.
We expect that these challenges, among other factors, may continue to have an adverse effect on our business.
2. DISCONTINUED OPERATIONS
A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation as described below.
Discontinued Operations - Kidney Care
On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction. We recognized a pre-tax gain on the sale of $191 million ($111 million net of tax).
We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.
Upon closing of the sale of the Kidney Care business, pursuant to the Equity Purchase Agreement (EPA), Baxter and Vantive entered into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a Transition Services Agreement (Kidney Care TSA), a Long Term Master Services Agreement, a Distribution Agreement and certain other arrangements providing for short-term supply of saline products, and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities provide each other with certain dialysis-related products, other products, product components and fulfillment services for up to 10 years post-closing (with certain extension rights and early exit rights as provided therein). Pursuant to the Kidney Care MSA, our sales to Vantive are recognized in net sales in the condensed consolidated statements of income (loss). Pursuant to the Kidney Care TSA, Baxter and the entities that were divested in connection with the Kidney Care sale (the Kidney Care divested entities) provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights and early exit rights as provided therein) to help ensure business continuity and help minimize disruptions to the operations of both parties post-closing. Services provided under the Kidney Care TSA include information technology applications and support, supply chain and certain other corporate and administrative services. Billings by us under the Kidney Care TSA are recorded in other operating income, net in the condensed consolidated statements of income. The costs to provide each respective service is recorded in the applicable expense category in the condensed consolidated statements of income (loss).
In accordance with the EPA, we have agreed to indemnify Vantive for certain items, including taxes imposed on or with respect to the Kidney Care divested entities, for pre-closing tax periods. The net indemnification liability as of March 31, 2025 was $37 million. Further, in accordance with the EPA, Baxter recorded a contingent liability for payments to reimburse Vantive for qualifying capital expenditures over a period of three years post sale. The contingent liability as of March 31, 2025 was $133 million. Certain of the business guarantees originally entered by us on behalf of the Kidney Care business were not released prior to the completion of the sale and remain outstanding. These legacy guarantees primarily relate to leases, performance contracts and ones to support regulatory requirements of the Kidney Care business. As of March 31, 2025, the total amount of Kidney Care business guarantees retained by us is approximately $300 million. Under terms of the EPA, Carlyle has agreed to indemnify us for any cost or expense, or payments made in the future under these arrangements.
8

Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations
The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
(in millions)20252024
Net sales$352 $1,102 
Cost of sales206 676 
Gross margin146 426 
Selling, general and administrative expenses116 298 
Research and development expenses16 56 
Operating income (loss)14 72 
Interest expense, net13 — 
Other (income) expense, net7 2 
Income (loss) from discontinued operations before gain on disposition and income taxes(6)70 
Gain on disposition191 — 
Income tax expense (benefit)123 37 
Income from discontinued operations, net of tax62 33 
Less: Net income attributable to noncontrolling interest included in discontinued operations— 2 
Net income attributable to Baxter stockholders included in discontinued operations$62 $31 
For the three months ended March 31, 2025 and 2024, selling, general and administrative expenses (SG&A) includes $37 million and $88 million, respectively, of separation-related costs incurred in connection with the sale of our Kidney Care business.
9

The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of December 31, 2024:
(in millions)December 31, 2024
Cash and cash equivalents$648 
Accounts receivable, net of allowances942 
Inventories821 
Prepaid expenses and other current assets200 
Current assets of discontinued operations2,611 
Property, plant and equipment, net1,516 
Goodwill265 
Other intangible assets, net148 
Operating lease right-of-use assets204 
Other non-current assets367 
Non-current assets of discontinued operations2,500 
Assets of discontinued operations$5,111 
Current maturities of finance lease obligations$1 
Accounts payable344 
Accrued expenses and other current liabilities585 
Current liabilities of discontinued operations930 
Long-term finance lease obligations, less current portion37 
Operating lease liabilities173 
Other non-current liabilities344 
Non-current liabilities of discontinued operations554 
Liabilities of discontinued operations$1,484 
3. SUPPLEMENTAL FINANCIAL INFORMATION
Allowance for Doubtful Accounts
The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
(in millions)20252024
Balance at beginning of period$71 $62 
Charged to costs and expenses(4)(1)
Write-offs(2)(3)
Currency translation adjustments1 (2)
Balance at end of period$66 $56 
10

Inventories
(in millions)March 31,
2025		December 31,
2024
Raw materials$550 $510 
Work in process310 266 
Finished goods1,310 1,270 
Inventories$2,170 $2,046 
Property, Plant and Equipment, Net
(in millions)March 31,
2025		December 31,
2024
Property, plant and equipment, at cost$7,431 $7,648 
Accumulated depreciation(4,714)(4,778)
Property, plant and equipment, net$2,717 $2,870 
Other Current Assets and Liabilities
In connection with the sale of our Kidney Care business and pursuant to the EPA, the Kidney Care assets and liabilities in certain countries are to be transferred at a later date for operational, regulatory or other reasons. Accordingly, the related assets, primarily consisting of accounts receivable, of $95 million and liabilities, consisting of accounts payable, of $7 million of these deferred markets and are presented within prepaid and other current assets and accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of March 31, 2025.
In the first quarter of 2025, we signed a purchase agreement with a buyer to sell our manufacturing facility in Opelika, Alabama for $25 million, subject to the satisfaction of various closing conditions. The related assets are classified as held-for-sale and are presented within prepaid and other current assets in the accompanying condensed consolidated balance sheet as of March 31, 2025. While the closing remains subject to the satisfaction of various closing conditions, we currently expect the transaction to close in 2025 and the net book value of the assets as of March 31, 2025 approximates the transaction price net of estimated selling costs.
Interest Expense, Net
Three Months Ended March 31,
(in millions)20252024
Interest expense, net of capitalized interest$81 $103 
Interest income(17)(25)
Interest expense, net$64 $78 
Other (Income) Expense, Net
Three Months Ended March 31,
(in millions)20252024
Foreign exchange losses, net$— $14 
Pension and other postretirement benefit plans(11)(13)
Change in fair value of marketable equity securities1 (3)
Equity method investment impairment9 — 
Other, net(2)(7)
Other (income) expense, net$(3)$(9)
Non-Cash Operating and Investing Activities
Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2025 and 2024 were $5 million and $16 million, respectively.
11

Purchases of property, plant and equipment included in accounts payable as of March 31, 2025 and 2024 were $39 million and $35 million, respectively.
4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The following is a reconciliation of goodwill by segment.
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsTotal
Balance as of December 31, 2024$1,185 $3,550 $540 $5,275 
Currency translation 38 8 17 63 
Balance as of March 31, 2025$1,223 $3,558 $557 $5,338 
Other intangible assets, net
The following is a summary of our other intangible assets.
Indefinite-lived intangible assets
(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and Development
Total
December 31, 2024
Gross other intangible assets$3,387 $3,131 $958 $86 $680 $107 $8,349 
Accumulated amortization(878)(2,075)(107)(66)— — (3,126)
Other intangible assets, net$2,509 1,056 851 20 680 107 5,223 
March 31, 2025
Gross other intangible assets$3,389 $3,154 $953 $88 $680 $107 $8,371 
Accumulated amortization(932)(2,170)(119)(69)— — (3,290)
Other intangible assets, net$2,457 $984 $834 $19 $680 $107 $5,081 
Intangible asset amortization expense was $155 million and $158 million for the three months ended March 31, 2025 and 2024, respectively.
5. FINANCING ARRANGEMENTS
Significant Debt Activity
In February 2025, we repaid $1.00 billion under our $1.64 billion five-year term loan facility maturing in 2026.
Credit Facilities
On July 17, 2024, we entered into a credit agreement pursuant to which a group of banks provided us senior unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We also incurred a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banks’ funding commitments under the bridge facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we were required to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contained financial and other covenants, including a net leverage
12

covenant, and provided for customary events of default. There was $1.83 billion outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the approximately $3.3 billion of net after-tax cash proceeds from the sale of our Kidney Care business to repay the $1.83 billion outstanding under the bridge facility, at which time it was terminated.
As of March 2025, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of term loans outstanding, a U.S Dollar-denominated revolving credit facility and a Euro-denominated revolving credit facility. Our U.S. Dollar-denominated revolving credit facility has a current capacity of $2.00 billion and our Euro-denominated revolving credit facility has a capacity of €200 million. Each of the facilities is scheduled to mature in 2026. There were no borrowings outstanding under these credit facilities as of March 31, 2025 or December 31, 2024. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of March 31, 2025 we have capacity to draw $2.04 billion under our credit facilities.
Commercial Paper
There was no commercial paper outstanding as of March 31, 2025. As of December 31, 2024, we had $300 million of commercial paper outstanding with a weighted-average interest rate of 4.78% and an original term of 45 days. In the first quarter of 2025, we repaid the $300 million balance outstanding as of December 31, 2024.
6. COMMITMENTS AND CONTINGENCIES
We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2025 and December 31, 2024, our total recorded reserves with respect to legal and environmental matters were $46 million and $40 million, respectively.
We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.
In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.
Environmental
We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of March 31, 2025 and December 31, 2024, our environmental reserves, which are measured on an undiscounted basis, were $28 million and $29 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.
13

General Litigation
In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 41 lawsuits (after giving effect to the September 2024 amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. In the second quarter of 2025, plaintiffs filed a motion to voluntarily dismiss Baxter from 29 of the filed cases, which was granted by the Court. The parties have reached an agreement in principle to resolve the remaining filed cases, along with certain additional matters, for an amount not material to Baxter.
We acquired Hill-Rom Holdings, Inc. (Hillrom) on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (the 2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws.
On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery. Fact discovery is ongoing.
On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020” and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint. On November 8, 2024, Hillrom
14

filed a Motion to Dismiss Plaintiff's Amended Complaint. Briefing was completed in January 2025, and the court held a hearing on the motion on March 25, 2025. The motion is pending before the court.
7. STOCKHOLDERS’ EQUITY
Cash Dividends
Cash dividends declared per share for the three months ended March 31, 2025 and 2024 were $0.17 and $0.29, respectively.
Stock Repurchase Programs
In July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first three months of 2025 and 2024 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of March 31, 2025.
8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.
The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2025 and 2024.
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2024
$(3,430)$(475)$(108)$3 $(4,010)
Other comprehensive income (loss) before reclassifications(57)14 — — (43)
Amounts reclassified from AOCI (a)126 (13)(2)— 111 
Net other comprehensive income (loss) 69 1 (2)— 68 
Balance as of March 31, 2025$(3,361)$(474)$(110)$3 $(3,942)
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2023$(2,985)$(452)$(120)$3 $(3,554)
Other comprehensive income (loss) before reclassifications(180)5 6 — (169)
Amounts reclassified from AOCI (a)
— (1)2 — 1 
Net other comprehensive income (loss) (180)4 8 — (168)
Balance as of March 31, 2024$(3,165)$(448)$(112)$3 $(3,722)
(a)    See table below for details about these reclassifications.
15

The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2025 and 2024.
Amounts reclassified from AOCI (a)
(in millions)Three Months Ended March 31, 2025Three Months Ended March 31, 2024Location of impact in income statement
CTA
Reclassification of cumulative translation loss to earnings from Kidney Care separation$(126)$— Income from discontinued operations, net of tax
Less: Tax effect— — Income from discontinued operations, net of tax
$(126)$— Net of tax
Pension and OPEB items
Amortization of net losses and prior service costs or credits$3 $2 Other (income) expense, net
Pension settlement from Kidney Care separation14 — Income from discontinued operations, net of tax
17 2 Total before tax
Less: Tax effect(1)(1)Income tax expense
Less: Tax effect on pension settlement from Kidney Care separation(3)— Income from discontinued operations, net of tax
$13 $1 Net of tax
Gains (losses) on hedging activities
Foreign exchange contracts$(1)$2 Cost of sales
Interest rate contracts4 (1)Interest expense, net
Fair value hedges— (3)Other (income) expense, net
3 (2)Total before tax
Less: Tax effect(1)— Income tax expense
$2 $(2)Net of tax
Total reclassifications for the period$(111)$(1)Total net of tax
(a)    Amounts in parentheses indicate reductions to net income
Refer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity.
9. REVENUES
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30 to 90 days.
Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.
16

To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems & Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.
As of March 31, 2025, we had $10.19 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products & Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 15% of this amount as revenue over the remainder of 2025, 20% in 2026, 15% in each of 2027 and 2028 and 35% thereafter.
Significant Judgments
Revenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and distributor chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three months ended March 31, 2025 and 2024 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement.
Contract Balances
The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.49 billion and $1.54 billion as of March 31, 2025 and December 31, 2024, respectively.
For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years.
17

The following table summarizes our contract assets:
(in millions)March 31,
2025		December 31,
2024
Contract manufacturing services$4 $2 
Software sales39 44 
Bundled equipment and consumable medical products contracts89 87 
Contract assets$132 $133 
Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months.
The following table summarizes contract liability activity for the three months ended March 31, 2025 and 2024. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Three Months Ended March 31,
(in millions)
2025
2024
Balance at beginning of period$171 $169 
New revenue deferrals128 93 
Revenue recognized upon satisfaction of performance obligations(124)(91)
Currency translation— (2)
Balance at end of period$175 $169 
For the three months ended March 31, 2025 and 2024, $34 million and $43 million of revenue was recognized that was included in contract liabilities as of December 31, 2024 and 2023, respectively.
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)March 31,
2025		December 31,
2024
Prepaid expenses and other current assets$54 $51 
Other non-current assets78 82 
Contract assets$132 $133 
Accrued expenses and other current liabilities$135 $131 
Other non-current liabilities40 40 
Contract liabilities$175 $171 
Disaggregation of Net Sales
Refer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location.
18

Lease Revenue
We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.
The components of lease revenue for the three months ended March 31, 2025 and 2024 were:
Three Months Ended March 31,
(in millions)20252024
Sales-type lease revenue$8 $2 
Operating lease revenue91 104 
Variable lease revenue7 8 
Total lease revenue$106 $114 
Our net investment in sales-type leases was $47 million as of March 31, 2025, of which $13 million originated in 2021 and prior, $6 million in 2022, $7 million in 2023, $10 million in 2024, and $11 million in 2025.
10. BUSINESS OPTIMIZATION CHARGES
In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization into verticalized segments, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $4 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.

During the three months ended March 31, 2025 and 2024, we recorded the following charges related to business optimization programs.
Three Months Ended March 31,
(in millions)20252024
Restructuring charges$44 $17 
Costs to implement business optimization programs1 5 
Total business optimization charges$45 $22 
Costs to implement business optimization programs for the three months ended March 31, 2025 and 2024, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense.
19

During the three months ended March 31, 2025 and 2024, we recorded the following restructuring charges.
Three months ended March 31, 2025
(in millions)COGSSG&AR&DTotal
Employee termination costs$12 $13 $1 $26 
Asset write offs1 17 — 18 
Total restructuring charges$13 $30 $1 $44 
Three months ended March 31, 2024
(in millions)COGSSG&ATotal
Employee termination costs$3 $11 $14 
Contract termination and other costs— 3 3 
Total restructuring charges$3 $14 $17 
For the three months ended March 31, 2025, $25 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.
For the three months ended March 31, 2024, $6 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our operating model intended to streamline our operations.
The following table summarizes activity in the liability related to our restructuring initiatives.
(in millions)
Liability balance as of December 31, 2024$122 
Charges26 
Payments(36)
Currency translation2 
Liability balance as of March 31, 2025$114 
Substantially all of our restructuring liabilities as of March 31, 2025 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025.
11. PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS
The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.
Three Months Ended March 31,
(in millions)20252024
Pension benefits
Service cost$3 $6 
Interest cost34 45 
Expected return on plan assets(44)(59)
Amortization of net losses and prior service costs1 4 
Net periodic pension cost$(6)$(4)
OPEB
Interest cost$2 $2 
Amortization of net loss and prior service credit(4)(5)
Net periodic OPEB cost (income)$(2)$(3)
20

12. INCOME TAXES
For the three months ended March 31, 2025 and 2024, our effective income tax rate differs significantly from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards.
For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.
For the three months ended March 31, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by income tax expense resulting from internal reorganization transactions related to the sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and an increase in our liabilities for various uncertain tax positions.
13. EARNINGS PER SHARE
The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.
The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.
Three Months Ended March 31,
(in millions)20252024
Income (loss) from continuing operations$64 $6 
Less: Net income attributable to noncontrolling interests included in continuing operations— — 
Income (loss) from continuing operations attributable to Baxter stockholders64 6 
Income (loss) from discontinued operations62 33 
Less: Net income attributable to noncontrolling interests included in discontinued operations— 2 
Income (loss) from discontinued operations attributable to Baxter stockholders62 31 
Net income (loss) attributable to Baxter stockholders$126 $37 

The following table is a reconciliation of basic shares and diluted shares.
Three Months Ended March 31,
(in millions)20252024
Basic shares512 508 
Effect of dilutive securities2 2 
Diluted shares514 510 
The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 20 million and 16 million shares issuable under equity awards for the three months ended March 31, 2025 and 2024, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.
14. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.

21

We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Canadian Dollar, Australian Dollar, Indian Rupee, Turkish Lira, Japanese Yen, Mexican Peso, Korean Wan and Swiss Franc. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.
We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.
We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.
Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.
Cash Flow Hedges
We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.
For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged transaction. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.
The notional amounts of foreign exchange contracts designated as cash flow hedges were $49 million and $99 million as of March 31, 2025 and December 31, 2024, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at March 31, 2025 is eight months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of March 31, 2025 and December 31, 2024.
Fair Value Hedges
We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.
There were no outstanding interest rate contracts designated as fair value hedges as of March 31, 2025 and December 31, 2024.
In October 2023, we entered into a foreign currency forward contract with a notional amount of $798 million and designated that derivative as a fair value hedge of our €750 million of 0.40% senior notes due May 2024. This forward contract matured in May 2024.
22

Net Investment Hedges
In May 2017, we issued €600 million of 1.3% senior notes due May 2025. We had designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In March 2025, we dedesignated this previously designated net investment hedge and concurrently entered into forward contracts to manage foreign exchange risk in earnings relating to these outstanding debt balances.
In May 2019, we issued €750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI.
In May 2019, we issued €750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above.
As of March 31, 2025, we had an accumulated pre-tax unrealized translation gain in AOCI of $63 million related to the Euro-denominated senior notes.
Dedesignations
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged transactions. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings.
There were no cash flow hedge dedesignations in the first three months of 2025 or 2024 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur.
If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2025 or 2024.
If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In March 2025, we dedesignated one of our net investment hedges as discussed in the "Net Investment Hedges" section above. There were no net investment hedges terminated during the first three months of 2024.
Undesignated Derivative Instruments
We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.
In March 2025, as discussed in the "Net Investment Hedges" section above, we entered into forward contracts with a notional amount of $655 million to hedge the repayment of our Euro-denominated senior notes due May 2025. The total notional amount of undesignated derivative instruments was $955 million as of March 31, 2025 and $389 million as of December 31, 2024.
Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments
The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2025 and
23

2024.
Gain (loss) recognized in OCILocation of gain (loss)
in income statement		Gain (loss) reclassified from AOCI into income
(in millions)2025202420252024
Cash flow hedges
Interest rate contracts$— $— Interest expense, net$(1)$(1)
Foreign exchange contracts— 10 Cost of sales4 2 
Fair value hedges
Foreign exchange contracts— (2)Other (income) expense, net— (3)
Net investment hedges61 38 Other (income) expense, net— — 
Total$61 $46 $3 $(2)
Location of gain (loss) in income statementGain (loss) recognized in income
(in millions)20252024
Fair value hedges
Foreign exchange contractsOther (income) expense, net$— $(23)
Undesignated derivative instruments
Foreign exchange contractsOther (income) expense, net(2)(5)
Total$(2)$(28)
As of March 31, 2025, $2 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
Derivative Assets and Liabilities
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2025.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$3 Accrued expenses and other current liabilities$—
Net investment hedgesLong-term debt and finance lease obligations, less current portion761
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets— Accrued expenses and other current liabilities4
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations648
Total derivative instruments$3 $1,413
24

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2024.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$6 Accrued expenses and other current liabilities$— 
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations618 
Net investment hedgesLong-term debt and finance lease obligations, less current portion727 
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets1 Accrued expenses and other current liabilities2 
Total derivative instruments$7 $1,347 
While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.
The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.
March 31, 2025December 31, 2024
(in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheets$3 $4 $7 $2 
Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(2)(2)(1)(1)
Total$1 $2 $6 $1 
The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:
Carrying amount of hedged itemCumulative amount of fair value hedging adjustment included
 in the carrying amount of the hedged item (a)
(in millions)Balance as of March 31, 2025Balance as of December 31, 2024Balance as of March 31, 2025Balance as of December 31, 2024
Long-term debt$99 $99 $2 $2 
(a) These fair value hedges were terminated in 2018 and earlier periods.
25

15. FAIR VALUE MEASUREMENTS
The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.
Basis of fair value measurement
(in millions)Balance as of March 31, 2025Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$3 $— $3 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities12 12 — — 
Total$16 $12 $3 $1 
Liabilities
Foreign exchange contracts$4 $— $4 $— 
Contingent payments related to acquisitions12 — — 12 
Indemnifications related to Kidney Care separation1
37 — — 37 
Total$53 $— $4 $49 
1 Recorded in connection with the sale of our Kidney Care business and was measured as of January 31, 2025. See Note 2 for additional information.
Basis of fair value measurement
(in millions)Balance as of December 31, 2024Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$7 $— $7 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities13 13 — — 
Total$21 $13 $7 $1 
Liabilities
Foreign exchange contracts$2 $— $2 $— 
Contingent payments related to acquisitions12 — — 12 
Total$14 $— $2 $12 
As of March 31, 2025 and December 31, 2024, cash and cash equivalents of $2.29 billion and $1.76 billion, respectively, included money market fund and other short-term funds of approximately $1.21 billion and $583 million, respectively, that are considered Level 2 in the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.
Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.
26

Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated.
In addition, we have contingent payments related related to the Kidney Care separation, which consist of reimbursements to Vantive for certain indemnifications contemplated in the EPA. For additional information on these items see Note 2.
The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.
Three Months Ended March 31,
20252024
(in millions)Indemnifications related to Kidney Care separationContingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securities
Fair value at beginning of period$— $12 $1 $14 $1 
Additions37 — — — — 
Fair value at end of period$37 $12 $1 $14 $1 
Financial Instruments Not Measured at Fair Value
In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2025 and December 31, 2024.
Book valuesFair values(a)
(in millions)2025202420252024
Liabilities
Short-term debt$11 $2,126 $11 $2,126 
Current maturities of long-term debt and finance lease obligations651 626 650 619 
Long-term debt and finance lease obligations9,412 10,374 8,398 9,295 
(a)    These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.
Investments Without Readily Determinable Fair Values
The carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $37 million as of March 31, 2025 and December 31, 2024. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. These investments are included in Other non-current assets on our condensed consolidated balance sheets.
27

16. SEGMENT INFORMATION
Our business is comprised of three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment
primarily includes sales to Vantive, pursuant to the Kidney Care MSA, and sales of products and services provided directly through certain of our manufacturing facilities.
Disaggregation of Net Sales
The following tables present our U.S. and International disaggregated net sales.
Three Months Ended March 31,
20252024
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Infusion Therapies and Technologies
$584 $410 $994 $526 $440 $966 
Advanced Surgery
145 123 268 147 116 263 
Medical Products & Therapies729 533 1,262 673 556 1,229 
Care and Connectivity Solutions
316 111 427 278 124 402 
Front Line Care
202 75 277 195 70 265 
Healthcare Systems & Technologies
518 186 704 473 194 667 
Injectables and Anesthesia
195 140 335 191 137 328 
Drug Compounding— 246 246 — 250 250 
Pharmaceuticals195 386 581 191 387 578 
Other48 30 78 11 5 16 
Total Baxter$1,490 $1,135 $2,625 $1,348 $1,142 $2,490 
Geographic Sales Information
Our net sales are attributed to the following geographic regions based on the location of the customer.
Three Months Ended March 31,
(in millions)20252024
United States$1,490 $1,348 
Emerging markets1
297 307 
Rest of world2
838 835 
Total Baxter$2,625 $2,490 
1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
Segment Operating Income
In the first quarter of 2025, in conjunction with the change in our Chief Executive Officer, we determined that our chief operating decision maker (CODM) comprises of our Chair and Interim Chief Executive Officer, and the Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products & Therapies, who review the financial information presented for purposes of evaluating the performance of our segments and to make resource allocation decisions. The change in CODM during the first quarter of 2025 did not result in a change in our segments.
28

Segment operating income is the measure of segment profitability and represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period.
Corporate costs, inclusive of global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs.
Segment results include net sales, cost of sales, selling, general and administrative expenses, research and development expenses, corporate costs that had previously been allocated to our former Kidney Care segment which did not convey in the related sale, and other segment items which are directly allocated to each segment. Beginning in 2024 annual reporting, we adopted ASU 2023-07 retrospectively. The following table presents our segment information of net sales, significant expense and operating income during the periods presented.
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsMedical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticals
Net sales$1,262 $704 $581 $1,229 $667 $578 
Cost of sales694 356 396 668 346 382 
Selling, general and administrative expenses286 217 103 284 207 96 
Research and development expenses59 45 26 52 47 22 
Other segment items(21)(7)(7)(2)— — 
Segment operating income$244 $93 $63 $227 $67 $78 
29

The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.
Three Months Ended March 31,
(in millions)20252024
Medical Products & Therapies$244 $227 
Healthcare Systems & Technologies93 67 
Pharmaceuticals63 78 
Total reportable segment operating income400 372 
Other9 4 
Unallocated corporate costs(17)(69)
Intangible asset amortization expense(155)(158)
Legal matters(11)— 
Business optimization items(45)(22)
Acquisition and integration items(1)(5)
Separation-related costs(13)— 
European Medical Devices Regulation(5)(7)
Hurricane Helene costs(98)— 
Product-related items(6)— 
Total operating income 58 115 
Interest expense, net64 78 
Other (income) expense, net(3)(9)
Income from continuing operations before income taxes$(3)$46 
Additional financial information for our segments is as follows:
Three Months Ended March 31,
(in millions)20252024
Depreciation Expense1
Medical Products & Therapies$49 $58 
Healthcare Systems & Technologies27 30 
Pharmaceuticals16 25 
Total depreciation expense$92 $113 
1Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.
Our CODM does not receive asset or capital expenditure information by reportable segment and, accordingly, we do not report that information for our segments.

30

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Refer to our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report) for management’s discussion and analysis of our financial condition and results of operations. The following is management’s discussion and analysis of our financial condition and results of operations for the three months ended March 31, 2025 and 2024.
RECENT STRATEGIC ACTIONS
In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of increasing stockholder value. As part of that review process, we identified and evaluated a range of potential strategic actions, including opportunities for sales and other separation transactions. In January 2023, following the completion of that review, we announced a number of planned strategic actions, as discussed below, which were intended to enhance our operational effectiveness, accelerate innovation and drive additional stockholder value. We completed the last of these strategic actions on January 31, 2025 in connection with the sale of our Kidney Care business.
Sale of Kidney Care Business
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain closing adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the net after tax proceeds of approximately $3.3 billion, subject to certain post-closing adjustments. As of March 31, 2025, we repaid $3.13 billion of short- and long-term indebtedness primarily with the net after-tax cash proceeds from the sale of our Kidney Care business, and we expect to use substantially all of the remaining net after-tax proceeds to continue to repay indebtedness through the second quarter of 2025.
The financial position, results of operations and cash flows of our Kidney Care business, including our gain from the sale of that business and the related cash proceeds received, are reported as discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations.
We expect to incur dis-synergies following our sale of our Kidney Care business due to the reduced size of our company and, as a result, we have begun to undertake certain actions (and intend to undertake additional actions) to help ensure our cost structuring is appropriate to support our remaining business.
See Notes 2 and 5 of this Quarterly Report on Form 10-Q for additional information.
Implementation of Operating Model and Resulting Segment Change
In the third quarter of 2023, we completed the implementation of an operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this operating model, our business is currently comprised of three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our segments were changed during the third quarter of 2023 to align with our operating model.
The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services. Other sales not allocated to a segment primarily includes sales to Vantive, pursuant to the Manufacturing and Supply Agreement (Kidney Care MSA), and sales of products and services provided directly through certain of our manufacturing facilities.
31

For financial information about our segments, see Note 16 in Item 1 of this Quarterly Report on Form 10-Q for additional information.
Sale of BioPharma Solutions (BPS) Business
On September 29, 2023, we completed the sale of our BioPharma Solutions (BPS) business and received cash proceeds of $3.96 billion from that transaction. We used substantially all of the after-tax proceeds from this transaction to repay certain of our debt obligations, including $514 million of commercial paper borrowings and $2.28 billion of long-term debt that we repaid during the fourth quarter of 2023, as well as €750 million of senior notes that we repaid during the second quarter of 2024.
FACTORS AFFECTING OUR RESULTS OF OPERATIONS
Hurricane Helene
In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, North Carolina and disrupted operations at that facility. While we continue to increase allocation levels across key impacted product groups, the facility was fully operational by the end of the first quarter of 2025. See Note 1 in Item 1 of this Quarterly Report on Form 10-Q for additional information.
Supply Constraints, Tariffs and Global Economic Conditions
We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which resulted in the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East, and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative or lower cost raw materials or component parts.

Our results of operations are also affected by macroeconomic conditions and levels of business confidence. The aforementioned tariffs and any retaliatory countermeasures, operational and policy changes in the governments of the U.S. and other countries, the war in Ukraine, the conflict in the Middle East, other geopolitical events (and the potential for escalation of these and other conflicts), and recent political changes to trade policies, have increased the levels of economic and political uncertainty and we continue to closely monitor the developing situations and the estimated impact on our business, results of operations, financial condition and cash flows. While we have substantially completed our wind down efforts related to our business in Russia, a significant escalation or expansion of economic disruption or the current scope of the war in Ukraine could have an adverse effect on our operations (including our supply chain) in the region.

The existence of high inflation rates in the United States and in many of the countries where we conduct business has resulted in, and is likely in the future to result in, higher interest rates, shipping costs, labor costs, and other costs and expenses. Additionally, adverse changes in foreign currency exchange rates have increased, and could continue to increase, our costs of sourcing certain raw materials in some jurisdictions. We have experienced and are likely in the future to experience inflationary increases in manufacturing costs and operating expenses (including as a result of the aforementioned tariffs) and may be limited in our ability to pass these cost increases on to our customers in a timely
32

manner or at all due to the longer term nature of our customer contracts and arrangements, which could have a material adverse impact on our profitability and results of operations. Inflation and general macroeconomic factors have caused certain of our customers to reduce or delay orders for our products and services and could cause them to do so in the future, which could have a material adverse impact on our sales and results of operations.
As a medical products company, our operations and many of the products manufactured or sold by us are subject to extensive regulation by numerous government agencies, both within and outside the United States. These regulations (as described in Item 1, Government Regulation, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024) require that we obtain specific approval from the Food and Drug Administration (FDA) or applicable non-U.S. regulatory authorities before we can market and sell most of our products in a particular country. Failure to obtain or maintain those approvals or clearances (including temporary importation authorizations) could have a material adverse impact on our business (including with respect to our ability to compete in the product markets in which we currently operate). Furthermore, FDA in the United States, the European Medicines Agency in Europe, the China Food and Drug Administration in China, and other government agencies, inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, pricing, distribution, and post-market surveillance of our products. Our failure to comply with these requirements may subject us to various actions, including warning letters, product recalls or seizures, monetary sanctions, injunctions to halt the manufacture and distribution of products, civil or criminal sanctions, refusal of a government to grant approvals or licenses, restrictions on operations or withdrawal of existing approvals and licenses, and may have a material adverse impact on our results of operations.
For further discussion, please refer to Item 1A, Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
NON-GAAP FINANCIAL MEASURES
Our presentation of percentage changes in net sales at operational sales growth excludes the impact of the Kidney Care MSA sales not reflected in reportable segments, reflects the exit of IV solutions in China in our Infusion Therapies & Technologies division, in our Medical Products & Therapies reportable segment, and is calculated at constant currency rates. Constant currency rates are computed using current period local currency sales at the prior period’s foreign exchange rates. Operational sales growth is a non-GAAP financial measure. This measure provides information about growth (or declines) in our net sales as if the Kidney Care MSA and the exit of IV solutions in China had no impact on our sales and foreign currency exchange rates had not changed between the prior period and the current period. We believe that the non-GAAP measure of percent change in net sales at operational sales growth, when used in conjunction with the U.S. GAAP measure of percent change in net sales at actual rates, may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.
RESULTS OF OPERATIONS
Net income (loss) attributable to Baxter stockholders for the three months ended March 31, 2025 was $126 million, or $0.25 per diluted share, compared to $37 million, or $0.07 per diluted share for the three months ended March 31, 2024. For the three months ended March 31, 2025, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $194 million, or $0.37 per diluted share. For the three months ended March 31, 2024, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $294 million, or $0.58 per diluted share.
Net income (loss) from continuing operations for the three months ended March 31, 2025 was $64 million, or $0.13 per diluted share, compared to $6 million, or $0.01 per diluted share for the three months ended March 31, 2024. Net income (loss) from continuing operations for the three months ended March 31, 2025 included special items that adversely impacted net income (loss) by $221 million, or $0.42 per diluted share. Net income (loss) from continuing operations for the three months ended March 31, 2024 included special items that adversely impacted net income (loss) by $177 million, or $0.35 per diluted share.
See the subsection entitled “Special Items” for information about special items for all periods presented.
33

CONSOLIDATED NET SALES
Three Months Ended March 31,Percent change
(in millions)20252024At actual
rates
At operational sales growth 1
United States$1,490 $1,348 11 %7 %
Emerging markets2
297 307 (3)%4 %
Rest of world3
838 835 0 %2 %
Total net sales$2,625 $2,490 5 %5 %
1     Percent change in net sales at operational sales growth is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial Measures” for additional information about our use of that measure.
2    Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).
3    Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
In the first quarter of 2025, the Kidney Care MSA sales favorably impacted sales growth by 3% and the exit of IV solutions in China adversely impacted sales by 1%. Additionally, in the first quarter of 2025, foreign currency rates adversely impacted net sales growth by 2%, compared to the prior year period, due to the weakening of the U.S. Dollar relative to the Euro, Australian Dollar, Canadian Dollar, Brazilian Real and the Mexican Peso.
NET SALES BY SEGMENT
Medical Products & Therapies
Our Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products.
Three Months Ended March 31,Percent change
(in millions)20252024At actual
rates
At operational sales growth 1
Infusion Therapies and Technologies
$994 $966 3 %6 %
Advanced Surgery268 263 2 %4 %
Total Medical Product & Therapies net sales$1,262 $1,229 3 %6 %
1     Percent change in net sales at operational sales growth is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial Measures” for additional information about our use of that measure.
Medical Product and Therapies segment net sales increased 3% in the first quarter of 2025, as compared to the prior year period.
Infusion Therapies and Technologies net sales increased 3% in the first quarter of 2025, as compared to the prior year period. Sales performance in the first quarter of 2025 primarily reflected growth in Infusion Systems as a result of increased U.S. sales for our infusion pump portfolio. Growth in our IV Solutions business was the result of price increases globally, but also benefited from the build back of distributor inventory in the U.S. following the flooding at our North Cove facility in Marion, North Carolina caused by Hurricane Helene in September 2024. The distributor build was offset by reduced U.S. demand as hospital customers continued fluid conservation efforts during the first quarter of 2025 originally instituted in response to Hurricane Helene. We expect some hospital customers to continue a level of conservation during 2025 with the impact waning over the course of the year as product allocations are lifted. Nutrition sales in the quarter reflected price increases globally and growth in the U.S. driven by the clearance of back orders and some distributor stock replenishment. The previously announced exit of IV solutions in China adversely impacted sales growth by 1% and foreign currency exchange rates adversely impacted sales growth by 2%, as compared to the prior year period.
Advanced Surgery net sales increased 2% in the first quarter of 2025, as compared to the prior year period. Sales performance was primarily driven by growth in hemostats and sealants and was primarily attributable to increased sales volume outside the U.S.. Foreign currency exchange rates adversely impacted sales growth by 2%, as compared to the prior year period.
34

Healthcare Systems & Technologies
Our Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories.
Three Months Ended March 31,Percent change
(in millions)20252024At actual
rates
At operational sales growth 1
Care and Connectivity Solutions$427 $402 6 %7 %
Front Line Care277 265 5 %5 %
Total Healthcare Systems & Technologies net sales$704 $667 6 %6 %
1     Percent change in net sales at operational sales growth is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial Measures” for additional information about our use of that measure.
Healthcare Systems & Technologies segment net sales increased 6% in the first quarter of 2025, as compared to the prior year period.
Care and Connectivity Solutions net sales increased 6% in the first quarter of 2025, as compared to the prior year period. Sales performance was primarily driven by increased order volume associated with increased capital spending in the U.S., as compared to the prior year period, as well as higher installations of our care communications products. These increases were partially offset by lower international sales. Foreign currency exchange rates adversely impacted sales growth by 1%, as compared to the prior year period.
Front Line Care net sales increased 5% in the first quarter of 2025, as compared to the prior year period. Sales performance was primarily driven by increased demand across a majority of our products including patient monitoring systems, cardiology products and physical assessment tools.
Pharmaceuticals
Our Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding.
Three Months Ended March 31,Percent change
(in millions)20252024At actual
rates
At operational sales growth 1
Injectables and Anesthesia
$335 $328 2 %4 %
Drug Compounding246 250 (2)%2 %
Total Pharmaceuticals net sales$581 $578 1 %3 %
1     Percent change in net sales at operational growth rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial Measures” for additional information about our use of that measure.
Pharmaceuticals segment net sales increased 1% in the first quarter of 2025, as compared to the prior year period.
Injectables and Anesthesia net sales increased 2% in the first quarter of 2025, as compared to the prior year period. Sales performance was primarily due to growth in our specialty injectable products, driven by strong sales volume in our core portfolio and recent product launches, partially offset by declines for inhaled anesthetics. Foreign currency exchange rates adversely impacted sales growth by 2%, as compared to the prior year period.
Drug Compounding net sales decreased 2% in the first quarter of 2025, as compared to the prior year period. Sales performance was driven by decreased demand for our international pharmacy compounding offerings due, in part, to the short-term outsourcing of compounding activities by select customers in the prior year which did not continue in the current year. Foreign currency exchange rates adversely impacted sales growth by 4%, as compared to the prior year period.
35

Other
During the three months ended March 31, 2025 and 2024, we earned $78 million and $16 million, respectively, of revenues that were not attributable to our reportable segments. In the current year period, Other sales primarily represented revenue recognized under the Kidney Care MSA and to a lesser extent, revenues earned by certain of our manufacturing facilities from contract manufacturing activities. In the prior year period, Other sales primarily represented revenues earned by certain of our manufacturing facilities from contract manufacturing activities. The increase in Other sales for the three months ended March 31, 2025 as compared to the prior year period reflects the impact of the Kidney Care MSA entered into upon the sale of our Kidney Care business in January 2025.
COSTS AND EXPENSES
Special Items
The following table provides a summary of our special items from continuing operations and the related impact by line item on our results for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
(in millions)20252024
Gross Margin
Intangible asset amortization expense$(104)$(106)
Business optimization items1
(13)(5)
Acquisition and integration items2
— (1)
European medical devices regulation3
(5)(7)
Product related items5
(6)— 
Hurricane Helene costs6
(98)— 
Legal matters7
(11)— 
Total Special Items$(237)$(119)
Impact on Gross Margin Ratio(9.0) pts(4.8) pts
Selling, General and Administrative (SG&A) Expenses
Intangible asset amortization expense$51 $52 
Business optimization items1
30 17 
Acquisition and integration items2
1 4 
Separation-related costs4
13 $— 
Total Special Items$95 $73 
Impact on SG&A Ratio3.6 pts3.0 pts
Research and Development (R&D) Expenses
Business optimization items1
$2 $— 
Total Special Items$2 $— 
Impact on R&D Ratio(0.0) pts0.0 pts
Other (Income) Expense, net
Investment impairments8
$9 $— 
Acquisition and integration items2
5 — 
Total Special Items$14 $— 
Income Tax Expense
Tax matters9
$(43)$32 
Tax effects of special items10
(84)(47)
Total Special Items$(127)$(15)
Impact on Effective Tax Rate2,215.9 pts63.9 pts
1Our results for first quarter of 2025 and 2024 included business optimization charges of $45 million and $22 million, respectively. These restructuring and business optimization costs in 2025 included costs primarily related to its initiatives to reduce our cost structure following the
36

sale of our former Kidney Care segment. These restructuring and business optimization costs in 2024 included costs primarily related to the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities and to a lesser extent, third-party costs incurred to support the transformation of certain general and administrative functions. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities.
2Our results for the first quarter of 2025 included $6 million of integration costs which primarily reflected the recognition of a noncash impairment of properly, plant and equipment related to integration activities. Our results for the first quarter of 2024 included $5 million of integration costs which primarily reflected third party consulting costs related to our integration of Hillrom.
3Our results for the first quarter of 2025 and 2024 included $5 million and $7 million, respectively, of incremental costs to comply with the European Union's medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs. We consider the adoption of these regulations to be a significant one-time regulatory change and believe that the costs of initial compliance for previously registered products over the implementation period are not indicative of our core operating results.
4Our results for the first quarter of 2025 included $13 million of separation-related costs primarily reflecting costs of external advisors supporting our activities related to the separation of our Kidney Care segment.
5Our results for the first quarter of 2025 included charges of $6 million related to a revised estimate of warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022.
6Our results in the first quarter of 2025 included pre-tax charges of $98 million related to damages caused by Hurricane Helene. This amount consisted of remediation, air freight and other costs. Refer to Note 1 in Item 1 of this Quarterly Report on Form 10-Q for further information.
7Our results in the first quarter of 2025 included charges of $11 million related to matters involving alleged injury from environmental exposure.
8Our results in first quarter of 2025 included $9 million of losses from a noncash impairment write-down in an equity method investment.
9Our results in the first quarter of 2025 included $43 million of income tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss. Our results in the first quarter of 2024 included $32 million of income tax expense driven by a change in its permanent reinvestment assertion resulting from internal reorganization transactions related to the sale of our Kidney Care segment.
10This item reflects the income tax impact of the special items identified in this table. The tax effect of each special item is based on the jurisdiction in which the item was incurred and the tax laws in effect for each such jurisdiction.
Gross Margin and Expense Ratios
Three Months Ended March 31,
2025% of net sales2024% of net sales$ change% change
Gross margin$861 32.8 %$961 38.6 %$(100)(10.4)%
SG&A$703 26.8 %$729 29.3 %$(26)(3.6)%
R&D$140 5.3 %$120 4.8 %$20 16.7 %
Gross Margin
Our gross margin ratio was 32.8% and 38.6% for the three months ended March 31, 2025 and 2024, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 9.0 and 4.8 percentage points on the gross margin ratio for the three months ended March 31, 2025 and 2024, respectively. Refer to the Special Items caption above for additional detail.
Excluding the impact of special items, the gross margin ratio decreased by 1.6% percentage points in the first quarter of 2025 compared to the prior year period. The lower gross margins were driven primarily by the impact of the Kidney Care MSA and increased shipping costs, partially offset by initiatives to reduce our manufacturing and supply chain costs.
SG&A
Our SG&A expenses ratio was 26.8% and 29.3% for the three months ended March 31, 2025 and 2024, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 3.6 and 3.0 percentage points on the SG&A expenses ratio for the three months ended March 31, 2025 and 2024, respectively.
Excluding the impact of special items, the SG&A expenses ratio decreased by 3.1 percentage points in the first quarter of 2025 compared to the prior year period. The decrease primarily reflects an updated estimate of indirect costs previously recorded in SG&A now capitalized into inventory after the separation of our Kidney Care business.
37

R&D
Our R&D expenses ratio was 5.3% and 4.8% for the three months ended March 31, 2025 and 2024, respectively. The special items identified earlier in this section had no impact on the R&D expense ratio in the first quarter of 2025 and 2024.
The R&D expenses ratio increased by 0.5 percentage points in the first quarter of 2025, compared to the prior year period, primarily reflecting increased project-related expenditures.
Business Optimization Items
In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts have included restructuring the organization into verticalized segments, optimizing our manufacturing footprint, R&D operations, and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. The related costs of these actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments.
For the three months ended March 31, 2025, $25 million of the restructuring charges, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.
We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $4 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our business optimization programs.
Other Operating Income, Net
Other operating income, net was $40 million and $3 million in the first quarter of 2025 and 2024, respectively. In the first quarter of 2025, this amount was primarily related to the income recognized under the Kidney Care TSA entered into upon the sale of the Kidney Care business in January 2025.
Interest Expense, Net
Interest expense, net was $64 million and $78 million in the first quarter of 2025 and 2024, respectively. The decrease in 2025 was driven by debt repayments in first quarter of 2025 and the fourth quarter of 2024.
Other (Income) Expense, net
Other (income) expense, net was income of $3 million and $9 million in the first quarter of 2025 and 2024, respectively. In the current and prior year periods, other income, net was primarily driven by pension and other postretirement benefits.
Income Taxes
For the three months ended March 31, 2025 and 2024, our effective income tax rate differs significantly from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards.
For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.
For the three months ended March 31, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by income tax expense resulting from internal reorganization transactions related to the sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and an increase in our liabilities for various uncertain tax positions.
38

The Organization of Economic Co-operation and Development (OECD) reached agreement among over 140 countries to implement a minimum 15% tax rate on certain multinational enterprises, commonly referred to as Pillar Two. We currently expect that the impact of the Pillar Two legislation on our income tax expense for the year ending December 31, 2025 is not expected to be material. We will continue to evaluate the impact of legislative changes as additional guidance becomes available.
Discontinued Operations
On January 31, 2025, we completed the sale of our Kidney Care business and its results have been presented as discontinued operations for the three months ended March 31, 2025 and 2024. Income from discontinued operations, net of tax was $62 million in the first quarter of 2025, compared to $33 million in the first quarter of 2024.The increase in the current year period was primarily driven by the $191 million pre-tax gain from the sale our Kidney Care business ($111 million net of tax). Refer to Note 2 within Item 1 for additional information.
SEGMENT OPERATING INCOME
The following is a summary of our operating income for our reportable segments.
Three Months Ended March 31,
(in millions)20252024
Medical Products & Therapies$244 $227 
% of Segment Net Sales19.3 %18.5 %
Healthcare Systems & Technologies93 67 
% of Segment Net Sales13.2 %10.0 %
Pharmaceuticals63 78 
% of Segment Net Sales10.8 %13.5 %
Total reportable segment operating income400 372 
Other9 4 
Unallocated corporate costs(17)(69)
Intangible asset amortization expense(155)(158)
Legal matters(11)— 
Business optimization items(45)(22)
Acquisition and integration items(1)(5)
Separation-related costs(13)— 
European Medical Devices Regulation(5)(7)
Product-related items(6)— 
Hurricane Helene Costs(98)— 
Total operating income58 115 
Interest expense, net64 78 
Other (income) expense, net(3)(9)
Loss from continuing operations before income taxes$(3)$46 
Medical Products & Therapies
Segment operating income was $244 million and $227 million in the first quarter of 2025 and 2024, respectively. The increase in segment operating income in the first quarter compared to the prior year period was primarily driven by increased pricing, partially offset by increased manufacturing and supply costs and R&D investments.
Healthcare Systems & Technologies
Segment operating income was $93 million and $67 million in the first quarter of 2025 and 2024, respectively. Segment operating income increased in the first quarter compared to the prior year period primarily due to increased gross profit from higher sales.
39

Pharmaceuticals
Segment operating income was $63 million and $78 million in the first quarter of 2025 and 2024, respectively. Segment operating income decreased in the first quarter compared to the prior year period due to lower gross margin percentages, primarily driven by increased product costs, increased royalties due to commercial sales growth, and higher corporate shared costs post separation of our Kidney Care business.
Other
Other operating income, which represents operating income not attributable to our reportable segments, was $9 million and $4 million in the first quarter of 2025 and 2024, respectively. In the current year period, other operating income primarily represents income from revenues earned under the Kidney Care MSA. In the prior year period, other operating income primarily represents income from revenues earned by certain of our manufacturing facilities from contract manufacturing activities. The increase in the current year compared to the prior year period reflects the revenues earned under the Kidney Care MSA following the closing of the sale of the Kidney Care business on January 31, 2025.
Unallocated Corporate Costs
Under our operating model, most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. Additionally, intangible asset amortization and other special items are not allocated to our segments. Certain of the costs that were previously maintained at corporate under our prior segment structure that are now allocated to our segments include manufacturing variances and centrally managed supply chain costs, certain R&D costs, product category support costs, stock compensation expense, and certain employee benefit plan costs.
LIQUIDITY AND CAPITAL RESOURCES
The following table is a summary of the statement of cash flows for the three-month periods ended March 31, 2025 and 2024.
Three Months Ended March 31,
(in millions)20252024
Cash flows from operations - continuing operations$(99)$67 
Cash flows from investing activities - continuing operations(124)$(100)
Cash flows from financing activities(3,226)$(140)
Cash Flows from Operations - Continuing Operations
For the three months ended March 31, 2025 cash used in operations from continuing operations were $99 million. For the three months ended March 31, 2024, operating cash flows from continuing operations were $67 million. Operating cash flows from continuing operations in the current year period were unfavorably impacted by accounts payable payments related to Hurricane Helene and the timing of accounts receivable collections.
Cash Flows from Investing Activities - Continuing Operations
For the three months ended March 31, 2025, cash used in investing activities from continuing operations primarily included capital expenditures of $122 million. For the three months ended March 31, 2024, cash used in investing activities from continuing operations primarily included capital expenditures of $110 million.
Cash Flows from Financing Activities
For the three months ended March 31, 2025, cash used in financing activities included debt repayments of $2.83 billion, a decrease in commercial paper borrowings of $300 million, and dividend payments of $87 million, partially offset by proceeds from stock issued under employee benefit plans of $10 million. For the three months ended March 31, 2024, cash used for financing activities included dividend payments of $147 million and debt repayments of $15 million, partially offset by proceeds from stock issued under employee benefit plans of $40 million.
40

As authorized by our Board of Directors, we repurchase our stock depending upon our cash flows, net debt levels and market conditions. In July 2012, our Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. We did not repurchase any shares under this authority in the first three months of 2025. We had $1.30 billion remaining available under this authorization as of March 31, 2025.
Credit Facilities, Commercial Paper Program and Access to Capital and Credit Ratings
Credit Facilities and Commercial Paper Program
As of March 31, 2025, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of term loans outstanding, a U.S. Dollar-denominated revolving credit facility and a Euro-denominated revolving credit facility.
As of March 31, 2025, we had $645 million outstanding under our U.S. Dollar-denominated term loan credit facility that matures in 2026. Borrowings under the term loan credit facility bear interest on the principal amount outstanding at either Term SOFR plus an applicable margin plus a credit spread adjustment or a “base rate” plus an applicable margin. The term loan credit facility contains various covenants, including a maximum net leverage ratio. In February 2025, we repaid $1.00 billion under this five-year term loan facility maturing in 2026.
As of March 31, 2025, our U.S. Dollar-denominated revolving credit facility and Euro-denominated revolving credit facility had a maximum capacity of $2.00 billion and €200 million, respectively. There were no borrowings outstanding under these credit facilities as of March 31, 2025 or December 31, 2024. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our credit facilities for an amount at least equal to our outstanding commercial paper borrowings.
On July 17, 2024, we entered into a credit agreement in which a group of banks have committed to provide us senior unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We will also incur a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banks’ funding commitments under the bridge facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we are required to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contains financial and other covenants, including a net leverage covenant, and provided for customary events of default. There was $1.83 billion outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the approximately $3.3 billion of net after-tax proceeds from the sale of our Kidney Care business to repay the $1.83 billion outstanding under this bridge facility as of December 31. 2024, at which time it was terminated.
As of March 31, 2025, we were in compliance with the financial covenants in these agreements. Based on our covenant calculations as of March 31, 2025, we had capacity to draw $2.04 billion under our credit facilities. The non-performance of any financial institution supporting either of the credit facilities would reduce the maximum capacity of these facilities by the institution’s respective commitment. Additionally, a deterioration in our financial performance may further reduce our ability to draw on our credit facilities.
We have a commercial paper program that currently enables us to borrow efficiently at short-term interest rates. Upon maturity of any commercial paper borrowings under this program, and to the extent old issuances are not repaid by cash on hand, we are exposed to the rollover risk of not being able to issue new commercial paper. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit facilities for an amount at least equal to our outstanding commercial paper borrowings. If we were not able to issue new commercial paper, we have the option of drawing on the revolving credit facilities; however, electing to do so would result in higher interest expense. We had no commercial paper borrowings outstanding as of March 31, 2025. As of December 31, 2024 we had $300 million of commercial paper outstanding, which was repaid in full in the first quarter of 2025.
41

Access to Capital and Credit Ratings
We intend to fund short-term and long-term obligations as they mature through cash on hand, including proceeds from the recently completed sale of our Kidney Care business, future cash flows from operations, or by issuing additional debt, which could include commercial paper. We had $2.29 billion of cash and cash equivalents as of March 31, 2025, with adequate cash available to meet operating requirements in each jurisdiction in which we operate. We invest our excess cash in money market and other funds and diversify the concentration of cash among different financial institutions. As of March 31, 2025, we had approximately $10.07 billion of long-term debt and finance lease obligations, including current maturities, and short-term debt. In the first quarter of 2025, we repaid $3.13 billion of short-and long-term indebtedness primarily with the net after-tax cash proceeds from the sale of our Kidney Care business, and we expect to use substantially all of the remaining net after-tax proceeds to continue to repay indebtedness through the second quarter of 2025. Subject to market conditions, we regularly evaluate opportunities with respect to our capital structure (including with respect to the potential refinancing of our outstanding indebtedness).
Our ability to generate cash flows from operations, issue debt, including commercial paper, or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings, or other significantly unfavorable changes in conditions. However, we believe we have sufficient financial flexibility to issue debt, enter into other financing arrangements, and attract long-term capital on acceptable terms to support our growth objectives and reduce our debt levels as we take actions consistent with our capital allocation priorities. There have been no changes to our investment grade credit ratings that we disclosed in our 2024 Annual Report.
CRITICAL ACCOUNTING POLICIES
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. A summary of our significant accounting policies is included in Note 1 to our consolidated financial statements in our 2024 Annual Report. Certain of our accounting policies are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in our 2024 Annual Report.
Impairment of Goodwill and Other Long-Lived Assets

Front Line Care Reporting Unit
In connection with our November 1, 2024 annual goodwill impairment tests, we recorded a goodwill impairment
related to our Front Line Care reporting unit within our Healthcare Systems & Technologies segment to reduce the carrying value of the reporting unit to its fair value. While no triggering events were identified during the three months ended March 31, 2025, we are continuing to closely monitor the performance of this reporting unit (including in light of recent global macroeconomic conditions and capital spending patterns), and if there is a significant adverse change in our outlook for this business in the future, a goodwill impairment could arise at that time. As of March 31, 2025, the carrying amount of goodwill for our Front Line Care reporting unit was $1.99 billion.
There have been no significant changes in the application of our critical accounting policies during the first three months of 2025.
RECENT ACCOUNTING PRONOUNCEMENTS
Recently issued accounting standards not yet adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of certain expenses on an interim and annual basis in the notes to the financial statements. This standard is effective for annual
42

consolidated financial statements for the year ending December 31, 2027 and for interim periods beginning in 2028. We are currently evaluating the impact of this new standard on our consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, which requires (1) disclosure of specific categories in the rate reconciliation and (2) additional information for reconciling items that meet a quantitative threshold. Additionally, the amendment requires disclosure of certain disaggregated information about income taxes paid, income from continuing operations before income tax expense (benefit) and income tax expense (benefit). The standard is effective for our annual consolidated financial statements for the year ending December 31, 2025. We are currently evaluating the impact of this standard on our consolidated financial statements.
LEGAL CONTINGENCIES
Refer to Note 6 within Item 1 for a discussion of our legal contingencies. Upon resolution of any of these uncertainties, we may incur charges in excess of presently established liabilities. While our liability in connection with certain claims cannot be estimated with any certainty, and although the resolution in any reporting period of one or more of these matters could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and we may in the future incur material judgments or enter into material settlements of claims.
CERTAIN REGULATORY MATTERS
In July 2017, immediately prior to the closing of our acquisition of Claris Injectables Limited (Claris), the U.S. Food and Drug Administration (FDA) commenced an inspection of the Claris’ facilities in Ahmedabad, India. FDA completed the inspection and subsequently issued a Warning Letter based on observations identified in the 2017 inspection (2017 Warning Letter).¹ FDA re-inspected the facilities and issued a Form FDA 483 on May 17, 2022. On September 1, 2022, FDA notified us that the inspection had been classified as voluntary action indicated. From January 19, 2023 to January 27, 2023, FDA performed an inspection at the Ahmedabad site, concluding with the issuance of a Form FDA 483. On April 26, 2023, FDA notified us that the inspection had been classified as official action indicated. We received a Warning Letter on July 25, 2023 based on observations identified in the January 2023 inspection (2023 Warning Letter)2. Since the issuance of the 2017 Warning Letter, we have implemented corrective and preventive actions to address FDA's related observations, as well as other enhancements at the site. We have fully responded to the 2023 Warning Letter and have implemented additional corrective and preventive actions. In addition, since the issuance of the 2017 Warning Letter, we have secured other sites in our manufacturing network and have launched and distribute select products from those sites in the U.S.
1 Available online at https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm613538.htm
2 Available online at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-healthcare-corporation-654136-07252023
FORWARD-LOOKING INFORMATION
Certain statements contained in this quarterly report on Form 10-Q may constitute “forward-looking statements,” as defined in the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. These statements by their nature address matters that are uncertain to different degrees. Use of the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,” “impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of those words or other similar expressions may identify forward-looking statements, although not all forward-looking statements contain such words.

These forward-looking statements are based on certain assumptions and analyses made in light of our experience and perception of historical trends, current conditions, and expected future developments as well as other factors that we believe are appropriate in the circumstances. While these statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any events or
43

financial results. Whether actual future results and developments will conform to expectations and predictions is subject to a number of risks and uncertainties, including the following factors, many of which are beyond our control:
•our ability to achieve the intended benefits of our strategic actions, including the sale of our Kidney Care business, business strategy and development activities and cost saving initiatives;
•our ability to successfully integrate acquisitions, including the acquisition of Hillrom, and the related impact on our organization structure, senior leadership, culture, functional alignment, outsourcing and other areas, our management of resulting related personnel capacity constraints and potential institutional knowledge loss, and our ability to achieve anticipated performance or financial targets and maintain our reputation following integration;
•the impact of global economic conditions (including, among other things, changes in tariffs, taxation, trade policies and treaties, sanctions, embargos, export control restrictions, the potential for a recession, supply chain disruptions, inflation levels and interest rates, financial market volatility, banking crises, the war in Ukraine, the conflict in the Middle East and other geopolitical events and the potential for escalation of these and other conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars, global public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on our operations and our employees, customers, suppliers, and foreign governments in countries in which we operate) and our ability to identify actions to mitigate the impact of those conditions (or to realize the anticipated benefits of any such mitigating actions;
•the continuity, availability, and pricing of acceptable raw materials and component parts, our ability to pass some or all of these costs to our customers through price increases or otherwise, and the related continuity of our manufacturing, sterilization, supply and distribution and those of our suppliers;
•failure to accurately forecast or achieve our short-and long-term financial performance and goals, market and category growth rates, growth rates for our segments and related impacts on our liquidity;
•our ability to execute on our capital allocation plans, including our debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds;
•downgrades to our credit ratings or ratings outlooks, or withdrawals by rating agencies from rating us and our indebtedness, and the related impact on our funding costs and liquidity;
•fluctuations in foreign exchange and interest rates;
•the impact of any accounting estimates and assumptions, including with respect to goodwill, intangible asset, or other long-lived asset impairments on our operating results;
•our ability to finance and develop new products or services, or enhancements thereto, on commercially acceptable terms or at all;
•product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle;
•demand and market acceptance risks for, and competitive pressures (including pricing) related to, new and existing products and services, challenges and reputational risks associated with converting customers to new products and challenges with accurately predicting changing customer preferences and future expenditures and inventory levels and with being able to monetize new and existing products and services (and to sustain any related price increases), the impact of those products and services on quality and patient safety concerns, and the need for ongoing training and support for our products and services;
•future actions of, or failures to act or delays in acting by FDA, the European Medicines Agency, or any other regulatory body or government authority (including the SEC, DOJ, or the Attorney General of any state), or any product quality or patient safety issues that could delay, limit or suspend product development, manufacturing, or sale or otherwise lead to product recalls, withdrawals, labeling changes, launch delays, warning letters, import bans, denial of import certifications, sanctions, seizures, injunctions, monetary sanctions, criminal or civil liabilities or litigation;
•actions by tax authorities in connection with ongoing tax audits (including with respect to transfer pricing matters) and the outcome of pending or future litigation;
•failures with respect to our quality, compliance or ethics programs;
44

•our ability to attract, develop, retain and engage employees, including senior management, and the occurrence of labor disruptions (including as a result of labor disagreements under bargaining agreements or national trade union agreements or disputes with works councils);
•inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster or severe weather event (such as Hurricane Helene), war, terrorism, global public health crises and epidemics/pandemics, regulatory actions, or otherwise;
•future actions of third parties, including third-party payors and our customers and distributors (including GPOs and IDNs);
•breaches and breakdowns affecting our information technology systems or protected information, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in our information technology systems or products;
•ability to effectively develop, integrate or deploy artificial intelligence, machine learning and other emerging technologies into our products, services and operations in a manner that is compliant with existing and emerging regulations;
•the impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-related events;
•changes to legislation and regulation and other governmental pressures in the United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation (including taxation of income, whether with respect to current or future tax reform) and rebate policies;
•ability to meet evolving and varied corporate responsibility expectations of our stakeholders, including compliance with new and emerging sustainability regulations;
•the ability to protect or enforce our patents or other proprietary rights (including trademarks, copyrights, trade secrets, and know-how) or where the patents of third parties prevent or restrict our manufacture, sale, or use of affected products or technology; and
•other factors discussed elsewhere in this report and other filings with the SEC, including those factors described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, all of which are available on our website.
Actual results may differ materially from those projected in the forward-looking statements, which are more fully discussed in Item 1A. Risk Factors and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024. These forward-looking statements are not exclusive and are in addition to other factors discussed elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024. Further, other unknown or unpredictable factors could also have material adverse effects on future results. Any forward-looking statement in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Except as required by law, we assume no obligation, and expressly disclaim any obligation, to update or revise any forward-looking statements, whether as a result of new information or future events.
45

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Currency Risk
We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, British Pound, Canadian Dollar, Australian Dollar, Indian Rupee, Turkish Lira, Japanese Yen, Mexican Peso, Korean Wan and Swiss Franc. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders’ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.
We primarily use forward contracts to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities denominated in foreign currencies. The maximum term over which we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of March 31, 2025 is eight months. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.
As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.
A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of March 31, 2025, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, the net pre-tax liability balance of $1 million with respect to those contracts would change by $73 million.
The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of March 31, 2025 by replacing the actual exchange rates as of March 31, 2025 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.
In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, on April 1, 2022, we began reporting the results of our subsidiary in that jurisdiction using highly inflationary accounting, which requires that the functional currency of the entity be changed to the reporting currency of its parent. As of March 31, 2025, our subsidiary in Turkey had net monetary assets of $29 million.
Interest Rate and Other Risks
Refer to the caption “Interest Rate and Other Risks” in the “Financial Instrument Market Risk” section of the 2024 Annual Report. There were no significant changes during the quarter ended March 31, 2025.
46

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Interim Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of March 31, 2025. Based on that evaluation, our Interim Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2025.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
47

PART II. OTHER INFORMATION
Item 1.    Legal Proceedings
The information in Part I, Item 1, Note 6 is incorporated herein by reference.
Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors previously disclosed in our 2024 Annual Report.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
In July 2012, the Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. During the first quarter of 2025, we did not repurchase any shares under this authority. We had $1.30 billion remaining under this program as of March 31, 2025. This program does not have an expiration date.
Item 5. Other Information
Certain of our officers and directors have made elections to participate in, and are participating in, our employee stock purchase plan or have made, and may from time to time make, elections to have shares withheld to cover withholding taxes or pay the exercise price of options, which may constitute non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K). Further, our officers are eligible to participate in Baxter’s U.S. tax-qualified Section 401(k) plan (401(k) Plan). The 401(k) Plan permits both employer and employee contributions to be invested through a self-directed “brokerage window”, which is subject to Rule 10b5-1(c)(1).


48

Item 6.    Exhibits
Exhibit Index:
Exhibit
Number		Description
C10.1*
C10.2*
C10.3*
31.1*
31.2*
32.1**
32.2**
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained within the Inline XBRL Instance Document in Exhibit 101)
_____________________________________
*    Filed herewith.
**    Furnished herewith. This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
C    Management contract or compensatory plan or arrangement

49

Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BAXTER INTERNATIONAL INC.
(Registrant)
Date: May 6, 2025
By:/s/ Joel T. Grade
Joel T. Grade
Executive Vice President and Chief Financial Officer, (duly authorized officer and principal financial officer)

50
 EX-10.1 2 bax-20250331xex101.htm EX-10.1 Document

Exhibit 10.1
BAXTER INTERNATIONAL INC.
AMENDED AND RESTATED 2021 INCENTIVE PLAN
PERFORMANCE SHARE UNIT AWARD GRANT NOTICE
Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of performance share units set forth below (the “PSUs”). The PSUs are subject to the terms and conditions set forth in this Performance Share Unit Grant Notice (the “Grant Notice”), the Performance Share Unit Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement. The PSUs granted hereunder shall be designated as a Performance Compensation Award under Section 11 of the Plan.

Participant:
[•]
Participant ID:
[•]
Date of Grant:
[•]
Target Number of PSUs:
[•]
Performance Period:
[•]
Vesting Schedule:
Except as otherwise provided in the Agreement, the PSUs are subject to the three-year performance period shown above and shall vest in accordance with the terms set forth in Addendum 1 to Exhibit A following Committee certification.
Applicable Recoupment Policy:
The Baxter International Inc. Mandatory Clawback Policy shall apply to Participants who are Executive Officers in the case of a restatement, while the Baxter International Inc. Compensation Recoupment Policy shall apply to all Participants, inclusive of Executive Officers, in any circumstance in which the Compensation Recoupment Policy is applicable. Both polices are attached hereto as Exhibit B.

By accepting this Award electronically through the stock plan administrator’s online grant acceptance procedure, the Participant agrees to be bound by the terms and conditions of the Plan, the Agreement, and the Grant Notice. If the Participant does not accept this Award through the online acceptance process, the Participant’s Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award. The Participant has reviewed the Agreement, the Plan, and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement, and the Plan. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan, the Grant Notice, or the Agreement.
If the Participant declines the Award, the Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award.


EXHIBIT A
PERFORMANCE SHARE UNIT AWARD AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to the Participant the number of PSUs set forth in the Grant Notice.
ARTICLE I.

GENERAL

Section 1.1    Defined Terms. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice. For purposes of this Agreement:
(a)“Employer” means the member of the Company Group that employs the Participant.
(b)“Performance Period” means the three-year period beginning with the first day of the calendar year of the Grant Date and ending on the last day of the third calendar year thereafter.
(c)“Qualifying Retirement” shall mean a Termination of a Participant who is at least 65 years of age, or at least 55 years of age with at least 10 years of active continuous service with a member of the Company Group.
Section 1.2    Incorporation of Terms of Plan. The PSUs and the shares of Common Stock issued to the Participant hereunder (“Shares”) are subject to the terms and conditions set forth in this Agreement, the Grant Notice, and the Plan, which are incorporated herein by reference.

ARTICLE II.
AWARD OF PERFORMANCE SHARE UNITS

Section 2.1 Award of PSUs. In consideration of the Participant’s continued employment with or service to a member of the Company Group . execution of the Agreement Regarding Competition and Protection of Proprietary Interests (attached as Exhibit C) or other restrictive covenants, and for other good and valuable consideration, effective as of the Date of Grant, the Company has granted to the Participant the target number of PSUs set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan, and this Agreement, subject to adjustment as provided in Section 12 of the Plan. Except as otherwise provided herein, each PSU represents the right to receive Shares in the amounts, at the times and subject to the conditions set forth herein and in Addendum 1 to Exhibit A. However, unless and until the PSUs have vested and been earned in accordance with Addendum 1 to Exhibit A, the Participant will have no right to the payment of any Shares subject thereto. Prior to the actual delivery of any Shares, the PSUs will represent an unsecured obligation of the Company.
Section 2.2 Vesting and Earning of PSUs. Subject to the Participant’s continued employment with or service to a member of the Company Group through the end of the Performance Period and subject to the terms of this Agreement, the PSUs shall vest on the date specified in the Grant Notice and be earned in accordance with the terms set forth in Addendum 1 to Exhibit A following Committee certification.
2

Section 2.3 Impact of Termination on PSUs. In the event the Participant incurs a Termination prior to the end of the Performance Period, then any unvested PSUs shall be canceled and forfeited, except as may be otherwise provided herein, in the Grant Notice, by the Committee or as set forth in a written agreement between the Participant and the Company or Employer. For the avoidance of doubt, a transfer of employment within the Company Group will not constitute a Termination.
(a)Qualifying Retirement. In the event the Participant incurs a Termination as a result of a Qualifying Retirement for any reason other than for Cause, or by reason of the Participant’s death or Disability, then (i) if the date of such Termination is after the calendar year of the Date of Grant, the PSUs will remain eligible for payout at the end of the Performance Period on the terms (and in accordance with the timing) provided in Addendum 1 to Exhibit A and Section 2.5(a), or (ii) if the date of such Termination is in the calendar year of the Date of Grant a pro-rata portion of the unearned PSUs shall remain eligible for payout at the end of the Performance Period on the terms provided in Addendum 1 to Exhibit A and Section 2.5(a). For purposes of the foregoing, the pro-rata portion of the unearned PSUs shall be determined by multiplying (x) the Target Number of PSUs specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve (12).
(b)Death or Disability. In the event the Participant incurs a Termination as a result of the Participant’s death or Disability, any unvested PSUs shall vest immediately as follows: (i) if the date of such Termination is after the calendar year of the Date of Grant, the PSUs shall be paid out at 100% of the target PSUs awarded, or (ii) if the date of such Termination is in the calendar year of the Date of Grant, a pro-rata portion of the unearned PSUs shall immediately vest. For purposes of the foregoing, the pro-rata portion of the unearned PSUs that shall immediately vest shall be determined by multiplying (x) the Target Number of PSUs specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve
(12). Settlement of the PSUs subject to vesting hereunder will occur within sixty (60) days following the Participant’s Termination due to death or Disability.
(c)All Other Terminations. In the event the Participant incurs a Termination other than as set forth in Section 2.3(a) or Section 2.3(b), except as may be otherwise provided herein or by the Committee or as set forth in a written agreement between the Participant and the Company or Employer, the Participant shall immediately forfeit any and all PSUs granted under this Agreement that have not vested or do not vest on or prior to the date on which such Termination occurs, and the Participant’s rights in any such PSUs that are not so vested shall lapse and expire.
(d)Outside the United States. For purposes of this Agreement, if the Participant is employed or providing services outside the United States, the Committee (or its delegate) may determine that the date the Participant incurs a Termination shall mean the date the Participant is no longer actively providing services to a member of the Company Group (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction in which the Participant is employed or providing services or the terms of the Participant’s employment agreement, if any) and that the Participant’s right to vest in and earn the PSUs under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction in which the Participant is employed or providing service or the terms of the Participant’s employment or service agreement, if any); the Committee (or its delegate) shall have the exclusive discretion to determine when the Participant is no longer actively providing services
3

for purposes of the PSUs (including whether the Participant may still be considered to be providing services while on a leave of absence).
Section 2.4    Impact of a Change in Control on PSUs. In the event of a Change in Control, the treatment of PSUs shall be governed by Section 12(b) of the Plan.
Section 2.5    Settlement of PSUs.
(a)Except as otherwise provided herein, the Participant’s PSUs shall be settled in Shares (either in book-entry form or otherwise). Following the end of the Performance Period, the Committee shall certify the PSU payout, which certification shall be final and binding. Shares earned will be delivered or otherwise made available to the Participant as soon as practical after the Committee makes its determination but not later than the March 15 after the end of the Performance Period. Notwithstanding the foregoing, the Company may delay settlement of PSUs if it reasonably determines that such settlement will violate U.S. federal securities laws or any other applicable law, including non-U.S. laws, provided that such settlement shall be made at the earliest date at which the Company reasonably determines that the making of settlement will not cause such violation, as required by U.S. Treasury Regulation Section 1.409A-2(b)(7)(ii), and provided further that no settlement shall be delayed under this Section 2.5(a) if such delay will result in a violation of Code Section 409A.
(b)All distributions shall be made by the Company in the form of whole Shares. Any fractional share may be distributed in cash or, at the discretion of the Committee, withheld to account for Tax-Related Items (as defined in Section 2.7). The value of a fractional share shall be determined based on the Fair Market Value as of the date the PSUs are certified by the Committee, and if that date is not a trading day, the Fair Market Value on next trading day will be used.
(c)Notwithstanding the foregoing, if the Participant is a resident or employed outside of the United States, the Company, in its sole discretion, may settle the PSUs in the form of a cash payment to the extent settlement in Shares: (i) is prohibited under applicable law; (ii) would require the Participant or a member of the Company Group to obtain the approval of any governmental and/or regulatory body in the Participant’s country; (iii) would result in adverse tax consequences for the Participant or a member of the Company Group; or (iv) is administratively burdensome. Alternatively, the Company, in its sole discretion, may settle the PSUs in the form of Shares but require the Participant to sell such Shares immediately or within a specified period following the Participant’s Termination (in which case, this Agreement shall give the Company authorization to issue sales instructions on the Participant’s behalf).

(d)For the avoidance of doubt, this Award represents a right to receive Shares, and not a right to receive cash, and the Company shall only be authorized to deliver cash in settlement of all or any portion of the Award under the specific circumstances contemplated above in Section 2.5(b) and Section 2.5(c) or in connection with a transaction or event contemplated by Section 12 of the Plan.
Section 2.6 Conditions to Issuance of Certificates. The Company shall not be required to issue or deliver any certificate or certificates for any Shares or to cause any Shares to be held in book-entry form prior to the fulfillment of all of the following conditions: (a) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (b) the completion of any registration or other qualification of the Shares under any U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or other governmental regulatory body, which the Committee shall, in its absolute discretion, deem necessary or advisable, (c) the obtaining of any approval or other clearance from any U.S. state or federal governmental agency or non-U.S. regulatory agency that the Committee shall, in its absolute discretion, determine to be necessary or advisable, and (d) the receipt of
4

full payment of any applicable Tax-Related Items in accordance with Section 2.7 by the member of the Company Group with respect to which the applicable withholding obligation arises.
Section 2.7    Tax Withholding. Notwithstanding any other provision of this Agreement:
(a)The provisions of Section 14(e) of the Plan are incorporated herein by reference and made a part hereof. The Participant acknowledges that the Participant may be required to pay to the Company or, if different, the Employer, and that the Company, the Employer, or any Subsidiary shall have the right and are hereby authorized to withhold from any compensation or other amount owing to the Participant, applicable income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax- related items (including taxes that are imposed on the Company or the Employer as a result of the Participant’s participation in the Plan but are deemed by the Company or the Employer to be an appropriate charge to the Participant) (collectively, “Tax-Related Items”), with respect to any issuance, transfer, or other taxable event under this Agreement or under the Plan and to take such action as may be necessary in the opinion of the Company to satisfy all obligations for the payment of such Tax-Related Items. The Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSUs, including, but not limited to the grant, vesting and/or settlement of the PSUs and the subsequent sale of Shares acquired upon settlement of the vested PSUs; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve a particular tax result. Further, if the Participant is subject to Tax-Related Items in more than one jurisdiction, the Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(b)The Company shall withhold, or cause to be withheld, Shares otherwise vesting or issuable under the PSUs in satisfaction of any applicable tax withholding obligations, unless the Committee permits the Participant to elect to satisfy such obligations by (i) cash, wire transfer of immediately available funds or check; (ii) delivering Shares (which are not subject to any pledge or other security interest) that have been held by the Participant for not less than six (6) months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying GAAP) having a Fair Market Value equal to such withholding liability; or (iii) if approved by the Committee, by delivery of a written or electronic notice that the Participant has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon settlement of the PSUs, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate applicable tax withholding obligations; provided that payment of such proceeds is then made to the Company upon settlement of such sale in satisfaction of the applicable tax withholding obligations. Notwithstanding the foregoing, the Participant authorizes the Company to satisfy the applicable tax withholding obligations from proceeds of the sale of Shares issuable under the PSUs through a mandatory sale arranged by the Company (on the Participant’s behalf pursuant to this authorization) and/or through withholding from any cash, other securities, or other property issuable or deliverable under any Award or from any compensation or other amounts owing to the Participant. If the obligation for Tax-Related Items is satisfied by withholding in Shares, the number of Shares that may be so withheld or surrendered shall be limited to the number of Shares that have a Fair Market Value on the date of withholding no greater than the aggregate amount of such obligations based on the maximum individual statutory withholding rates or other rates that will not have a negative accounting impact in the Participant’s applicable jurisdictions for U.S. federal, state, local and non-U.S. income tax and payroll tax purposes that are applicable to such taxable income, and the Participant is deemed to have been issued the full number of Shares subject to the vested and earned PSUs, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items. The Participant acknowledges that,
5

regardless of any action taken by the Company, the Employer, or any Subsidiary the ultimate liability for all Tax-Related Items, is and remains the Participant’s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.
(c)Notwithstanding any other provision of this Agreement, the Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the PSUs to, or to cause any such Shares to be held in book-entry form by, the Participant or the Participant’s legal representative unless and until the Participant or the Participant’s legal representative shall have paid the Tax-Related Items resulting from the grant, vesting or settlement of the PSUs or any other taxable event related to the PSUs.
Section 2.8 Rights as Stockholder. Neither the Participant nor any Person claiming under or through the Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars and delivered to the Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such issuance, recordation and delivery, the Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. From and after the Date of Grant and until the earlier of (a) the time when the Shares are delivered in settlement of the PSUs and (b) the time when the Participant’s right to receive Shares in settlement of the PSUs is forfeited, on the date that the Company pays a dividend (if any) to holders of Shares generally, the Participant shall be permitted to receive additional PSUs with respect to the PSUs based on the dividends and distributions paid on Shares to the same extent as if each PSU were a Share (without adjustment prior to vesting for payment levels set forth in Addendum 1 to Exhibit A) (the “Dividend Equivalent Unit”). These additional PSUs will be accrued through the Performance Period at target performance, then adjusted (upwards or downwards, as applicable) to reflect final actual Company performance certified in accordance with Addendum 1 to Exhibit A. Such Dividend Equivalent Units (if any) shall be subject to the same terms and conditions, including payment timing, Performance Goals, vesting, and the obligation to satisfy any tax withholding obligations, in the same manner and at the same time as the PSUs to which the Dividend Equivalent Units relate or as otherwise determined by the Company. For the avoidance of doubt, Dividend Equivalent Units shall not be eligible for the crediting of dividend equivalents or otherwise.
ARTICLE III.

NATURE OF GRANT
Section 3.1 In accepting the grant of the PSUs, the Participant acknowledges, understands, and agrees that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company at any time, to the extent permitted by the Plan;
(b)the grant of the PSUs is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of an award, or benefits in lieu of an award, even if PSUs have been granted in the past;
(c)all decisions with respect to future grants of PSUs or other grants, if any, will be at the sole discretion of the Company;
6

(d)the Participant is voluntarily participating in the Plan;
(e)the PSUs and the Shares subject to the PSUs, and the income from and value of same, are not intended to replace any pension rights or compensation;
(f)the Plan is established, operated, and administered exclusively by the Company, and the PSUs are granted solely by the Company. Only the Company is a party to this Agreement; accordingly, any rights the Participant may have under this Agreement may be raised only against the Company and may not be raised against any Subsidiary of the Company. No Subsidiary of the Company has any obligation to make any payment of any kind under this Agreement;
(g)the PSUs, the Shares subject to the PSUs, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;
(h)unless otherwise agreed with the Company in writing, the PSUs and the Shares subject to the PSUs, and the income from and value of same, are not granted as consideration for, or in connection with, the service the Participant may provide as a director of a Subsidiary;
(i)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the PSUs resulting from the Participant’s Termination (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and/or (ii) the forfeiture or cancellation of the RSUs and/or recoupment of any Shares, cash or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies as provided for in Section 5.12; and
(k)neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the United States Dollar that may affect the value of the PSUs or of any amounts due to the Participant pursuant to the settlement of PSUs or the subsequent sale of any Shares acquired upon settlement.
ARTICLE IV.

DATA PRIVACY
The Company is processing personal data of the Participant for purposes related to Plan administration services, based on the appropriate legal basis, depending on the Participant’s country, as stipulated in the HR Privacy Notice shared with the Participant and as in force. The Company further shares such data with its affiliates or processors, as appropriate, and only on a “need to know basis”. That may also include human resources personnel, certain executives, managers, and employees at other worldwide affiliates of the Company Group, who may have access to certain of the Participant’s personal data. Some of those recipients may be located or may have relevant operations outside of the Participant’s country, such as in the United States, where the data protection laws may not provide a level of protection equivalent to the laws of the Participant’s country. The Company implements the appropriate legal, technical, and organizational measures and mechanisms in this regard.
7

For further information about the HR Privacy Notice and the processing of the Participant’s data in relation to the Plan, the Participant may contact local HR or send an email to: privacy@baxter.com.


ARTICLE V.

OTHER PROVISIONS

Section 5.1 Administration. The Committee (and its delegates) shall have the power to interpret the Plan, the Grant Notice, and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice, and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee will be final and binding upon the Participant, the Company, and all other interested Persons. To the extent allowable pursuant to applicable law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice, or this Agreement.
Section 5.2 PSUs Not Transferable. The PSUs may not be sold, pledged, assigned, or transferred in any manner other than by will or the laws of descent and distribution, unless and until the Shares underlying the PSUs have been issued, and all restrictions applicable to such Shares have lapsed. No PSUs or any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Participant or the Participant’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. Notwithstanding the foregoing, with the consent of the Committee, the PSUs may be transferred as described in Section 14(b)(ii) of the Plan, pursuant to any such conditions and procedures the Committee may require.
Section 5.3 Adjustments. The Participant acknowledges that the PSUs and the Shares subject to the PSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan, including Section 12 of the Plan.
Section 5.4 Cooperation; Repatriation and Compliance Obligations. The Participant agrees to cooperate with the Company and the Employer in taking any action reasonably necessary or advisable to consummate the transactions contemplated by this Agreement. Further, the Participant agrees to repatriate all payments attributable to the PSUs in accordance with local foreign exchange rules and regulations in the Participant’s country of residence (and country of employment, if different). In addition, the Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with applicable law in the Participant’s country of residence (and country of employment, if different). Finally, the Participant agrees to take any and all actions that may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules, and regulations in the Participant’s country of residence (and country of employment, if different).
8

Section 5.5 Non-U.S. Addendum. Notwithstanding any provisions in this Agreement to the contrary, the PSUs shall be subject to any terms and conditions set forth in the Non-U.S. Addendum to this Agreement for the Participant’s country of residence (and country of employment or service, if different) (“Addendum 2”). Moreover, if the Participant relocates to or otherwise becomes subject to the local laws, rules and/or regulations in another country, any special terms and conditions for such country will apply to the Participant, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer). The Non-U.S. Addendum (Addendum 2) constitutes part of this Agreement.
Section 5.6 Notices. For the purpose of the Plan and this Agreement, notices and all other communications shall be in writing and shall be deemed to have been duly given when delivered or mailed by overnight courier or United States registered mail, return receipt requested, postage prepaid (or similar foreign postal service), addressed to the Plan to the General Counsel, Baxter International Inc., One Baxter Parkway, Deerfield, Illinois 60015, USA and to the Participant to the address set forth in the Company’s payroll records or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.
Section 5.7 Imposition of Other Requirements. The Company reserves the right to impose other requirements on the Participant’s participation in the Plan, on the PSUs and on any Shares acquired under the Plan, to the extent the Company determines, in its sole discretion, it is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of the PSUs and the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
Section 5.8 Language. The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable the Participant to understand the provisions of this Agreement and the Plan. If the Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control, unless otherwise required by applicable law.
Section 5.9 Electronic Delivery and Acceptance. The Company, in its sole discretion, may decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
Section 5.10 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
Section 5.11 Governing Law; Venue. Except to the extent preempted by US federal law, the laws of the State of Illinois, USA shall govern the interpretation, validity, administration, enforcement, and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts in Chicago, Illinois.
9

Section 5.12 Repayment of Proceeds; Clawback and Offset Policy. The Shares underlying the PSUs and all proceeds related to such Shares are subject to the Company’s Compensation Recoupment Policy and/or Mandatory Clawback Policy, as applicable, and as specified in the Grant Notice, which are attached to the Grant Notice as Exhibit B.
Additionally, where applicable, if (i) the Participant’s employment with the Company Group terminates for any reason and (ii) such Participant violates (either during and/or after employment with the Company Group) the terms of the Participant’s Competition and Protection of Proprietary Interests Agreement as described in and required by Exhibit C, , or any other restrictive covenant between Participant and Company Group where applicable, then any Awards that have not vested or are not exercisable as of the Termination date (including any Awards that would later be settled as a result of a Qualifying Retirement) shall be cancelled and shall not vest, be settled or be exercisable. Furthermore, any Awards that have vested or became exercisable within the 12 months preceding the Termination date shall be forfeited and shall be returned to the Company, and any Awards that vested after the Termination date as a result of a Qualifying Retirement shall be forfeited. If the Participant has exercised any such Awards or sold any Shares underlying Awards, then the Participant shall make a cash payment to the Company in an amount equal to the amount of the net gain recognized from the exercise of such Awards or sale of such shares within 30 business days of written notice by the Company to the Participant.
Section 5.13 Conformity to Securities Laws. The Participant acknowledges that the Plan, the Grant Notice, and this Agreement, are intended to conform to the extent necessary with all applicable laws, including, without limitation, the provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the Securities and Exchange Commission, and other applicable securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the PSUs are granted, only in such a manner as to conform to applicable laws. To the extent permitted by applicable laws, the Plan, the Grant Notice, and this Agreement, shall be deemed amended to the extent necessary to conform to applicable laws.
Section 5.14 Amendment, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the PSUs in any material way without the prior written consent of the Participant.
Section 5.15 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in Section 5.2 of this Agreement and the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.
Section 5.16 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if the Participant is subject to Section 16 of the Exchange Act, the Plan, the PSUs, the Grant Notice, and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable laws, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.
Section 5.17 Not a Contract of Employment. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee of any member of the Company Group or shall interfere with or restrict in any way the rights of any member of the Company Group, which rights
10

are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or without cause, except to the extent (i) expressly provided otherwise in a written agreement between a Member of the Company Group and the Participant or (ii) where such provisions are not consistent with applicable foreign or local laws, in which case such applicable foreign or local laws shall control.
Section 5.18 Entire Agreement. The Plan, the Grant Notice, and this Agreement (including the Addenda attached hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof. Except as specifically provided in the Grant Notice or this Agreement, in the event of any inconsistency between the Plan, the Grant Notice or this Agreement, the Plan will control.
Section 5.19 Code Section 409A. The intent of the parties is that the payments and benefits under this Agreement comply with or be exempt from Code Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or otherwise exempt. The Company may unilaterally amend the terms of this Agreement (or the Plan) to avoid the application of, or to comply with, Code Section 409A, in a particular circumstance or as necessary or desirable to satisfy any of the requirements under Code Section 409A or to mitigate any additional tax, interest and/or penalties that may apply under Code Section 409A if exemption or compliance is not practicable, but the Company or the Participant shall not be under any obligation to make any such amendment. Nothing in this Agreement (or the Plan) shall provide a basis for any person to take action against the Company or any Subsidiary based on matters covered by Code Section 409A, including the tax treatment of any amount paid under the Agreement, and neither the Company nor any of its Subsidiaries shall under any circumstances have any liability to the Participant or his estate or any other party for any taxes, penalties or interest due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Code Section 409A.
Without limiting the generality of the foregoing and anything in the Agreement to the contrary notwithstanding, if PSUs payable on or by reference to the timing of the Participant’s Termination constitute non-qualified deferred compensation subject to Section 409A, as determined in the Company’s sole discretion, such PSUs shall not be paid unless and until the Participant experiences a “separation from service” (within the meaning of Code Section 409A), and if the Participant is a “specified employee” (within the meaning of Code Section 409A) as of the date of the separation from service (as determined in accordance with the methodology established by the Company as in effect on the date of Termination), shall instead be paid to the Participant on the first business day that immediately follows the earlier of (i) the date that is six (6) months following the date of the Participant’s separation from service or (ii) the date of the Participant’s death, to the extent such delayed payment is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2).
Section 5.20 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.
Section 5.21 Limitation on the Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. The Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs.
11

Section 5.22 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to applicable law, each of which shall be deemed an original and all of which together shall constitute one instrument.
Section 5.23 Private Offering. If the Participant is a resident outside the United States, the grant of the PSUs is not intended to be a public offering of securities in the Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus, or other filing with the local securities authorities with respect to the grant of the PSUs unless otherwise required under local law. No employee of the Company is permitted to advise the Participant on whether the Participant should acquire Shares under the Plan or provide the Participant with any legal, tax or financial advice with respect to the grant of the PSUs. Investment in Shares involves a degree of risk. Before deciding to acquire Shares pursuant to the PSUs, the Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, the Participant should carefully review all of the materials related to the PSUs and the Plan, and the Participant should consult with the Participant’s personal legal, tax and financial advisors for professional advice in relation to the Participant’s personal circumstances.
Section 5.24 Exchange Control, Foreign Asset/Account and/or Tax Reporting. The Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements that may affect the Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the receipt of any dividends paid on Shares and the proceeds from the sale of Shares) in a brokerage or bank account outside the Participant’s country. The Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in the Participant’s country. The Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to the Participant’s country within a certain time after receipt. The Participant acknowledges that it is the Participant’s responsibility to comply with such regulations and that the Participant should speak to the Participant’s personal advisor on this matter.
Section 5.25 Insider Trading/Market Abuse. The Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, the Participant’s country and the designated broker’s country (including any Company Group securities trading policy), which may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., the PSUs) or rights linked to the value of Shares under the Plan during such times that the Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in the Participant’s country). Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any applicable restrictions and that the Participant should speak to the Participant’s advisor on this matter.
Section 5.26 Waiver. The waiver by the Company with respect to the Participant’s (or any other participant’s) compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.
Section 5.27 Consent and Agreement with Respect to Plan. The Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to the Participant; (b) represents that the Participant has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of the Participant’s choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts the PSUs subject to all of the terms
12

and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement.

To the extent that the Company has established, either itself or through a third-party plan administrator, the ability to accept this award electronically, such acceptance shall constitute the Participant’s signature hereof.


Company:Participant:
Title: Vice President, Total Rewards


* * * * *
13

ADDENDUM 1 TO

THE PERFORMANCE SHARE UNIT AWARD AGREEMENT PERFORMANCE GOALS AND PAYOUT SCHEDULE
Capitalized terms not specifically defined herein shall have the meanings specified in the Plan, the Grant Notice and/or the Agreement.

The target number of PSUs specified in the Grant Notice will be earned one-half under Section 1 (“Compound Annual Growth Rate”) and one-half under Section 2 (“Adjusted Return on Invested Capital”), with the resulting payouts modified under Section 3 (“Total Shareholder Return”) as set forth below.

Section 1. Compound Annual Growth Rate.

The PSUs earned under this Section 1 will be earned based on the Company’s Compound Annual Growth Rate (“CAGR”) performance for Net Sales (the “CAGR PSUs”) over the Performance Period. CAGR will be calculated as follows:

Net Sales for the last calendar year of the Performance Period divided by Net Sales for the calendar year immediately preceding the Date of Grant, then raising the result to an exponent of one divided by the number of calendar years within the Performance Period. Subtract one from the subsequent result to arrive at the applicable CAGR.

For purposes of the CAGR calculation, Net Sales means net sales of the Company that shall be (a) computed on a constant currency basis using the average foreign exchange rates in each applicable jurisdiction for the calendar year immediately preceding the Date of Grant, and (b) adjusted to exclude the revenue for any business or asset acquisition or divestiture with annualized revenue of greater than $75 million at the time of the acquisition or divestiture (determined based on the trailing four quarters preceding the acquisition or divestiture date) from all periods within the Performance Period (as well as the Net Sales for the calendar year immediately preceding the Date of Grant for divestitures).

CAGR PSUs will be measured over the Performance Period, beginning with the first day of the Performance Period and ending on the last day of the Performance Period. The Committee will set a target CAGR performance within the first ninety (90) days of the Performance Period and assess performance relative to that target after the completion of the Performance Period, which shall be finalized in accordance with Section 2.5(a) of the Agreement.

CAGR PSUs will pay out in Shares in a range of 0% to 200% of the number of target CAGR PSUs awarded to the Participant as follows:

Baxter International Inc. CAGR Performance*
Percentage of Target Grant Earned
[•] percent and above
[•] %
[•] percent
[•] %
[•] percent
[•] %
Below [•] percent
[•] %

*May not foot due to rounding
14

CAGR PSUs will pay out linearly between each set of performance data points specified above.

Section 2. Adjusted Return on Invested Capital.

The PSUs earned under this Section 2 will be earned based on the Company’s adjusted return on invested capital (“ROIC”) performance (the “ROIC PSUs”) over the Performance Period, as specified below.

ROIC shall be calculated over the Performance Period based on each applicable individual calendar year’s adjusted operating income less adjusted income tax expense, divided by average invested capital. Average invested capital for a particular year shall be measured as the simple average of invested capital at the beginning and end of that year. For purposes of the ROIC calculation, average invested capital is defined as working capital plus the sum of net property, plant and equipment, capitalized operating leases, net intangible assets, and goodwill. Working capital shall be measured as current assets (defined as total current assets reported under U.S. GAAP less cash and cash equivalents) less current liabilities (defined as total current liabilities reported under U.S. GAAP less short-term debt and finance lease obligations and the current portion of long-term debt and finance lease obligations). Additionally, in order to present the numerator and denominator on a like-for-like basis, accrued restructuring liabilities are removed and present intangible assets are reported at cost.

For purposes of the ROIC calculation, the adjusted operating income less adjusted income tax expense from any business or asset acquisition or divestiture with annualized revenue of greater than $75 million at the time of the acquisition or divestiture (determined based on the trailing four quarters immediately preceding the acquisition or divestiture date) shall be excluded from the numerator and the average invested capital related to such acquisition or divestiture shall be excluded from the denominator.

Final ROIC performance will be calculated by first determining the annual ROIC performance for each of the three individual calendar years in the Performance Period and then determining the three-year simple average.

The Committee will set a target ROIC performance within the first ninety (90) days of the Performance Period and assess performance relative to that target after the completion of the Performance Period, which shall be finalized in accordance with Section 2.5(a) of the Agreement.

The ROIC PSUs will pay out in Shares in a range of 0% to 200% of the number of target ROIC PSUs awarded to the Participant as follows:

Baxter International Inc. ROIC Performance*
Percentage of Target Grant Earned
[•] percent and above
[•] %
[•] percent
[•] %
[•] percent
[•] %
Below [•] percent
[•] %

*May not foot due to rounding
The ROIC PSUs will pay out linearly between each set of performance data points specified above.

15


Section 3. Total Shareholder Return.

The resulting payouts calculated in Section 1 and Section 2 above will be modified based on the rank of Baxter’s total shareholder return (“TSR”) relative to the TSR of companies in an index or set of peers to be selected by the Compensation Committee annually (the “Index”), the applicable peer group selected by the Committee within the first ninety (90) days of the Performance Period set forth in the Grant Notice. TSR will be measured based on the average closing stock prices over the last twenty (20) trading days of the Performance Period (plus reinvested dividends) divided by the average closing stock prices over the twenty (20) trading days prior to the beginning of the Performance Period. Any companies in the Index who are no longer publicly traded as of the end of the Performance Period will not be included in the final assessment of the results.

TSR performance will adjust the Sales CAGR payout (Section 1) and Adjusted ROIC payout (Section 2) as follows:

Baxter International Inc. TSR Percentile Rank (Relative to the Index)
Sales CAGR and Adjusted ROIC Payouts Multiplied by:
  [•] percentile or above
[•]
Between [•] percentile and up to [•] percentile
[•]
Below [•] percentile
[•]


The Committee shall have sole and exclusive authority and discretion to make all determinations and resolve all ambiguities, questions and disputes relating to the calculation of Performance Goals and the level of vesting and earning of the PSUs. With respect to the determination of the achievement of any of the Performance Goals and the percentage of the target grant earned, the Committee, in its discretion, may modify or adjust such performance objectives or related level of achievement in accordance with the terms of the Plan.


*    *    *    *

16
 EX-10.2 3 bax-20250331xex102.htm EX-10.2 Document

Exhibit 10.2
BAXTER INTERNATIONAL INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD GRANT NOTICE

Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of Restricted Stock Units set forth below (the “RSUs”). The RSUs are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”), the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.

Participant:
[•]
Participant ID:
[•]
Date of Grant:
[•]
Number of RSUs:
[•]
Vesting Schedule:
[•]
Applicable Recoupment Policy:
The Baxter International Inc. Mandatory Clawback Policy shall apply to Participants who are Executive Officers in the case of a restatement, while the Baxter International Inc. Compensation Recoupment Policy shall apply to all Participants, inclusive of Executive Officers, in any
circumstance in which the Compensation Recoupment Policy is applicable. Both polices are attached hereto as Exhibit B.

By accepting this Award electronically through the stock plan administrator’s online grant acceptance procedure, the Participant agrees to be bound by the terms and conditions of the Plan, the Agreement, and the Grant Notice. If the Participant does not accept this Award through the online acceptance process, the Participant’s Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award. The Participant has reviewed the Agreement, the Plan, and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement, and the Plan. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan, the Grant Notice, or the Agreement.
If the Participant declines the Award, the Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award.


EXHIBIT A
RESTRICTED STOCK UNIT AWARD AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to the Participant the number of RSUs set forth in the Grant Notice.
ARTICLE I.

GENERAL
Section 1.1    Defined Terms. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice. For purposes of this Agreement:
(a)“Delivery Date” shall mean the date the Participant’s RSUs are settled in Shares, which shall be within a reasonable period of time following the Vesting Date and, in all cases, no later than 2 1/2 months following the applicable Vesting Date.
(b)“Employer” means the member of the Company Group that employs the
Participant.
(c)“Qualifying Retirement” shall mean a Termination of a Participant who is at least 65 years of age, or at least 55 years of age with at least 10 years of active continuous service with a member of the Company Group.
(d)“Trading Day” means a date Shares are traded on the New York Stock Exchange or, if the Shares are not traded on the New York Stock Exchange, a date the Shares are traded or reported by an applicable automated quotation system or such other exchange or automated quotation system, if applicable.
(e)“Vesting Date” means the applicable date(s) when the restrictions on the RSUs lapse as provided in the Grant Notice or Section 2.3 of this Agreement. If RSUs would become earned and vested on a date that is not a Trading Day, the next Trading Day shall be the Vesting Date.
Section 1.2 Incorporation of Terms of Plan. The RSUs and the shares of Common Stock issued to the Participant hereunder (“Shares”) are subject to the terms and conditions set forth in this Agreement, the Grant Notice, and the Plan, which are incorporated herein by reference.
2

ARTICLE II.

AWARD OF RESTRICTED STOCK UNITS
Section 2.1 Award of RSUs. In consideration of the Participant’s continued employment with or service to a member of the Company Group, execution of the Agreement Regarding Competition and Protection of Proprietary Interests (attached as Exhibit C) or other restrictive covenants, and for other good and valuable consideration, effective as of the Date of Grant, the Company has granted to the Participant the number of RSUs set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan, and this Agreement, subject to adjustment as provided in Section 12 of the Plan. Except as otherwise provided herein, each RSU represents the right to receive one Share at the times and subject to the conditions set forth herein. However, unless and until the RSUs have vested, the Participant will have no right to the payment of any Shares subject thereto. Prior to the actual delivery of any Shares, the RSUs will represent an unsecured obligation of the Company.
Section 2.2 Vesting of RSUs. Subject to the Participant’s continued employment with or service to a member of the Company Group on each applicable Vesting Date and subject to the terms of this Agreement, the RSUs shall vest in such amounts and at such times as are set forth in the Grant Notice or Section 2.3 of this Agreement.
Section 2.3 Impact of Termination on RSUs. In the event the Participant incurs a Termination prior to a Vesting Date set forth in the Grant Notice, then any unvested RSUs shall be canceled and forfeited, except as may be otherwise provided herein, in the Grant Notice, by the Committee or as set forth in a written agreement between the Participant and the Company or Employer. For the avoidance of doubt, a transfer of employment within the Company Group will not constitute a Termination.
(a)Qualifying Retirement. In the event the Participant incurs a Termination as a result of a Qualifying Retirement for any reason other than for Cause, or by reason of the Participant’s death or Disability, then (i) if the date of such Termination is after the calendar year of the Date of Grant, the RSUs will remain eligible for payout on the terms provided in the Grant Notice and Section 2.2, or (ii) if the date of such Termination is in the calendar year of the Date of Grant a pro-rata portion of the unvested RSUs shall remain eligible for payout on the terms provided in the Grant Notice and Section 2.2. For purposes of the foregoing, the pro-rata portion of the unvested RSUs shall be determined by multiplying (x) the Number of RSUs specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve (12).
(b)Death or Disability. In the event the Participant incurs a Termination as a result of the Participant’s death or Disability, any unvested RSUs shall vest as follows: (i) if the date of such Termination is after the calendar year of the Date of Grant, all unvested RSUs shall immediately vest, or
(ii) if the date of such Termination is in the calendar year of the Date of Grant, a pro-rata portion of the unvested RSUs shall immediately vest. For purposes of the foregoing, the pro-rata portion of the unvested RSUs that shall immediately vest shall be determined by multiplying (x) the Number of RSUs specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve (12).
(c)All Other Terminations. In the event the Participant incurs a Termination other than as set forth in Section 2.3(a) or Section 2.3(b), except as may be otherwise provided herein or by the Committee or as set forth in a written agreement between the Participant and the Company or Employer, the Participant shall immediately forfeit any and all RSUs granted under this Agreement that have not vested or do not vest on or prior to the date on which such Termination occurs, and the Participant’s rights in any such RSUs that are not so vested shall lapse and expire.
3

(d)Outside the United States. For purposes of this Agreement, if the Participant is employed or providing services outside the United States, the Committee (or its delegate) may determine that the date the Participant incurs a Termination shall mean the date the Participant is no longer actively providing services to a member of the Company Group (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction in which the Participant is employed or providing services or the terms of the Participant’s employment agreement, if any) and that the Participant’s right to vest in the RSUs under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction in which the Participant is employed or providing service or the terms of the Participant’s employment or service agreement, if any); the Committee (or its delegate) shall have the exclusive discretion to determine when the Participant is no longer actively providing services for purposes of the RSUs (including whether the Participant may still be considered to be providing services while on a leave of absence).
Section 2.4    Impact of a Change in Control on RSUs. In the event of a Change in Control, the treatment of RSUs shall be governed by Section 12(b) of the Plan.
Section 2.5    Settlement of RSUs.
(a)Except as otherwise provided herein (including Section 2.7), the Participant’s RSUs shall be settled in Shares (either in book-entry form or otherwise) on the Delivery Date applicable to the vested portion of the RSUs. Notwithstanding the foregoing, the Company may delay settlement of RSUs if it reasonably determines that such settlement will violate U.S. federal securities laws or any other applicable law, including non-U.S. laws, provided that such settlement shall be made at the earliest date at which the Company reasonably determines that the making of settlement will not cause such violation, as required by U.S. Treasury Regulation Section 1.409A-2(b)(7)(ii), and provided further that no settlement shall be delayed under this Section 2.5(a) if such delay will result in a violation of Code Section 409A.
(b)All distributions shall be made by the Company in the form of whole Shares. Any fractional share may be distributed in cash or, at the discretion of the Committee, withheld to account for Tax-Related Items (as defined in Section 2.7). The value of a fractional share shall be determined based on the Fair Market Value as of the date(s) the RSUs vest.
(c)Notwithstanding the foregoing, if the Participant is a resident or employed outside of the United States, the Company, in its sole discretion, may settle the RSUs in the form of a cash payment to the extent settlement in Shares: (i) is prohibited under applicable law; (ii) would require the Participant or a member of the Company Group to obtain the approval of any governmental and/or regulatory body in the Participant’s country; (iii) would result in adverse tax consequences for the Participant or a member of the Company Group; or (iv) is administratively burdensome. Alternatively, the Company, in its sole discretion, may settle the RSUs in the form of Shares but require the Participant to sell such Shares immediately or within a specified period following the Participant’s Termination (in which case, this Agreement shall give the Company authorization to issue sales instructions on the Participant’s behalf).
(d)For the avoidance of doubt, this Award represents a right to receive Shares, and not a right to receive cash, and the Company shall only be authorized to deliver cash in settlement of all or any portion of the Award under the specific circumstances contemplated above in Section 2.5(b) and Section 2.5(c) or in connection with a transaction or event contemplated by Section 12 of the Plan.

4


Section 2.6 Conditions to Issuance of Certificates. The Company shall not be required to issue or deliver any certificate or certificates for any Shares or to cause any Shares to be held in book-entry form prior to the fulfillment of all of the following conditions: (a) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (b) the completion of any registration or other qualification of the Shares under any U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or other governmental regulatory body, which the Committee shall, in its absolute discretion, deem necessary or advisable, (c) the obtaining of any approval or other clearance from any U.S. state or federal governmental agency or non-U.S. regulatory agency that the Committee shall, in its absolute discretion, determine to be necessary or advisable, and (d) the receipt of full payment of any applicable Tax-Related Items in accordance with Section 2.7 by the member of the Company Group with respect to which the applicable withholding obligation arises.
Section 2.7    Tax Withholding. Notwithstanding any other provision of this Agreement:
(a)The provisions of Section 14(e) of the Plan are incorporated herein by reference and made a part hereof. The Participant acknowledges that the Participant may be required to pay to the Company or, if different, the Employer, and that the Company, the Employer, or any Subsidiary shall have the right and are hereby authorized to withhold from any compensation or other amount owing to the Participant, applicable income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax- related items (including taxes that are imposed on the Company or the Employer as a result of the Participant’s participation in the Plan but are deemed by the Company or the Employer to be an appropriate charge to the Participant) (collectively, “Tax-Related Items”), with respect to any issuance, transfer, or other taxable event under this Agreement or under the Plan and to take such action as may be necessary in the opinion of the Company to satisfy all obligations for the payment of such Tax-Related Items. The Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to the grant, vesting and/or settlement of the RSUs and the subsequent sale of Shares acquired upon settlement of the vested RSUs; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve a particular tax result. Further, if the Participant is subject to Tax-Related Items in more than one jurisdiction, the Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(b)The Company shall withhold, or cause to be withheld, Shares otherwise vesting or issuable under the RSUs in satisfaction of any applicable tax withholding obligations, unless the Committee permits the Participant to elect to satisfy such obligations by (i) cash, wire transfer of immediately available funds or check; (ii) delivering Shares (which are not subject to any pledge or other security interest) that have been held by the Participant for not less than six (6) months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying GAAP) having a Fair Market Value equal to such withholding liability; or (iii) if approved by the Committee, by delivery of a written or electronic notice that the Participant has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon settlement of the RSUs, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate applicable tax withholding obligations; provided that payment of such proceeds is then made to the Company upon settlement of such sale in satisfaction of the applicable tax withholding obligations. Notwithstanding the foregoing, the Participant authorizes the Company to satisfy the applicable tax withholding obligations from proceeds of the sale of Shares issuable under the RSUs through a mandatory sale arranged by the Company (on the Participant’s behalf pursuant to this authorization) and/or through withholding from any cash, other securities, or other property issuable or
5

deliverable under any Award or from any compensation or other amounts owing to the Participant. If the obligation for Tax-Related Items is satisfied by withholding in Shares, the number of Shares that may be so withheld or surrendered shall be limited to the number of Shares that have a Fair Market Value on the date of withholding no greater than the aggregate amount of such obligations based on the maximum individual statutory withholding rates or other rates that will not have a negative accounting impact in the Participant’s applicable jurisdictions for U.S. federal, state, local and non-U.S. income tax and payroll tax purposes that are applicable to such taxable income, and the Participant is deemed to have been issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items. The Participant acknowledges that, regardless of any action taken by the Company, the Employer, or any Subsidiary the ultimate liability for all Tax- Related Items, is and remains the Participant’s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.
(c)Notwithstanding any other provision of this Agreement, the Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the RSUs to, or to cause any such Shares to be held in book-entry form by, the Participant or the Participant’s legal representative unless and until the Participant or the Participant’s legal representative shall have paid the Tax-Related Items resulting from the grant, vesting or settlement of the RSUs or any other taxable event related to the RSUs.
Section 2.8 Rights as Stockholder. Neither the Participant nor any Person claiming under or through the Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars and delivered to the Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such issuance, recordation and delivery, the Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. From and after the Date of Grant and until the earlier of (a) the time when the Shares are delivered in settlement of the RSUs and (b) the time when the Participant’s right to receive Shares in settlement of the RSUs is forfeited, on the date that the Company pays a dividend (if any) to holders of Shares generally, the Participant shall be permitted to receive additional RSUs with respect to the RSUs based on the dividends and distributions paid on Shares to the same extent as if each RSU were a Share (the “Dividend Equivalent Units”). Such Dividend Equivalent Units (if any) shall be subject to the same terms and conditions, including payment timing, vesting and the obligation to satisfy any tax withholding obligations, in the same manner and at the same time as the RSUs to which the Dividend Equivalent Units relate. For the avoidance of doubt, Dividend Equivalent Units shall not be eligible for the crediting of dividend equivalents or otherwise.
ARTICLE III.

NATURE OF GRANT
Section 3.1 In accepting the grant of the RSUs, the Participant acknowledges, understands, and agrees that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company at any time, to the extent permitted by the Plan;
6

(b)the grant of the RSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of an award, or benefits in lieu of an award, even if RSUs have been granted in the past;
(c)all decisions with respect to future grants of RSUs or other grants, if any, will be at the sole discretion of the Company;
(d)the Participant is voluntarily participating in the Plan;
(e)the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not intended to replace any pension rights or compensation;
(f)the Plan is established, operated, and administered exclusively by the Company, and the RSUs are granted solely by the Company. Only the Company is a party to this Agreement; accordingly, any rights the Participant may have under this Agreement may be raised only against the Company and may not be raised against any Subsidiary of the Company. No Subsidiary of the Company has any obligation to make any payment of any kind under this Agreement;
(g)the RSUs, the Shares subject to the RSUs, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;
(h)unless otherwise agreed with the Company in writing, the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not granted as consideration for, or in connection with, the service the Participant may provide as a director of a Subsidiary;
(i)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the RSUs resulting from the Participant’s Termination (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and / or (ii) the forfeiture or cancellation of the RSUs and/or recoupment of any Shares, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies as provided for in Section 5.12; and neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to the Participant pursuant to the settlement of RSUs or the subsequent sale of any Shares acquired upon settlement.
ARTICLE IV.

DATA PRIVACY
The Company is processing personal data of the Participant for purposes related to Plan administration services, based on the appropriate legal basis, depending on the Participant’s country, as stipulated in the HR Privacy Notice shared with the Participant and as in force. The Company further shares such data with its affiliates or processors, as appropriate, and only on a “need to know basis.” That may also include human resources personnel, certain executives, managers, and employees at other worldwide affiliates of the Company Group, who may have access to certain of the Participant’s personal data. Some of those recipients may be located or may have relevant operations outside of the Participant’s country, such as in the United States, where the data protection laws may not provide a level of protection
7

equivalent to the laws of the Participant’s country. The Company implements the appropriate legal, technical, and organizational measures and mechanisms in this regard.
For further information about the HR Privacy Notice and the processing of the Participant’s data in relation to the Plan, the Participant may contact local HR or send an email to: privacy@baxter.com.

ARTICLE V.

OTHER PROVISIONS
Section 5.1 Administration. The Committee (and its delegates) shall have the power to interpret the Plan, the Grant Notice, and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice, and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee will be final and binding upon the Participant, the Company, and all other interested Persons. To the extent allowable pursuant to applicable law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice, or this Agreement.
Section 5.2 RSUs Not Transferable. The RSUs may not be sold, pledged, assigned, or transferred in any manner other than by will or the laws of descent and distribution, unless and until the Shares underlying the RSUs have been issued, and all restrictions applicable to such Shares have lapsed. No RSUs or any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Participant or the Participant’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. Notwithstanding the foregoing, with the consent of the Committee, the RSUs may be transferred as described in Section 14(b)(ii) of the Plan, pursuant to any such conditions and procedures the Committee may require.
Section 5.3 Adjustments. The Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan, including Section 12 of the Plan.
Section 5.4 Cooperation; Repatriation and Compliance Obligations. The Participant agrees to cooperate with the Company and the Employer in taking any action reasonably necessary or advisable to consummate the transactions contemplated by this Agreement. Further, the Participant agrees to repatriate all payments attributable to the RSUs in accordance with local foreign exchange rules and regulations in the Participant’s country of residence (and country of employment, if different). In addition, the Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with applicable law in the Participant’s country of residence (and country of employment, if different). Finally, the Participant agrees to take any and all actions that may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules, and regulations in the Participant’s country of residence (and country of employment, if different).
Section 5.5 Non-U.S. Addendum. Notwithstanding any provisions in this Agreement to the contrary, the RSUs shall be subject to any terms and conditions set forth in the Non-U.S. Addendum to this Agreement for the Participant’s country of residence (and country of employment or service, if different). Moreover, if the Participant relocates to or otherwise becomes subject to the local laws, rules,
8

and/or regulations in another country, any special terms and conditions for such country will apply to the Participant, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer). The Non-U.S. Addendum constitutes part of this Agreement.
Section 5.6 Notices. For the purpose of the Plan and this Agreement, notices and all other communications shall be in writing and shall be deemed to have been duly given when delivered or mailed by overnight courier or United States registered mail, return receipt requested, postage prepaid (or similar foreign postal service), addressed to the Plan to the General Counsel, Baxter International Inc., One Baxter Parkway, Deerfield, Illinois 60015, USA and to the Participant to the address set forth in the Company’s payroll records or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.
Section 5.7 Imposition of Other Requirements. The Company reserves the right to impose other requirements on the Participant’s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines, in its sole discretion, it is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of the RSUs and the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
Section 5.8 Language. The Participant acknowledges that the Participant is proficient in the English language or has consulted with an advisor who is proficient in the English language, so as to enable the Participant to understand the provisions of this Agreement and the Plan. If the Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control, unless otherwise required by applicable law.
Section 5.9 Electronic Delivery and Acceptance. The Company, in its sole discretion, may decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
Section 5.10 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
Section 5.11 Governing Law; Venue. Except to the extent preempted by US federal law, the laws of the State of Illinois, USA shall govern the interpretation, validity, administration, enforcement, and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts in Chicago, Illinois.
Section 5.12 Repayment of Proceeds; Clawback and Offset Policy. The Shares underlying the RSUs and all proceeds related to such Shares are subject to the Company’s Compensation Recoupment Policy and/or Mandatory Clawback Policy, as applicable, and as specified in the Grant Notice, which are attached to the Grant Notice as Exhibit B.
Additionally, where applicable, if (i) the Participant’s employment with the Company Group terminates for any reason and (ii) such Participant violates (either during and/or after employment with the Company Group) the terms of the Participant’s Competition and Protection of Proprietary Interests Agreement as described in and required by Exhibit C, or any other restrictive covenant between Participant and Company Group where applicable, then any Awards that have not vested or are not
9

exercisable as of the Termination date (including any Awards that would later be settled as a result of a Qualifying Retirement) shall be cancelled and shall not vest, be settled or be exercisable. Furthermore, any Awards that have vested or became exercisable within the 12 months preceding the Termination date shall be forfeited and shall be returned to the Company, and any Awards that vested after the Termination date as a result of a Qualifying Retirement shall be forfeited. If the Participant has exercised any such Awards or sold any Shares underlying Awards, then the Participant shall make a cash payment to the Company in an amount equal to the amount of the net gain recognized from the exercise of such Awards or sale of such Shares within 30 business days of written notice by the Company to the Participant.
Section 5.13 Conformity to Securities Laws. The Participant acknowledges that the Plan, the Grant Notice, and this Agreement, are intended to conform to the extent necessary with all applicable laws, including, without limitation, the provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the Securities and Exchange Commission, and other applicable securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to applicable laws. To the extent permitted by applicable laws, the Plan, the Grant Notice, and this Agreement, shall be deemed amended to the extent necessary to conform to applicable laws.
Section 5.14 Amendment, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of the Participant.
Section 5.15 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in Section 5.2 of this Agreement and the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.
Section 5.16 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if the Participant is subject to Section 16 of the Exchange Act, the Plan, the RSUs, the Grant Notice, and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable laws, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.
Section 5.17 Not a Contract of Employment. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee of any member of the Company Group or shall interfere with or restrict in any way the rights of any member of the Company Group, which rights are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or without cause, except to the extent (i) expressly provided otherwise in a written agreement between a Member of the Company Group and the Participant or (ii) where such provisions are not consistent with applicable foreign or local laws, in which case such applicable foreign or local laws shall control.
Section 5.18 Entire Agreement. The Plan, the Grant Notice, and this Agreement (including the Addenda attached hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof. Except as specifically provided in the Grant Notice or this Agreement, in the event of any inconsistency between the Plan, the Grant Notice or this Agreement, the Plan will control.
10

Section 5.19 Code Section 409A. The intent of the parties is that the payments and benefits under this Agreement comply with or be exempt from Code Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or otherwise exempt. The Company may unilaterally amend the terms of this Agreement (or the Plan) to avoid the application of, or to comply with, Code Section 409A, in a particular circumstance or as necessary or desirable to satisfy any of the requirements under Code Section 409A or to mitigate any additional tax, interest and/or penalties that may apply under Code Section 409A if exemption or compliance is not practicable, but the Company or the Participant shall not be under any obligation to make any such amendment. Nothing in this Agreement (or the Plan) shall provide a basis for any person to take action against the Company or any Subsidiary based on matters covered by Code Section 409A, including the tax treatment of any amount paid under the Agreement, and neither the Company nor any of its Subsidiaries shall under any circumstances have any liability to the Participant or his estate or any other party for any taxes, penalties or interest due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Code Section 409A.
Without limiting the generality of the foregoing and anything in the Agreement to the contrary notwithstanding, if RSUs payable on or by reference to the timing of the Participant’s Termination constitute non-qualified deferred compensation subject to Section 409A, as determined in the Company’s sole discretion, such RSUs shall not be paid unless and until the Participant experiences a “separation from service” (within the meaning of Code Section 409A), and if the Participant is a “specified employee” (within the meaning of Code Section 409A) as of the date of the separation from service (as determined in accordance with the methodology established by the Company as in effect on the date of Termination), shall instead be paid to the Participant on the first business day that immediately follows the earlier of (i) the date that is six (6) months following the date of the Participant’s separation from service or (ii) the date of the Participant’s death, to the extent such delayed payment is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2).
Section 5.20 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.
Section 5.21 Limitation on the Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. The Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs.
Section 5.22 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to applicable law, each of which shall be deemed an original and all of which together shall constitute one instrument.
Section 5.23 Private Offering. If the Participant is a resident outside the United States, the grant of the RSUs is not intended to be a public offering of securities in the Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus, or other filing with the local securities authorities with respect to the grant of the RSUs unless otherwise required under local law. No employee of the Company is permitted to advise the Participant on whether the Participant should acquire Shares under the Plan or provide the Participant with any legal, tax or financial advice with respect to the grant of the RSUs. Investment in Shares involves a degree of risk. Before deciding to acquire Shares pursuant to the RSUs, the Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of
11

them. Further, the Participant should carefully review all of the materials related to the RSUs and the Plan, and the Participant should consult with the Participant’s personal legal, tax and financial advisors for professional advice in relation to the Participant’s personal circumstances.
Section 5.24 Exchange Control, Foreign Asset/Account and/or Tax Reporting. The Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements that may affect the Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the receipt of any dividends paid on Shares and the proceeds from the sale of Shares) in a brokerage or bank account outside the Participant’s country. The Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in the Participant’s country. The Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to the Participant’s country within a certain time after receipt. The Participant acknowledges that it is the Participant’s responsibility to comply with such regulations and that the Participant should speak to the Participant’s personal advisor on this matter.
Section 5.25 Insider Trading/Market Abuse. The Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, the Participant’s country and the designated broker’s country (including any Company Group securities trading policy), which may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., the RSUs) or rights linked to the value of Shares under the Plan during such times that the Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in the Participant’s country). Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any applicable restrictions and that the Participant should speak to the Participant’s personal advisor on this matter.
Section 5.26 Waiver. The waiver by the Company with respect to the Participant’s (or any other participant’s) compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.
Section 5.27 Consent and Agreement with Respect to Plan. The Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to the Participant;(b) represents that the Participant has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of the Participant’s choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts the RSUs subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement.
To the extent that the Company has established, either itself or through a third-party plan administrator, the ability to accept this award electronically, such acceptance shall constitute the Participant’s signature hereof.
Company:Participant:
Title: Vice President, Total Rewards

* * * *
12
 EX-10.3 4 bax-20250331xex103.htm EX-10.3 Document

Exhibit 10.3
BAXTER INTERNATIONAL INC.
AMENDED AND RESTATED 2021 INCENTIVE PLAN

STOCK OPTION AWARD GRANT NOTICE

Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of stock options set forth below (the “Options”). The Options are subject to the terms and conditions set forth in this Stock Option Award Grant Notice (the “Grant Notice”), the Stock Option Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.
Participant:
[•]
Participant ID:
[•]
Date of Grant:
[•]
Number of Options:
[•]
Exercise Price:
[•]
Vesting Schedule:[•]
Expiration Date:
[•]
Applicable Recoupment Policy:
The Baxter International Inc. Mandatory Clawback Policy shall apply to Participants who are Executive Officers in the case of a restatement, while the Baxter International Inc. Compensation Recoupment Policy shall apply to all Participants, inclusive of Executive Officers, in any circumstance in which the Compensation Recoupment Policy is applicable. Both polices are attached hereto as Exhibit B.
By accepting this Award electronically through the stock plan administrator’s online grant acceptance procedure, the Participant agrees to be bound by the terms and conditions of the Plan, the Agreement, and the Grant Notice. If the Participant does not accept this Award through the online acceptance process, the Participant’s Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award. The Participant has reviewed the Agreement, the Plan, and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement, and the Plan. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan, the Grant Notice, or the Agreement.
If the Participant declines the Award, the Award will be canceled, and the Participant will not be entitled to any benefits from the Award or to any compensation or benefits in lieu of the canceled Award.



EXHIBIT A
STOCK OPTION AWARD AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to the Participant the number of Options set forth in the Grant Notice.
ARTICLE I.
GENERAL
Section 1.1    Defined Terms. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice. For purposes of this Agreement:
(a)“Employer” means the member of the Company Group that employs the Participant.

(b)“Qualifying Retirement” shall mean a Termination of a Participant who is at least 65 years of age, or at least 55 years of age with at least 10 years of active continuous service with a member of the Company Group.
(c)“Trading Day” means a date Shares are traded on the New York Stock Exchange or, if the Shares are not traded on the New York Stock Exchange, a date the Shares are traded or reported by an applicable automated quotation system or such other exchange or automated quotation system, if applicable.
(d)“Vesting Date” means the applicable date(s) when the restrictions on the Options lapse, as provided in the Grant Notice or herein.
Section 1.2 Incorporation of Terms of Plan. The Options and the shares of Common Stock issued to the Participant hereunder (“Shares”) are subject to the terms and conditions set forth in this Agreement, the Grant Notice, and the Plan, which are incorporated herein by reference.
ARTICLE II.
AWARD OF STOCK OPTIONS
Section 2.1 Award of Options. In consideration of the Participant’s continued employment with or service to a member of the Company Group, up, execution of the Agreement Regarding Competition and Protection of Proprietary Interests (attached as Exhibit C) or other restrictive covenants, and for other good and valuable consideration, effective as of the Date of Grant, the Company has granted to the Participant the number of Options set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan, and this Agreement, subject to adjustment as provided in Section 12 of the Plan. Except as otherwise provided herein, each Option represents the right to receive one Share at the times and subject to the conditions set forth herein. However, unless and until the Options have vested, the Participant will have no right to the payment of any Shares subject thereto. Prior to the actual delivery of any Shares, the Options will represent an unsecured obligation of the Company. All Options granted hereunder are Nonqualified Stock Options.
Section 2.2 Term of Options. Unless terminated earlier as provided below or otherwise pursuant to the Plan, the Options shall expire on the date set forth in the Grant Notice. If Options would expire on a date that is not a Trading Day (for any reason, including, without limitation, a Participant’s Termination for any reason or at the normal expiration date), they will expire at the close of trading on the last Trading Day preceding that date. If the Options would expire at a time when trading in the Shares is prohibited by the
2


Company’s insider trading policy (or Company-imposed “blackout period”), then the expiration date shall be automatically extended under the earlier of (i) the thirtieth (30th) day following the expiration of such prohibition and (ii) the normal expiration date of the Options, as set forth in the Grant Notice. Under no circumstances may Options be exercised after they have expired.
Section 2.3 Vesting of Options. Subject to the Participant’s continued employment with or service to a member of the Company Group on each applicable Vesting Date and subject to the terms of this Agreement, the Options shall vest in such amounts and at such times as are set forth in the Grant Notice or Section 2.4 of this Agreement and become exercisable.
Section 2.4 Impact of Termination on Options. In the event the Participant incurs a Termination prior to a Vesting Date set forth in the Grant Notice, then any unvested Options shall be canceled and forfeited, except as may be otherwise provided herein, in the Grant Notice, by the Committee or as set forth in a written agreement between the Participant and the Company or Employer. For the avoidance of doubt, a transfer of employment within the Company Group will not constitute a Termination.
(a) Qualifying Retirement. In the event the Participant incurs a Termination as a result of a Qualifying Retirement for any reason other than for Cause, or by reason of the Participant’s death or Disability, then (i) if the date of such Termination is after the calendar year of the Date of Grant, the Options shall continue to become exercisable on the Vesting Date(s) specified in the Grant Notice, or (ii) if the date of such Termination is in the calendar year of the Date of Grant, a pro-rata portion of the unvested Options shall continue to become exercisable on the Vesting Date(s) specified in the Grant Notice. For purposes of the foregoing, the pro-rata portion of the unvested Options that shall continue to become exercisable shall be determined by multiplying (x) the Number of Options specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve (12). Subject to Section 2.2, such Options shall expire on the first to occur of the fifth anniversary of the Termination as a result of a Qualifying Retirement or the normal expiration date of the Options, as set forth in the Grant Notice.
(b)Death or Disability. In the event the Participant incurs a Termination as a result of the Participant’s death or Disability, any unvested Options shall vest as follows: (i) if the date of such Termination is after the calendar year of the Date of Grant, all unvested Options shall immediately vest and become exercisable, or (ii) if the date of such Termination is in the calendar year of the Date of Grant, a pro-rata portion of the unvested Options shall immediately vest and become exercisable. For purposes of the foregoing, the pro-rata portion of the unvested Options that shall immediately vest and become exercisable shall be determined by multiplying (x) the Number of Options specified in the Grant Notice by (y) the percentage equal to the number of months worked in the applicable calendar year of the Date of Grant, rounded to the nearest whole month, divided by twelve (12). Subject to Section 2.2, such Options shall expire on the first to occur of the fifth anniversary of the Termination as a result of the Participant’s death or Disability or the normal expiration date of the Options, as set forth in the Grant Notice.
(c)Termination for Cause. In the event the Participant incurs a Termination for Cause, except as may be otherwise provided by the Committee or as set forth in a written agreement between the Participant and the Company or Employer, the Participant shall immediately forfeit any and all Options granted under this Agreement (whether or not vested), the Participant’s rights in any such Options shall lapse and expire, and the Participant shall also be subject to the Executive Compensation Recoupment Policy or Incentive Compensation Recoupment Policy, as applicable.
3


(d)All Other Terminations. In the event the Participant incurs a Termination other than as set forth in Section 2.4(a), Section 2.4(b) or Section 2.4(c), except as may be otherwise provided herein or by the Committee or as set forth in a written agreement between the Participant and the Company or Employer, any unvested Options shall expire immediately and any vested Options that are exercisable will expire as of the first to occur of, subject to Section 2.2, (i) ninety (90) days after the Participant incurs a Termination (or the prior trading day if the 90th day after Termination is a non-trading day) or (ii) the normal expiration date of the Option, as set forth in the Grant Notice. If the Participant dies or becomes disabled during the ninety (90) day period, subject to Section 2.2, the Options will expire on the first to occur of the fifth anniversary of the Termination (or the prior trading day if the fifth anniversary of the Termination is a non-trading day) or the normal expiration date of the Option, as set forth in the Grant Notice.
(e)Outside the United States. For purposes of this Agreement, if the Participant is employed or providing services outside the United States, the Committee (or its delegate) may determine that the date the Participant incurs a Termination shall mean the date the Participant is no longer actively providing services to a member of the Company Group (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction in which the Participant is employed or providing services or the terms of the Participant’s employment agreement, if any) and that the Participant’s right to vest in the Options under the Plan, if any, will terminate as of such date, the post-Termination exercise period (if any) with respect to vested Options will begin as of such date, and will not be extended by any notice period (e.g., the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction in which the Participant is employed or providing service or the terms of the Participant’s employment or service agreement, if any); the Committee (or its delegate) shall have the exclusive discretion to determine when the Participant is no longer actively providing services for purposes of the Options (including whether the Participant may still be considered to be providing services while on a leave of absence).

Section 2.5    Impact of a Change in Control on Options. In the event of a Change in Control, the treatment of the Options shall be governed by Section 12(b) of the Plan.
Section 2.6    Exercise of Options.
Options that have become exercisable may be exercised in whole or in part (but with respect to whole Shares only) by delivery of written or electronic notice of exercise to the Company (or any other notice of exercise method provided by the Company, in its sole discretion), in such form and pursuant to such procedures as may be designated by the Company from time to time, indicating the number of Shares with respect to which the Options are being exercised, which notice shall be accompanied by payment in full for the Shares. If Options would become exercisable on a date that is not a Trading Day, they will become exercisable on the next Trading Day. The Exercise Price may be paid in accordance with Section 7(d) of the Plan, or by such other method as the Committee may permit, in its sole discretion.
Notwithstanding the foregoing, the Committee may suspend or eliminate any of the specified methods of exercise, require payment in a particular or different method of exercise than those specified, may allow the Participant to exercise the Options only by means of a cashless exercise (either a cashless “sell all” exercise or a cashless “sell-to-cover” exercise) as it shall determine in its sole discretion, or may require the Participant to sell any Shares acquired under the Plan immediately or within a specified period following the Participant’s
4


Termination (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).
Except as the Committee otherwise may provide and in accordance with Section 14(b) of the Plan, Options may be exercised only by the Participant, the Participant’s legal representative, or a person to whom the Participant’s rights in the Options are transferred by will or the laws of descent and distribution.
Following the exercise of Options hereunder, as promptly as practical after receipt of such notification and full payment of the Exercise Price and any required Tax-Related Items (as defined and provided in Section 2.8 hereof), the Company shall issue or transfer, or cause such issue or transfer, to the Participant the number of Shares with respect to which the Options have been so exercised. All distributions shall be made by the Company in the form of whole Shares.
Section 2.7 Conditions to Exercise and Issuance of Certificates. The Company shall not be required to permit the Participant to exercise the Options in a manner that Committee determines would violate the Sarbanes-Oxley Act of 2002, as it may be amended from time to time, or issue or deliver any certificate or certificates for any Shares or to cause any Shares to be held in book-entry form prior to the fulfillment of all of the following conditions: (a) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (b) the completion of any registration or other qualification of the Shares under any U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or other governmental regulatory body, which the Committee shall, in its absolute discretion, deem necessary or advisable, (c) the obtaining of any approval or other clearance from any U.S. state or federal governmental agency or non-U.S. regulatory agency that the Committee shall, in its absolute discretion, determine to be necessary or advisable, and (d) the receipt of full payment of any applicable Tax-Related Items in accordance with Section 2.8 by the member of the Company Group with respect to which the applicable withholding obligation arises.
Section 2.8    Tax Withholding. Notwithstanding any other provision of this Agreement:
(a)The provisions of Section 14(e) of the Plan are incorporated herein by reference and made a part hereof. The Participant acknowledges that the Participant may be required to pay to the Company or, if different, the Employer, and that the Company, the Employer, or any Subsidiary shall have the right and are hereby authorized to withhold from any compensation or other amount owing to the Participant, applicable income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax- related items (including taxes that are imposed on the Company or the Employer as a result of the Participant’s participation in the Plan but are deemed by the Company or the Employer to be an appropriate charge to the Participant) (collectively, “Tax-Related Items”), with respect to any issuance, transfer, or other taxable event under this Agreement or under the Plan and to take such action as may be necessary in the opinion of the Company to satisfy all obligations for the payment of such Tax-Related Items. The Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Options, including, but not limited to the grant, exercise and/or settlement of the Options and the subsequent sale of Shares acquired upon exercise of the Options; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Options to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve a particular tax result. Further, if the Participant is subject to Tax- Related Items in more than one jurisdiction, the Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(b)The Committee may permit the Participant to elect to satisfy such obligations by (i) cash, wire transfer of immediately available funds or check; (ii) delivering Shares (which are not subject
5


to any pledge or other security interest) that have been held by the Participant for not less than six (6) months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying GAAP) having a Fair Market Value equal to such withholding liability; (iii) delivery of a written or electronic notice that the Participant has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon exercise of the Options, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate applicable tax withholding obligations; provided that payment of such proceeds is then made to the Company upon settlement of such sale in satisfaction of the applicable tax withholding obligations; or (iv) the Company withholding, or causing to be withheld, Shares otherwise issuable under the Options; provided that the number of Shares that may be so withheld or surrendered shall be limited to the number of Shares that have a Fair Market Value on the date of withholding no greater than the aggregate amount of such obligations based on the maximum individual statutory withholding rates or other rates that will not have a negative accounting impact, in the Participant’s applicable jurisdictions for U.S. federal, state, local and non-U.S. income tax and payroll tax purposes that are applicable to such taxable income. Notwithstanding the foregoing, the Participant authorizes the Company to satisfy the applicable tax withholding obligations from proceeds of the sale of Shares issuable under the Options through a mandatory sale arranged by the Company (on the Participant’s behalf pursuant to this authorization) and/or through withholding from any cash, other securities, or other property issuable or deliverable under any Award or from any compensation or other amounts owing to the Participant. If the obligation for Tax-Related Items is satisfied by withholding in Shares, the Participant is deemed to have been issued the full number of Shares subject to the exercised Options, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items. The Participant acknowledges that, regardless of any action taken by the Company, the Employer, or any Subsidiary the ultimate liability for all Tax-Related Items, is and remains the Participant’s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.
(c)Notwithstanding any other provision of this Agreement, the Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the Options to, or to cause any such Shares to be held in book-entry form by, the Participant or the Participant’s legal representative unless and until the Participant or the Participant’s legal representative shall have paid the Tax-Related Items resulting from the grant, exercise or settlement of the Options or any other taxable event related to the Options.
Section 2.9 Rights as Stockholder. Neither the Participant nor any Person claiming under or through the Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars and delivered to the Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such issuance, recordation and delivery, the Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares.
ARTICLE III.
NATURE OF GRANT
Section 3.1 In accepting the grant of the Options, the Participant acknowledges, understands, and agrees that:
6


(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company at any time, to the extent permitted by the Plan;
(b)the grant of the Options is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of an award, or benefits in lieu of an award, even if Options have been granted in the past;
(c)all decisions with respect to future grants of Options or other grants, if any, will be at the sole discretion of the Company;
(d)the Participant is voluntarily participating in the Plan;
(e)the Options and the Shares subject to the Options, and the income from and value of same, are not intended to replace any pension rights or compensation;
(f)the Plan is established, operated, and administered exclusively by the Company, and the Options are granted solely by the Company. Only the Company is a party to this Agreement; accordingly, any rights the Participant may have under this Agreement may be raised only against the Company and may not be raised against any Subsidiary of the Company. No Subsidiary of the Company has any obligation to make any payment of any kind under this Agreement;
(g)the Options, the Shares subject to the Options, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;
(h)unless otherwise agreed with the Company in writing, the Options and the Shares subject to the Options, and the income from and value of same, are not granted as consideration for, or in connection with, the service the Participant may provide as a director of a Subsidiary;
(i)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the Options resulting from the Participant’s Termination (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and / or (ii) the forfeiture or cancellation of the Options and/or recoupment of any Shares, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies as provided for in Section 5.12; and
(k)neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the United States Dollar that may affect the value of the Options or of any amounts due to the Participant pursuant to the settlement of the Options upon exercise or the subsequent sale of any Shares acquired upon settlement.
7


ARTICLE IV.
DATA PRIVACY
The Company is processing personal data of the Participant for purposes related to Plan administration services, based on the appropriate legal basis, depending on the Participant’s country, as stipulated in the HR Privacy Notice shared with the Participant and as in force. The Company further shares such data with its affiliates or processors, as appropriate, and only on a “need to know basis”. That may also include human resources personnel, certain executives, managers, and employees at other worldwide affiliates of the Company Group, who may have access to certain of the Participant’s personal data. Some of those recipients may be located or may have relevant operations outside of the Participant’s country, such as in the United States, where the data protection laws may not provide a level of protection equivalent to the laws of the Participant’s country. The Company implements the appropriate legal, technical, and organizational measures and mechanisms in this regard.
For further information about the HR Privacy Notice and the processing of the Participant’s data in relation to the Plan, the Participant may contact local HR or send an email to: privacy@baxter.com.

ARTICLE V.
OTHER PROVISIONS
Section 5.1 Administration. The Committee (and its delegates) shall have the power to interpret the Plan, the Grant Notice, and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice, and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee will be final and binding upon the Participant, the Company, and all other interested Persons. To the extent allowable pursuant to applicable law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice, or this Agreement.
Section 5.2 Options Not Transferable. The Options may not be sold, pledged, assigned, or transferred in any manner other than by will or the laws of descent and distribution, unless and until the Shares underlying the Options have been issued, and all restrictions applicable to such Shares have lapsed. No Options or any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Participant or the Participant’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. Notwithstanding the foregoing, with the consent of the Committee, the Options may be transferred as described in Section 14(b)(ii) of the Plan, pursuant to any such conditions and procedures the Committee may require.
Section 5.3 Adjustments. The Participant acknowledges that the Options and the Shares subject to the Options are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan, including Section 12 of the Plan.
Section 5.4 Cooperation; Repatriation and Compliance Obligations. The Participant agrees to cooperate with the Company and the Employer in taking any action reasonably necessary or advisable to consummate the
8


transactions contemplated by this Agreement. Further, the Participant agrees to repatriate all payments attributable to the Options in accordance with local foreign exchange rules and regulations in the Participant’s country of residence (and country of employment, if different). In addition, the Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with applicable law in the Participant’s country of residence (and country of employment, if different). Finally, the Participant agrees to take any and all actions that may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules, and regulations in the Participant’s country of residence (and country of employment, if different).
Section 5.5 Non-U.S. Addendum. Notwithstanding any provisions in this Agreement to the contrary, the Options shall be subject to any terms and conditions set forth in the Non-U.S. Addendum to this Agreement for the Participant’s country of residence (and country of employment or service, if different). Moreover, if the Participant relocates to or otherwise becomes subject to the local laws, rules, and/or regulations in another country, any special terms and conditions for such country will apply to the Participant, to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer). The Non-U.S. Addendum constitutes part of this Agreement.
Section 5.6 Notices. For the purpose of the Plan and this Agreement, notices and all other communications shall be in writing and shall be deemed to have been duly given when delivered or mailed by overnight courier or United States registered mail, return receipt requested, postage prepaid (or similar foreign postal service), addressed to the Plan to the General Counsel, Baxter International Inc., One Baxter Parkway, Deerfield, Illinois 60015, USA and to the Participant to the address set forth in the Company’s payroll records or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.
Section 5.7 Imposition of Other Requirements. The Company reserves the right to impose other requirements on the Participant’s participation in the Plan, on the Options and on any Shares acquired under the Plan, to the extent the Company determines, in its sole discretion, it is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of the Options and the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
Section 5.8 Language. The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable the Participant to understand the provisions of this Agreement and the Plan. If the Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control, unless otherwise required by applicable law.
Section 5.9 Electronic Delivery and Acceptance. The Company, in its sole discretion, may decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
Section 5.10 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
9


Section 5.11 Governing Law; Venue. Except to the extent preempted by US federal law, the laws of the State of Illinois, USA shall govern the interpretation, validity, administration, enforcement, and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive jurisdiction and venue of the federal courts in Chicago, Illinois.
Section 5.12 Repayment of Proceeds; Clawback and Offset Policy. The Shares underlying the Options and all proceeds related to such Shares are subject to the Company’s Incentive Compensation Recoupment Policy or Executive Compensation Recoupment Policy, as specified in the Grant Notice, which are attached to the Grant Notice as Exhibit B.
Additionally, where applicable, if (i) the Participant’s employment with the Company Group terminates for any reason and (ii) such Participant violates (either during and/or after employment with the Company Group) the terms of the Participant’s Competition and Protection of Proprietary Interests Agreement as described in and required by Exhibit C, or any other restrictive covenant between Participant and Company Group where applicable, then any Awards that have not vested or are not exercisable as of the Termination date (including any Awards that would later vest as a result of a Qualifying Retirement) shall be cancelled and shall not vest, be settled, or be exercisable. Furthermore, any Awards which have vested or became exercisable within the 12 months preceding the Termination date shall be forfeited and shall be returned to the Company, and any Awards that vested after the Termination date as a result of a Qualifying Retirement shall be forfeited. If the Participant has sold or exercised any such Awards, then the Participant shall make a cash payment to the Company in an amount equal to the amount of the net gain recognized from the sale or exercise of such Awards within 30 business days of written notice by the Company to the Participant.
Section 5.13 Conformity to Securities Laws. The Participant acknowledges that the Plan, the Grant Notice, and this Agreement, are intended to conform to the extent necessary with all applicable laws, including, without limitation, the provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the Securities and Exchange Commission, and other applicable securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Options are granted, only in such a manner as to conform to applicable laws. To the extent permitted by applicable laws, the Plan, the Grant Notice, and this Agreement, shall be deemed amended to the extent necessary to conform to applicable laws.
Section 5.14 Amendment, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended, or terminated at any time or from time to time by the Committee or the Board, provided that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Options in any material way without the prior written consent of the Participant.
Section 5.15 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in Section 5.2 of this Agreement and the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.
Section 5.16 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if the Participant is subject to Section 16 of the Exchange Act, the Plan, the Options, the Grant Notice, and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange
10


Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable laws, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.
Section 5.17 Not a Contract of Employment. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee of any member of the Company Group or shall interfere with or restrict in any way the rights of any member of the Company Group, which rights are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or without cause, except to the extent (i) expressly provided otherwise in a written agreement between a Member of the Company Group and the Participant or (ii) where such provisions are not consistent with applicable foreign or local laws, in which case such applicable foreign or local laws shall control.
Section 5.18 Entire Agreement. The Plan, the Grant Notice, and this Agreement (including the Addenda attached hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof. Except as specifically provided in the Grant Notice or this Agreement, in the event of any inconsistency between the Plan, the Grant Notice or this Agreement, the Plan will control.
Section 5.19 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.
Section 5.20 Limitation on the Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. The Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Options.
Section 5.21 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to applicable law, each of which shall be deemed an original and all of which together shall constitute one instrument.
Section 5.22 Private Offering. If the Participant is a resident outside the United States, the grant of the Options is not intended to be a public offering of securities in the Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus, or other filing with the local securities authorities with respect to the grant of the Options unless otherwise required under local law. No employee of the Company is permitted to advise the Participant on whether the Participant should acquire Shares under the Plan or provide the Participant with any legal, tax or financial advice with respect to the grant of the Options. Investment in Shares involves a degree of risk. Before deciding to acquire Shares pursuant to the Options, the Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, the Participant should carefully review all of the materials related to the Options and the Plan, and the Participant should consult with the Participant’s personal legal, tax and financial advisors for professional advice in relation to the Participant’s personal circumstances.
Section 5.23 Exchange Control, Foreign Asset/Account and/or Tax Reporting. The Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements that may affect the Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the receipt of any dividends paid on Shares and the proceeds from the sale of Shares) in a brokerage or bank account outside the Participant’s country. The Participant may be required to report such accounts, assets or
11


related transactions to the tax or other authorities in the Participant’s country. The Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to the Participant’s country within a certain time after receipt. The Participant acknowledges that it is the Participant’s responsibility to comply with such regulations and that the Participant should speak to his or her personal advisor on this matter.
Section 5.24 Insider Trading/Market Abuse. The Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, the Participant’s country and the designated broker’s country (including any Company Group securities trading policy), which may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., the Options) or rights linked to the value of Shares under the Plan during such times that the Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in the Participant’s country). Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any applicable restrictions and that the Participant should speak to the Participant’s personal advisor on this matter.
Section 5.25 Waiver. The waiver by the Company with respect to the Participant’s (or any other participant’s) compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.
Section 5.26 Consent and Agreement with Respect to Plan. The Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to the Participant; (b) represents that the Participant has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of the Participant’s choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts the Options subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement.
To the extent that the Company has established, either itself or through a third-party plan administrator, the ability to accept this award electronically, such acceptance shall constitute the Participant’s signature hereof.

Company:Participant:
Title: Vice President, Total Rewards



* * * * *

12

 EX-31.1 5 bax-20250331xex311.htm EX-31.1 Document

EXHIBIT 31.1
Certification of Chief Executive Officer
Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended
I, Brent Shafer, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Brent Shafer
Brent Shafer
Chair and Interim Chief Executive Officer
Date: May 6, 2025

 EX-31.2 6 bax-20250331xex312.htm EX-31.2 Document

EXHIBIT 31.2
Certification of Chief Financial Officer
Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended
I, Joel T. Grade, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Joel T. Grade
Joel T. Grade
Executive Vice President and Chief Financial Officer
Date: May 6, 2025

 EX-32.1 7 bax-20250331ex321.htm EX-32.1 Document

EXHIBIT 32.1
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Brent Shafer, as Chair and Interim Chief Executive Officer of Baxter International Inc. (the “Company”), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Brent Shafer
Brent Shafer
Chair and Interim Chief Executive Officer
May 6, 2025

 EX-32.2 8 bax-20250331xex322.htm EX-32.2 Document

EXHIBIT 32.2
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Joel T. Grade, as Executive Vice President and Chief Financial Officer of Baxter International Inc. (the “Company”), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Joel T. Grade
Joel T. Grade
Executive Vice President and Chief Financial Officer
May 6, 2025

 EX-101.SCH 9 bax-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - REVENUES link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - FINANCING ARRANGEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - REVENUES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - REVENUES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - REVENUES - Contract Assets and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - REVENUES - Lease Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - EARNINGS PER SHARE - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bax-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bax-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bax-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Adjustments to reconcile net loss to cash flows from operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Remaining value available under stock repurchase programs Share Repurchase Program, Remaining Authorized, Amount Debt obligations Long-Term Debt and Lease Obligation, Including Current Maturities Cover [Abstract] Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In process Research and Development In Process Research and Development [Member] Sales-type lease revenue Sales-type Lease, Revenue Trading Symbol Trading Symbol Fair value hedges Fair Value Hedging [Member] Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] Fair value and carrying value by balance sheet grouping. Derivative asset, fair value Gross amounts recognized in the condensed consolidated balance sheets Derivative Asset, Subject to Master Netting Arrangement, before Offset Pension and OPEB plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Non-NEOs Non-NEOs [Member] Debt term Long-Term Debt, Term Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Allowance for accounts receivable, current Accounts Receivable, Allowance for Credit Loss, Current Total lease revenue Lease Income Disposal Group Name [Domain] Disposal Group Name [Domain] Bundled equipment and consumable medical products contracts Bundled Equipment And Consumable Medical Products Contracts [Member] Bundled Equipment And Consumable Medical Products Contracts Accounts receivable, net Increase (Decrease) in Accounts Receivable Other Intangible Assets, Net Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill [Table Text Block] Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income (loss) from continuing operations Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Hedging Relationship Hedging Relationship [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Net investment hedge Net Investment Hedging Net Investment Hedging [Member] Total Derivative, Gain (Loss) on Derivative, Net Stock issued under employee benefit plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] United States UNITED STATES Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Other non-current assets Other Assets, Noncurrent Gross other intangible assets, finite-lived Finite-Lived Intangible Assets, Gross Operating Segments Operating Segments [Member] Cash flows from operations Net Cash Provided by (Used in) Operating Activities Comprehensive income (loss) from continuing operations Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest Cash flows from operations Net Cash Provided by (Used in) Operating Activities [Abstract] Summary of Changes in AOCI Income (Loss) by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] 1.3% Global Notes due 2029 Global Notes 1.3% due 2029 [Member] Global Notes 1.3% due 2029 Contingent liability Loss Contingency Accrual, Period Increase (Decrease) Award Timing Method Award Timing Method [Text Block] Net periodic pension cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type Restructuring Type [Axis] Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Income (loss) from continuing operations per common share Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional contributed capital Additional Paid in Capital, Common Stock Derivative liability, not subject to master netting arrangement, fair value Derivative Liability, Not Subject to Master Netting Arrangement Compensation Amount Outstanding Recovery Compensation Amount Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Environmental reserves Accrual for Environmental Loss Contingencies Accrued expenses and other current liabilities Accrued Liabilities, Current Anti-dilutive securities excluded from computation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Litigation reserve Estimated Litigation Liability Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Credit Facility [Domain] Credit Facility [Domain] Pension and other postretirement benefits, net of tax expense (benefit) of $(3) and zero for the three months ended March 31, 2025 and 2024, respectively. Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Available-for-sale debt securities Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Non-current assets of discontinued operations Non-current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Hurricane Hurricane [Member] Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss Other comprehensive income (loss) from continuing operations, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation Other Comprehensive Income (Loss), From Distributions Other Comprehensive Income (Loss), From Distributions Employee Stock Option Share-Based Payment Arrangement, Option [Member] Depreciation Depreciation Derivative, fair value, net Derivative, Fair Value, Net Other financing activities, net Proceeds from (Payments for) Other Financing Activities Other segment items Other Expenses Comprehensive income (loss) attributable to Baxter stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension benefits Pension Plan [Member] Capitalized Contract Cost Capitalized Contract Cost [Domain] Award Type Award Type [Axis] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Repayments of debt Repayments of debt Repayments of Debt Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Cash flows from operations – continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Total Shareholder Return Amount Total Shareholder Return Amount Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Hurricane Helene costs Loss from Catastrophes Long-term debt and finance lease obligations, less current portion Long-Term Debt and Lease Obligation [Member] Long-Term Debt and Lease Obligation Property, plant and equipment, at cost Property, Plant and Equipment, Gross Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] R&D Research and Development Expense [Member] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected additional pre-tax costs Restructuring and Related Cost, Expected Cost Other (income) expense, net Other Nonoperating Income (Expense) [Member] Long-term debt and finance lease obligations Long -Term Debt and Finance Lease Obligations, Noncurrent Long-term debt and finance lease obligations noncurrent. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total Baxter stockholders’ equity Equity, Attributable to Parent Environmental Remediation Contingency Environmental Remediation Contingency [Axis] Commercial paper, weighted-average interest rate Commercial Paper, Weighted-Average Interest Rate Commercial Paper, Weighted-Average Interest Rate Litigation Case [Axis] Litigation Case [Axis] Net sales Disposal Group, Including Discontinued Operation, Revenue Goodwill Schedule of Goodwill [Table Text Block] Selling, general and administrative expenses Selling, General and Administrative Expense COGS Cost of sales Cost of Sales [Member] Document Fiscal Period Focus Document Fiscal Period Focus Exchange [Domain] Exchange [Domain] All Executive Categories All Executive Categories [Member] Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Summary of Activity in Reserves Related to Restructuring Initiatives Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Change in noncontrolling interests Noncontrolling Interest, Period Increase (Decrease) Discontinued operations, currency translation adjustments, net of tax Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Retirement Plan Type Retirement Plan Type [Domain] Pension and other postretirement benefits, tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Document Type Document Type Derivative Contract Derivative Contract [Domain] Summary of Financial Information for Our Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Cash, cash equivalents and restricted cash at start of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Contract with Customer, Contract Asset Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Pension and other postretirement benefits, net of tax expense (benefit) of ($4) and $3 for the three months ended March 31, 2025 and 2024, respectively. Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Other intangible assets, net, finite-lived Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Range Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income (loss) from continuing operations before income taxes Income (loss) from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Interest income Interest Income (Expense), Nonoperating, Net Of Capitalized Interest Interest Income (Expense), Nonoperating, Net Of Capitalized Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Comprehensive income (loss) Comprehensive Income (Loss), From Continuing And Discontinued Operations, Including Portion Attributable To Noncontrolling Interest, Net Of Tax Comprehensive Income (Loss), From Continuing And Discontinued Operations, Including Portion Attributable To Noncontrolling Interest, Net Of Tax Name Outstanding Recovery, Individual Name Revenue From Contract With Customer [Line Items] Disaggregation of Revenue [Line Items] Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Money market funds, at carrying value Money Market Funds, at Carrying Value Goodwill Disposal Group, Including Discontinued Operation, Goodwill Award Timing Predetermined Award Timing Predetermined [Flag] Sales-type Lease, Lease Income Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Cash dividends on common stock Payments of Ordinary Dividends, Common Stock Customer relationships Customer Relationships [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Current maturities of long-term debt and finance lease obligations Long-Term Debt and Finance Lease Obligations, Current Fair Value Disclosure Long-term debt and finance lease obligations, current, fair value disclosure. Forecast Forecast [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Revenue From Contract With Customer [Roll Forward] Revenue From Contract With Customer [Roll Forward] Revenue From Contract With Customer Separation costs Disposal Group, Including Discontinued Operation, Separation Costs Disposal Group, Including Discontinued Operation, Separation Costs Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contract manufacturing services Manufacturing Arrangements [Member] Manufacturing arrangements. Derivative liability, fair value, total Derivative Liability, Subject to Master Netting Arrangement, after Offset Net income (loss) Net loss Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Indemnification Agreement Indemnification Agreement [Member] Gain (loss) recognized in income, undesignated derivative instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Derivative, notional amount Derivative, Notional Amount Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] STOCKHOLDERS' EQUITY Shareholders' Equity and Share-Based Payments [Text Block] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current maturities of long-term debt and finance lease obligations Long-Term Debt and Lease Obligation, Current [Member] Long-Term Debt and Lease Obligation, Current Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Accrued expenses and other current liabilities Increase (Decrease) In Accrued Expenses And Other Current Liabilities Increase (Decrease) In Accrued Expenses And Other Current Liabilities Other Other Operating Activities, Cash Flow Statement All Adjustments to Compensation All Adjustments to Compensation [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other (Income) Expense-, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Charges Restructuring charges Restructuring Charges Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative, fair value, terminated Derivative, Number Of Fair Value Hedges Terminated Derivative, Number Of Fair Value Hedges Terminated Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Carrying amount of hedged item Hedged Liability, Fair Value Hedge Interest expense, net Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Indemnifications related to Kidney Care separation Separation-Related Costs [Member] Separation-Related Costs Currency translation Contract With Customer, Liability, Currency Translation Contract With Customer, Liability, Currency Translation Operating lease revenue Operating Lease, Lease Income Scenario [Domain] Scenario [Domain] Operating lease right-of-use assets Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets Remaining performance obligations period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Restricted cash included in other non-current assets Restricted Cash Hedging activities Gains (losses) on hedging activities Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Income from discontinued operations per common share, basic (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Reportable Segment Reportable Segment [Member] Reportable Segment Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current assets of discontinued operations Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Agreed purchase price Purchase price Disposal Group, Including Discontinued Operation, Consideration Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Financial Instruments Financial Instruments [Domain] Long-term debt and finance lease obligations, less current portion Long-Term Debt and Lease Obligation, Excluding Current Maturities Long-Term Debt and Lease Obligation, Excluding Current Maturities Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans Schedule of Net Benefit Costs [Table Text Block] Costs to implement business optimization programs Separation-related costs Restructuring and Related Cost, Incurred Cost Restatement Determination Date Restatement Determination Date Fair values Estimate of Fair Value Measurement [Member] Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral Current maturities of finance lease obligations Disposal Group, Including Discontinued Operation, Other Liabilities, Current Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate contracts Interest Rate Contract [Member] New Operating Model New Operating Model [Member] New Operating Model Injectables and Anesthesia Injectables and Anesthesia [Member] Injectables and Anesthesia Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Fair Value Disclosures [Table] Fair Value Disclosures [Table] Fair value disclosures table. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Superfund Sites Superfund Sites [Member] Superfund sites. Accrued expenses and other current liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Maximum length of time hedge in cash flow hedge Maximum Length of Time Hedged in Cash Flow Hedge SUPPLEMENTAL FINANCIAL INFORMATION Additional Financial Information Disclosure [Text Block] EARNINGS PER SHARE Earnings Per Share [Text Block] Discontinued Operations Discontinued Operations [Member] Subsequent Event Subsequent Event [Member] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] European Medical Devices Regulation European Medical Devices Regulation Expenses European Medical Devices Regulation Expenses Write-offs Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments Restructuring Plan [Axis] Restructuring Plan [Axis] Segments Segments [Domain] 0.4% Senior Notes Due May 2024 0.4% Senior Notes Due May 2024 [Member] Zero point four percentage senior notes due May two thousand twenty four. Less cash and cash equivalents of discontinued operations Cash and cash equivalents of discontinued operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations PEO PEO [Member] 1.3% Senior Notes Due May 2029 1.3% Senior Notes Due May 2029 [Member] One point three percentage senior notes due May two thousand twenty nine. Name Trading Arrangement, Individual Name Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Common stock in treasury, at cost, 170,414,885 shares in 2025 and 172,567,636 shares in 2024 Treasury Stock, Common, Value Pharmaceuticals Pharmaceuticals [Member] Pharmaceuticals. Software sales Software Arrangements [Member] Software arrangements. Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Income, net Other Nonoperating Income (Expense) [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Gross margin Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Summary of Business Optimization Charges Business Optimization Charge [Table Text Block] Business optimization charge. Product-related items Product Related Income (Loss) Product Related Income (Loss) Income from discontinued operations per common share, diluted (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Local Phone Number Local Phone Number Gross other intangible assets Intangible Assets, Gross (Excluding Goodwill) Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Changes in balance sheet items: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Contingent payments related to acquisitions Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Derivative liability, fair value Gross amounts recognized in the condensed consolidated balance sheets Derivative Liability, Subject to Master Netting Arrangement, before Offset Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common stock Common Stock [Member] Environmental Clean-up Enviromental Clean Up [Member] Enviromental clean-up. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Bridge Facility Line Of Credit Line of Credit [Member] Business Optimization Programs Business Optimization Programs [Member] Business Optimization Programs Global payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Environmental Remediation Site Environmental Remediation Site [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Other Segment Reporting, Other Segment Item, Amount Inventories Schedule of Inventory, Current [Table Text Block] Unallocated corporate costs Corporate Costs, Unallocated Corporate Costs, Unallocated Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Catastrophic Event [Domain] Catastrophic Event [Domain] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument Financial Instrument [Axis] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Exposure to Ethylene Oxide Exposure to Ethylene Oxide [Member] Exposure to Ethylene Oxide Title Trading Arrangement, Individual Title Earnings, fair value hedge, gain (loss), reclassification, before tax Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax CTA Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] City Area Code City Area Code Income tax expense (benefit) Discontinued Operation, Tax Effect of Discontinued Operation Current liabilities: Liabilities, Current [Abstract] Net decreases in debt with original maturities of three months or less Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Contingent payments related to acquisitions Business Combination, Contingent Consideration, Liability Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Interest Expense, Net Interest Income and Interest Expense Disclosure [Table Text Block] 2021 2021 And Prior Years [Member] 2021 And Prior Years Document Information [Line Items] Document Information [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Remaining revenue performance obligation, percentage of revenue expected to be recognized Revenue, Remaining Performance Obligation, Percentage Income (loss) per common share Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Net income attributable to noncontrolling interests included in continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Retained earnings Retained Earnings (Accumulated Deficit) Summary of Reclassification from AOCI to Net Income (Loss) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Deferred, net after-tax gains on derivative instruments Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Inventories Increase (Decrease) in Inventories Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax Deferred income taxes Deferred Income Taxes and Tax Credits Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Underlying Securities Award Underlying Securities Amount Dividends declared on common stock Dividends, Common Stock, Cash Amendment Flag Amendment Flag Book values Reported Value Measurement [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other long-lived asset impairments Other Asset Impairment Charges Currency translation adjustments Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments Term Loan Due Two Thousand and Twenty Six Term Loan Due Two Thousand and Twenty Six [Member] Term Loan Due Two Thousand and Twenty Six Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Senior notes Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Interest rate swap Interest Rate Swap [Member] Capitalized Contract Cost Capitalized Contract Cost [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Interest Income Expense Net Interest Income (Expense), Operating [Abstract] Other investing activities, net Payments for (Proceeds from) Other Investing Activities 1.30% Senior Notes Due May 2025 1.30% Senior Notes Due May 2025 [Member] 1.30% Senior Notes Due May 2025 Other non-current assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Front Line Care Front Line Care [Member] Front Line Care Raw materials Inventory, Raw Materials, Gross YearOf Origination [Axis] YearOf Origination [Axis] YearOf Origination Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Opelika, Alabama Manufacturing Facility Opelika, Alabama Manufacturing Facility [Member] Opelika, Alabama Manufacturing Facility Accounts payable Increase (Decrease) in Accounts Payable Environmental Remediation Contingency Environmental Remediation Contingency [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Asset Derivative Asset [Abstract] Derivative instruments designated as hedges Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted-average number of shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Cost of sales Costs of sales Cost of Goods and Services Sold Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and contingencies Commitments and Contingencies Currency translation adjustments, net of tax expense (benefit) of zero and $(2) for the three months ended March 31, 2025 and 2024, respectively. Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Discontinued Operations, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Termination Date Trading Arrangement Termination Date Accrued expenses and other current liabilities Accounts Payable and Accrued Liabilities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Undesignated derivative instruments Not Designated as Hedging Instrument [Member] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Debt Instrument Debt Instrument [Axis] Net income (loss) attributable to Baxter stockholders Net income (loss) attributable to Baxter stockholders Net Income (Loss) Attributable to Parent Other operating income, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Available-for-sale debt securities Available-For-Sale, Debt Securities [Member] Available-For-Sale, Debt Securities Book Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Line of credit, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Noncontrolling interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Reconciliation of Basic Shares to Diluted Shares Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Currency translation Restructuring Reserve, Foreign Currency Translation Gain (Loss) Indemnification liability, net Indemnification Agreement, Liability, Net Indemnification Agreement, Liability, Net Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Proceeds from divestiture of businesses, net of tax Proceeds From Divestiture Of Businesses, Net Of Tax Proceeds From Divestiture Of Businesses, Net Of Tax PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Income from continuing operations per common share, diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Comprehensive income attributable to noncontrolling interests Less: Comprehensive income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Liability Derivative Liability [Abstract] Currency translation adjustments, tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Disclosure Basis Of Presentation Details [Table] Disclosure Basis Of Presentation Details [Table] Disclosure Basis Of Presentation Details [Table] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Total equity Balance, beginning of period (in usd) Balance, end of period (in usd) Equity, Including Portion Attributable to Noncontrolling Interest Other, net Other Nonoperating Gains (Losses) Name Awards Close in Time to MNPI Disclosures, Individual Name Derivative, net investment terminated Derivative, Number Of Net Investment Terminated Derivative, Number Of Net Investment Terminated Entity Filer Category Entity Filer Category Transaction price allocated to remaining performance obligations Revenue, Remaining Performance Obligation, Amount Operating Lease, Lease Income Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revenue related to performance obligations Contract with Customer, Performance Obligation Satisfied in Previous Period Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued Expenses And Other Current Liabilities Fair Value Disclosures [Line Items] Fair Value Disclosures [Line Items] Fair value disclosure Line items. Currency translation adjustments, net of tax expense (benefit) of $6 and $13 for the three months ended March 31, 2025 and 2024, respectively. Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Work in process Inventory, Work in Process, Gross Range Statistical Measurement [Domain] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Kidney Care Manufacturing and Supply Agreement Kidney Care Manufacturing and Supply Agreement [Member] Kidney Care Manufacturing and Supply Agreement Developed technology, including patents Developed Technology Including Patents [Member] Developed technology including patents. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Medical Products & Therapies Medical Products And Therapies [Member] Medical Products And Therapies All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Net Income (Loss) attributable to Stockholder Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] New York Stock Exchange NEW YORK STOCK EXCHANGE, INC. [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long-term debt Long-Term Debt [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income (loss) from discontinued operations per common share Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Weighted-average term Original Weighted-Average Term Original Weighted-Average Term Classification and Fair Values of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Goodwill [Line Items] Goodwill [Line Items] Balance, beginning of period (in shares) Balance, end of period (in shares) Common Stock, Shares, Outstanding Operating lease liabilities Operating Lease, Liability, Noncurrent Cash Flow Hedging Cash Flow Hedging [Member] Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Service cost Defined Benefit Plan, Service Cost Fair Value And Carrying Value By Balance Sheet Grouping [Table] Fair Value And Carrying Value By Balance Sheet Grouping [Table] Fair Value And Carrying Value By Balance Sheet Grouping [Table] Entity Tax Identification Number Entity Tax Identification Number Equity method investment impairment Equity Method Investment, Other-than-Temporary Impairment Purchases of treasury stock (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type Retirement Plan Type [Axis] SG&A Selling, General and Administrative Expenses [Member] Common stock in treasury Treasury Stock, Common [Member] Bridge Facility Bridge Facility [Member] Bridge Facility Other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Equity Components Equity Components [Axis] Available-for-sale debt securities Debt Securities, Available-for-Sale Trade names Trade Names [Member] Cash flows from investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Geographical Geographical [Axis] Components of Restructuring Charges Restructuring and Related Costs [Table Text Block] Gain on disposition Gain (Loss) on Disposition of Business Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Net income attributable to noncontrolling interests included in discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Payments Payments for Restructuring Environmental Remediation Site Environmental Remediation Site [Domain] Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Marketable equity securities Equity Securities, FV-NI, Current Current assets: Assets, Current [Abstract] Care and Connectivity Solutions Care and Connectivity Solutions [Member] Care and Connectivity Solutions Consolidation Items Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Treasury stock, shares (in shares) Balance, treasury, beginning period (in shares) Balance, treasury, ending period (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Security Exchange Name Security Exchange Name Rate increase following December 31, 2024 milestone Debt Instrument, Basis Spread on Variable Rate Pre-tax gain from divestiture of business Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Pre-Tax Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Pre-Tax Amounts reclassified from AOCI Reclassification out of Accumulated Other Comprehensive Income [Member] Discontinued operations, pension and other postretirement benefits, tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Less: Other comprehensive loss attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Capital expenditures Payments to Acquire Other Productive Assets 2024 2024 [Member] 2024 Short-term debt Short-Term Debt Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expenses Research and Development Expense Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] Revenue recognized contract period Revenue Recognized Contract Period Revenue recognized contract period. Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income (loss), before tax Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net trade accounts receivable Accounts Receivable, after Allowance for Credit Loss Common stock, authorized (in shares) Common Stock, Shares Authorized YearOf Origination [Domain] YearOf Origination [Domain] YearOf Origination [Domain] Total other comprehensive income (loss) from continuing operations, net of tax Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax Total business optimization charges Restructuring Costs Total other comprehensive income (loss) from discontinued operations Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Infusion Therapies and Technologies Infusion Therapies and Technologies [Member] Infusion Therapies and Technologies Amortization of net losses and prior service costs Defined Benefit Plan, Amortization of Gain (Loss) Hedging Designation Hedging Designation [Domain] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Interest expense, net of capitalized interest Interest Expense, Nonoperating Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Intangible Asset Excluding Goodwill [Table] Intangible Asset Excluding Goodwill [Table] Intangible Asset Excluding Goodwill [Table] Pension and other postretirement benefit plans Pension and Other Postretirement Benefits Cost (Reversal of Cost) Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable, net of allowances of $66 in 2025 and $71 in 2024 Accounts Receivable, after Allowance for Credit Loss, Current Severance, Contract Termination, And Other Employee Related Costs Severance, Contract Termination, And Other Employee Related Costs [Member] Severance, Contract Termination, And Other Employee Related Costs Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Kidney Care Transition Services Agreement Kidney Care Transition Services Agreement [Member] Kidney Care Transition Services Agreement Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Current liabilities of discontinued operations Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net Of Distributions, Net Of Tax Other Comprehensive Income (Loss), Net Of Distributions, Net Of Tax Total Baxter stockholders' equity Parent [Member] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Hedging activities, net of tax expense (benefit) of ($1) and $2 for the three months ended March 31, 2025 and 2024, respectively. Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Intangible asset amortization expense Amortization of Intangible Assets Contract liabilities Balance at beginning of period Balance at end of period Contract with Customer, Liability International Non-US [Member] Long-term finance lease obligations, less current portion Disposal Group, Including Discontinued Operations, Financing Lease Liabilities Disposal Group, Including Discontinued Operations, Financing Lease Liabilities Current Fiscal Year End Date Current Fiscal Year End Date Catastrophic Event [Axis] Catastrophic Event [Axis] PEO Name PEO Name All Award Types Award Type [Domain] Accounts receivable, net of allowances Assets held for sale Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Foreign exchange contracts Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax Discontinued Operations, Held-for-Sale Discontinued Operations, Held-for-Sale [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Indemnifications related to kidney care separation Business Separation, Indemnification, Liability Business Separation, Indemnification, Liability Foreign exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Additional contributed capital Additional Paid-in Capital [Member] Hedging Relationship Hedging Relationship [Axis] Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS Retirement Benefits [Text Block] Emerging Markets Eastern Europe, Middle East, Africa, Latin America, Asia [Member] Eastern Europe, Middle East, Africa, Latin America, Asia Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Reconciliation of Basic Shares to Diluted Shares Schedule of Weighted Average Number of Shares [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Common Stock, $1.00 par value Common Stock, $1.00 per Value [Member] Common Stock, $1.00 per Value Type of Restructuring Type of Restructuring [Domain] Income (loss) from discontinued operations attributable to Baxter stockholders Income (loss) from discontinued operations attributable to Baxter stockholders Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Sales-type lease, net of investment in lease Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Number of sites Site Contingency Number Of Sites Site contingency, number of sites. Number of operating segments Number of Operating Segments number of de-designations Derivative, Number Of De-designations Derivative, Number Of De-designations Summary of Financial Instruments Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Revenue From Contract With Customer [Table] Disaggregation of Revenue [Table] Foreign exchange losses, net Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Employee termination costs Employee Severance [Member] Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current BUSINESS OPTIMIZATION CHARGES Restructuring and Related Activities Disclosure [Text Block] Stock compensation Share-Based Payment Arrangement, Noncash Expense Total derivative instruments, liabilities Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement Pension and OPEB items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Inventories Disposal Group, Including Discontinued Operation, Inventory Senior notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Allowance for Doubtful Accounts Receivable [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Summary of Gains and Losses on Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Domain] Change in fair value of marketable equity securities Increase (Decrease) in Equity Securities, FV-NI Revenue recognized upon satisfaction of performance obligations Contract with Customer, Liability, Total Revenue Recognized Contract with Customer, Liability, Total Revenue Recognized Operating income Operating income Operating Income (Loss) Contract termination and other costs Contract Termination And Other Costs [Member] Contract termination and other costs. Total liabilities and equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Acquisition and integration items Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Hedging Designation Hedging Designation [Axis] DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax Less: Income (loss) from discontinued operations, net of tax Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Current maturities of long-term debt and finance lease obligations Long-Term Debt and Lease Obligation, Current Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Accumulated other comprehensive loss Total AOCI Attributable to Parent [Member] Inventories Inventories Inventory, Net Liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities Cash flows from investing activities - continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Product and Service Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Operating Income to Income Before Income Taxes Reconciliation Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Number of complaints Number of Complaints Number of Complaints Disclosure Basis Of Presentation Details [Line Items] Disclosure Basis Of Presentation Details [Line Items] Disclosure Basis Of Presentation Details [Line Items] Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Minimum Minimum [Member] Number of lawsuits Loss Contingency, Number Of Lawsuits Loss Contingency, Number Of Lawsuits Adoption Date Trading Arrangement Adoption Date Asset write offs Asset Write Offs [Member] Asset Write Offs Rest of world Western Europe, Canada, Japan, Australia and New Zealand [Member] Western Europe, Canada, Japan, Australia and New Zealand Charged to costs and expenses Accounts Receivable, Credit Loss Expense (Reversal) Segments Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] U.S. Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument Derivative Instrument [Axis] Exercise Price Award Exercise Price Selling, general and administrative expenses Disposal Group, Including Discontinued Operation, General and Administrative Expense Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Kidney Care Kidney Care [Member] Kidney Care GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill and Intangible Assets Disclosure [Text Block] Income from continuing operations per common share, basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other (income) expense, net Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) OPEB Other Postretirement Benefits Plan [Member] Gain from divestiture of business, net of tax Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Net of Tax Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Net of Tax Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangible assets, net Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Accumulated pre-tax unrealized translation gain in AOCI Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Proceeds from stock issued under employee benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Disposition of noncontrolling interest associated with the Kidney Care separation Noncontrolling Interest, Decrease From Distributed Related To Kidney Care Separation Noncontrolling Interest, Decrease From Distributed Related To Kidney Care Separation Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Risks and Uncertainties Risks and Uncertainties Policy [Policy Text Block] Risks and Uncertainties Policy Interest expense, net Interest Expense [Member] Senior Unsecured Term Loans Senior Unsecured Term Loans [Member] Senior Unsecured Term Loans COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Healthcare Systems & Technologies Healthcare Systems and Technologies [Member] Healthcare Systems and Technologies Measure: Measure [Axis] Stock issued under employee benefit plans and other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Available-for-sale debt securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total liabilities Liabilities, Fair Value Disclosure Intangible Asset Excluding Goodwill [Line Items] Intangible Asset Excluding Goodwill [Line Items] Intangible Asset Excluding Goodwill [Line Items] Consumable Medical Products Consumable Medical Products [Member] Consumable medical products [Member]. 2023 2023 [Member] 2023 Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Contingent payments related to acquisitions Acquisition-related Costs [Member] Equity Component Equity Component [Domain] Cash flows from operations – discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Amounts reclassified from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Statement [Table] Statement [Table] Fair Value, Measurement Frequency Measurement Frequency [Domain] Net periodic pension and other postretirement costs Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash Consolidation Items Consolidation Items [Domain] Variable lease revenue Variable Lease, Income Income (loss) from discontinued operations before gain on disposition and income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Derivative asset, fair value, total Derivative Asset, Subject to Master Netting Arrangement, after Offset Interest expense, net Interest Income (Expense), Operating and Nonoperating Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Foreign exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] 2025 2025 [Member] 2025 Other equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Other amortized intangible assets Other Intangible Assets [Member] INCOME TAXES Income Tax Disclosure [Text Block] 2022 2022 [Member] 2022 Other non-current liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Business optimization items Business Optimization Income (Loss) Business Optimization Income (Loss) Hedging activities, tax Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Credit Facility [Axis] Credit Facility [Axis] 1.3% Global Notes due 2025 Global Notes 1.3% due 2025 [Member] Global Notes 1.3% due 2025 Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Gross margin Gross Profit Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Axis] Business guarantees retained Business Guarantees Retained, Value Business Guarantees Retained, Value Fair Value as of Grant Date Award Grant Date Fair Value Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical Geographical [Domain] Other intangible assets, net Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net Property, Plant and Equipment Property, Plant and Equipment [Member] Basis of Presentation Consolidation, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2025 and 2024 Common Stock, Value, Issued Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Derivative Positions Presented On Net Basis Schedule Of Derivative Positions Presented On Net Basis Table [Table Text Block] Schedule of derivative positions presented on net basis. NYSE CHICAGO, INC. NYSE CHICAGO, INC. [Member] Research and development expenses Disposal Group, Including Discontinued Operations, Research And Development Expense Disposal Group, Including Discontinued Operations, Research And Development Expense Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Finished goods Inventory, Finished Goods, Gross Forward Contracts Forward Contracts [Member] Basic (in dollars per share) Earnings Per Share, Basic New revenue deferrals Contract With Customer, Liability, Deferred Revenue Contract With Customer, Liability, Deferred Revenue Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Commercial paper, outstanding Commercial Paper, Average Outstanding Capital expenditures incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Total current liabilities Liabilities, Current Borrowings outstanding Long-Term Line of Credit Operating lease liabilities Disposal Group, Including Discontinued Operation, Operating Lease Liability Disposal Group, Including Discontinued Operation, Operating Lease Liability Entity Address, City or Town Entity Address, City or Town Non-current liabilities of discontinued operations Non-current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Drug Compounding Pharmaceutical Compounding [Member] Pharmaceutical Compounding ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Liabilities Liabilities, Fair Value Disclosure [Abstract] REVENUES Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Debt Instrument, Name Debt Instrument, Name [Domain] Comprehensive income (loss) from discontinued operations Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax Total assets Assets, Fair Value Disclosure Document Period End Date Document Period End Date Insider Trading Arrangements [Line Items] Segment Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Revenue recognized upon satisfaction of performance obligations Contract with Customer, Liability, Revenue Recognized Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Foreign exchange contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Advanced Surgery Advanced Surgery [Member] Advanced surgery. Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Retained earnings Retained Earnings [Member] Short-term debt Short-term Debt, Current Fair Value Disclosure Short-term Debt, Current Fair Value Disclosure Legal matters Litigation Settlement, Fee Expense Transaction service agreement, period Transaction Service Agreement, Period Transaction Service Agreement, Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Liabilities held for sale Disposal Group, Including Discontinued Operation, Accounts Payable, Current Sales-type leases, receivables Sales-type and Direct Financing Leases, Lease Receivable Reserve, beginning balance Reserve, ending balance Restructuring Reserve Income Statement Location Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 13 bax-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - shares
 3 Months Ended
Mar. 31, 2025
Apr. 30, 2025
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 1-4448  
Entity Registrant Name BAXTER INTERNATIONAL INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 36-0781620  
Entity Address, Address Line One One Baxter Parkway,  
Entity Address, City or Town Deerfield,  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60015  
City Area Code 224.  
Local Phone Number 948.2000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   513,174,623
Amendment Flag false  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000010456  
Current Fiscal Year End Date --12-31  
Common Stock, $1.00 par value | New York Stock Exchange    
Document Information [Line Items]    
Title of 12(b) Security Common Stock, $1.00 par value  
Trading Symbol BAX (NYSE)  
Security Exchange Name NYSE  
Common Stock, $1.00 par value | NYSE CHICAGO, INC.    
Document Information [Line Items]    
Title of 12(b) Security Common Stock, $1.00 par value  
Trading Symbol BAX (NYSE)  
1.3% Global Notes due 2025 | New York Stock Exchange    
Document Information [Line Items]    
Title of 12(b) Security 1.3% Global Notes due 2025  
Trading Symbol BAX 25  
Security Exchange Name NYSE  
1.3% Global Notes due 2029 | New York Stock Exchange    
Document Information [Line Items]    
Title of 12(b) Security 1.3% Global Notes due 2029  
Trading Symbol BAX 29  
Security Exchange Name NYSE  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 2,294 $ 1,764
Accounts receivable, net of allowances of $66 in 2025 and $71 in 2024 1,646 1,679
Inventories 2,170 2,046
Prepaid expenses and other current assets 925 753
Current assets of discontinued operations 0 2,611
Total current assets 7,035 8,853
Property, plant and equipment, net 2,717 2,870
Goodwill 5,338 5,275
Other intangible assets, net 5,081 5,223
Operating lease right-of-use assets 301 306
Other non-current assets 832 755
Non-current assets of discontinued operations 0 2,500
Total assets 21,304 25,782
Current liabilities:    
Short-term debt 11 2,126
Current maturities of long-term debt and finance lease obligations 651 626
Accounts payable 963 968
Accrued expenses and other current liabilities 1,856 1,861
Current liabilities of discontinued operations 0 930
Total current liabilities 3,481 6,511
Long-term debt and finance lease obligations, less current portion 9,412 10,374
Operating lease liabilities 235 243
Other non-current liabilities 1,122 1,076
Non-current liabilities of discontinued operations 0 554
Total liabilities 14,250 18,758
Commitments and contingencies
Equity:    
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2025 and 2024 683 683
Common stock in treasury, at cost, 170,414,885 shares in 2025 and 172,567,636 shares in 2024 (10,937) (11,059)
Additional contributed capital 6,309 6,421
Retained earnings 14,968 14,929
Accumulated other comprehensive loss (3,942) (4,010)
Total Baxter stockholders’ equity 7,081 6,964
Noncontrolling interests (27) 60
Total equity 7,054 7,024
Total liabilities and equity $ 21,304 $ 25,782
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Allowance for accounts receivable, current $ 66 $ 71
Common stock, par value (in dollars per share) $ 1 $ 1
Common stock, authorized (in shares) 2,000,000,000 2,000,000,000
Common stock, issued (in shares) 683,494,944 683,494,944
Treasury stock, shares (in shares) 170,414,885 172,567,636
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Loss (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Net sales $ 2,625 $ 2,490
Cost of sales 1,764 1,529
Gross margin 861 961
Selling, general and administrative expenses 703 729
Research and development expenses 140 120
Other operating income, net (40) (3)
Operating income 58 115
Interest expense, net 64 78
Other (income) expense, net 3 9
Income (loss) from continuing operations before income taxes (3) 46
Income tax expense (benefit) (67) 40
Income (loss) from continuing operations 64 6
Income (loss) from discontinued operations, net of tax 62 33
Net income (loss) 126 39
Net income attributable to noncontrolling interests included in continuing operations 0 0
Net income attributable to noncontrolling interests included in discontinued operations 0 2
Less: Comprehensive income attributable to noncontrolling interests 0 2
Net income (loss) attributable to Baxter stockholders $ 126 $ 37
Income (loss) from continuing operations per common share    
Income from continuing operations per common share, basic (in dollars per share) $ 0.13 $ 0.01
Income from continuing operations per common share, diluted (in dollars per share) 0.13 0.01
Income (loss) from discontinued operations per common share    
Income from discontinued operations per common share, basic (in dollars per share) 0.12 0.06
Income from discontinued operations per common share, diluted (in dollars per share) 0.12 0.06
Income (loss) per common share    
Basic (in dollars per share) 0.25 0.07
Diluted (in dollars per share) $ 0.25 $ 0.07
Weighted-average number of shares outstanding    
Basic (in shares) 512 508
Diluted (in shares) 514 510
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Income (loss) from continuing operations $ 64 $ 6
Other comprehensive income (loss) from continuing operations, net of tax:    
Currency translation adjustments, net of tax expense (benefit) of $6 and $13 for the three months ended March 31, 2025 and 2024, respectively. (68) (119)
Pension and other postretirement benefits, net of tax expense (benefit) of ($4) and $3 for the three months ended March 31, 2025 and 2024, respectively. 12 4
Hedging activities, net of tax expense (benefit) of ($1) and $2 for the three months ended March 31, 2025 and 2024, respectively. (2) 8
Total other comprehensive income (loss) from continuing operations, net of tax (58) (107)
Comprehensive income (loss) from continuing operations 6 (101)
Income (loss) from discontinued operations, net of tax 62 33
Currency translation adjustments, net of tax expense (benefit) of zero and $(2) for the three months ended March 31, 2025 and 2024, respectively. 137 (65)
Pension and other postretirement benefits, net of tax expense (benefit) of $(3) and zero for the three months ended March 31, 2025 and 2024, respectively. (11) 0
Total other comprehensive income (loss) from discontinued operations 126 (65)
Comprehensive income (loss) from discontinued operations 188 (32)
Comprehensive income (loss) 194 (133)
Less: Comprehensive income attributable to noncontrolling interests 0 2
Less: Other comprehensive loss attributable to noncontrolling interests 0 (4)
Comprehensive income (loss) attributable to Baxter stockholders $ 194 $ (131)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Currency translation adjustments, tax $ 6,000,000 $ 13,000,000
Pension and other postretirement benefits, tax (4,000,000) 3,000,000
Hedging activities, tax (1,000,000) 2,000,000
Discontinued operations, currency translation adjustments, net of tax 0 (2,000,000)
Discontinued operations, pension and other postretirement benefits, tax $ (3,000,000) $ 0
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Equity (unaudited) - USD ($)
$ in Millions
Total
Total Baxter stockholders' equity
Common stock
Common stock in treasury
Additional contributed capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interests
Balance, beginning of period (in shares) at Dec. 31, 2023     683,000,000          
Balance, beginning of period (in usd) at Dec. 31, 2023 $ 8,468 $ 8,402 $ 683 $ (11,230) $ 6,389 $ 16,114 $ (3,554) $ 66
Balance, treasury, beginning period (in shares) at Dec. 31, 2023       176,000,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss 39 37       37   2
Other comprehensive income (loss) (172) (168)         (168) (4)
Stock issued under employee benefit plans and other (in shares)       (2,000,000)        
Stock issued under employee benefit plans and other 50 50   $ 100 (50)      
Dividends declared on common stock (148) (148)       (148)    
Change in noncontrolling interests (2)             (2)
Balance, end of period (in shares) at Mar. 31, 2024     683,000,000          
Balance, end of period (in usd) at Mar. 31, 2024 8,235 8,173 $ 683 $ (11,130) 6,339 16,003 (3,722) 62
Balance, treasury, ending period (in shares) at Mar. 31, 2024       174,000,000        
Balance, beginning of period (in shares) at Dec. 31, 2024     683,000,000          
Balance, beginning of period (in usd) at Dec. 31, 2024 $ 7,024 6,964 $ 683 $ (11,059) 6,421 14,929 (4,010) 60
Balance, treasury, beginning period (in shares) at Dec. 31, 2024 172,567,636     173,000,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss $ 126 126       126   0
Other comprehensive income (loss) (47) (47)         (47)  
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation 115 115         115  
Stock issued under employee benefit plans and other (in shares)       (3,000,000)        
Stock issued under employee benefit plans and other 10 10   $ 122 (112)      
Dividends declared on common stock (87) (87)       (87)    
Disposition of noncontrolling interest associated with the Kidney Care separation (87)             (87)
Balance, end of period (in shares) at Mar. 31, 2025     683,000,000          
Balance, end of period (in usd) at Mar. 31, 2025 $ 7,054 $ 7,081 $ 683 $ (10,937) $ 6,309 $ 14,968 $ (3,942) $ (27)
Balance, treasury, ending period (in shares) at Mar. 31, 2025 170,414,885     170,000,000        
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operations    
Net income (loss) $ 126 $ 39
Less: Income (loss) from discontinued operations, net of tax 62 33
Income (loss) from continuing operations 64 6
Adjustments to reconcile net loss to cash flows from operations:    
Depreciation and amortization 247 271
Deferred income taxes (142) (58)
Stock compensation 10 17
Net periodic pension and other postretirement costs (8) (7)
Other long-lived asset impairments 22 0
Other 6 5
Changes in balance sheet items:    
Accounts receivable, net 26 125
Inventories (122) (145)
Prepaid expenses and other current assets (24) (4)
Accounts payable 16 119
Accrued expenses and other current liabilities (143) (240)
Other (51) (22)
Cash flows from operations – continuing operations (99) 67
Cash flows from operations – discontinued operations (94) 96
Cash flows from operations (193) 163
Cash flows from investing activities    
Capital expenditures (122) (110)
Other investing activities, net (2) 10
Cash flows from investing activities - continuing operations (124) (100)
Cash flows from investing activities - discontinued operations 3,389 (66)
Cash flows from investing activities 3,265 (166)
Cash flows from financing activities    
Repayments of debt (2,825) (15)
Net decreases in debt with original maturities of three months or less (300) 0
Cash dividends on common stock (87) (147)
Proceeds from stock issued under employee benefit plans 10 40
Other financing activities, net (24) (18)
Cash flows from financing activities (3,226) (140)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations 36 (25)
Increase (decrease) in cash, cash equivalents and restricted cash (118) (168)
Cash, cash equivalents and restricted cash at start of period [1] 2,414 3,198
Cash, cash equivalents and restricted cash at end of period [1] 2,296 3,030
Less cash and cash equivalents of discontinued operations 0 200
Cash, cash equivalents and restricted cash $ 2,296 $ 2,830
[1] The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of March 31, 2025, December 31, 2024, and March 31, 2024 (in millions):
March 31, 2025December 31, 2024March 31, 2024
Cash and cash equivalents$2,294 $1,764 $2,826 
Restricted cash included in other non-current assets2 2 4 
Cash and cash equivalents of discontinued operations— 648 200 
Cash, cash equivalents and restricted cash$2,296 $2,414 $3,030 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Statement of Cash Flows [Abstract]      
Cash and cash equivalents $ 2,294 $ 1,764 $ 2,826
Restricted cash included in other non-current assets 2 2 4
Cash and cash equivalents of discontinued operations 0 648 200
Cash, cash equivalents and restricted cash [1] $ 2,296 $ 2,414 $ 3,030
[1] The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of March 31, 2025, December 31, 2024, and March 31, 2024 (in millions):
March 31, 2025December 31, 2024March 31, 2024
Cash and cash equivalents$2,294 $1,764 $2,826 
Restricted cash included in other non-current assets2 2 4 
Cash and cash equivalents of discontinued operations— 648 200 
Cash, cash equivalents and restricted cash$2,296 $2,414 $3,030 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.25.1
BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).
In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the net after tax proceeds of approximately $3.3 billion, subject to certain post-closing adjustments. The financial position, results of operations and cash flows of our Kidney Care business, including the gain on sale of that business and the related cash proceeds received, are reported as discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations. See Note 2 for additional information.
Hurricane Helene
In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, North Carolina and disrupted operations at that facility. Since then, we have actively worked with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we worked towards resuming our North Cove manufacturing operations. While we continue to increase allocation levels across key impacted product groups, the facility was fully operational by the end of the first quarter of 2025. In the first quarter of 2025, we recorded $98 million of pre-tax net charges related to remediation, air freight and other costs as a result of the damages caused by Hurricane Helene. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three month period ended March 31, 2025.
Risks and Uncertainties
Supply Constraints, Tariffs and Global Economic Conditions
We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which caused the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify
additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative of lower cost raw material or component parts.
We expect that these challenges, among other factors, may continue to have an adverse effect on our business.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS
A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation as described below.
Discontinued Operations - Kidney Care
On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction. We recognized a pre-tax gain on the sale of $191 million ($111 million net of tax).
We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation.
Upon closing of the sale of the Kidney Care business, pursuant to the Equity Purchase Agreement (EPA), Baxter and Vantive entered into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a Transition Services Agreement (Kidney Care TSA), a Long Term Master Services Agreement, a Distribution Agreement and certain other arrangements providing for short-term supply of saline products, and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities provide each other with certain dialysis-related products, other products, product components and fulfillment services for up to 10 years post-closing (with certain extension rights and early exit rights as provided therein). Pursuant to the Kidney Care MSA, our sales to Vantive are recognized in net sales in the condensed consolidated statements of income (loss). Pursuant to the Kidney Care TSA, Baxter and the entities that were divested in connection with the Kidney Care sale (the Kidney Care divested entities) provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights and early exit rights as provided therein) to help ensure business continuity and help minimize disruptions to the operations of both parties post-closing. Services provided under the Kidney Care TSA include information technology applications and support, supply chain and certain other corporate and administrative services. Billings by us under the Kidney Care TSA are recorded in other operating income, net in the condensed consolidated statements of income. The costs to provide each respective service is recorded in the applicable expense category in the condensed consolidated statements of income (loss).
In accordance with the EPA, we have agreed to indemnify Vantive for certain items, including taxes imposed on or with respect to the Kidney Care divested entities, for pre-closing tax periods. The net indemnification liability as of March 31, 2025 was $37 million. Further, in accordance with the EPA, Baxter recorded a contingent liability for payments to reimburse Vantive for qualifying capital expenditures over a period of three years post sale. The contingent liability as of March 31, 2025 was $133 million. Certain of the business guarantees originally entered by us on behalf of the Kidney Care business were not released prior to the completion of the sale and remain outstanding. These legacy guarantees primarily relate to leases, performance contracts and ones to support regulatory requirements of the Kidney Care business. As of March 31, 2025, the total amount of Kidney Care business guarantees retained by us is approximately $300 million. Under terms of the EPA, Carlyle has agreed to indemnify us for any cost or expense, or payments made in the future under these arrangements.
Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations
The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
(in millions)20252024
Net sales$352 $1,102 
Cost of sales206 676 
Gross margin146 426 
Selling, general and administrative expenses116 298 
Research and development expenses16 56 
Operating income (loss)14 72 
Interest expense, net13 — 
Other (income) expense, net7 2 
Income (loss) from discontinued operations before gain on disposition and income taxes(6)70 
Gain on disposition191 — 
Income tax expense (benefit)123 37 
Income from discontinued operations, net of tax62 33 
Less: Net income attributable to noncontrolling interest included in discontinued operations— 2 
Net income attributable to Baxter stockholders included in discontinued operations$62 $31 
For the three months ended March 31, 2025 and 2024, selling, general and administrative expenses (SG&A) includes $37 million and $88 million, respectively, of separation-related costs incurred in connection with the sale of our Kidney Care business.
The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of December 31, 2024:
(in millions)December 31, 2024
Cash and cash equivalents$648 
Accounts receivable, net of allowances942 
Inventories821 
Prepaid expenses and other current assets200 
Current assets of discontinued operations2,611 
Property, plant and equipment, net1,516 
Goodwill265 
Other intangible assets, net148 
Operating lease right-of-use assets204 
Other non-current assets367 
Non-current assets of discontinued operations2,500 
Assets of discontinued operations$5,111 
Current maturities of finance lease obligations$1 
Accounts payable344 
Accrued expenses and other current liabilities585 
Current liabilities of discontinued operations930 
Long-term finance lease obligations, less current portion37 
Operating lease liabilities173 
Other non-current liabilities344 
Non-current liabilities of discontinued operations554 
Liabilities of discontinued operations$1,484 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTAL FINANCIAL INFORMATION
Allowance for Doubtful Accounts
The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
(in millions)20252024
Balance at beginning of period$71 $62 
Charged to costs and expenses(4)(1)
Write-offs(2)(3)
Currency translation adjustments1 (2)
Balance at end of period$66 $56 
Inventories
(in millions)March 31,
2025		December 31,
2024
Raw materials$550 $510 
Work in process310 266 
Finished goods1,310 1,270 
Inventories$2,170 $2,046 
Property, Plant and Equipment, Net
(in millions)March 31,
2025		December 31,
2024
Property, plant and equipment, at cost$7,431 $7,648 
Accumulated depreciation(4,714)(4,778)
Property, plant and equipment, net$2,717 $2,870 
Other Current Assets and Liabilities
In connection with the sale of our Kidney Care business and pursuant to the EPA, the Kidney Care assets and liabilities in certain countries are to be transferred at a later date for operational, regulatory or other reasons. Accordingly, the related assets, primarily consisting of accounts receivable, of $95 million and liabilities, consisting of accounts payable, of $7 million of these deferred markets and are presented within prepaid and other current assets and accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of March 31, 2025.
In the first quarter of 2025, we signed a purchase agreement with a buyer to sell our manufacturing facility in Opelika, Alabama for $25 million, subject to the satisfaction of various closing conditions. The related assets are classified as held-for-sale and are presented within prepaid and other current assets in the accompanying condensed consolidated balance sheet as of March 31, 2025. While the closing remains subject to the satisfaction of various closing conditions, we currently expect the transaction to close in 2025 and the net book value of the assets as of March 31, 2025 approximates the transaction price net of estimated selling costs.
Interest Expense, Net
Three Months Ended March 31,
(in millions)20252024
Interest expense, net of capitalized interest$81 $103 
Interest income(17)(25)
Interest expense, net$64 $78 
Other (Income) Expense, Net
Three Months Ended March 31,
(in millions)20252024
Foreign exchange losses, net$— $14 
Pension and other postretirement benefit plans(11)(13)
Change in fair value of marketable equity securities1 (3)
Equity method investment impairment9 — 
Other, net(2)(7)
Other (income) expense, net$(3)$(9)
Non-Cash Operating and Investing Activities
Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2025 and 2024 were $5 million and $16 million, respectively.
Purchases of property, plant and equipment included in accounts payable as of March 31, 2025 and 2024 were $39 million and $35 million, respectively.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS, NET GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The following is a reconciliation of goodwill by segment.
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsTotal
Balance as of December 31, 2024$1,185 $3,550 $540 $5,275 
Currency translation 38 8 17 63 
Balance as of March 31, 2025$1,223 $3,558 $557 $5,338 
Other intangible assets, net
The following is a summary of our other intangible assets.
Indefinite-lived intangible assets
(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and Development
Total
December 31, 2024
Gross other intangible assets$3,387 $3,131 $958 $86 $680 $107 $8,349 
Accumulated amortization(878)(2,075)(107)(66)— — (3,126)
Other intangible assets, net$2,509 1,056 851 20 680 107 5,223 
March 31, 2025
Gross other intangible assets$3,389 $3,154 $953 $88 $680 $107 $8,371 
Accumulated amortization(932)(2,170)(119)(69)— — (3,290)
Other intangible assets, net$2,457 $984 $834 $19 $680 $107 $5,081 
Intangible asset amortization expense was $155 million and $158 million for the three months ended March 31, 2025 and 2024, respectively
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.25.1
FINANCING ARRANGEMENTS
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
FINANCING ARRANGEMENTS FINANCING ARRANGEMENTS
Significant Debt Activity
In February 2025, we repaid $1.00 billion under our $1.64 billion five-year term loan facility maturing in 2026.
Credit Facilities
On July 17, 2024, we entered into a credit agreement pursuant to which a group of banks provided us senior unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%. We also incurred a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banks’ funding commitments under the bridge facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we were required to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contained financial and other covenants, including a net leverage
covenant, and provided for customary events of default. There was $1.83 billion outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the approximately $3.3 billion of net after-tax cash proceeds from the sale of our Kidney Care business to repay the $1.83 billion outstanding under the bridge facility, at which time it was terminated.
As of March 2025, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of term loans outstanding, a U.S Dollar-denominated revolving credit facility and a Euro-denominated revolving credit facility. Our U.S. Dollar-denominated revolving credit facility has a current capacity of $2.00 billion and our Euro-denominated revolving credit facility has a capacity of €200 million. Each of the facilities is scheduled to mature in 2026. There were no borrowings outstanding under these credit facilities as of March 31, 2025 or December 31, 2024. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of March 31, 2025 we have capacity to draw $2.04 billion under our credit facilities.
Commercial Paper
There was no commercial paper outstanding as of March 31, 2025. As of December 31, 2024, we had $300 million of commercial paper outstanding with a weighted-average interest rate of 4.78% and an original term of 45 days. In the first quarter of 2025, we repaid the $300 million balance outstanding as of December 31, 2024.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2025 and December 31, 2024, our total recorded reserves with respect to legal and environmental matters were $46 million and $40 million, respectively.
We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.
In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.
Environmental
We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of March 31, 2025 and December 31, 2024, our environmental reserves, which are measured on an undiscounted basis, were $28 million and $29 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.
General Litigation
In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 41 lawsuits (after giving effect to the September 2024 amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. In the second quarter of 2025, plaintiffs filed a motion to voluntarily dismiss Baxter from 29 of the filed cases, which was granted by the Court. The parties have reached an agreement in principle to resolve the remaining filed cases, along with certain additional matters, for an amount not material to Baxter.
We acquired Hill-Rom Holdings, Inc. (Hillrom) on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (the 2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws.
On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery. Fact discovery is ongoing.
On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020” and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint. On November 8, 2024, Hillrom
filed a Motion to Dismiss Plaintiff's Amended Complaint. Briefing was completed in January 2025, and the court held a hearing on the motion on March 25, 2025. The motion is pending before the court.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS’ EQUITY
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Cash Dividends
Cash dividends declared per share for the three months ended March 31, 2025 and 2024 were $0.17 and $0.29, respectively.
Stock Repurchase Programs
In July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first three months of 2025 and 2024 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of March 31, 2025.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.25.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.
The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2025 and 2024.
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2024
$(3,430)$(475)$(108)$3 $(4,010)
Other comprehensive income (loss) before reclassifications(57)14 — — (43)
Amounts reclassified from AOCI (a)126 (13)(2)— 111 
Net other comprehensive income (loss) 69 1 (2)— 68 
Balance as of March 31, 2025$(3,361)$(474)$(110)$3 $(3,942)
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2023$(2,985)$(452)$(120)$3 $(3,554)
Other comprehensive income (loss) before reclassifications(180)5 6 — (169)
Amounts reclassified from AOCI (a)
— (1)2 — 1 
Net other comprehensive income (loss) (180)4 8 — (168)
Balance as of March 31, 2024$(3,165)$(448)$(112)$3 $(3,722)
(a)    See table below for details about these reclassifications.
The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2025 and 2024.
Amounts reclassified from AOCI (a)
(in millions)Three Months Ended March 31, 2025Three Months Ended March 31, 2024Location of impact in income statement
CTA
Reclassification of cumulative translation loss to earnings from Kidney Care separation$(126)$— Income from discontinued operations, net of tax
Less: Tax effect— — Income from discontinued operations, net of tax
$(126)$— Net of tax
Pension and OPEB items
Amortization of net losses and prior service costs or credits$3 $2 Other (income) expense, net
Pension settlement from Kidney Care separation14 — Income from discontinued operations, net of tax
17 2 Total before tax
Less: Tax effect(1)(1)Income tax expense
Less: Tax effect on pension settlement from Kidney Care separation(3)— Income from discontinued operations, net of tax
$13 $1 Net of tax
Gains (losses) on hedging activities
Foreign exchange contracts$(1)$2 Cost of sales
Interest rate contracts4 (1)Interest expense, net
Fair value hedges— (3)Other (income) expense, net
3 (2)Total before tax
Less: Tax effect(1)— Income tax expense
$2 $(2)Net of tax
Total reclassifications for the period$(111)$(1)Total net of tax
(a)    Amounts in parentheses indicate reductions to net income
Refer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30 to 90 days.
Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.
To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems & Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.
As of March 31, 2025, we had $10.19 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products & Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 15% of this amount as revenue over the remainder of 2025, 20% in 2026, 15% in each of 2027 and 2028 and 35% thereafter.
Significant Judgments
Revenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and distributor chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three months ended March 31, 2025 and 2024 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement.
Contract Balances
The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.49 billion and $1.54 billion as of March 31, 2025 and December 31, 2024, respectively.
For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years.
The following table summarizes our contract assets:
(in millions)March 31,
2025		December 31,
2024
Contract manufacturing services$4 $2 
Software sales39 44 
Bundled equipment and consumable medical products contracts89 87 
Contract assets$132 $133 
Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months.
The following table summarizes contract liability activity for the three months ended March 31, 2025 and 2024. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Three Months Ended March 31,
(in millions)
2025
2024
Balance at beginning of period$171 $169 
New revenue deferrals128 93 
Revenue recognized upon satisfaction of performance obligations(124)(91)
Currency translation— (2)
Balance at end of period$175 $169 
For the three months ended March 31, 2025 and 2024, $34 million and $43 million of revenue was recognized that was included in contract liabilities as of December 31, 2024 and 2023, respectively.
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)March 31,
2025		December 31,
2024
Prepaid expenses and other current assets$54 $51 
Other non-current assets78 82 
Contract assets$132 $133 
Accrued expenses and other current liabilities$135 $131 
Other non-current liabilities40 40 
Contract liabilities$175 $171 
Disaggregation of Net Sales
Refer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location.
Lease Revenue
We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.
The components of lease revenue for the three months ended March 31, 2025 and 2024 were:
Three Months Ended March 31,
(in millions)20252024
Sales-type lease revenue$8 $2 
Operating lease revenue91 104 
Variable lease revenue7 8 
Total lease revenue$106 $114 
Our net investment in sales-type leases was $47 million as of March 31, 2025, of which $13 million originated in 2021 and prior, $6 million in 2022, $7 million in 2023, $10 million in 2024, and $11 million in 2025.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES
 3 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
BUSINESS OPTIMIZATION CHARGES BUSINESS OPTIMIZATION CHARGES
In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization into verticalized segments, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $4 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.

During the three months ended March 31, 2025 and 2024, we recorded the following charges related to business optimization programs.
Three Months Ended March 31,
(in millions)20252024
Restructuring charges$44 $17 
Costs to implement business optimization programs1 5 
Total business optimization charges$45 $22 
Costs to implement business optimization programs for the three months ended March 31, 2025 and 2024, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense.
During the three months ended March 31, 2025 and 2024, we recorded the following restructuring charges.
Three months ended March 31, 2025
(in millions)COGSSG&AR&DTotal
Employee termination costs$12 $13 $1 $26 
Asset write offs1 17 — 18 
Total restructuring charges$13 $30 $1 $44 
Three months ended March 31, 2024
(in millions)COGSSG&ATotal
Employee termination costs$3 $11 $14 
Contract termination and other costs— 3 3 
Total restructuring charges$3 $14 $17 
For the three months ended March 31, 2025, $25 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.
For the three months ended March 31, 2024, $6 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our operating model intended to streamline our operations.
The following table summarizes activity in the liability related to our restructuring initiatives.
(in millions)
Liability balance as of December 31, 2024$122 
Charges26 
Payments(36)
Currency translation2 
Liability balance as of March 31, 2025$114 
Substantially all of our restructuring liabilities as of March 31, 2025 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.25.1
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS
 3 Months Ended
Mar. 31, 2025
Retirement Benefits [Abstract]  
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS
The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.
Three Months Ended March 31,
(in millions)20252024
Pension benefits
Service cost$3 $6 
Interest cost34 45 
Expected return on plan assets(44)(59)
Amortization of net losses and prior service costs1 4 
Net periodic pension cost$(6)$(4)
OPEB
Interest cost$2 $2 
Amortization of net loss and prior service credit(4)(5)
Net periodic OPEB cost (income)$(2)$(3)
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
For the three months ended March 31, 2025 and 2024, our effective income tax rate differs significantly from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards.
For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.
For the three months ended March 31, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by income tax expense resulting from internal reorganization transactions related to the sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and an increase in our liabilities for various uncertain tax positions.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.
The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.
Three Months Ended March 31,
(in millions)20252024
Income (loss) from continuing operations$64 $6 
Less: Net income attributable to noncontrolling interests included in continuing operations— — 
Income (loss) from continuing operations attributable to Baxter stockholders64 6 
Income (loss) from discontinued operations62 33 
Less: Net income attributable to noncontrolling interests included in discontinued operations— 2 
Income (loss) from discontinued operations attributable to Baxter stockholders62 31 
Net income (loss) attributable to Baxter stockholders$126 $37 

The following table is a reconciliation of basic shares and diluted shares.
Three Months Ended March 31,
(in millions)20252024
Basic shares512 508 
Effect of dilutive securities2 2 
Diluted shares514 510 
The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 20 million and 16 million shares issuable under equity awards for the three months ended March 31, 2025 and 2024, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.
We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Canadian Dollar, Australian Dollar, Indian Rupee, Turkish Lira, Japanese Yen, Mexican Peso, Korean Wan and Swiss Franc. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.
We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.
We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.
Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.
Cash Flow Hedges
We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.
For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged transaction. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.
The notional amounts of foreign exchange contracts designated as cash flow hedges were $49 million and $99 million as of March 31, 2025 and December 31, 2024, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at March 31, 2025 is eight months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of March 31, 2025 and December 31, 2024.
Fair Value Hedges
We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.
There were no outstanding interest rate contracts designated as fair value hedges as of March 31, 2025 and December 31, 2024.
In October 2023, we entered into a foreign currency forward contract with a notional amount of $798 million and designated that derivative as a fair value hedge of our €750 million of 0.40% senior notes due May 2024. This forward contract matured in May 2024.
Net Investment Hedges
In May 2017, we issued €600 million of 1.3% senior notes due May 2025. We had designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In March 2025, we dedesignated this previously designated net investment hedge and concurrently entered into forward contracts to manage foreign exchange risk in earnings relating to these outstanding debt balances.
In May 2019, we issued €750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI.
In May 2019, we issued €750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above.
As of March 31, 2025, we had an accumulated pre-tax unrealized translation gain in AOCI of $63 million related to the Euro-denominated senior notes.
Dedesignations
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged transactions. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings.
There were no cash flow hedge dedesignations in the first three months of 2025 or 2024 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur.
If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2025 or 2024.
If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In March 2025, we dedesignated one of our net investment hedges as discussed in the "Net Investment Hedges" section above. There were no net investment hedges terminated during the first three months of 2024.
Undesignated Derivative Instruments
We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.
In March 2025, as discussed in the "Net Investment Hedges" section above, we entered into forward contracts with a notional amount of $655 million to hedge the repayment of our Euro-denominated senior notes due May 2025. The total notional amount of undesignated derivative instruments was $955 million as of March 31, 2025 and $389 million as of December 31, 2024.
Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments
The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2025 and
2024.
Gain (loss) recognized in OCILocation of gain (loss)
in income statement		Gain (loss) reclassified from AOCI into income
(in millions)2025202420252024
Cash flow hedges
Interest rate contracts$— $— Interest expense, net$(1)$(1)
Foreign exchange contracts— 10 Cost of sales4 2 
Fair value hedges
Foreign exchange contracts— (2)Other (income) expense, net— (3)
Net investment hedges61 38 Other (income) expense, net— — 
Total$61 $46 $3 $(2)
Location of gain (loss) in income statementGain (loss) recognized in income
(in millions)20252024
Fair value hedges
Foreign exchange contractsOther (income) expense, net$— $(23)
Undesignated derivative instruments
Foreign exchange contractsOther (income) expense, net(2)(5)
Total$(2)$(28)
As of March 31, 2025, $2 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
Derivative Assets and Liabilities
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2025.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$3 Accrued expenses and other current liabilities$—
Net investment hedgesLong-term debt and finance lease obligations, less current portion761
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets— Accrued expenses and other current liabilities4
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations648
Total derivative instruments$3 $1,413
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2024.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$6 Accrued expenses and other current liabilities$— 
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations618 
Net investment hedgesLong-term debt and finance lease obligations, less current portion727 
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets1 Accrued expenses and other current liabilities2 
Total derivative instruments$7 $1,347 
While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.
The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.
March 31, 2025December 31, 2024
(in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheets$3 $4 $7 $2 
Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(2)(2)(1)(1)
Total$1 $2 $6 $1 
The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:
Carrying amount of hedged itemCumulative amount of fair value hedging adjustment included
 in the carrying amount of the hedged item (a)
(in millions)Balance as of March 31, 2025Balance as of December 31, 2024Balance as of March 31, 2025Balance as of December 31, 2024
Long-term debt$99 $99 $2 $2 
(a) These fair value hedges were terminated in 2018 and earlier periods.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.
Basis of fair value measurement
(in millions)Balance as of March 31, 2025Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$3 $— $3 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities12 12 — — 
Total$16 $12 $3 $1 
Liabilities
Foreign exchange contracts$4 $— $4 $— 
Contingent payments related to acquisitions12 — — 12 
Indemnifications related to Kidney Care separation1
37 — — 37 
Total$53 $— $4 $49 
1 Recorded in connection with the sale of our Kidney Care business and was measured as of January 31, 2025. See Note 2 for additional information.
Basis of fair value measurement
(in millions)Balance as of December 31, 2024Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$7 $— $7 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities13 13 — — 
Total$21 $13 $7 $1 
Liabilities
Foreign exchange contracts$2 $— $2 $— 
Contingent payments related to acquisitions12 — — 12 
Total$14 $— $2 $12 
As of March 31, 2025 and December 31, 2024, cash and cash equivalents of $2.29 billion and $1.76 billion, respectively, included money market fund and other short-term funds of approximately $1.21 billion and $583 million, respectively, that are considered Level 2 in the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.
Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.
Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated.
In addition, we have contingent payments related related to the Kidney Care separation, which consist of reimbursements to Vantive for certain indemnifications contemplated in the EPA. For additional information on these items see Note 2.
The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.
Three Months Ended March 31,
20252024
(in millions)Indemnifications related to Kidney Care separationContingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securities
Fair value at beginning of period$— $12 $1 $14 $1 
Additions37 — — — — 
Fair value at end of period$37 $12 $1 $14 $1 
Financial Instruments Not Measured at Fair Value
In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2025 and December 31, 2024.
Book valuesFair values(a)
(in millions)2025202420252024
Liabilities
Short-term debt$11 $2,126 $11 $2,126 
Current maturities of long-term debt and finance lease obligations651 626 650 619 
Long-term debt and finance lease obligations9,412 10,374 8,398 9,295 
(a)    These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.
Investments Without Readily Determinable Fair Values
The carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $37 million as of March 31, 2025 and December 31, 2024. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. These investments are included in Other non-current assets on our condensed consolidated balance sheets.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Our business is comprised of three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment
primarily includes sales to Vantive, pursuant to the Kidney Care MSA, and sales of products and services provided directly through certain of our manufacturing facilities.
Disaggregation of Net Sales
The following tables present our U.S. and International disaggregated net sales.
Three Months Ended March 31,
20252024
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Infusion Therapies and Technologies
$584 $410 $994 $526 $440 $966 
Advanced Surgery
145 123 268 147 116 263 
Medical Products & Therapies729 533 1,262 673 556 1,229 
Care and Connectivity Solutions
316 111 427 278 124 402 
Front Line Care
202 75 277 195 70 265 
Healthcare Systems & Technologies
518 186 704 473 194 667 
Injectables and Anesthesia
195 140 335 191 137 328 
Drug Compounding— 246 246 — 250 250 
Pharmaceuticals195 386 581 191 387 578 
Other48 30 78 11 5 16 
Total Baxter$1,490 $1,135 $2,625 $1,348 $1,142 $2,490 
Geographic Sales Information
Our net sales are attributed to the following geographic regions based on the location of the customer.
Three Months Ended March 31,
(in millions)20252024
United States$1,490 $1,348 
Emerging markets1
297 307 
Rest of world2
838 835 
Total Baxter$2,625 $2,490 
1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
Segment Operating Income
In the first quarter of 2025, in conjunction with the change in our Chief Executive Officer, we determined that our chief operating decision maker (CODM) comprises of our Chair and Interim Chief Executive Officer, and the Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products & Therapies, who review the financial information presented for purposes of evaluating the performance of our segments and to make resource allocation decisions. The change in CODM during the first quarter of 2025 did not result in a change in our segments.
Segment operating income is the measure of segment profitability and represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period.
Corporate costs, inclusive of global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs.
Segment results include net sales, cost of sales, selling, general and administrative expenses, research and development expenses, corporate costs that had previously been allocated to our former Kidney Care segment which did not convey in the related sale, and other segment items which are directly allocated to each segment. Beginning in 2024 annual reporting, we adopted ASU 2023-07 retrospectively. The following table presents our segment information of net sales, significant expense and operating income during the periods presented.
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsMedical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticals
Net sales$1,262 $704 $581 $1,229 $667 $578 
Cost of sales694 356 396 668 346 382 
Selling, general and administrative expenses286 217 103 284 207 96 
Research and development expenses59 45 26 52 47 22 
Other segment items(21)(7)(7)(2)— — 
Segment operating income$244 $93 $63 $227 $67 $78 
The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.
Three Months Ended March 31,
(in millions)20252024
Medical Products & Therapies$244 $227 
Healthcare Systems & Technologies93 67 
Pharmaceuticals63 78 
Total reportable segment operating income400 372 
Other9 4 
Unallocated corporate costs(17)(69)
Intangible asset amortization expense(155)(158)
Legal matters(11)— 
Business optimization items(45)(22)
Acquisition and integration items(1)(5)
Separation-related costs(13)— 
European Medical Devices Regulation(5)(7)
Hurricane Helene costs(98)— 
Product-related items(6)— 
Total operating income 58 115 
Interest expense, net64 78 
Other (income) expense, net(3)(9)
Income from continuing operations before income taxes$(3)$46 
Additional financial information for our segments is as follows:
Three Months Ended March 31,
(in millions)20252024
Depreciation Expense1
Medical Products & Therapies$49 $58 
Healthcare Systems & Technologies27 30 
Pharmaceuticals16 25 
Total depreciation expense$92 $113 
1Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.
Our CODM does not receive asset or capital expenditure information by reportable segment and, accordingly, we do not report that information for our segments.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net income (loss) attributable to Baxter stockholders $ 126 $ 37
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.25.1
BASIS OF PRESENTATION (Policies)
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).
In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.
Risks and Uncertainties
Risks and Uncertainties
Supply Constraints, Tariffs and Global Economic Conditions
We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which caused the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify
additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative of lower cost raw material or component parts.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS (Tables)
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations
The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
(in millions)20252024
Net sales$352 $1,102 
Cost of sales206 676 
Gross margin146 426 
Selling, general and administrative expenses116 298 
Research and development expenses16 56 
Operating income (loss)14 72 
Interest expense, net13 — 
Other (income) expense, net7 2 
Income (loss) from discontinued operations before gain on disposition and income taxes(6)70 
Gain on disposition191 — 
Income tax expense (benefit)123 37 
Income from discontinued operations, net of tax62 33 
Less: Net income attributable to noncontrolling interest included in discontinued operations— 2 
Net income attributable to Baxter stockholders included in discontinued operations$62 $31 
The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of December 31, 2024:
(in millions)December 31, 2024
Cash and cash equivalents$648 
Accounts receivable, net of allowances942 
Inventories821 
Prepaid expenses and other current assets200 
Current assets of discontinued operations2,611 
Property, plant and equipment, net1,516 
Goodwill265 
Other intangible assets, net148 
Operating lease right-of-use assets204 
Other non-current assets367 
Non-current assets of discontinued operations2,500 
Assets of discontinued operations$5,111 
Current maturities of finance lease obligations$1 
Accounts payable344 
Accrued expenses and other current liabilities585 
Current liabilities of discontinued operations930 
Long-term finance lease obligations, less current portion37 
Operating lease liabilities173 
Other non-current liabilities344 
Non-current liabilities of discontinued operations554 
Liabilities of discontinued operations$1,484 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
(in millions)20252024
Balance at beginning of period$71 $62 
Charged to costs and expenses(4)(1)
Write-offs(2)(3)
Currency translation adjustments1 (2)
Balance at end of period$66 $56 
Inventories
Inventories
(in millions)March 31,
2025		December 31,
2024
Raw materials$550 $510 
Work in process310 266 
Finished goods1,310 1,270 
Inventories$2,170 $2,046 
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net
(in millions)March 31,
2025		December 31,
2024
Property, plant and equipment, at cost$7,431 $7,648 
Accumulated depreciation(4,714)(4,778)
Property, plant and equipment, net$2,717 $2,870 
Interest Expense, Net
Interest Expense, Net
Three Months Ended March 31,
(in millions)20252024
Interest expense, net of capitalized interest$81 $103 
Interest income(17)(25)
Interest expense, net$64 $78 
Other (Income) Expense-, Net
Other (Income) Expense, Net
Three Months Ended March 31,
(in millions)20252024
Foreign exchange losses, net$— $14 
Pension and other postretirement benefit plans(11)(13)
Change in fair value of marketable equity securities1 (3)
Equity method investment impairment9 — 
Other, net(2)(7)
Other (income) expense, net$(3)$(9)
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
The following is a reconciliation of goodwill by segment.
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsTotal
Balance as of December 31, 2024$1,185 $3,550 $540 $5,275 
Currency translation 38 8 17 63 
Balance as of March 31, 2025$1,223 $3,558 $557 $5,338 
Other Intangible Assets, Net
The following is a summary of our other intangible assets.
Indefinite-lived intangible assets
(in millions)Customer relationshipsDeveloped technology, including patentsTrade namesOther amortized intangible assetsTrade namesIn process Research and Development
Total
December 31, 2024
Gross other intangible assets$3,387 $3,131 $958 $86 $680 $107 $8,349 
Accumulated amortization(878)(2,075)(107)(66)— — (3,126)
Other intangible assets, net$2,509 1,056 851 20 680 107 5,223 
March 31, 2025
Gross other intangible assets$3,389 $3,154 $953 $88 $680 $107 $8,371 
Accumulated amortization(932)(2,170)(119)(69)— — (3,290)
Other intangible assets, net$2,457 $984 $834 $19 $680 $107 $5,081 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.25.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Summary of Changes in AOCI Income (Loss) by Component
The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2025 and 2024.
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2024
$(3,430)$(475)$(108)$3 $(4,010)
Other comprehensive income (loss) before reclassifications(57)14 — — (43)
Amounts reclassified from AOCI (a)126 (13)(2)— 111 
Net other comprehensive income (loss) 69 1 (2)— 68 
Balance as of March 31, 2025$(3,361)$(474)$(110)$3 $(3,942)
Gains (losses)
(in millions)CTAPension and OPEB plansHedging activitiesAvailable-for-sale debt securitiesTotal
Balance as of December 31, 2023$(2,985)$(452)$(120)$3 $(3,554)
Other comprehensive income (loss) before reclassifications(180)5 6 — (169)
Amounts reclassified from AOCI (a)
— (1)2 — 1 
Net other comprehensive income (loss) (180)4 8 — (168)
Balance as of March 31, 2024$(3,165)$(448)$(112)$3 $(3,722)
(a)    See table below for details about these reclassifications.
Summary of Reclassification from AOCI to Net Income (Loss)
The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2025 and 2024.
Amounts reclassified from AOCI (a)
(in millions)Three Months Ended March 31, 2025Three Months Ended March 31, 2024Location of impact in income statement
CTA
Reclassification of cumulative translation loss to earnings from Kidney Care separation$(126)$— Income from discontinued operations, net of tax
Less: Tax effect— — Income from discontinued operations, net of tax
$(126)$— Net of tax
Pension and OPEB items
Amortization of net losses and prior service costs or credits$3 $2 Other (income) expense, net
Pension settlement from Kidney Care separation14 — Income from discontinued operations, net of tax
17 2 Total before tax
Less: Tax effect(1)(1)Income tax expense
Less: Tax effect on pension settlement from Kidney Care separation(3)— Income from discontinued operations, net of tax
$13 $1 Net of tax
Gains (losses) on hedging activities
Foreign exchange contracts$(1)$2 Cost of sales
Interest rate contracts4 (1)Interest expense, net
Fair value hedges— (3)Other (income) expense, net
3 (2)Total before tax
Less: Tax effect(1)— Income tax expense
$2 $(2)Net of tax
Total reclassifications for the period$(111)$(1)Total net of tax
(a)    Amounts in parentheses indicate reductions to net income
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset
The following table summarizes our contract assets:
(in millions)March 31,
2025		December 31,
2024
Contract manufacturing services$4 $2 
Software sales39 44 
Bundled equipment and consumable medical products contracts89 87 
Contract assets$132 $133 
The following table summarizes contract liability activity for the three months ended March 31, 2025 and 2024. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Three Months Ended March 31,
(in millions)
2025
2024
Balance at beginning of period$171 $169 
New revenue deferrals128 93 
Revenue recognized upon satisfaction of performance obligations(124)(91)
Currency translation— (2)
Balance at end of period$175 $169 
For the three months ended March 31, 2025 and 2024, $34 million and $43 million of revenue was recognized that was included in contract liabilities as of December 31, 2024 and 2023, respectively.
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)March 31,
2025		December 31,
2024
Prepaid expenses and other current assets$54 $51 
Other non-current assets78 82 
Contract assets$132 $133 
Accrued expenses and other current liabilities$135 $131 
Other non-current liabilities40 40 
Contract liabilities$175 $171 
Sales-type Lease, Lease Income
The components of lease revenue for the three months ended March 31, 2025 and 2024 were:
Three Months Ended March 31,
(in millions)20252024
Sales-type lease revenue$8 $2 
Operating lease revenue91 104 
Variable lease revenue7 8 
Total lease revenue$106 $114 
Operating Lease, Lease Income
The components of lease revenue for the three months ended March 31, 2025 and 2024 were:
Three Months Ended March 31,
(in millions)20252024
Sales-type lease revenue$8 $2 
Operating lease revenue91 104 
Variable lease revenue7 8 
Total lease revenue$106 $114 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES (Tables)
 3 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
Summary of Business Optimization Charges
During the three months ended March 31, 2025 and 2024, we recorded the following charges related to business optimization programs.
Three Months Ended March 31,
(in millions)20252024
Restructuring charges$44 $17 
Costs to implement business optimization programs1 5 
Total business optimization charges$45 $22 
Components of Restructuring Charges
During the three months ended March 31, 2025 and 2024, we recorded the following restructuring charges.
Three months ended March 31, 2025
(in millions)COGSSG&AR&DTotal
Employee termination costs$12 $13 $1 $26 
Asset write offs1 17 — 18 
Total restructuring charges$13 $30 $1 $44 
Three months ended March 31, 2024
(in millions)COGSSG&ATotal
Employee termination costs$3 $11 $14 
Contract termination and other costs— 3 3 
Total restructuring charges$3 $14 $17 
Summary of Activity in Reserves Related to Restructuring Initiatives
The following table summarizes activity in the liability related to our restructuring initiatives.
(in millions)
Liability balance as of December 31, 2024$122 
Charges26 
Payments(36)
Currency translation2 
Liability balance as of March 31, 2025$114 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.25.1
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)
 3 Months Ended
Mar. 31, 2025
Retirement Benefits [Abstract]  
Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans
The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.
Three Months Ended March 31,
(in millions)20252024
Pension benefits
Service cost$3 $6 
Interest cost34 45 
Expected return on plan assets(44)(59)
Amortization of net losses and prior service costs1 4 
Net periodic pension cost$(6)$(4)
OPEB
Interest cost$2 $2 
Amortization of net loss and prior service credit(4)(5)
Net periodic OPEB cost (income)$(2)$(3)
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Net Income (Loss) attributable to Stockholder
The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.
Three Months Ended March 31,
(in millions)20252024
Income (loss) from continuing operations$64 $6 
Less: Net income attributable to noncontrolling interests included in continuing operations— — 
Income (loss) from continuing operations attributable to Baxter stockholders64 6 
Income (loss) from discontinued operations62 33 
Less: Net income attributable to noncontrolling interests included in discontinued operations— 2 
Income (loss) from discontinued operations attributable to Baxter stockholders62 31 
Net income (loss) attributable to Baxter stockholders$126 $37 
Reconciliation of Basic Shares to Diluted Shares
The following table is a reconciliation of basic shares and diluted shares.
Three Months Ended March 31,
(in millions)20252024
Basic shares512 508 
Effect of dilutive securities2 2 
Diluted shares514 510 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Gains and Losses on Derivative Instruments
The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2025 and
2024.
Gain (loss) recognized in OCILocation of gain (loss)
in income statement		Gain (loss) reclassified from AOCI into income
(in millions)2025202420252024
Cash flow hedges
Interest rate contracts$— $— Interest expense, net$(1)$(1)
Foreign exchange contracts— 10 Cost of sales4 2 
Fair value hedges
Foreign exchange contracts— (2)Other (income) expense, net— (3)
Net investment hedges61 38 Other (income) expense, net— — 
Total$61 $46 $3 $(2)
Location of gain (loss) in income statementGain (loss) recognized in income
(in millions)20252024
Fair value hedges
Foreign exchange contractsOther (income) expense, net$— $(23)
Undesignated derivative instruments
Foreign exchange contractsOther (income) expense, net(2)(5)
Total$(2)$(28)
As of March 31, 2025, $2 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
Classification and Fair Values of Derivative Instruments
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2025.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$3 Accrued expenses and other current liabilities$—
Net investment hedgesLong-term debt and finance lease obligations, less current portion761
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets— Accrued expenses and other current liabilities4
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations648
Total derivative instruments$3 $1,413
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2024.
Derivatives in asset positionsDerivatives in liability positions
(in millions)Balance sheet locationFair valueBalance sheet locationFair value
Derivative instruments designated as hedges
Foreign exchange contractsPrepaid expenses and other current assets$6 Accrued expenses and other current liabilities$— 
Net investment hedgesCurrent maturities of long-term debt and finance lease obligations618 
Net investment hedgesLong-term debt and finance lease obligations, less current portion727 
Undesignated derivative instruments
Foreign exchange contractsPrepaid expenses and other current assets1 Accrued expenses and other current liabilities2 
Total derivative instruments$7 $1,347 
Derivative Positions Presented On Net Basis
The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.
March 31, 2025December 31, 2024
(in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheets$3 $4 $7 $2 
Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(2)(2)(1)(1)
Total$1 $2 $6 $1 
Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges
The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:
Carrying amount of hedged itemCumulative amount of fair value hedging adjustment included
 in the carrying amount of the hedged item (a)
(in millions)Balance as of March 31, 2025Balance as of December 31, 2024Balance as of March 31, 2025Balance as of December 31, 2024
Long-term debt$99 $99 $2 $2 
(a) These fair value hedges were terminated in 2018 and earlier periods.
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Summary of Financial Instruments Measured at Fair Value on Recurring Basis
The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.
Basis of fair value measurement
(in millions)Balance as of March 31, 2025Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$3 $— $3 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities12 12 — — 
Total$16 $12 $3 $1 
Liabilities
Foreign exchange contracts$4 $— $4 $— 
Contingent payments related to acquisitions12 — — 12 
Indemnifications related to Kidney Care separation1
37 — — 37 
Total$53 $— $4 $49 
1 Recorded in connection with the sale of our Kidney Care business and was measured as of January 31, 2025. See Note 2 for additional information.
Basis of fair value measurement
(in millions)Balance as of December 31, 2024Quoted prices in active markets for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable inputs
(Level 3)
Assets
Foreign exchange contracts$7 $— $7 $— 
Available-for-sale debt securities1 — — 1 
Marketable equity securities13 13 — — 
Total$21 $13 $7 $1 
Liabilities
Foreign exchange contracts$2 $— $2 $— 
Contingent payments related to acquisitions12 — — 12 
Total$14 $— $2 $12 
Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs
The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.
Three Months Ended March 31,
20252024
(in millions)Indemnifications related to Kidney Care separationContingent payments related to acquisitionsAvailable-for-sale debt securitiesContingent payments related to acquisitionsAvailable-for-sale debt securities
Fair value at beginning of period$— $12 $1 $14 $1 
Additions37 — — — — 
Fair value at end of period$37 $12 $1 $14 $1 
Book Values and Fair Values of Financial Instruments For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2025 and December 31, 2024.
Book valuesFair values(a)
(in millions)2025202420252024
Liabilities
Short-term debt$11 $2,126 $11 $2,126 
Current maturities of long-term debt and finance lease obligations651 626 650 619 
Long-term debt and finance lease obligations9,412 10,374 8,398 9,295 
(a)    These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Financial Information for Our Segments
The following tables present our U.S. and International disaggregated net sales.
Three Months Ended March 31,
20252024
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Infusion Therapies and Technologies
$584 $410 $994 $526 $440 $966 
Advanced Surgery
145 123 268 147 116 263 
Medical Products & Therapies729 533 1,262 673 556 1,229 
Care and Connectivity Solutions
316 111 427 278 124 402 
Front Line Care
202 75 277 195 70 265 
Healthcare Systems & Technologies
518 186 704 473 194 667 
Injectables and Anesthesia
195 140 335 191 137 328 
Drug Compounding— 246 246 — 250 250 
Pharmaceuticals195 386 581 191 387 578 
Other48 30 78 11 5 16 
Total Baxter$1,490 $1,135 $2,625 $1,348 $1,142 $2,490 
The following table presents our segment information of net sales, significant expense and operating income during the periods presented.
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
(in millions)Medical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticalsMedical Products & TherapiesHealthcare Systems & TechnologiesPharmaceuticals
Net sales$1,262 $704 $581 $1,229 $667 $578 
Cost of sales694 356 396 668 346 382 
Selling, general and administrative expenses286 217 103 284 207 96 
Research and development expenses59 45 26 52 47 22 
Other segment items(21)(7)(7)(2)— — 
Segment operating income$244 $93 $63 $227 $67 $78 
Revenue from External Customers by Geographic Areas
Our net sales are attributed to the following geographic regions based on the location of the customer.
Three Months Ended March 31,
(in millions)20252024
United States$1,490 $1,348 
Emerging markets1
297 307 
Rest of world2
838 835 
Total Baxter$2,625 $2,490 
1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
Operating Income to Income Before Income Taxes Reconciliation
The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.
Three Months Ended March 31,
(in millions)20252024
Medical Products & Therapies$244 $227 
Healthcare Systems & Technologies93 67 
Pharmaceuticals63 78 
Total reportable segment operating income400 372 
Other9 4 
Unallocated corporate costs(17)(69)
Intangible asset amortization expense(155)(158)
Legal matters(11)— 
Business optimization items(45)(22)
Acquisition and integration items(1)(5)
Separation-related costs(13)— 
European Medical Devices Regulation(5)(7)
Hurricane Helene costs(98)— 
Product-related items(6)— 
Total operating income 58 115 
Interest expense, net64 78 
Other (income) expense, net(3)(9)
Income from continuing operations before income taxes$(3)$46 
Additional financial information for our segments is as follows:
Three Months Ended March 31,
(in millions)20252024
Depreciation Expense1
Medical Products & Therapies$49 $58 
Healthcare Systems & Technologies27 30 
Pharmaceuticals16 25 
Total depreciation expense$92 $113 
1Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.25.1
BASIS OF PRESENTATION (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2025
Mar. 31, 2025
Hurricane    
Disclosure Basis Of Presentation Details [Line Items]    
Hurricane Helene costs   $ 98
Discontinued Operations, Disposed of by Sale | Kidney Care    
Disclosure Basis Of Presentation Details [Line Items]    
Agreed purchase price $ 3,800  
Proceeds from divestiture of businesses 3,710  
Proceeds from divestiture of businesses, net of tax $ 3,300  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2025
Dec. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Separation costs     $ 37  
Indemnification Agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Indemnification liability, net     37  
Contingent liability     133  
Business guarantees retained     $ 300  
Kidney Care Manufacturing and Supply Agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Transaction service agreement, period   10 years    
Kidney Care Transition Services Agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Transaction service agreement, period   30 months    
Discontinued Operations, Disposed of by Sale | Kidney Care        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Purchase price $ 3,800      
Proceeds from divestiture of businesses 3,710      
Pre-tax gain from divestiture of business 191      
Gain from divestiture of business, net of tax $ 111      
Separation costs       $ 88
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Operating income $ 58 $ 115
Interest expense, net 64 78
Other (income) expense, net (3) (9)
Income from discontinued operations, net of tax 62 33
Net income attributable to noncontrolling interests included in discontinued operations 0 2
Income (loss) from discontinued operations attributable to Baxter stockholders 62 31
Discontinued Operations, Disposed of by Sale | Kidney Care    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Net sales 352 1,102
Cost of sales 206 676
Gross margin 146 426
Selling, general and administrative expenses 116 298
Research and development expenses 16 56
Operating income 14 72
Interest expense, net 13 0
Other (income) expense, net 7 2
Income (loss) from discontinued operations before gain on disposition and income taxes (6) 70
Gain on disposition 191 0
Income tax expense (benefit) 123 37
Income from discontinued operations, net of tax 62 33
Net income attributable to noncontrolling interests included in discontinued operations 0 2
Income (loss) from discontinued operations attributable to Baxter stockholders $ 62 $ 31
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Current assets of discontinued operations $ 0 $ 2,611
Non-current assets of discontinued operations 0 2,500
Current liabilities of discontinued operations 0 930
Non-current liabilities of discontinued operations $ 0 554
Discontinued Operations    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Cash and cash equivalents   648
Accounts receivable, net of allowances   942
Inventories   821
Prepaid expenses and other current assets   200
Current assets of discontinued operations   2,611
Property, plant and equipment, net   1,516
Goodwill   265
Other intangible assets, net   148
Operating lease right-of-use assets   204
Other non-current assets   367
Non-current assets of discontinued operations   2,500
Assets of discontinued operations   5,111
Current maturities of finance lease obligations   1
Accounts payable   344
Accrued expenses and other current liabilities   585
Current liabilities of discontinued operations   930
Long-term finance lease obligations, less current portion   37
Operating lease liabilities   173
Other non-current liabilities   344
Non-current liabilities of discontinued operations   554
Liabilities of discontinued operations   $ 1,484
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Allowance for Doubtful Accounts Receivable [Roll Forward]    
Balance at beginning of period $ 71 $ 62
Charged to costs and expenses (4) (1)
Write-offs (2) (3)
Currency translation adjustments 1 (2)
Balance at end of period $ 66 $ 56
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 550 $ 510
Work in process 310 266
Finished goods 1,310 1,270
Inventories $ 2,170 $ 2,046
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Property, plant and equipment, at cost $ 7,431 $ 7,648
Accumulated depreciation (4,714) (4,778)
Property, plant and equipment, net $ 2,717 $ 2,870
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Property, Plant and Equipment [Line Items]    
Right-of-use asset obtained in exchange for operating lease liability $ 5 $ 16
Discontinued Operations, Held-for-Sale | Opelika, Alabama Manufacturing Facility    
Property, Plant and Equipment [Line Items]    
Agreed purchase price 25  
Discontinued Operations, Held-for-Sale | Kidney Care    
Property, Plant and Equipment [Line Items]    
Assets held for sale 95  
Liabilities held for sale 7  
Property, Plant and Equipment    
Property, Plant and Equipment [Line Items]    
Capital expenditures incurred but not yet paid $ 39 $ 35
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Interest Income Expense Net    
Interest expense, net of capitalized interest $ 81 $ 103
Interest income (17) (25)
Interest expense, net $ 64 $ 78
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Other Income, net    
Foreign exchange losses, net $ 0 $ 14
Pension and other postretirement benefit plans (11) (13)
Change in fair value of marketable equity securities 1 (3)
Equity method investment impairment 9 0
Other, net (2) (7)
Other (income) expense, net $ (3) $ (9)
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 5,275
Currency translation 63
Goodwill, ending balance 5,338
Medical Products & Therapies  
Goodwill [Roll Forward]  
Goodwill, beginning balance 1,185
Currency translation 38
Goodwill, ending balance 1,223
Healthcare Systems & Technologies  
Goodwill [Roll Forward]  
Goodwill, beginning balance 3,550
Currency translation 8
Goodwill, ending balance 3,558
Pharmaceuticals  
Goodwill [Roll Forward]  
Goodwill, beginning balance 540
Currency translation 17
Goodwill, ending balance $ 557
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Intangible Asset Excluding Goodwill [Line Items]    
Gross other intangible assets $ 8,371 $ 8,349
Accumulated amortization (3,290) (3,126)
Other intangible assets, net 5,081 5,223
Trade names    
Intangible Asset Excluding Goodwill [Line Items]    
Indefinite-lived intangible assets 680 680
In process Research and Development    
Intangible Asset Excluding Goodwill [Line Items]    
Indefinite-lived intangible assets 107 107
Customer relationships    
Intangible Asset Excluding Goodwill [Line Items]    
Gross other intangible assets, finite-lived 3,389 3,387
Accumulated amortization (932) (878)
Other intangible assets, net, finite-lived 2,457 2,509
Developed technology, including patents    
Intangible Asset Excluding Goodwill [Line Items]    
Gross other intangible assets, finite-lived 3,154 3,131
Accumulated amortization (2,170) (2,075)
Other intangible assets, net, finite-lived 984 1,056
Trade names    
Intangible Asset Excluding Goodwill [Line Items]    
Gross other intangible assets, finite-lived 953 958
Accumulated amortization (119) (107)
Other intangible assets, net, finite-lived 834 851
Other amortized intangible assets    
Intangible Asset Excluding Goodwill [Line Items]    
Gross other intangible assets, finite-lived 88 86
Accumulated amortization (69) (66)
Other intangible assets, net, finite-lived $ 19 $ 20
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible asset amortization expense $ 155 $ 158
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.25.1
FINANCING ARRANGEMENTS (Details)
€ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
Mar. 31, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Jul. 17, 2024
USD ($)
Debt Instrument [Line Items]                
Repayments of debt     $ 2,825,000,000 $ 15,000,000        
Commercial Paper                
Debt Instrument [Line Items]                
Debt obligations     300,000,000       $ 300,000,000  
Commercial paper, outstanding     $ 0          
Commercial paper, weighted-average interest rate             4.78%  
Weighted-average term     45 days          
Discontinued Operations, Disposed of by Sale | Kidney Care                
Debt Instrument [Line Items]                
Proceeds from divestiture of businesses, net of tax $ 3,300,000,000              
Senior Notes                
Debt Instrument [Line Items]                
Senior notes, interest rate               1.322%
Senior Notes | Forecast                
Debt Instrument [Line Items]                
Rate increase following December 31, 2024 milestone         0.25%      
Term Loan Due Two Thousand and Twenty Six                
Debt Instrument [Line Items]                
Repayments of debt   $ 1,000,000,000            
Debt obligations     $ 1,640,000,000          
Debt term     5 years     5 years    
Bridge Facility Line Of Credit | Senior Unsecured Term Loans                
Debt Instrument [Line Items]                
Borrowings outstanding             $ 1,830,000,000  
Revolving Credit Facility                
Debt Instrument [Line Items]                
Borrowings outstanding     $ 0       $ 0  
Line of credit, current borrowing capacity     2,000,000,000     € 200    
Revolving Credit Facility | Commercial Paper                
Debt Instrument [Line Items]                
Line of credit, current borrowing capacity     $ 2,040,000,000.00          
Bridge Facility | Senior Unsecured Term Loans                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity               $ 2,050,000,000.00
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
 1 Months Ended 3 Months Ended 15 Months Ended
Jul. 16, 2024
lawsuit
Mar. 31, 2020
lawsuit
Jun. 30, 2025
lawsuit
Mar. 31, 2025
USD ($)
site
Mar. 31, 2025
USD ($)
lawsuit
site
Dec. 31, 2024
USD ($)
Sep. 11, 2024
complaint
Loss Contingencies [Line Items]              
Litigation reserve       $ 46 $ 46 $ 40  
Number of complaints | complaint             1
Indemnification Agreement              
Loss Contingencies [Line Items]              
Contingent liability       $ 133      
Exposure to Ethylene Oxide              
Loss Contingencies [Line Items]              
Number of lawsuits | lawsuit 40 2     41    
Exposure to Ethylene Oxide | Subsequent Event              
Loss Contingencies [Line Items]              
Number of lawsuits | lawsuit     29        
Superfund Sites | Environmental Clean-up              
Loss Contingencies [Line Items]              
Number of sites | site       6 6    
Environmental reserves       $ 28 $ 28 $ 29  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]    
Cash dividends declared per common share (in dollars per share) $ 0.17 $ 0.29
Purchases of treasury stock (in shares) 0 0
Remaining value available under stock repurchase programs $ 1,300  
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.25.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) $ 7,024 $ 8,468
Balance, end of period (in usd) 7,054 8,235
CTA    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) (3,430) (2,985)
Other comprehensive income (loss) before reclassifications (57) (180)
Amounts reclassified from AOCI 126 0
Net other comprehensive income (loss) 69 (180)
Balance, end of period (in usd) (3,361) (3,165)
Pension and OPEB plans    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) (475) (452)
Other comprehensive income (loss) before reclassifications 14 5
Amounts reclassified from AOCI (13) (1)
Net other comprehensive income (loss) 1 4
Balance, end of period (in usd) (474) (448)
Hedging activities    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) (108) (120)
Other comprehensive income (loss) before reclassifications 0 6
Amounts reclassified from AOCI (2) 2
Net other comprehensive income (loss) (2) 8
Balance, end of period (in usd) (110) (112)
Available-for-sale debt securities    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) 3 3
Other comprehensive income (loss) before reclassifications 0 0
Amounts reclassified from AOCI 0 0
Net other comprehensive income (loss) 0 0
Balance, end of period (in usd) 3 3
Total    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in usd) (4,010) (3,554)
Other comprehensive income (loss) before reclassifications (43) (169)
Amounts reclassified from AOCI 111 1
Net other comprehensive income (loss) 68 (168)
Balance, end of period (in usd) $ (3,942) $ (3,722)
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.25.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Income (loss) from discontinued operations, net of tax $ 62 $ 33
Income tax expense (benefit) 67 (40)
Net income (loss) attributable to Baxter stockholders 126 37
Other (income) expense, net 3 9
Costs of sales (1,764) (1,529)
Amounts reclassified from AOCI    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Net income (loss) attributable to Baxter stockholders (111) (1)
Amounts reclassified from AOCI | CTA    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Income (loss) from discontinued operations, net of tax (126) 0
Income tax expense (benefit) 0 0
Net income (loss) attributable to Baxter stockholders (126) 0
Amounts reclassified from AOCI | Pension and OPEB items    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Income (loss) from discontinued operations, net of tax (14) 0
Income tax expense (benefit) (1) (1)
Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax (3) 0
Net income (loss) attributable to Baxter stockholders 13 1
Other (income) expense, net 3 2
Income (loss), before tax 17 2
Amounts reclassified from AOCI | Gains (losses) on hedging activities    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Income tax expense (benefit) (1) 0
Net income (loss) attributable to Baxter stockholders 2 (2)
Income (loss), before tax 3 (2)
Amounts reclassified from AOCI | Gains (losses) on hedging activities | Foreign exchange contracts    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Costs of sales (1) 2
Amounts reclassified from AOCI | Gains (losses) on hedging activities | Interest rate contracts    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Interest expense, net 4 (1)
Amounts reclassified from AOCI | Gains (losses) on hedging activities | Fair value hedges    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Other (income) expense, net $ 0 $ (3)
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Revenue From Contract With Customer [Line Items]      
Transaction price allocated to remaining performance obligations $ 10,190,000,000    
Revenue related to performance obligations 0 $ 0  
Net trade accounts receivable 1,490,000,000   $ 1,540,000,000
Revenue recognized upon satisfaction of performance obligations 34,000,000 $ 43,000,000  
Sales-type lease, net of investment in lease 47,000,000    
2021      
Revenue From Contract With Customer [Line Items]      
Sales-type leases, receivables 13,000,000    
2022      
Revenue From Contract With Customer [Line Items]      
Sales-type leases, receivables 6,000,000    
2023      
Revenue From Contract With Customer [Line Items]      
Sales-type leases, receivables 7,000,000    
2024      
Revenue From Contract With Customer [Line Items]      
Sales-type leases, receivables 10,000,000    
2025      
Revenue From Contract With Customer [Line Items]      
Sales-type leases, receivables $ 11,000,000    
Minimum      
Revenue From Contract With Customer [Line Items]      
Global payment terms 30 days    
Minimum | Software sales      
Revenue From Contract With Customer [Line Items]      
Revenue recognized contract period 1 year    
Minimum | Consumable Medical Products      
Revenue From Contract With Customer [Line Items]      
Revenue recognized contract period 1 year    
Maximum      
Revenue From Contract With Customer [Line Items]      
Global payment terms 90 days    
Maximum | Contract manufacturing services      
Revenue From Contract With Customer [Line Items]      
Revenue recognized contract period 90 days    
Maximum | Software sales      
Revenue From Contract With Customer [Line Items]      
Revenue recognized contract period 5 years    
Maximum | Consumable Medical Products      
Revenue From Contract With Customer [Line Items]      
Revenue recognized contract period 7 years    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-04-01      
Revenue From Contract With Customer [Line Items]      
Remaining revenue performance obligation, percentage of revenue expected to be recognized 15.00%    
Remaining performance obligations period 9 months    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01      
Revenue From Contract With Customer [Line Items]      
Remaining revenue performance obligation, percentage of revenue expected to be recognized 20.00%    
Remaining performance obligations period 1 year    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01      
Revenue From Contract With Customer [Line Items]      
Remaining revenue performance obligation, percentage of revenue expected to be recognized 15.00%    
Remaining performance obligations period 1 year    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01      
Revenue From Contract With Customer [Line Items]      
Remaining revenue performance obligation, percentage of revenue expected to be recognized 15.00%    
Remaining performance obligations period 1 year    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2029-01-01      
Revenue From Contract With Customer [Line Items]      
Remaining revenue performance obligation, percentage of revenue expected to be recognized 35.00%    
Remaining performance obligations period 1 year    
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES - Contract Assets and Contract Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Revenue From Contract With Customer [Line Items]      
Contract assets $ 132   $ 133
Contract liabilities 175 $ 169 171
Revenue From Contract With Customer [Roll Forward]      
Balance at beginning of period 171 169  
New revenue deferrals 128 93  
Revenue recognized upon satisfaction of performance obligations (124) (91)  
Currency translation 0 (2)  
Balance at end of period 175 $ 169  
Prepaid expenses and other current assets      
Revenue From Contract With Customer [Line Items]      
Contract assets 54   51
Other non-current assets      
Revenue From Contract With Customer [Line Items]      
Contract assets 78   82
Accrued expenses and other current liabilities      
Revenue From Contract With Customer [Line Items]      
Contract liabilities 135   131
Revenue From Contract With Customer [Roll Forward]      
Balance at beginning of period 131    
Balance at end of period 135    
Other non-current liabilities      
Revenue From Contract With Customer [Line Items]      
Contract liabilities 40   40
Revenue From Contract With Customer [Roll Forward]      
Balance at beginning of period 40    
Balance at end of period 40    
Contract manufacturing services      
Revenue From Contract With Customer [Line Items]      
Contract assets 4   2
Software sales      
Revenue From Contract With Customer [Line Items]      
Contract assets 39   44
Bundled equipment and consumable medical products contracts      
Revenue From Contract With Customer [Line Items]      
Contract assets $ 89   $ 87
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES - Lease Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]    
Sales-type lease revenue $ 8 $ 2
Operating lease revenue 91 104
Variable lease revenue 7 8
Total lease revenue $ 106 $ 114
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Expected additional pre-tax costs $ 4  
Charges 44 $ 17
Employee termination costs    
Restructuring Cost and Reserve [Line Items]    
Charges 26 14
Employee termination costs | Kidney Care    
Restructuring Cost and Reserve [Line Items]    
Charges $ 25  
Employee termination costs | New Operating Model    
Restructuring Cost and Reserve [Line Items]    
Charges   $ 6
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 44 $ 17
Business Optimization Programs    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 44 17
Costs to implement business optimization programs 1 5
Total business optimization charges $ 45 $ 22
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 44 $ 17
COGS    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 13 3
SG&A    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 30 14
R&D    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 1  
Employee termination costs    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 26 14
Employee termination costs | COGS    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 12 3
Employee termination costs | SG&A    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 13 11
Employee termination costs | R&D    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 1  
Asset write offs    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 18  
Asset write offs | COGS    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 1  
Asset write offs | SG&A    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 17  
Asset write offs | R&D    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 0  
Contract termination and other costs    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   3
Contract termination and other costs | COGS    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   0
Contract termination and other costs | SG&A    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   $ 3
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Restructuring Reserve [Roll Forward]    
Charges $ 44 $ 17
Severance, Contract Termination, And Other Employee Related Costs    
Restructuring Reserve [Roll Forward]    
Reserve, beginning balance 122  
Charges 26  
Payments (36)  
Currency translation 2  
Reserve, ending balance $ 114  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.25.1
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pension benefits    
Net periodic benefit cost    
Service cost $ 3 $ 6
Interest cost 34 45
Expected return on plan assets (44) (59)
Amortization of net losses and prior service costs 1 4
Net periodic pension cost (income) (6) (4)
OPEB    
Net periodic benefit cost    
Interest cost 2 2
Amortization of net losses and prior service costs (4) (5)
Net periodic pension cost (income) $ (2) $ (3)
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES (Details)
 3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
U.S. Federal statutory rate 21.00%
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Reconciliation of Basic Shares to Diluted Shares    
Basic (in shares) 512 508
Effect of dilutive securities (in shares) 2 2
Diluted (in shares) 514 510
Income (loss) from continuing operations $ 64 $ 6
Net income attributable to noncontrolling interests included in continuing operations 0 0
Income (loss) from continuing operations 64 6
Income (loss) from discontinued operations, net of tax 62 33
Net income attributable to noncontrolling interests included in discontinued operations 0 2
Income (loss) from discontinued operations attributable to Baxter stockholders 62 31
Net income (loss) attributable to Baxter stockholders $ 126 $ 37
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE - Additional Information (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Earnings Per Share [Abstract]    
Anti-dilutive securities excluded from computation of EPS (in shares) 20 16
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)
€ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
de-designation
terminate
Mar. 31, 2024
terminate
de-designation
Dec. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Oct. 31, 2023
EUR (€)
May 31, 2019
EUR (€)
May 31, 2017
EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, fair value, terminated | terminate 0 0          
Derivative, net investment terminated | terminate   0          
Deferred, net after-tax gains on derivative instruments $ 2,000,000            
Undesignated derivative instruments              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, notional amount $ 955,000,000   $ 389,000,000        
Derivative instruments designated as hedges              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
number of de-designations | de-designation 0 0          
Derivative instruments designated as hedges | Forward Contracts              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, notional amount $ 655,000,000            
Net investment hedge              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Accumulated pre-tax unrealized translation gain in AOCI 63,000,000            
1.30% Senior Notes Due May 2025              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Senior notes | €             € 600
Senior notes, interest rate             1.30%
0.4% Senior Notes Due May 2024              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Senior notes | €         € 750 € 750  
Senior notes, interest rate       0.40% 0.40% 0.40%  
1.3% Senior Notes Due May 2029              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Senior notes | €           € 750  
Senior notes, interest rate             1.30%
Interest rate contracts | Cash Flow Hedging              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, fair value, net 0   0        
Foreign exchange contracts              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, notional amount $ 49,000,000   99,000,000        
Maximum length of time hedge in cash flow hedge 8 months            
Fair value hedges              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, notional amount       $ 798,000,000      
Interest rate swap | Fair value hedges              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, fair value, net $ 0   $ 0        
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax $ 61 $ 46
Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax 3 (2)
Total (2) (28)
Fair value hedges    
Derivative Instruments, Gain (Loss) [Line Items]    
Foreign exchange contracts 0 (2)
Fair value hedges | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax 0 (3)
Earnings, fair value hedge, gain (loss), reclassification, before tax 0 (23)
Net Investment Hedging    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax 61 38
Net Investment Hedging | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Net investment hedges 0 0
Interest rate contracts | Cash Flow Hedging    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax 0 0
Interest rate contracts | Cash Flow Hedging | Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax (1) (1)
Foreign exchange contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) recognized in income, undesignated derivative instruments (2) (5)
Foreign exchange contracts | Cash Flow Hedging    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax 0 10
Foreign exchange contracts | Cash Flow Hedging | Cost of sales    
Derivative Instruments, Gain (Loss) [Line Items]    
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax $ 4 $ 2
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Derivatives, Fair Value [Line Items]    
Derivative asset, fair value $ 3 $ 7
Total derivative instruments, liabilities 1,413 1,347
Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Derivative asset, fair value 3 7
Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Derivative liability, fair value 4 2
Derivative instruments designated as hedges | Long-term debt and finance lease obligations, less current portion    
Derivatives, Fair Value [Line Items]    
Derivative liability, not subject to master netting arrangement, fair value 761 727
Derivative instruments designated as hedges | Current maturities of long-term debt and finance lease obligations    
Derivatives, Fair Value [Line Items]    
Derivative liability, not subject to master netting arrangement, fair value   618
Derivative instruments designated as hedges | Foreign exchange contracts | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Derivative asset, fair value 3 6
Derivative instruments designated as hedges | Foreign exchange contracts | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Derivative liability, fair value 0 0
Undesignated derivative instruments | Current maturities of long-term debt and finance lease obligations    
Derivatives, Fair Value [Line Items]    
Derivative liability, not subject to master netting arrangement, fair value 648  
Undesignated derivative instruments | Foreign exchange contracts | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Derivative asset, fair value 0 1
Undesignated derivative instruments | Foreign exchange contracts | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Derivative liability, fair value $ 4 $ 2
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Asset    
Gross amounts recognized in the condensed consolidated balance sheets $ 3 $ 7
Prepaid expenses and other current assets    
Asset    
Gross amounts recognized in the condensed consolidated balance sheets 3 7
Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet (2) (1)
Derivative asset, fair value, total 1 6
Accrued expenses and other current liabilities    
Liability    
Gross amounts recognized in the condensed consolidated balance sheets 4 2
Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet (2) (1)
Derivative liability, fair value, total $ 2 $ 1
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) - Long-term debt - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Derivatives, Fair Value [Line Items]    
Carrying amount of hedged item $ 99 $ 99
Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item $ 2 $ 2
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Assets    
Foreign exchange contracts $ 3 $ 7
Available-for-sale debt securities 1 1
Marketable equity securities 12 13
Total assets 16 21
Liabilities    
Foreign exchange contracts 4 2
Contingent payments related to acquisitions 12 12
Indemnifications related to kidney care separation 37  
Total liabilities 53 14
Quoted prices in active markets for identical assets (Level 1)    
Assets    
Foreign exchange contracts 0 0
Available-for-sale debt securities 0 0
Marketable equity securities 12 13
Total assets 12 13
Liabilities    
Foreign exchange contracts 0 0
Contingent payments related to acquisitions 0 0
Indemnifications related to kidney care separation 0  
Total liabilities 0 0
Significant other observable inputs (Level 2)    
Assets    
Foreign exchange contracts 3 7
Available-for-sale debt securities 0 0
Marketable equity securities 0 0
Total assets 3 7
Liabilities    
Foreign exchange contracts 4 2
Contingent payments related to acquisitions 0 0
Indemnifications related to kidney care separation 0  
Total liabilities 4 2
Significant unobservable inputs (Level 3)    
Assets    
Foreign exchange contracts 0 0
Available-for-sale debt securities 1 1
Marketable equity securities 0 0
Total assets 1 1
Liabilities    
Foreign exchange contracts 0 0
Contingent payments related to acquisitions 12 12
Indemnifications related to kidney care separation 37  
Total liabilities $ 49 $ 12
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Fair Value Disclosures [Line Items]      
Cash and cash equivalents $ 2,294 $ 1,764 $ 2,826
Other Assets      
Fair Value Disclosures [Line Items]      
Other equity investments without readily determinable fair values 37 37  
Significant other observable inputs (Level 2)      
Fair Value Disclosures [Line Items]      
Money market funds, at carrying value $ 1,210 $ 583  
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Indemnifications related to Kidney Care separation        
Contingent payments related to acquisitions        
Fair value at beginning of period $ 37   $ 0  
Additions 37      
Fair value at end of period 37      
Contingent payments related to acquisitions        
Contingent payments related to acquisitions        
Fair value at beginning of period 12 $ 14 $ 12 $ 14
Additions 0 0    
Fair value at end of period 12 14    
Available-for-sale debt securities        
Available-for-sale debt securities        
Fair value at beginning of period 1 1    
Additions 0 0    
Fair value at end of period $ 1 $ 1    
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Book values    
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]    
Short-term debt $ 11 $ 2,126
Current maturities of long-term debt and finance lease obligations 651 626
Long-term debt and finance lease obligations 9,412 10,374
Fair values    
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]    
Short-term debt 11 2,126
Current maturities of long-term debt and finance lease obligations 650 619
Long-term debt and finance lease obligations $ 8,398 $ 9,295
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Narrative (Details)
 3 Months Ended
Mar. 31, 2025
segment
Segment Reporting [Abstract]  
Number of operating segments 3
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Net sales $ 2,625 $ 2,490
United States    
Segment Reporting Information [Line Items]    
Net sales 1,490 1,348
International    
Segment Reporting Information [Line Items]    
Net sales 1,135 1,142
Operating Segments | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 1,262 1,229
Operating Segments | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 704 667
Operating Segments | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 581 578
Operating Segments | United States | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 729 673
Operating Segments | United States | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 518 473
Operating Segments | United States | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 195 191
Operating Segments | International | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 533 556
Operating Segments | International | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 186 194
Operating Segments | International | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 386 387
Operating Segments | Infusion Therapies and Technologies | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 994 966
Operating Segments | Infusion Therapies and Technologies | United States | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 584 526
Operating Segments | Infusion Therapies and Technologies | International | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 410 440
Operating Segments | Advanced Surgery | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 268 263
Operating Segments | Advanced Surgery | United States | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 145 147
Operating Segments | Advanced Surgery | International | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 123 116
Operating Segments | Care and Connectivity Solutions | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 427 402
Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 316 278
Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 111 124
Operating Segments | Front Line Care | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 277 265
Operating Segments | Front Line Care | United States | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 202 195
Operating Segments | Front Line Care | International | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 75 70
Operating Segments | Injectables and Anesthesia | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 335 328
Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 195 191
Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 140 137
Operating Segments | Drug Compounding | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 246 250
Operating Segments | Drug Compounding | United States | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 0 0
Operating Segments | Drug Compounding | International | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 246 250
Other    
Segment Reporting Information [Line Items]    
Net sales 78 16
Other | United States    
Segment Reporting Information [Line Items]    
Net sales 48 11
Other | International    
Segment Reporting Information [Line Items]    
Net sales $ 30 $ 5
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Net sales $ 2,625 $ 2,490
United States    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Net sales 1,490 1,348
Emerging Markets    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Net sales 297 307
Rest of world    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Net sales $ 838 $ 835
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Net sales $ 2,625 $ 2,490
Cost of sales 1,764 1,529
Selling, general and administrative expenses 703 729
Research and development expenses 140 120
Operating income 58 115
Operating Segments | Medical Products & Therapies    
Segment Reporting Information [Line Items]    
Net sales 1,262 1,229
Cost of sales 694 668
Selling, general and administrative expenses 286 284
Research and development expenses 59 52
Other segment items (21) (2)
Operating income 244 227
Operating Segments | Healthcare Systems & Technologies    
Segment Reporting Information [Line Items]    
Net sales 704 667
Cost of sales 356 346
Selling, general and administrative expenses 217 207
Research and development expenses 45 47
Other segment items (7) 0
Operating income 93 67
Operating Segments | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Net sales 581 578
Cost of sales 396 382
Selling, general and administrative expenses 103 96
Research and development expenses 26 22
Other segment items (7) 0
Operating income $ 63 $ 78
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Operating income $ 58 $ 115
Intangible asset amortization expense 155 158
Interest expense, net 64 78
Other (income) expense, net (3) (9)
Income (loss) from continuing operations before income taxes (3) 46
Depreciation 92 113
Operating Segments | Medical Products & Therapies    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Operating income 244 227
Depreciation 49 58
Operating Segments | Healthcare Systems & Technologies    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Operating income 93 67
Depreciation 27 30
Operating Segments | Pharmaceuticals    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Operating income 63 78
Depreciation 16 25
Operating Segments | Reportable Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Operating income 400 372
Segment Reconciling Items    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Unallocated corporate costs (17) (69)
Intangible asset amortization expense (155) (158)
Legal matters (11) 0
Business optimization items (45) (22)
Acquisition and integration items (1) (5)
Separation-related costs (13) 0
European Medical Devices Regulation (5) (7)
Hurricane Helene costs (98) 0
Product-related items (6) 0
Segment Reconciling Items | Reportable Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Other $ 9 $ 4
EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

  •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
    8<\#)I)3,5B"'"#3E53"@1MS MNB?]&&T=;FO0/_]4GSIWWH(=SU;,I0ZR];E' FKDNDTPQTPDX%_>J<0@Z-,@ MF9!+'\E-^_;I5\W8JWM_8^;7>!/L7'FQV VQN6-60SW2FK5MYC ML'OXMI#G;HB(5)/0D#BDPOH*1G2/Q)I 9".52%_J^_N4^K?'4 M#_FQX:VS]I[83=9!/]8QJUY0CFW8,V_&U2$ XY0F.K0F>VB]C,JE!HPK756A M@](8D?!#*^C@H:-"S$.F22I6JCE>KLR59$1(Z3UKR&J'_Z1UTBF/--$LF0YR/Z@L,I1>0/O] MD[*9[?TI(KU[3Z0HH4AO0P%)V-L; !GV=++48JB/<()J,=F9$! +EKFEB8S< M#9E,&0LAX267.Y!X_YJ2[!(+(&MUIU8;LUV]% 7UP7 M5](V66?HM2>/XTY)7GT&[K0_@=/PU"PW,#_ORO0&O>"W2*L+*SZPR[ B\B)M MO4"--W5%]*1PE==>@TUQ*J+TJ-0EA.Y6OV(M9K1LP$Z8P:7\VH2(M$6@G[&+ MHIM;00, 1P>20H"6C%NZLK3P%!CF&X$E01JXJ48F;1/-P6F!X9L@$$-XG%>) MF_JZD+^']'AWRE:3([?:+%+7>Q=IYIH<7J-RZE=\@_<*A(YT'_AN&H/8*X3W MWV,[\+##.@41!$48;KD1-XW$&8 *.0!:4=, R M:7@6]AFH=:D!OJ6^0C#*)>BG&[$H%\[%,)=U\XX4!@A@SV;6"[S?N _LHJXH5 XSK,B72,9PF,WO60&_RQ&FKTN(*6[V, M:V2\[;-*V>;8;&,J?V"B,MV)KL>)X Y8JQZ&AC&:DW:?NKBVBGM3^50]P?8Y MHB[!RHX_]%)@NF%.(3@D!@-]8G*O?OC2#5=E3WP%@=YZXB-=EC$N.$GL7^+R M@ZJCTVE3;4 WEH#HEJ6 M1 J]K6$86S=VF-MQ^H-,7_)XUWAY'I]PHTFY3\WY5^*[$&,XP'4[2FVTH.%M= M>^W=U6U+Z(,36^77EL[2/TJ\9SZW9FP-IGU^-U5)_EEUY!.C1'=Z_AECUZSA M->$MC:.-4PR%94-G8:N#FFY=L>U"ZL4-:J&0 E44&)?GAJU*JC<\,$"L1RTW M#/);^(#KPEP,>K[";M]8+5Q2+G J.'P&?5-V?\V]GOI+=P_X$Q]"D.2VTD1( M=G_3P;JP!PN-C^&%@*L&M^+M@#9&G,_28.S)9-*&Y:_C]V,G/V8X3^@BS+)- MJ2+_)DXS71;4$2<')R^WIMN6RFF%^<5-4F,QF>%1."5I7-H ,)=%46LEBP>L MN?Z603_7,2?YEQC=:'*Q'HHI._&8H>&8+[5,0G2/"5H'+;#K B_F0F+L%DM8 M!K;T.GQ8' VW;6.KR%3Q].D;RYULMF;;8CQ7-F+NPAULE'W=9/#-J-E%LNWT M;>1;HY05;JX1RE[=R4G'S3-Z#*;79.#M_G)NY;2P7@K'UUT$PK?21FA:$?U7 M(/WUV;":>P?C3;:IGGWO$P&9@^ FKIT2@U$D0#A&MO'D28_-B/IB[K!B6]*A MM1W)"DG==)PRGOP8*>,== VW8M'10.FKV@7"K"P)T-@<70S?:TGW/L.2ULPZ MK3.@6".P TN;Q8G.9Q;?O4BI2>D._>BE#$W2IOA(L$*P.C"3Q]+C M^&O)$!X?CX\FE"2L2_C_1#]8\H=C^NK;.NE^=[ [WCTY7OGU[GBR\KMUMST< MGSP_^N1WW3\9'QX<]+KMMS01/!DPW15LD[\_VW_62C"_V%M^C%JH:MP![1GG MR?[R)Y42OZ;:ZN#XI=G/\OYK7FTW8@K 'I=^#;/@:_+63,AJMZ *$S9H/]DT M/?;2KW%T^VL&)^*,9"<(\JK J@W< 2\_S[ ?^+P_T=&G%KVTW:/?T )\IV%R MH^BRJ,% NE#4<^7SB(7NK'Y+&FJ].MWE:-+GL)$"P)?^8]@_'#\_ZHQ!?SH\ MG(C-LO\;\?\]P; >!L/:6PW#^G9:)'?PQW6]R+[__U!+ P04 " !0A*9: MJ8PPJ9H[ #LGP$ %@ &)A>"TR,#(U,#,S,7AE>#$P,RYH=&WM?6MSVT:: M[O?S*W"<.K/2*8J19,O73*H46\FH-K&]LI+9_72J"31%C$" @XMDSJ\_[ZUO M $C1'CN$)>[6;F02!+H;W>_U>9_WAUD]SW[\8:95\N/_^N%_'QQ$;XJXF>N\ MCN)2JUHG45.E^57T]T17U]'!@5SUNE@LR_1J5D?'A\JZ>G1P_/DZ.GDPGQ^KH M<*H.#Y_KZ1,5'TX/_]_1(_@I7,Z_J>IEIO_Z:)[F!S.-SW_Y]-GXZ?-%_>HV M3>K9RZ/#P__SB"[]\8=ID=?PO!)^SW_R;3HWJ_7'^D!EZ57^DJ;TB']JOHZ+ MK"A??G=(__,*OSF8JGF:+5_^QV4ZUU7T5M]&%\5'52Z3*=\897^ M2[\\.H+AT3]O>OHZ'#\.!QQ_UAC6%Q=?O7! M/NL=[$^G_WUY=A&=OX7___;T\OS=V]-?X5^OQ[C>I[^=O7US]B8Z??LFNCC[ M<'EZ"?^ ?7*$5YR]O3S_XRQZ_^OIVT^>9<_;'.#:?+A\]_H_HW?O<56BT[^? M7KR)?KDX?7L9O7UW>?[Z;//QOZ)/TCR!?[U\_'11;[0,P?&8%'5=S&%( M,&;OSO]HJCJ=+E?=^L_>]#^ICS#1Z!RGFZLZ+7*5P;_B\2A2T1N=J5M5ZB@N MRD51TM?17CW3T5^^>WY\?/C*K,&?/W)>OT3',JR7#2QEB5<]^O%U,5^H?+F] MP3WZD=;GZ-7^*%HT9=4H&$%=1+AR*Q<\.@5IG8"\5WD27>BJ)N'/IS;'_9C> MZ.A]IG)X,U4T5\MHHB,EOYF6Q3RJ80;T&/SO\%\3SF48[VBF2SU91E^1!6=AQ=PFK)@"(4TE4S^8>.K: !^3*O2)C$19ZD M[25/<[@JK:(/]$KX/M$I2/LD^@7/0?2V@(WT+<@1?[A#>#,C6OZ>=3V]*K4F MTU[5M8IG(%90\L#[ H$^S+4U-O'I-A?V&]B#]M4.80/2H<)6FUR-3R99K3&M*/7H56 M^PDL^(U&5:HR,=SI[?/7XNN^.!D?/WZ.[FX-[D"=F >+)SPF3_C[.NE^=_QT M_.SH>.77A^.CE=^MN^TS^/+Y\XUN^ST-F8<-"U.!P?#71X\?M5;WY?'B8W04 M.C"XX.VUX65YM,8-@O=CEK@N%O3/X T>CY\]\SZC.(!\N"4OTK.D_O+=R?-7 M42N*(2O\[R\>K,>WNG*KY-"+HUZ*9;\4_> M,X>M/1.=OZ%M8^>^VR^[_=+>+V] !:-J)B6XVRZ[[;)^N[RUCK3X?;LML]LR MZ[?,V4==QFC!OR_!P/Y*^^7;-O\&N&7X &YCO_RAJQK3C1\P/-%DG[MC!C;7 MSBL^7/^*[^G+/?NX2"6+@Y;'3GOL1,&:W7*Z6&0P$(RH7.BX:!84NGQ?P(?+ M/WGKX$9Y/GYZTMXK1\?C%\>=S7(R7I%TW8*<>0H+>;DV[?>;RA-5%^4R>IVI MVXF*KV6-)8RFX#4L,:CO.9=5=#LK*.@/^CUN*#7X;CH%#5_:P%JL*O(M5%1R M,A%?WPBC@)F^(Q.)"52=5RPI.N^^/2[\AS^V$088LZ;"0<'SNR/$"R*5+Z,X M+>-F#H/+8XV?<802QW;'"-**'L^[^#AM@D_CZ3]L; MWJ,?QZODV?<4&MT,XN"=U*%#'I:1BF.](#N'XE45S MQ=N1\Y8+C&VK9)[F:567>&91*1P]>U5%!862.8,L=Z=-O2B+&.RH4G/(W(\/ M*8QQ4[9YHJ-) 9L"@_ K,W=PDEQ(/XB1CVS8W(^ECZ/S:>>920%/S LS1'_V M_G1E-NUY5%5G%G8!^":W*^%&F$SZ0S6->69:9:2M"-[DB+3!KRDU:^=O#_^'*;8(SZUD/ M!D&X;2E[!"8V@4,+0QOA?C22G4:5HLK D8!T,P,I87E@!R]@752P=4&FS].Z MUCIJ%@4K@'\VZ&YP CLEF"--L;73PTD5Y:8IHCNDU-'X1=>@>#9^T;$GX,-G M0Y5H1YCNZ3OI.L;K*G>$1MYI&O Y7?DV#=STZ?CX";ZBHB+)^++4F4+SH@- M=7E >O^'[B=J4A594Z_^R>?A'^_RE,[BO],&DU.KZ M0$UAX"]5=JN6U:,_!;V[1=3G6B/KO_]V_M/YI0,Q?")DWD_(*CO6PC)0/G!9\8K0%/%(FC0 Q C?V0]!A0[J(C)#&-9U99I(1[M70>) MUH-*N%/!L,T[/CP9Q+8!>8'.^\7E^>M?SZ+S3U*/VQ\];XE?SMZ>79S^>A_V M]SK!] $<#M2.1^.C[>*&CIX>ONK^_V%"K=X(D.@2O:1M+MLX>JT6:0U[[E\H M:\AI0VNI6H Q/!4O,@1.M9%1%@PEOVGAJ,34#=VZG^'315.",:/%M/8%8QB8 M6RNPS*&1$_+L>&L:8$_M;W&OA='GQ^/GN Z#1AN>S1=9L=3E ,"&M(4KVR:!;PB:HC3<.NVCIY0XR?MS^_=/W--K?^9$A;_VCX>_^_&GB/TR7& M"BXT1E\&@KH5T8['(5*DG-)7@)KGMR.),A'^Y7G8+B0TX]_;+MXN%5^*=F3BM4&C ^373!D5C%I M537]X4C.8,S[JSF*Y =-AM$+! M:V+!@QDK)3C>_1SY:8\/#T4+'&\W#CQ4+2"999NNV:[".&G6RJ+_JP-#XD M*-0GGD)2"J "M'$%U_9WIN*:JKB%3@ <47@IFLA* MT.+&_8F/+G6L"769BP>+@2*:,!T!''A+<_;.7VSOZ&_%K;[1X%4W7 Z.OV]@ M0V>!34_)C!N-+"E=D!M!2.B*O'#CQ*L6BD\#!J[@?8O#;8?'P,TQEJTPI(3< MCKAN%(*-,I@E;.+@MZ-@5/1@NT[HKB/@*FY*=.4GH!Z"LRN[;AR=PJ_,+.3/%3_#A"I#W/T].2;5V<[IZ8OZ ;29S#:3)@>:HE7 MHZ92,$[<[)[P8GX>(^Q90+50&PZN9Z4Q!<0UUIQH$PB@ -MZM 7B5NTI+IHL M\6YA(W2*$""$9(V\(&:TAQH)94*I585JAZ#H#%Y$O5LT=92E\[06K:1ZU;8? MO0]O**%Y4C]%.5, M!87?XFTMFK=W910N [%^<11&[B6K*Z(UI?=)ZEU;J/%=:+MG3\>/C[>%MONS M3\/QU_$S[L#[;1.[]T45TY;>FNAN>WA3-COM*5APR<@>G%RY]""=(WHB,91" MDTS%UR@9%C""(@EXG/@(M0ZYB+:)#?P+V .6A.GX'(K92%,X]GLITZ&![0@B M1X/XVWM\6,_VX99+$#,9B%B#__:>AZQIF#\P9]>8]GNIW*Y?#AG+1N0%Q5SO MD+N_TZ#!3O/+?#.TH]+#PW)(P4/.B0>\/;PG* MGSX3'T^X -<==9S5,/>..UI/MGJT.F^$5GH"8YY;"?BE,[,#EW7;?2$#W:_G M3?5(T$ZRN0XLSKZ:L'EJ*1(8> M*@Q;7X6ATCJM&U02_OO8L/*@4\3VO+>$;8-PT@X#C.MWPLBM@T\YV*3]U@BKX!+H>4:0X&$0(8;T -& M$:@5#O*")KW5&7CR>T?'^X'C-$Q).) \PX@/V[JP]S0M*UK((@9A:+=R.D5< M=IYC-JM2G-#"+SY#4HIA\J6"00_)\!A.!<8)H5+7%[]U=-@WKOH_25NO\3$H M/@+WYD J,V-^'<6.3ULQB'0^UTD*EV=+&5!OV& P6GO#\7XU3;SA\W:>2 MAZN2/T&"[=3T?2CMHOC 70@/'S] CNJWIJ<]#WN3(-V?&(?KPLRZVD1"C&0Q M4):D!]AELK1!H'_O=J8IS%"4%)MCY;6_FOF,#E!E* U[Y X5O= @6 +UDRT) MJ6)6$1]<*T_D.!3O($8L2J]9W/IK2;QL4F3V$*$@JQN WG,HR'W2&,.I-[S; ML2/@*?[*G]T59SG,-?H6U&2C K_PW %K9JIJ+C MLWE"51(G?Y[5MB9Z([Z9;\&1U98OH[[H 4)<_/A @+9U 8JVBQ?4:0Q]*VW9 M@<;060Z?@].Z]^*00(I^H.Q.5; GKJY "@2,B5!'B7F].(3MA?_FF[9#FV^O M3JW.%XO.W+GQ-KK+RBWX!7??0XK>Z '9XG>8XN^:&A'D]+Y^SZE:X@/V3]BR M-;Z>]\]2WP2"N1(<$O/7L/['S2R85KC/JKF.6G8!GBHD;TYTIJ^PSH7,"QN. M9[5L4QD;:0B/,&OU#['()\J*_ HKDJA^-%OV3>1.=.Y>256RW->6+Q#(R-10 M]-1^C!>LCU8D*%.HIZ;$U,^L_6E^ ZP*J9)L.IX=F%@"V=JH,>^S&[SM/-=1RS+ M;369&&.TNOA^)5-45/6!OQ-,38'H45#S,D;"8)<:,SAV))XM*#3F5VG>?1"] M0)_ W-1F$'G3$C_&](]YXE<^VW3'ET06&F]PVO7X:JO"9G6T4]8+U]J0RU$E M&JXRU]II87_/07-RO6ZXU +I2*AP\G>!19%K=:,,XA"^;^\MW)BU=W"M861RPX=-)R 2S1N-0T)S@+3O9:ZJ7/ MDIS3GM2N.6![MGS2"L/V UF M26VH%KJ@5#BD5P4X0@*IY/]@*;BX9R5I[NSLC$3M;'^Z>ERRA@V->N^2GC:NU)\8=YX%ZKI^#$0%67 ]J8$'N XP;C:$*!^C,G?V1 MK7P$:V5.MKW//V$*I+G56N4%OQ-=P?M5=>=1TK<(.1-P#O!?? :8C,HVX7*P M+UFJ[CH:J]+R );XJO &]K48+CE9#%,.KN9W=="5X:K4C6P"?.$ MSV=J?.W<1C(=Y)'7MO(/X0CV\#\;#+9ZFTZ1O$CC!GTMN&V23HG@L#9O)SCU M,XK9()V)?=*(!J80?-OQ$;B_G?FM.RXH>PC'2<2R9,3$JII1C,;^8$^GM$N\ M[\1CK#0A9C+C+=J?%*NN!O_A "G,RO9/]G'WI0:%XURK_FU'>QBG:Q:R9\(\ M.,=LI6*Z-&E%3H*4%]Q5B@65]PK%\PT9(OK32'6C2F6:.%_JL@DYI_M.R$3# MS:=WAQF^#3/1\0:V*"2(%=JZB@V)0X*] M>]-)\Z7-ARWN@Y];W$$=E\Q1&!KN]?FB1H@%_HVQP1C;N%(:GB@D%[4-IJ/9 M.B6K6)(B9)UZY(UUUS(TR W1CDETJ3X>7*"N@;_/:SU'TM'*ML8B:]ZCR1RF MI^O" \^W"H+"5UE,]T.V5,$_DT3DI#<="3IB,6*X^67V7' GM^K&OH_XJ> U M5L[<2YA2TS]T7N!IKA+=]LODA).?AYZHYZO>"VM_LSWV;,>VTEV>UXZL%G:@ M%3HH/\XK# 9PL.&U+D5F;3ME?]DYHI*,M)(1YL$>[L8^$SD',+:<@;:UI_>M MVV)B!#=ID=F.-JJ<*/CJX-W'3"^C4XYP'Q\>'H_$]Q$UK^:<)^T)D&!@R8@0 M"1=QLL^M.$D<[P58"@<3;B)Z&99)WL><+9KIC#3 I"BN#^"4EDN6 PN?!!@4 MT!1TO"4/1G5O"A*-'G2TQE('JA@VII(Y3, K3G2/SU*A+JW!\+D&_X876 TH?"V&-K)M*F"9%UXA3+0=L/FR(_CS^,84"RNE.-I-I85D*,K'Q9V6341Y*Z%%TU6=AYG6[P =F/85&$"-JV M3:+](XOBV+PQ(X!+3&8;W;" MS$IDN7(D_UN[]'VMF$:XR4&/G,"!GZ4@WU1 M,>@*)I?J._NVVS M77ND'6=VJ1KROYQB_.2.PO[>[J)5[W*=GXY/=KQC\,GX,2[#Y4R[]T$ZW(O1 MZ"!&LU&'(M([Y&IQD%]<2#9/@^*-^#HO;C.=H,'3!PTT)F)@OJIE.PLHC1AM M"H%]5;\.) DT+:?^PFN,U=A,JC1)49>V8%&,3J100ZEI2@CLXP#AOWAH1EP[ M.R'V*V*M0<%LJI&$4#H.\HKE N@2YWJ*M@-]:/4\Z_"&(6-2-P>:/BI%U:<<)W$ +/A6>^4OAL.ZR%MK M'RSDIEP%"_.906F_=+&K[<6P <7-,ZC:#)AD8FN65[EG9?3#[ M8+FTH--&T:![H'4,L2&T0QMU+!<*HH@[/ I#07:;T59FZ%!O$;SU*YR@8=!S MK:XEEJ1BPX4A0L%9O;)]B@48\IT>*Y0;@[6MIDOVW:P=5=FDMV<,,R-.>^6[ MLFO:E'R6>V68>3;,XB_?/7GVJKUML=AICE/#+C5>E)KDKZP%3)U8Z^*.YR'#NQ8QCX3?6YOSP&E;@T2/@.3:L<(PQ5\PCH[WXAYE4I>LZ MTWU@+]NA$ 0J2&]*M*A,>Q$^EZ!<^)#L\#Z,8+7\\TDA_*5S"F$45AXWADO> M,Y/QQ5.6II&,:8"KI5D9L=^[-MSA*&D8F.ORWBN3#JEA7<%]U7TO^*QXENH; M'6:_X7R(Q!Q'/_.V6E5=X=5[X?VCSHN?%Z6DR[$GDP]+[I)8?.;618>W*.<6 M#"U!?J>S]OO4MM6-M JLB/J7:>TL/K?GT>'XZ O6-6W5?AP.?=PA99#9@.Q# MT?3&&#/9OT8F,R['$\I(D 5''>$4J&R\C!N>SZ!B]T:E&:F6*9Q_.F#Q3,?7 M+#188'#4$*6GB)T]UVH318DY43LL@[?'3G98AB\J/;;T&L4X6Y"(=_98Q8%9 MM)NX)^-^ /S4./1NG'UZSVMM+#B0_N_+<>I=KKOV)7R46F8LPZ@V"D M@1!0BV?'MEDT*8MK,B417D'RK.7@MDUNDT7 5 "9WOB;=694RP>6!^+HZ'TG M(&7CVOG7"I9G.H5)X.*VZ!5SF )!7W5B;2FR[%IC1@ MB7@5^S]75UUM_)CTQ[C4'DQJ+GZF,Z;.>'H8=E1LF-.KJ$,F_^XDC+#KL$P_9,&;RMV918Y MCH":!CL]DU)]EFT'TN?Z>>+2@R[4QQ E M%]MS]9(V'.3;D G3D/=#AY9 M&OBBFR*VC/9:&[=B#Q*0A8<[0Y'0&8F!261="='BE7203FN8Y)U=2MU%W9T\ MB )'WM$V5?$U@>29>9.#>'Q&\"=P=,R&WR"4UXF#C**0NX'"(:P.,1Z9=ZJ( M[DHEX/=('3U'Z1:&B5#2=L8X(CH8D &EGJLTKU9N;;0)L01:;LB)ER5Q[*#Z58@SA5P!. ,ZNEO*]R"]'. M"X*P,1)+=+P()-]4LX4,72$2H$X#Z>A+-PDWB]/5%7#[WHQ\DXJU/X+NG+_# M_Z[:$Q%"%QLE1VQA;:"9! (M>=PR,2*XT?8MT+< MI/UQY(J#UG14Y)H/6QO *6.>EJOX,,_J"G[OY6=9\.;O>-=M_>2]H2 #BM=A M8VYR?)5+FUEJ*@]&R3TS,._0+O,A]*[WB-5R^<\/^#]K'=3CQ\=P4$\O+L]? M_WH6G9^??ZX2V=+XI:#Y]/+WB[/HW<_1+Q>G;R\?BAY\/#[:KAX\SR5J;=PM MR:JW@L_K,L\CEOEDS$J%XEP-$AQS\@P M2."?:-T9PL9.^$%Q"Q6N_[%1HYH2400J\'Z#4PCR0_=NZPP'ZP%;Y\CNG3XI M3WN);$#<'-G(;B8.2Q5QK"KZALVE0C-;3$QI@ Z%HXO5!Y;7#<89:,1+6+2$U+7HDQK]057V_=]9P@EI&*#$12BPH M]+;%WGGM7I1$:LCHJQ8S+(*#.1G6HE1I>0CW^V4/IS%-($9:"09?^WCX<$Y, M/ QY/QS6H?\,$%LKQ*(]=)F>_WZ M,H244T$KS":3-K^RS=IR"2U:,A-ZZQ8,T%DYFAIUA1F[#I::+C75^'RYN;*5 M+ P5$Z;Q5W]+$"Z* 0:P=RHMH#,45OE>IWE_%\+/W6W3Z5=+]WO.SX>UY M2>NXG 4%'Q/V/UKI(L3_6NC4US6*C,(#\6XX[NWA& GA;JO(BX=E=F.?'K/, M;*@=&?-;E)P[<1KF?N_ =#@[\&3\]+&1NN+=VLU @"&*]R\#N 5\B)'SG+B# MA06$\I2XE6*5BX&Q /&6DF"E;8R92C UZGO^;O\QO'>;%YS:)F67UZE!>B 8 MI@7T2]1<8=I:^C(CQ0=+B3UI02<=IG&?M")O/4"3/BA+P(EI:)*D)]'M3-55 M@9IS]'7;$-UB*K@/7NAW1JG;Q9J?W&WHCIWP5>W6+:)#'OV(@H!@K$'[0G_O M(/@>K*,L"TB@/'5F4+"EZ^ = "1&!@)K(F_6H%G%.=RS005'W!N*L^!&^_P% M=A!/F6G=@@JFO/],,O1D?'1LRX7OK9"['HZ0,R94[F%\C+64M\N&O9H"KM@4 M^8. =%AGRWQ&X/QHFF'9-N^.%:U?'4*/D/0QU2_$2VMH!=WEHC=%1J76I@!" M3:=DI/*@OP5Z#72=/'*-%"E>LU<+Y6?1:O3T]Y?"^'=UBRLQJC\1 S MXL\>7$9\^[";%FSHCV\2-?3F]/(T>G]Q_L?IZ_^Y#Y A6XEO8J!4@%-1H1W3 M7H.@3%2M>LRJ,.KBX8N9C46"M^*$FMYJH[ >R^?@8=PT?)U62%B(N7]ANUPE MQPE(B*@_[&-;IXM&>(GX%W^[0++G&P42_JWM;%+ZCGJ[+;@B Q2FA7V7_84Q MU"V5\=BYAZ/B6Y$=,YVF66J*QF05B[(R1!=FENS64]B7>J$(G5"N>>G05>,E M$/8<'(=10%E5V :&LV;.5E+1E-BRCE]6KK.1\=U0<<0-2O *&U_D(')*B2J( MX8SJHA:#[+8HL^267'UO)CTTA&CL%R[&C5BNBA#YYK'K*)S\'36./F!8@R[' M(ARPW=)%2CA4B9&CFJ[9O+?/@VVF;PA*L)#XANL0N^;)=JI$/R?L?HPCV7(C\K1?CZ M3PJ&)^-9CL3HLJG**Y5+;9JBKK45MQK"5()&6RFMYC+SU) $W8L" .27+^TA M37-$20LX>(+8W'YI8,P^3^2M>4>T(0@ GMFDB?%6NG!%W"D(3L$N?6QMPO.I M=(.(YR,LTD)2 >;^7?# _O+=TR>O)NHCJ+7?SF!S7;S[X_S#^;NW'^[#B=H$2GRR;2CQ,$MJ3@/#9Q#L M[J:/+T,N72/?JM/)=U'<,H4*$;TL2EVWA-POA.-C"6I2%$%^6UCX5%(L:M:V M99-I1YP7VH4C]R!7S=$3Z/F4 7#^GW(@%:% 42MH(;5+@LD)VI03;S?%M5=J M2*/FUA!**O.YDI=&B*TL@H&;BZIB.!TP8+HO"6N4 4O=SBA\XH<=O))\L$VPHKK+/&TZ]?!K^ZG MLG,S=&/(@17;"LZH."0FK 5WUIHLV .%>6"Z;R=GCG9SM+H\) MDL$&P4:05,B&6W'[$M=O2B7IM:I JAJFU4)T4X4H X-L][I#(6\^G")IGB%U MO$AW\HEMHT;]%BD#[H]L3RUXAIXO M4"?YX^^\VKS)6/LQ65N>,- GTA1G'TEE0*N@@Z+QG;5)JVZEQP+1_S1(K+%% MDO$[Z6UL7 AM!R\<;Y5A"..0*(5_?*EE6!7#*>2S''2NH]1:8,\$*MD8'JXQ MC&D[9GH&AXK9:^[Y@%3AXYTJ[',Y\$V2"-R^]KN;+_B3<%!DS'M?*3O7D12- M>9W_?)L3X4XF$GI#VL'/!)LH6,MQL4?3R3A[AH_]P_N CMR3W9'K:_1FU2TC M""XT:'T,SYJ]B"X;F"_8W>*=HSD;V/F4LFG$%@GVO@MC- ?#)N93(K4RX%FA MN6)4$!@+RQ7-I?@I>=7,YX82?9>3]M[.\P>7DQYR-VBRZDS@!_T-S)FYZN,@ M$.$H^#M)17N^2B,>F(C$@+?16":?S>?P]?LHMIJH<2ZABX"A$!L3P+C6>FO8 M)R7CA!H-$>\)->&A^*#WC8/+A= $7"/O56@KH4\KM6W.QK+O#/*877/F=Q M(Y^SU5\!?R9WIFC9"239KSX&1)V,U..=B'&($6^_T9^X_QZ.\76R,[ZZR_/6 M\-^>)DBGU,R'U[/.ZX[6=35$SG,8R[!6&:G?%WLB?@M"-XO<-!&"2A,,!T$H M?-@Z2].M9K31M"]P,#FG3=">C@C[#;14<;.B,PU8<@7SH-7%@T5>&S@T51%- M-);Y=-S@?CGK ->!N(6OI &M149A6&FAJ0M<[PZ:FOX+YOU2F)G:(_0VFFO' MXYP"=;V=;2_:%H/"R,4 6CD^9J/N&Q_LW!7^!([X2_AB) MZM94'(/2A$?F_(O>A_>U#FO[-&BBS>=%LJ[/DXD1[K,+UCVD: K5:=W@@3!% MCP\VW?5TI_/Z=![F0;<ND7)Y=I\#3+F^A;+B=]H M74Y3ZH-QGL$;*V#]GQX>'IV,HM\_G!J\0UOYRD/4*03RI8P%?(N'Y ,?;:3H=WE.9_;E"'20=$6O& '>2#)$V.G(#-P M>2,Y/TMHQ@UU#@#H<#\149I9O#W>Z;I M<,@ML2^_,-GEEM3%S#^';(R.[#9O]:,W;HF,H;D@PS5(7#\@J?9\)]6ZR_,K MJ,(&S)+M2Z]/Z]3.U4:F9YP(IK/\BG9X)I,BA-1,."V:S!(44(41B PD29D5 MF]ZK*M!$P9ZBS('04^; M!K85T7LTI4W$IFYFY"/$S&PICLU#04B15];@W0<[(PIRQH9L(MM7R]Q*KAKU M?^ 8XYR4!+)M>9TZ(6X9:59A@?&:Z- L,"N>$4' M:;(,4FB&[I;A<784X>T2?\5=+LF-1@=CL5W5L*\V+E:KDVFU!,]X'C!",W,= M""KXORY9,TH]E(1E(BYB(H1;G4L?D)@X.MS)B>[Z7"+WS;9],AH#&?JMSB04 M?H;C=Z/SE)(D3.6(ITJ\ K3WT8EC\BPJZA4"DJ 2@F\#/DGCM4_=+/+[$&$R M+W8PF6]>W.WJ!GO6YQ>.58.Y_JNZ94SA'SIOMFP,G?6A\!BW*- ?+*&,^!!#54_!EN-8$ MI\E)$31M!#%CX)#"+]I)O_,*D<$E.)YPA*;XP"ZY\!Z'I&A4.(';PTS#O /, M$@6U:YDKJ_;G_;8G=]+JV46-:]A+U.+7-Q8[Z93S F] M1PJUY?:=L?55:R:W:%M'>VZ77YS6JB/HRW.=YVC:X%E[[5,M7CA6.5X2M-G. M#+O*'=*-A[JNSC[-TDM;13UO= M*_=!NF$M#X-/&/W)A#0N?D98*D/O>0?%90?(3_P]KI%2%;48/?$D49$:'1L_ MVG"3%AG]8D_2NTE32IK>()&X3^.=C]]O:^?^:="9JE.KZMX[>AT67:"5-=4^ MGDO99HL"("C#XTR1BT>:_?IZ%$9A;9GK#8+S0+WBW V98)LL*ES5[HNJ9YIS M/=2Q76+@E Q'Y_"&J_;Q\>(N"L\?<_/:Q?$96 EBY%5?MF]^6S19(N2K>']V M/)E)DSF;_ZN!/3\E$7IAB<;W7>Y<:#XEBN,Z/N/=1H1))$)!TSC)'[-%P<^+ M4H_\L;%THYF[64]TK.;!#6C#B'@\.H[F<%)FE5?&V;L:=N1"5QJ,G.#/B.5P M\C3D46BMGXR.=W+OXS9;T)Y1KV$/14V.%I([5_RX_@K@U$ MKFH;-X0SY>TOE)18T(LX0(%_\&>RT7)0^-A=@D >5SE(K,11KS+19.EQ44[] M,9I7]_@PFH"MFJ-UG8!3C)R'&-S12MUO,.DQ;XG5! M]%TI]V&!Q6H0( 1/!J]XV\' S5*<&U/5,'>_W\PHYLFWW&V' N#4I^!S749M MLX[$[52F]E?W-';IS#-35G0:UUY9O^6"<) +4JP$QH";SYOLB@UOUP);CKOW M(/R)?0!5LU>54"Y'U),H87YZ,7>HRBZ,E':7J@]I3:LD/;;#*WM M)33B&&\JG9J5H>E05>O=M=Y.FY,GX"KHO,E/W4-MF*3TSURYA]8/]0%)WUU= MWE@?J/]J94QPSQC:LAB^N\7KJ!U4$SS5[:Q SBJAFTF)P,J" AE$=*:K/MM%#ER:(QY&S!5I M#&*.3!6N$]^N34R-6-T@KAO0E16Y+;\**QT&NC,&POJW'NW84;#6"@VX+ F+ MN.;UPB.1DYS92+7\A2[& @'P>:V$OGS]-C"Y-#3YZ^(AB=;M5LH-\P#]:MU> MV)\!5:%EO'WHZ$6Q,0AW&!=SEZ.CEX MW/GI#DWE;4*'/-S!J0; .@3;>I\CB1AV"HJ/+']V3^%\>'H^-=S4?Z8_*YK$ M<;%5Q_HA:>9=_65_#7NDP&IG]E[%%0? M7WMD.\/+V:C3G/O .3!P;COPF.YM'?9U+[5L^8@)(8>U.IP'*%S"VFA4#$?8 MBM%J@YL;[(G\ *6.5!;HCVB#5YFM14U&PH(,>K2\TD$TC'TU:?'4Q\+L!\O6 M]1&5>9F02JR:2J^@ D84A!NDC0RY>!&NB0W%V()+F\]7T6]K%MTZ.R&5-,$C M.-=/LL[+J9@\OM=XH,T99C@"BI ^"ZO@Z2W$JM(=&=K[([!M4$M3JM*T'600#NFX;,KH1N#,G&X@;1T#!$$%A%QPMJ&S5FXGR]P&PEFV.7@^+1!*_MLXDD MN/R09--V"QV'*9J0Z@XK_6#;#B#A'>A100EQXV0VQPNF/$!0.S.DRLC]#B$3 M#KR((>ZS(Q"S05.2+>%2)*WF>UHAC]Y48@"= "QZ_NF5[15(-(KFXKJXDG91 M)AQ@/"0<=TJBZ*'9 [O*OY[UH=;'L"W>(=G0!J;OO;=>M9J'A)" >#DL\@ 6Y:K_<& M86P5]HB;%I348S4G\FL<4MS?PLL-6C(H MS0TP]@&RJ"_&9I[")'"?TL*"MP+>,]P+!"::\HZ::JI!<+NDK\_[NB?%:1DW M\XK(JQZ4@;NK8.JKAK;5+4*.][.D<$[1;:."V=.8=(A?0'L)V_1"+XJRWKI^ MWJC0J;3VLFVS9R9N60%-[DK9B:ONQ/%\EF;B(>C!9-GG@TKZT:\=4B9HUAX7JQ4%VULB*6 !10ULRWO>IA: VC M]>ADJ$^[73$-=ECSVPO!V7!^]"%93-NM M.ARFQ70NWLUEJ5#CDF'PFRJO=1V=3IIJ 'RP/1K6B^BE,OZ:QQ_6GWB6SISG MI'!.#..9**1\D+2#M9\* PC"3SWZHBRM3.@=I8*+(_K48$%H8$)LRP+(D3:-YBS3[7K$#HQ,O;="!Z096'1)CNNGI4U M,LD/!,+S,N[I\=4X +OO$Y".KX/7?^W-M\;3W7&DS["&^F\NX,%.STWZZA9<_Z_%TA*??VU=PMC:--TM,7,^W;Y7L! MF=:B>\4^G[C4$'7VP'9ZBA$P;FZ:DS/M5)!D5V;4"JH0YU;8BT&)5]C? M"W'!)27B)L*^Q.SDE#5?V/[I]C77 MGMKO4: (C%DL>]KZ@16)_2I=8LHUD<6+,+U%;?G4C4HSOY=Y(">0:'1OLN_J M>U>83-PV18FE"\_"-4E5Z>+^KENG!XVK&6;+,)F9XMSY F-?32X:OYBP&XTI M$0[U$ZQ#62J0P_Z6:=9&2=XGVQ M>:L@5^(#"5R*9=UZ\/V(W#'9]WH^\-U1A$K-]@@%JV$;-AF3C!Z#62T9>YO MWL=("]&)U'XO(^J<*+9C6E%9>$_*:3.!ZHO*DR=;X^<,:^OL]O43O5XWC)'I MA\@(+IZOM-2(J W& 2N:!9TU1W1=2*JMXP'Q>BGDW?.@)LP6:B*\TD:EBPI9 MM;TM4,4@U3MO864TD?Y?S61=)OB+[=L.X(5D:E'IE^:/5^B?96KY,J5.(@?T MHU>AGCR!=P"ZO,89B:JD]\Y?NQCG^)#CG#4,IT[,D^7K,7WU?9UTOWOR>/SB M^8N57Q^.CU9^M^ZV)^/G+YY\\;L^>3I^?O1LH]M^3PO!BP'K7<';_>NCQX]< M3#G! _[R>/$Q.@HMD4Q/.TO.J_WG'S!ZIY:4^>3Y*[O59/YKIG:($WNTT:7? MPBJ$>K.U$O*V6VF:HQ-:@"^V3)][Z;&T#8*+HLL*ORA2:^V:\C%KJK^CVIJ(VUX.KO M[DIR?MZO_FS3Y_]&\K^?Z?1^PI0?9.;Y>"N9Y^\G1;*$_\SJ>?;C_P=02P,$ M% @ 4(2F6EUME[Z;!P ^20 !8 !B87@M,C R-3 S,S%X97@S,3$N M:'1M[5K9;N,X%GV?K^ DF.H48#N6ERQ.*D!J:70>&C.] #UO#5JZBHC0HIJD M[+B_OL\EY26Q4^5:)DMCZB%EB=N]O(?G7)(Z+_Q$7YP7)+.+?YS_L]T6[TU: M3ZCT(K4D/66B=JJ\%K]EY&Y$N]W4>F>JN577A1>];F\H?C/V1DUE+/?*:[I8 M]'-^&)_/#\,@YV.3S2_.,S45*GNSIX[3?MH_3@:4]$\&IX/AR6DJA[TL':?] M(0V3H]^3/31%]=C&^;FF-WL35;8+XO%'@U[G>%CYLYG*?#%*NMU_[86J%^>Y M*3W&LV@??\9N-CKS=.O;4JOK_6KZ">= MY*Z=Z^Y*>PV/O:E&1^AUS> 4,TSV42U^1]:K7*72*U,*DXMWA:)X)HO2/P" MOZSR"C4_W*:%+*])7*:>BY/3_J EI!.70'I&V8X!_!_Y.]CJ[U5+O+6\GG\I M9$ZV)=(0OSE\D_[5_O#D;%?853++0 5M33DFM[< HH+GI1^U^X_M6=)96/Y8 M8]Z=@MYQY^B8?;X2A03N+4T5S<"8OE!._%1+"VSKN?B9*F.!EU)\;^Q$)-WV M3PR>M_(6Y>**5T 9%I/4>$H[",KIBPU*[[D$Y:UT" 4F?3(7-Z69:2 M#%NM5_AK0N_N#0V(9XH[;G&-6J,"0&> C#"<"_:DTA4BUV;F%HBT=*VAHYYZ5O8N(50G0E MI*4 !@17C35QT 0!@6.M7,'5N=H$M,?4Q\^9D:$S#0C!3%T-06'8!UILH%+D,M*D,_G,ZN6'"=22UI&4#5J.$*&*V&9;E0 M@1%ABS-:96'?Z^JQ4YF25K$#*FIVX/:2>ZH=ZVA8@RZ(;F ^XP@&^;!=:(D* M*:!*:RV9L.%6,&*EQV@1U7T]*<&O,7%%<"K:4_;E'/HL0#M^GJ#=F8HVL+L[ MB>T,8(%P%V7+$*A:2 MJL#++QRMZ5.C==#I#]CI#U.IZ\!#'$K*<^1T:HH@N"VYV3(EV(%7X^/V="V M$PW!B2XFA6-3^XN$FV0LE6G'T&![(LFS2M+0=Z30.W]#HQSN,]'PJB+Y>BHS_B M*8HX>*!)#L2"G>[5;@S'=H;"]IUW]F6]M.MUM*J0;IDP,*\%A%,6"#_,1T/& M_E[]5M?/45?A^IGL$\:ONQ]4CB[RQ;+H;5B'R;#=4BNB(A!]1D) MQ$;>N31-(O?TQKJE9H<7Z'(R4=X3?83JQP99 9=G"O:%3@X 7#"K8^;&_YP! M+U8;_5$KF!]65EVF8D?JVH MX@X2[NH)P(!9"LXT.K'UU.IOH-#/9K]R"2'.+0BAA1A3X#"@))SV-G!J11U3 MY=3H*;&8E?*Z.;2V#>W1I-)F3BB=%29RG;P#5H#KFRA]YQO)5W*RC/B6R]NO M[=:'S573PQ@P)]M&;+6L'(T6/\Z@!I66\Y$J0ZQ"H[-FO+'QWDQ&?.4\94E! MWM%<9H;Q8G%S&WUZVCD9]OE"VL,1GRT&;NZJ.^&N^M!GFV6#?J=WU'^PN-M) M'BS[6+?#06?8/]ZIV\-@I5MR*Y>R?-$;@_-W%: M'FLEAX\ 7NT/ .#P]\X-Z!)0S0Q\Q+DNN[;CA#1@8CBBD0CG2&+AV_.?K4>8 MH><_">\*J9JTD&E/33[Y;<.7S-!AX)//9+3A26=XG],&_.I1U5&\A_2$M%'\ M*.>O]I.C[ME1*WP#]"!/W_M.IS(NW$.-XK'LE#:^W%FMJ,"TW543.<:RJOUF MDT]\[-/\C9\>'89/GOX"4$L#!!0 ( %"$IEKNUA]7F@< )PD 6 M8F%X+3(P,C4P,S,Q>&5X,S$R+FAT;>U::6\CN1']GE_!V,BL!Y!DM0Y+EC4& M/,=N'&"Q1P;9? O8S6J),-7L)=F2E5^?JF+KL"W/:'8FMAQD@)'5XE7%>GRO MJKO'TS SE^,I2'7YI_&?FTWQWF;5#(H@,@GO,@XM6IY.59Z+K1ZIW6 MH%^&BX5683I*VNV_'''7RW%NBX#K.1P?O\9I'DP6X#8TI=&38L0N'<6AJ^;, M&NM&QVW^=T$MS5S.M%F.OKMR6IKO&EX6ONG!Z3PV>_UO0$O0*+Y<1$,'.-KH M E:&)QTR]<,__WK]]OJCZ":MSET[M]V5;H(>!UN.SG#6+8,SW&%P3VKQ.W!! MYSJ30=M"V%R\FVK(Q?>ZD$6&LXN?'VZSJ2PF(*ZR0,W)>;?7$-*+*T2Z M K5G /]+_O9V^GO=$'^S8,3'EOC!204-D7$ E^B<#*^.^\.+?7%72J60"YH& MM_(6V\4U'8&"3Q,>GNLB:V%0SE]L M4#J'$I2WTF,H<--G2W%3V(4!-4'T*@+BUJ'2TA=( $L154$5P$: MCNK'0HBADF*&5V2HR"6=?2?L3#.'<+\''0K(P'OIEM1E)F^ J60]I\??Z"CB MDH95M.::3#M43>Q6X'"T1"$^%E.=386OZ&,S?@$.ZDG(@9GV!N65E'JAPQ0= M]"5D;"#-6Z)I5J&;C]O:41XDK3Q WJ41GL@*"S MB Q>SK,]F?13D1N[\"M$.IAH'QP)IJ0?H]UH96,+6'YES -K7S2V>H>"K8]W M O'J>-A)!A>^1D\MYW3T;TW<,#T'! M\U ZNV'!;29U8"2#JE;##3 :-NKU&NEI=/D@(Z:S=Q> MT$R5)QWE,^A9=)GYK %!_G$,/ K3I88)V;RIZ@-W]26QO""/LYUH1,J7',H#86GI$->6!!%?I MU HZ"&8M4VUT6))&[UJ6#A*CC &TKM-WI2%1%&YKA\K*E0A@SSE%EEFGV #. M*"=08*I@$,?8 B4=$.J"V7+$*AXD72(OOW"T9L^-UEZKVR.G/\REJ9B'*)20 MYYC3Z3D&P>_(S=8IP1Z\&B]WIVL,3AR(G.AC4IC:*CQNP3[,+]>]@3+>_/,% MB4A7N32?-X@[@?8PMFB!EXLO]=SX6K-A#-U#"% -7"=;W+(39U_ @23+-LLJ M1X'>TL =L\ZL#_@[W17$N7R&$_T>[Z*(DT>&Y(A89*=[O6O#L9P!+M^ILB^J MM5VOHU53Z=<) _$:(QP4$S[O1TW&2RS2;\#4M?R]_HVOWJ*O0_4!U$G]EUTG M\;T[M3H.C0W[$!EN0W)#1 2J+T@@'N2=:],DYI[!.K_6;/X!IYS-= @ GZ#Z MU&)60.U*HWT\R0D"%YG5$W/C7\J 5Z<-?J\TFL\GJRHR+OE?_[\<^C9<>F4P MI\(UWJ[+D@7(&Q+0F&.QA')VR'<45_=BO@A==041B_T= MA"45#O2PYJM'D5CGE#@$X82I7R.JN$<)]]4,P8"[Q,[4.K'SKM7_@$(?3+UR MA4*<.R2$!L88F,,0)7RWMX93(^J8+N;6S('$K)"3^J:UJVD/9J6Q2\#6Q=1& MKI-WP(K@^B9*W_I&\I6P\^/ 55 ]0XIX!-?$(!A9>ABMOEP@;9=&+D>ZX$WE M01?U>JD-P:LWZ-*CX^#POUHM7#]5;O%3 MY=.@'K;UVZVS\\&CS>U6\FC;IZ;M#5I)N[O7M*=L]0I;T5R]^DQ1>#^WL1M>:HCQX_K7QWW$&G\>?=9Y1I1]19\PKLV^;;GCM1H M(CSB(,%W?,3*N>6+_$>Q0'3NS$CW+YZC@Y:U^<-?@UG4<)^MZK-*7U_*1H%&^< MSN'!RS6;D\04V]X,D2D>IRH\'/*9]W'JS_AVT"F_E?0?4$L#!!0 ( %"$ MIEIP,:R^(00 *T/ 6 8F%X+3(P,C4P,S,Q>&5X,S(R+FAT;=57;6_; M-A#^OE]Q<[ T 2Q9DN4WV0F0>NF6 47;I5OW;:!%*B)*BRI))_9^_8ZDY,3) MTF4MYF7^8%@^WO'N>1X>3[/2+,7IK&2$GGXS^S8(X'N9KY:L,I K1@RCL-*\ MNH(/E.F/$ 3-JKFL-XI?E0:2*!G !ZD^\FOB[88;P4[;.+.>?Y[UW":SA:2; MTQGEU\#I28S0E8&]U/H[W_Z, ^"&;8V 1'\ MJLI<21WOVIIS*:3*#B+WF5I+4) E%YOLQ9GB1+SH:E+I0#/%"V_6_ ^&F6!2 M[O'&)SI";\$KUB8>)S;5\]]^O'AY\1[Z29CLYGFW7**NL&(C:Q_V3L8Y0LS4 M7E.>,V5XP7-BN*Q %C O.2O@%:](E6-T>%.@E2EXNU)Z13 M(R$>PR_A93@/ MX9+EUO'P(!Y&T[@_B+J/UOW?UDDTG%%9VS-PMY*=_"?1T")@2@:71"U(Q73P M9BW8!LYR8RU)%#V9UW^INO0OJ_M),@'O0_A!$KUF^,OR:P:]('[Q5 M3'-J.P&IZ*,<8XDOR1JI@0M+4.5$@?:+*@_AR.)R>#!.DF@ZE\N:5!OW%$^/ MNY![&3'=A?J)0K%9DH:2^JLHZ:*=F,.#P7CZ%':&"&E-*,5.& A6H&*2]ACR MRF*4!?WAG@D\BH_;U/>UZ2X&23\04>K[.2U)=N5267&O7G"JWDN)%!B53#-F_JTF?6BM)*%8",\FQ$F&# M;C=2[-.**V9O,VT%=$^81^08L)YX<$2/M\J[S6V;5R._>-)/47B3J%.9]C5+(]=:R9" +HQFQJRK&LD5G>= M5['M=!B0V/*>6Z%F23\BN5;=?M[<3%"3 M89A.8CM$&9R<#&TW;N:KT,U7/4,?VM)A.!J-'S5'8?RH[7-A!VA,DB>%[;F4 M?=H(C$8R3CK]3NO0P)TE]1KBW3'*,G ?&P_+OHZ5&UP/#U)LGNX;=B[HK:(: M"#Y3761K>R(BC9K< %)CC5)P"FUQSQ^N?4#T_%'XHKGMJ]#JN>[R#_N;[68[ M_2T-!WN^M5Z3C;^TAWZH>+1/WWNWK*5V-T"FF" 6Z0=OF[<'RG7:Z-:%+/!4 MKMRS[VF_PE02P$"% ,4 " !0A*9:Y41I:>^? 0" HA< M$ @ $ 8F%X+3(P,C4P,S,Q+FAT;5!+ 0(4 Q0 ( M %"$IEHZIL<5/1D HE 0 0 " 1V@ 0!B87@M,C R-3 S M,S$N>'-D4$L! A0#% @ 4(2F6E< ]A2N, 1_P! !0 M ( !B+D! &)A>"TR,#(U,#,S,5]C86PN>&UL4$L! A0#% @ 4(2F6B%P MM=?PBP Z'@& !0 ( !:.H! &)A>"TR,#(U,#,S,5]D968N M>&UL4$L! A0#% @ 4(2F6O^BCV;570$ /9L- !0 ( ! MBG8" &)A>"TR,#(U,#,S,5]L86(N>&UL4$L! A0#% @ 4(2F6O([?]G? MU@ .0H* !0 ( !D=0# &)A>"TR,#(U,#,S,5]P&UL M4$L! A0#% @ 4(2F6F]O%T4;! E0\ !4 ( !HJL$ M &)A>"TR,#(U,#,S,65X,S(Q+FAT;5!+ 0(4 Q0 ( %"$IEK&R,/3DTX M %"TR,#(U,#,S,7AE>#$P,BYH=&U02P$"% ,4 " !0A*9:J8PPJ9H[ M #LGP$ %@ @ $E0 4 8F%X+3(P,C4P,S,Q>&5X,3 S+FAT M;5!+ 0(4 Q0 ( %"$IEI=;9>^FP< /DD 6 " ?-[ M!0!B87@M,C R-3 S,S%X97@S,3$N:'1M4$L! A0#% @ 4(2F6N[6'U>: M!P G"0 !8 ( !PH,% &)A>"TR,#(U,#,S,7AE>#,Q,BYH M=&U02P$"% ,4 " !0A*9:<#&LOB$$ "M#P %@ @ &0 MBP4 8F%X+3(P,C4P,S,Q>&5X,S(R+FAT;5!+!08 #0 - %\# #ECP4 " ! end XML 106 bax-20250331_htm.xml IDEA: XBRL DOCUMENT 0000010456 2025-01-01 2025-03-31 0000010456 bax:CommonStock100PerValueMember exch:XCHI 2025-01-01 2025-03-31 0000010456 bax:CommonStock100PerValueMember exch:XNYS 2025-01-01 2025-03-31 0000010456 bax:GlobalNotes13Due2025Member exch:XNYS 2025-01-01 2025-03-31 0000010456 bax:GlobalNotes13Due2029Member exch:XNYS 2025-01-01 2025-03-31 0000010456 2025-04-30 0000010456 2025-03-31 0000010456 2024-12-31 0000010456 2024-01-01 2024-03-31 0000010456 us-gaap:CommonStockMember 2024-12-31 0000010456 us-gaap:TreasuryStockCommonMember 2024-12-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000010456 us-gaap:RetainedEarningsMember 2024-12-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000010456 us-gaap:ParentMember 2024-12-31 0000010456 us-gaap:NoncontrollingInterestMember 2024-12-31 0000010456 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000010456 us-gaap:ParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000010456 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000010456 us-gaap:CommonStockMember 2025-03-31 0000010456 us-gaap:TreasuryStockCommonMember 2025-03-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000010456 us-gaap:RetainedEarningsMember 2025-03-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000010456 us-gaap:ParentMember 2025-03-31 0000010456 us-gaap:NoncontrollingInterestMember 2025-03-31 0000010456 us-gaap:CommonStockMember 2023-12-31 0000010456 us-gaap:TreasuryStockCommonMember 2023-12-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000010456 us-gaap:RetainedEarningsMember 2023-12-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000010456 us-gaap:ParentMember 2023-12-31 0000010456 us-gaap:NoncontrollingInterestMember 2023-12-31 0000010456 2023-12-31 0000010456 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000010456 us-gaap:ParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000010456 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000010456 us-gaap:CommonStockMember 2024-03-31 0000010456 us-gaap:TreasuryStockCommonMember 2024-03-31 0000010456 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000010456 us-gaap:RetainedEarningsMember 2024-03-31 0000010456 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000010456 us-gaap:ParentMember 2024-03-31 0000010456 us-gaap:NoncontrollingInterestMember 2024-03-31 0000010456 2024-03-31 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember bax:KidneyCareMember 2025-01-31 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember bax:KidneyCareMember 2025-01-31 2025-01-31 0000010456 us-gaap:HurricaneMember 2025-01-01 2025-03-31 0000010456 bax:KidneyCareManufacturingAndSupplyAgreementMember 2024-12-31 2024-12-31 0000010456 bax:KidneyCareTransitionServicesAgreementMember 2024-12-31 2024-12-31 0000010456 us-gaap:IndemnificationGuaranteeMember 2025-01-01 2025-03-31 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember bax:KidneyCareMember 2025-01-01 2025-03-31 0000010456 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember bax:KidneyCareMember 2024-01-01 2024-03-31 0000010456 us-gaap:SegmentDiscontinuedOperationsMember 2024-12-31 0000010456 us-gaap:DiscontinuedOperationsHeldforsaleMember bax:KidneyCareMember 2025-03-31 0000010456 us-gaap:DiscontinuedOperationsHeldforsaleMember bax:OpelikaAlabamaManufacturingFacilityMember 2025-03-31 0000010456 us-gaap:PropertyPlantAndEquipmentMember 2025-01-01 2025-03-31 0000010456 us-gaap:PropertyPlantAndEquipmentMember 2024-01-01 2024-03-31 0000010456 bax:MedicalProductsAndTherapiesMember 2024-12-31 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2024-12-31 0000010456 bax:PharmaceuticalsMember 2024-12-31 0000010456 bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 bax:MedicalProductsAndTherapiesMember 2025-03-31 0000010456 bax:HealthcareSystemsAndTechnologiesMember 2025-03-31 0000010456 bax:PharmaceuticalsMember 2025-03-31 0000010456 us-gaap:CustomerRelationshipsMember 2024-12-31 0000010456 bax:DevelopedTechnologyIncludingPatentsMember 2024-12-31 0000010456 us-gaap:TradeNamesMember 2024-12-31 0000010456 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000010456 us-gaap:TradeNamesMember 2024-12-31 0000010456 us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000010456 us-gaap:CustomerRelationshipsMember 2025-03-31 0000010456 bax:DevelopedTechnologyIncludingPatentsMember 2025-03-31 0000010456 us-gaap:TradeNamesMember 2025-03-31 0000010456 us-gaap:OtherIntangibleAssetsMember 2025-03-31 0000010456 us-gaap:TradeNamesMember 2025-03-31 0000010456 us-gaap:InProcessResearchAndDevelopmentMember 2025-03-31 0000010456 bax:TermLoanDueTwoThousandAndTwentySixMember 2025-02-01 2025-02-28 0000010456 bax:TermLoanDueTwoThousandAndTwentySixMember 2025-03-31 0000010456 bax:BridgeFacilityMember bax:SeniorUnsecuredTermLoansMember 2024-07-17 0000010456 us-gaap:SeniorNotesMember 2024-07-17 0000010456 srt:ScenarioForecastMember us-gaap:SeniorNotesMember 2025-01-01 2025-12-31 0000010456 us-gaap:LineOfCreditMember bax:SeniorUnsecuredTermLoansMember 2024-12-31 0000010456 us-gaap:RevolvingCreditFacilityMember 2025-03-31 0000010456 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0000010456 us-gaap:RevolvingCreditFacilityMember us-gaap:CommercialPaperMember 2025-03-31 0000010456 us-gaap:CommercialPaperMember 2025-01-01 2025-03-31 0000010456 us-gaap:CommercialPaperMember 2024-12-31 0000010456 us-gaap:CommercialPaperMember 2025-03-31 0000010456 bax:EnviromentalCleanUpMember bax:SuperfundSitesMember 2025-03-31 0000010456 bax:EnviromentalCleanUpMember bax:SuperfundSitesMember 2024-12-31 0000010456 bax:ExposureToEthyleneOxideMember 2020-03-01 2020-03-31 0000010456 bax:ExposureToEthyleneOxideMember 2023-12-31 2025-03-31 0000010456 bax:ExposureToEthyleneOxideMember 2024-07-16 2024-07-16 0000010456 2024-09-11 0000010456 bax:ExposureToEthyleneOxideMember us-gaap:SubsequentEventMember 2025-04-01 2025-06-30 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-12-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-12-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-12-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2025-01-01 2025-03-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2025-01-01 2025-03-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2025-01-01 2025-03-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2025-03-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2025-03-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2025-03-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0000010456 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000010456 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000010456 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000010456 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2025-01-01 2025-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:FairValueHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:FairValueHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000010456 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000010456 srt:MinimumMember 2025-01-01 2025-03-31 0000010456 srt:MaximumMember 2025-01-01 2025-03-31 0000010456 2025-04-01 2025-03-31 0000010456 2026-01-01 2025-03-31 0000010456 2028-01-01 2025-03-31 0000010456 2027-01-01 2025-03-31 0000010456 2029-01-01 2025-03-31 0000010456 srt:MaximumMember bax:ManufacturingArrangementsMember 2025-01-01 2025-03-31 0000010456 srt:MinimumMember bax:SoftwareArrangementsMember 2025-01-01 2025-03-31 0000010456 srt:MaximumMember bax:SoftwareArrangementsMember 2025-01-01 2025-03-31 0000010456 srt:MinimumMember bax:ConsumableMedicalProductsMember 2025-01-01 2025-03-31 0000010456 srt:MaximumMember bax:ConsumableMedicalProductsMember 2025-01-01 2025-03-31 0000010456 bax:ManufacturingArrangementsMember 2025-03-31 0000010456 bax:ManufacturingArrangementsMember 2024-12-31 0000010456 bax:SoftwareArrangementsMember 2025-03-31 0000010456 bax:SoftwareArrangementsMember 2024-12-31 0000010456 bax:BundledEquipmentAndConsumableMedicalProductsContractsMember 2025-03-31 0000010456 bax:BundledEquipmentAndConsumableMedicalProductsContractsMember 2024-12-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-03-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-12-31 0000010456 us-gaap:OtherNoncurrentAssetsMember 2025-03-31 0000010456 us-gaap:OtherNoncurrentAssetsMember 2024-12-31 0000010456 bax:AccruedExpensesAndOtherCurrentLiabilitiesMember 2025-03-31 0000010456 bax:AccruedExpensesAndOtherCurrentLiabilitiesMember 2024-12-31 0000010456 us-gaap:OtherNoncurrentLiabilitiesMember 2025-03-31 0000010456 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31 0000010456 bax:A2021AndPriorYearsMember 2025-03-31 0000010456 bax:A2022Member 2025-03-31 0000010456 bax:A2023Member 2025-03-31 0000010456 bax:A2024Member 2025-03-31 0000010456 bax:A2025Member 2025-03-31 0000010456 bax:BusinessOptimizationProgramsMember 2025-01-01 2025-03-31 0000010456 bax:BusinessOptimizationProgramsMember 2024-01-01 2024-03-31 0000010456 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000010456 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000010456 us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000010456 us-gaap:CostOfSalesMember bax:AssetWriteOffsMember 2025-01-01 2025-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember bax:AssetWriteOffsMember 2025-01-01 2025-03-31 0000010456 us-gaap:ResearchAndDevelopmentExpenseMember bax:AssetWriteOffsMember 2025-01-01 2025-03-31 0000010456 bax:AssetWriteOffsMember 2025-01-01 2025-03-31 0000010456 us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0000010456 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0000010456 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0000010456 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0000010456 us-gaap:CostOfSalesMember bax:ContractTerminationAndOtherCostsMember 2024-01-01 2024-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember bax:ContractTerminationAndOtherCostsMember 2024-01-01 2024-03-31 0000010456 bax:ContractTerminationAndOtherCostsMember 2024-01-01 2024-03-31 0000010456 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000010456 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0000010456 us-gaap:EmployeeSeveranceMember bax:KidneyCareMember 2025-01-01 2025-03-31 0000010456 us-gaap:EmployeeSeveranceMember bax:NewOperatingModelMember 2024-01-01 2024-03-31 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2024-12-31 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2025-01-01 2025-03-31 0000010456 bax:SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember 2025-03-31 0000010456 us-gaap:PensionPlansDefinedBenefitMember 2025-01-01 2025-03-31 0000010456 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2025-01-01 2025-03-31 0000010456 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000010456 us-gaap:ForeignExchangeContractMember 2025-03-31 0000010456 us-gaap:ForeignExchangeContractMember 2024-12-31 0000010456 us-gaap:ForeignExchangeContractMember 2025-01-01 2025-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2025-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-12-31 0000010456 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2025-03-31 0000010456 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2024-12-31 0000010456 us-gaap:FairValueHedgingMember 2023-10-31 0000010456 bax:A04SeniorNotesDueMay2024Member 2023-10-31 0000010456 bax:A130SeniorNotesDueMay2025Member 2017-05-31 0000010456 bax:A13SeniorNotesDueMay2029Member 2019-05-31 0000010456 bax:A13SeniorNotesDueMay2029Member 2017-05-31 0000010456 bax:A04SeniorNotesDueMay2024Member 2019-05-31 0000010456 us-gaap:NetInvestmentHedgingMember 2025-03-31 0000010456 us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0000010456 us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000010456 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0000010456 us-gaap:NondesignatedMember 2025-03-31 0000010456 us-gaap:NondesignatedMember 2024-12-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2025-01-01 2025-03-31 0000010456 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000010456 us-gaap:FairValueHedgingMember 2025-01-01 2025-03-31 0000010456 us-gaap:FairValueHedgingMember 2024-01-01 2024-03-31 0000010456 us-gaap:FairValueHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2025-01-01 2025-03-31 0000010456 us-gaap:FairValueHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000010456 us-gaap:NetInvestmentHedgingMember 2025-01-01 2025-03-31 0000010456 us-gaap:NetInvestmentHedgingMember 2024-01-01 2024-03-31 0000010456 us-gaap:NetInvestmentHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2025-01-01 2025-03-31 0000010456 us-gaap:NetInvestmentHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2025-01-01 2025-03-31 0000010456 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0000010456 bax:LongTermDebtAndLeaseObligationMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-03-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-03-31 0000010456 bax:LongTermDebtAndLeaseObligationCurrentMember us-gaap:NondesignatedMember 2025-03-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000010456 bax:LongTermDebtAndLeaseObligationCurrentMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000010456 bax:LongTermDebtAndLeaseObligationMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000010456 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2025-03-31 0000010456 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2024-12-31 0000010456 us-gaap:LongTermDebtMember 2025-03-31 0000010456 us-gaap:LongTermDebtMember 2024-12-31 0000010456 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000010456 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000010456 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000010456 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000010456 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000010456 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000010456 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000010456 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000010456 us-gaap:FairValueInputsLevel2Member 2025-03-31 0000010456 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000010456 bax:SeparationRelatedCostsMember 2024-12-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-12-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-12-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2023-12-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2023-12-31 0000010456 bax:SeparationRelatedCostsMember 2025-01-01 2025-03-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2025-01-01 2025-03-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-01-01 2024-03-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-01-01 2024-03-31 0000010456 bax:SeparationRelatedCostsMember 2025-03-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2025-03-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2025-03-31 0000010456 us-gaap:AcquisitionRelatedCostsMember 2024-03-31 0000010456 bax:AvailableForSaleDebtSecuritiesMember 2024-03-31 0000010456 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-31 0000010456 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0000010456 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-31 0000010456 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0000010456 us-gaap:OtherAssetsMember 2024-12-31 0000010456 us-gaap:OtherAssetsMember 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember country:US bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember country:US bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InfusionTherapiesAndTechnologiesMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember country:US bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember country:US bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember country:US bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember country:US bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:CareAndConnectivitySolutionsMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember country:US bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember country:US bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:FrontLineCareMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:HealthcareSystemsAndTechnologiesMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:HealthcareSystemsAndTechnologiesMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember country:US bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember country:US bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:InjectablesAndAnesthesiaMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember country:US bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember country:US bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalCompoundingMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalsMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember country:US bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:PharmaceuticalsMember 2024-01-01 2024-03-31 0000010456 us-gaap:CorporateNonSegmentMember country:US 2025-01-01 2025-03-31 0000010456 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2025-01-01 2025-03-31 0000010456 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0000010456 us-gaap:CorporateNonSegmentMember country:US 2024-01-01 2024-03-31 0000010456 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2024-01-01 2024-03-31 0000010456 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000010456 country:US 2025-01-01 2025-03-31 0000010456 us-gaap:NonUsMember 2025-01-01 2025-03-31 0000010456 country:US 2024-01-01 2024-03-31 0000010456 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2025-01-01 2025-03-31 0000010456 bax:EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember 2024-01-01 2024-03-31 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2025-01-01 2025-03-31 0000010456 bax:WesternEuropeCanadaJapanAustraliaAndNewZealandMember 2024-01-01 2024-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:ReportableSegmentMember 2025-01-01 2025-03-31 0000010456 us-gaap:OperatingSegmentsMember bax:ReportableSegmentMember 2024-01-01 2024-03-31 0000010456 us-gaap:MaterialReconcilingItemsMember bax:ReportableSegmentMember 2025-01-01 2025-03-31 0000010456 us-gaap:MaterialReconcilingItemsMember bax:ReportableSegmentMember 2024-01-01 2024-03-31 0000010456 us-gaap:MaterialReconcilingItemsMember 2025-01-01 2025-03-31 0000010456 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-03-31 shares iso4217:USD iso4217:USD shares pure iso4217:EUR bax:site bax:lawsuit bax:complaint bax:de-designation bax:terminate bax:segment false 2025 Q1 0000010456 --12-31 P1Y P1Y P9M P1Y P1Y P1Y P1Y 10-Q true 2025-03-31 false 1-4448 BAXTER INTERNATIONAL INC. DE 36-0781620 One Baxter Parkway, Deerfield, IL 60015 224. 948.2000 Common Stock, $1.00 par value Common Stock, $1.00 par value BAX (NYSE) BAX (NYSE) NYSE 1.3% Global Notes due 2025 BAX 25 NYSE 1.3% Global Notes due 2029 BAX 29 NYSE Yes Yes Large Accelerated Filer false false false 513174623 2294000000 1764000000 66000000 71000000 1646000000 1679000000 2170000000 2046000000 925000000 753000000 0 2611000000 7035000000 8853000000 2717000000 2870000000 5338000000 5275000000 5081000000 5223000000 301000000 306000000 832000000 755000000 0 2500000000 21304000000 25782000000 11000000 2126000000 651000000 626000000 963000000 968000000 1856000000 1861000000 0 930000000 3481000000 6511000000 9412000000 10374000000 235000000 243000000 1122000000 1076000000 0 554000000 14250000000 18758000000 1 1 2000000000 2000000000 683494944 683494944 683000000 683000000 170414885 172567636 10937000000 11059000000 6309000000 6421000000 14968000000 14929000000 -3942000000 -4010000000 7081000000 6964000000 -27000000 60000000 7054000000 7024000000 21304000000 25782000000 2625000000 2490000000 1764000000 1529000000 861000000 961000000 703000000 729000000 140000000 120000000 40000000 3000000 58000000 115000000 -64000000 -78000000 3000000 9000000 -3000000 46000000 -67000000 40000000 64000000 6000000 62000000 33000000 126000000 39000000 0 0 0 2000000 0 2000000 126000000 37000000 0.13 0.01 0.13 0.01 0.12 0.06 0.12 0.06 0.25 0.07 0.25 0.07 512000000 508000000 514000000 510000000 64000000 6000000 6000000 13000000 -68000000 -119000000 4000000 -3000000 -12000000 -4000000 -1000000 2000000 -2000000 8000000 -58000000 -107000000 6000000 -101000000 62000000 33000000 0 -2000000 137000000 -65000000 -3000000 0 11000000 0 126000000 -65000000 188000000 -32000000 194000000 -133000000 0 2000000 0 -4000000 194000000 -131000000 683000000 683000000 173000000 -11059000000 6421000000 14929000000 -4010000000 6964000000 60000000 7024000000 126000000 126000000 0 126000000 -47000000 -47000000 -47000000 115000000 115000000 115000000 3000000 122000000 -112000000 10000000 10000000 87000000 87000000 87000000 87000000 87000000 683000000 683000000 170000000 -10937000000 6309000000 14968000000 -3942000000 7081000000 -27000000 7054000000 683000000 683000000 176000000 -11230000000 6389000000 16114000000 -3554000000 8402000000 66000000 8468000000 37000000 37000000 2000000 39000000 -168000000 -168000000 -4000000 -172000000 2000000 100000000 -50000000 50000000 50000000 148000000 148000000 148000000 -2000000 -2000000 683000000 683000000 174000000 -11130000000 6339000000 16003000000 -3722000000 8173000000 62000000 8235000000 126000000 39000000 62000000 33000000 64000000 6000000 247000000 271000000 -142000000 -58000000 10000000 17000000 -8000000 -7000000 22000000 0 -6000000 -5000000 -26000000 -125000000 122000000 145000000 24000000 4000000 16000000 119000000 143000000 240000000 -51000000 -22000000 -99000000 67000000 -94000000 96000000 -193000000 163000000 122000000 110000000 2000000 -10000000 -124000000 -100000000 3389000000 -66000000 3265000000 -166000000 2825000000 15000000 -300000000 0 87000000 147000000 10000000 40000000 -24000000 -18000000 -3226000000 -140000000 36000000 -25000000 -118000000 -168000000 2414000000 3198000000 2296000000 3030000000 0 200000000 2296000000 2830000000 2294000000 1764000000 2826000000 2000000 2000000 4000000 0 648000000 200000000 2296000000 2414000000 3030000000 BASIS OF PRESENTATION<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the net after tax proceeds of approximately $3.3 billion, subject to certain post-closing adjustments. The financial position, results of operations and cash flows of our Kidney Care business, including the gain on sale of that business and the related cash proceeds received, are reported as discontinued operations in the accompanying condensed consolidated financial statements, and our prior period results have been adjusted to reflect discontinued operations. See Note 2 for additional information.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hurricane Helene</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at our North Cove facility in Marion, North Carolina and disrupted operations at that facility. Since then, we have actively worked with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we worked towards resuming our North Cove manufacturing operations. While we continue to increase allocation levels across key impacted product groups, the facility was fully operational by the end of the first quarter of 2025. In the first quarter of 2025, we recorded $98 million of pre-tax net charges related to remediation, air freight and other costs as a result of the damages caused by Hurricane Helene. These amounts were recorded as a component of cost of sales in the condensed consolidated statements of income for the three month period ended March 31, 2025. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Constraints, Tariffs and Global Economic Conditions</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which caused the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative of lower cost raw material or component parts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these challenges, among other factors, may continue to have an adverse effect on our business.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 (2024 Annual Report).</span></div>In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. 3800000000 3710000000 3300000000 98000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Constraints, Tariffs and Global Economic Conditions</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant challenges to our global supply chain, including production delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including Hurricane Helene, which caused the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle East and other geopolitical events. While we have seen improvements in the availability of component parts and improved pricing in raw materials and on transportation costs, some of these challenges are expected to have a negative impact on our results of operations in the future. In addition, recent announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential pharmaceutical tariffs), and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While we are in the process of implementing select offsets for 2025 and working to identify </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected (including as a result of a failure to achieve the anticipated offsets or an inability to identify additional mitigating actions). Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and in operational and policy changes in the governments of the U.S. and other countries, could contribute to further market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels, all of which could adversely affect our business, results of operations or financial condition. Sole source supplier relationships may limit our ability to respond to these tariffs with alternative of lower cost raw material or component parts.</span></div> DISCONTINUED OPERATIONS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation as described below. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations - Kidney Care</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction. We recognized a pre-tax gain on the sale of $191 million ($111 million net of tax). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We analyzed the quantitative and qualitative factors relevant to the sale of our Kidney Care business, including its significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those conditions for discontinued operations presentation had been met. As such, the financial position, results of operations and cash flows of that business are reported as discontinued operations in the accompanying condensed consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations presentation. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the sale of the Kidney Care business, pursuant to the Equity Purchase Agreement (EPA), Baxter and Vantive entered into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a Transition Services Agreement (Kidney Care TSA), a Long Term Master Services Agreement, a Distribution Agreement and certain other arrangements providing for short-term supply of saline products, and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities provide each other with certain dialysis-related products, other products, product components and fulfillment services for up to 10 years post-closing (with certain extension rights and early exit rights as provided therein). Pursuant to the Kidney Care MSA, our sales to Vantive are recognized in net sales in the condensed consolidated statements of income (loss). Pursuant to the Kidney Care TSA, Baxter and the entities that were divested in connection with the Kidney Care sale (the Kidney Care divested entities) provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights and early exit rights as provided therein) to help ensure business continuity and help minimize disruptions to the operations of both parties post-closing. Services provided under the Kidney Care TSA include information technology applications and support, supply chain and certain other corporate and administrative services. Billings by us under the Kidney Care TSA are recorded in other operating income, net in the condensed consolidated statements of income. The costs to provide each respective service is recorded in the applicable expense category in the condensed consolidated statements of income (loss). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the EPA, we have agreed to indemnify Vantive for certain items, including taxes imposed on or with respect to the Kidney Care divested entities, for pre-closing tax periods. The net indemnification liability as of March 31, 2025 was $37 million. Further, in accordance with the EPA, Baxter recorded a contingent liability for payments to reimburse Vantive for qualifying capital expenditures over a period of three years post sale. The contingent liability as of March 31, 2025 was $133 million. Certain of the business guarantees originally entered by us on behalf of the Kidney Care business were not released prior to the completion of the sale and remain outstanding. These legacy guarantees primarily relate to leases, performance contracts and ones to support regulatory requirements of the Kidney Care business. As of March 31, 2025, the total amount of Kidney Care business guarantees retained by us is approximately $300 million. Under terms of the EPA, Carlyle has agreed to indemnify us for any cost or expense, or payments made in the future under these arrangements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025 and 2024:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations before gain on disposition and income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposition</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interest included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Baxter stockholders included in discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, selling, general and administrative expenses (SG&amp;A) includes $37 million and $88 million, respectively, of separation-related costs incurred in connection with the sale of our Kidney Care business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of December 31, 2024:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.101%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of finance lease obligations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease obligations, less current portion</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3800000000 3710000000 191000000 111000000 P10Y P30M 37000000 133000000 300000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025 and 2024:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations before gain on disposition and income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposition</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interest included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Baxter stockholders included in discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as discontinued operations, related to our Kidney Care business, in the condensed consolidated balance sheets as of December 31, 2024:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.101%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets of discontinued operations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of finance lease obligations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease obligations, less current portion</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities of discontinued operations</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 352000000 1102000000 206000000 676000000 146000000 426000000 116000000 298000000 16000000 56000000 14000000 72000000 -13000000 0 -7000000 -2000000 -6000000 70000000 191000000 0 123000000 37000000 62000000 33000000 0 2000000 62000000 31000000 37000000 88000000 648000000 942000000 821000000 200000000 2611000000 1516000000 265000000 148000000 204000000 367000000 2500000000 5111000000 1000000 344000000 585000000 930000000 37000000 173000000 344000000 554000000 1484000000 SUPPLEMENTAL FINANCIAL INFORMATION<div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2025 and 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment, Net </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Current Assets and Liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our Kidney Care business and pursuant to the EPA, the Kidney Care assets and liabilities in certain countries are to be transferred at a later date for operational, regulatory or other reasons. Accordingly, the related assets, primarily consisting of accounts receivable, of $95 million and liabilities, consisting of accounts payable, of $7 million of these deferred markets and are presented within prepaid and other current assets and accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of March 31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we signed a purchase agreement with a buyer to sell our manufacturing facility in Opelika, Alabama for $25 million, subject to the satisfaction of various closing conditions. The related assets are classified as held-for-sale and are presented within prepaid and other current assets in the accompanying condensed consolidated balance sheet as of March 31, 2025. While the closing remains subject to the satisfaction of various closing conditions, we currently expect the transaction to close in 2025 and the net book value of the assets as of March 31, 2025 approximates the transaction price net of estimated selling costs. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of capitalized interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and other postretirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Cash Operating and Investing Activities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2025 and 2024 were $5 million and $16 million, respectively.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Purchases of property, plant and equipment included in accounts payable as of March 31, 2025 and 2024 were $39 million and $35 million, respectively. <div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2025 and 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 71000000 62000000 -4000000 -1000000 2000000 3000000 -1000000 2000000 66000000 56000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 550000000 510000000 310000000 266000000 1310000000 1270000000 2170000000 2046000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment, Net </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 7431000000 7648000000 4714000000 4778000000 2717000000 2870000000 95000000 7000000 25000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of capitalized interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 81000000 103000000 17000000 25000000 -64000000 -78000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and other postretirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 -14000000 -11000000 -13000000 -1000000 3000000 9000000 0 2000000 7000000 3000000 9000000 5000000 16000000 39000000 35000000 GOODWILL AND OTHER INTANGIBLE ASSETS, NET<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of goodwill by segment.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other intangible assets, net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our other intangible assets.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology, including patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other amortized intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In process Research and Development</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross other intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross other intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div>Intangible asset amortization expense was $155 million and $158 million for the three months ended March 31, 2025 and 2024, respectively <div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of goodwill by segment.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 1185000000 3550000000 540000000 5275000000 38000000 8000000 17000000 63000000 1223000000 3558000000 557000000 5338000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our other intangible assets.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology, including patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other amortized intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In process Research and Development</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross other intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross other intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 3387000000 3131000000 958000000 86000000 680000000 107000000 8349000000 878000000 2075000000 107000000 66000000 3126000000 2509000000 1056000000 851000000 20000000 680000000 107000000 5223000000 3389000000 3154000000 953000000 88000000 680000000 107000000 8371000000 932000000 2170000000 119000000 69000000 3290000000 2457000000 984000000 834000000 19000000 680000000 107000000 5081000000 155000000 158000000 FINANCING ARRANGEMENTS<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Debt Activity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, we repaid $1.00 billion under our $1.64 billion five-year term loan facility maturing in 2026.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2024, we entered into a credit agreement pursuant to which a group of banks provided us senior unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond December 31, 2024 would increase by 0.25%.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also incurred a ticking fee on undrawn commitments at a rate based on our long-term debt ratings in effect from time to time. The banks’ funding commitments under the bridge facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we were required to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to repay any outstanding borrowings under the bridge facility. The bridge facility contained financial and other covenants, including a net leverage </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covenant, and provided for customary events of default. There was $1.83 billion outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the approximately $3.3 billion of net after-tax cash proceeds from the sale of our Kidney Care business to repay the $1.83 billion outstanding under the bridge facility, at which time it was terminated. </span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 2025, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of term loans outstanding, a U.S Dollar-denominated revolving credit facility and a Euro-denominated revolving credit facility. Our U.S. Dollar-denominated revolving credit facility has a current capacity of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $2.00 billion and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Euro-denominated revolving credit facility has a capacity of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">€200 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of the facilities is scheduled to mature in 2026. There were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowings outstanding under these credit facilities as of March 31, 2025 or December 31, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of March 31, 2025 we have capacity to draw $2.04 billion under our credit facilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Paper</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no commercial paper outstanding as of March 31, 2025. As of December 31, 2024, we had $300 million of commercial paper outstanding with a weighted-average interest rate of 4.78% and an original term of 45 days. I</span>n the first quarter of 2025, we repaid the $300 million balance outstanding as of December 31, 2024. 1000000000 1640000000 P5Y 2050000000.00 0.01322 0.0025 1830000000 3300000000 1830000000 2000000000 200000000 0 0 2040000000.00 0 300000000 0.0478 P45D 300000000 COMMITMENTS AND CONTINGENCIES<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2025 and December 31, 2024, our total recorded reserves with respect to legal and environmental matters were $46 million and $40 million, respectively. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of March 31, 2025 and December 31, 2024, our environmental reserves, which are measured on an undiscounted basis, were $28 million and $29 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Litigation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December 31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 41 lawsuits (after giving effect to the September 2024 amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25, 2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant. In the second quarter of 2025, plaintiffs filed a motion to voluntarily dismiss Baxter from 29 of the filed cases, which was granted by the Court. The parties have reached an agreement in principle to resolve the remaining filed cases, along with certain additional matters, for an amount not material to Baxter. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired Hill-Rom Holdings, Inc. (Hillrom) on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom, received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom, and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (the 2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act, and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further discovery. Fact discovery is ongoing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020” and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint. On November 8, 2024, Hillrom </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a Motion to Dismiss Plaintiff's Amended Complaint. Briefing was completed in January 2025, and the court held a hearing on the motion on March 25, 2025. The motion is pending before the court.</span></div> 46000000 40000000 6 28000000 29000000 2 41 40 1 29 STOCKHOLDERS’ EQUITY<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends declared per share for the three months ended March 31, 2025 and 2024 were $0.17 and $0.29, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div>In July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first three months of 2025 and 2024 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of March 31, 2025. 0.17 0.29 0 0 1300000000 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income (loss), cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans, gains and losses on cash flow hedges, and unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2025 and 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension and OPEB plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedging activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,010)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,361)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension and OPEB plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedging activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,165)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,722)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    See table below for details about these reclassifications.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2025 and 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of impact in income statement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative translation loss to earnings from Kidney Care separation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and OPEB items</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net losses and prior service costs or credits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement from Kidney Care separation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect on pension settlement from Kidney Care separation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of tax</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    Amounts in parentheses indicate reductions to net income</span></div>Refer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity <div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2025 and 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension and OPEB plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedging activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,010)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,361)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension and OPEB plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedging activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,165)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,722)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    See table below for details about these reclassifications.</span></div> -3430000000 -475000000 -108000000 3000000 -4010000000 -57000000 14000000 0 0 -43000000 -126000000 13000000 2000000 0 -111000000 69000000 1000000 -2000000 0 68000000 -3361000000 -474000000 -110000000 3000000 -3942000000 -2985000000 -452000000 -120000000 3000000 -3554000000 -180000000 5000000 6000000 0 -169000000 0 1000000 -2000000 0 -1000000 -180000000 4000000 8000000 0 -168000000 -3165000000 -448000000 -112000000 3000000 -3722000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2025 and 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI (a)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of impact in income statement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CTA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative translation loss to earnings from Kidney Care separation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and OPEB items</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net losses and prior service costs or credits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement from Kidney Care separation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect on pension settlement from Kidney Care separation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of tax</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    Amounts in parentheses indicate reductions to net income</span></div> -126000000 0 0 0 -126000000 0 3000000 2000000 -14000000 0 17000000 2000000 1000000 1000000 3000000 0 13000000 1000000 1000000 -2000000 4000000 -1000000 0 -3000000 3000000 -2000000 1000000 0 2000000 -2000000 -111000000 -1000000 REVENUES<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30 to 90 days.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems &amp; Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, we had $10.19 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products &amp; Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 15% of this amount as revenue over the remainder of 2025, 20% in 2026, 15% in each of 2027 and 2028 and 35% thereafter.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Judgments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and distributor chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three months ended March 31, 2025 and 2024 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.49 billion and $1.54 billion as of March 31, 2025 and December 31, 2024, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over <span style="-sec-ix-hidden:f-683">one</span> to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over <span style="-sec-ix-hidden:f-685">one</span> to seven years. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bundled equipment and consumable medical products contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability activity for the three months ended March 31, 2025 and 2024. The contract liability balance represents the transaction price allocated to the remaining performance obligations.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New revenue deferrals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized upon satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, $34 million and $43 million of revenue was recognized that was included in contract liabilities as of December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Net Sales</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Revenue</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease revenue for the three months ended March 31, 2025 and 2024 were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases was $47 million as of March 31, 2025, of which $13 million originated in 2021 and prior, $6 million in 2022, $7 million in 2023, $10 million in 2024, and $11 million in 2025.</span></div> P30D P90D 10190000000 0.15 0.20 0.15 0.15 0.35 0 0 1490000000 1540000000 P90D P5Y P7Y <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bundled equipment and consumable medical products contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability activity for the three months ended March 31, 2025 and 2024. The contract liability balance represents the transaction price allocated to the remaining performance obligations.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New revenue deferrals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized upon satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, $34 million and $43 million of revenue was recognized that was included in contract liabilities as of December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4000000 2000000 39000000 44000000 89000000 87000000 132000000 133000000 171000000 169000000 128000000 93000000 124000000 91000000 0 2000000 175000000 169000000 34000000 43000000 54000000 51000000 78000000 82000000 132000000 133000000 135000000 131000000 40000000 40000000 175000000 171000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease revenue for the three months ended March 31, 2025 and 2024 were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease revenue for the three months ended March 31, 2025 and 2024 were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8000000 2000000 91000000 104000000 7000000 8000000 106000000 114000000 47000000 13000000 6000000 7000000 10000000 11000000 BUSINESS OPTIMIZATION CHARGES<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization into verticalized segments, optimizing the manufacturing footprint, R&amp;D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $4 million through the completion of initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, we recorded the following charges related to business optimization programs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs to implement business optimization programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business optimization charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to implement business optimization programs for the three months ended March 31, 2025 and 2024, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&amp;A expense.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, we recorded the following restructuring charges.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, $25 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, $6 million of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to the implementation of our operating model intended to streamline our operations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes activity in the liability related to our restructuring initiatives.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our restructuring liabilities as of March 31, 2025 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2025.</span></div> 4000000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, we recorded the following charges related to business optimization programs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs to implement business optimization programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business optimization charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 44000000 17000000 1000000 5000000 45000000 22000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, we recorded the following restructuring charges.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 12000000 13000000 1000000 26000000 1000000 17000000 0 18000000 13000000 30000000 1000000 44000000 3000000 11000000 14000000 0 3000000 3000000 3000000 14000000 17000000 25000000 6000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes activity in the liability related to our restructuring initiatives.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 122000000 26000000 36000000 2000000 114000000 PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net losses and prior service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic pension cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">OPEB</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss and prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic OPEB cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net losses and prior service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic pension cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">OPEB</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss and prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic OPEB cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3000000 6000000 34000000 45000000 44000000 59000000 -1000000 -4000000 -6000000 -4000000 2000000 2000000 4000000 5000000 -2000000 -3000000 INCOME TAXES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, our effective income tax rate differs significantly from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by income tax expense resulting from internal reorganization transactions related to the sale of our Kidney Care segment, an increase in a valuation allowance in a foreign jurisdiction resulting from changes in future projected income, and an increase in our liabilities for various uncertain tax positions.</span></div> 0.21 EARNINGS PER SHARE<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations attributable to Baxter stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations attributable to Baxter stockholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Baxter stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of basic shares and diluted shares.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 20 million and 16 million shares issuable under equity awards for the three months ended March 31, 2025 and 2024, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations attributable to Baxter stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations attributable to Baxter stockholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Baxter stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 64000000 6000000 0 0 64000000 6000000 62000000 33000000 0 2000000 62000000 31000000 126000000 37000000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of basic shares and diluted shares.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 512000000 508000000 2000000 2000000 514000000 510000000 20000000 16000000 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Canadian Dollar, Australian Dollar, Indian Rupee, Turkish Lira, Japanese Yen, Mexican Peso, Korean Wan and Swiss Franc. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce our net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flow Hed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">es</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged transaction. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of foreign exchange contracts designated as cash flow hedges were $49 million and $99 million as of March 31, 2025 and December 31, 2024, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at March 31, 2025 is eight months for foreign exchange contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of March 31, 2025 and December 31, 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Hed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">es</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no outstanding interest rate contracts designated as fair value hedges as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we entered into a foreign currency forward contract with a notional amount of $798 million and designated that derivative as a fair value hedge of our €750 million of 0.40% senior notes due May 2024. This forward contract matured in May 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Investment Hed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">es</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we issued €600 million of 1.3% senior notes due May 2025. We had designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In March 2025, we dedesignated this previously designated net investment hedge and concurrently entered into forward contracts to manage foreign exchange risk in earnings relating to these outstanding debt balances.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we issued €750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we issued €750 million of 0.40% senior notes due May 2024. We had designated these debt obligations as hedges of our investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered into a fair value hedging relationship as discussed in the "Fair Value Hedges" section above. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, we had an accumulated pre-tax unrealized translation gain in AOCI of $63 million related to the Euro-denominated senior notes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dedesignations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged transactions. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash flow hedge dedesignations in the first three months of 2025 or 2024 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2025 or 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In March 2025, we dedesignated one of our net investment hedges as discussed in the "Net Investment Hedges" section above. There were no net investment hedges terminated during the first three months of 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Undesignated Derivative Instruments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, as discussed in the "Net Investment Hedges" section above, we entered into forward contracts with a notional amount of $655 million to hedge the repayment of our Euro-denominated senior notes due May 2025. The total notional amount of undesignated derivative instruments was $955 million as of March 31, 2025 and $389 million as of December 31, 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2025 and </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of gain (loss)<br/>in income statement</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into income</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of gain (loss) in income statement</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in income</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, $2 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Assets and Liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2025.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in asset positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in liability positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative instruments designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in asset positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in liability positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative instruments designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount of hedged item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative amount of fair value hedging adjustment included<br/> in the carrying amount of the hedged item (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) These fair value hedges were terminated in 2018 and earlier periods.</span></div> 49000000 99000000 P8M 0 0 0 0 798000000 750000000 0.0040 600000000 0.013 750000000 0.013 750000000 0.0040 63000000 0 0 0 0 0 655000000 955000000 389000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2025 and </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of gain (loss)<br/>in income statement</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into income</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Location of gain (loss) in income statement</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in income</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, $2 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. </span> 0 0 -1000000 -1000000 0 10000000 4000000 2000000 0 -2000000 0 -3000000 61000000 38000000 0 0 61000000 46000000 3000000 -2000000 0 -23000000 -2000000 -5000000 -2000000 -28000000 -2000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2025.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in asset positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in liability positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative instruments designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in asset positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives in liability positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative instruments designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undesignated derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000 0 761000000 0 4000000 648000000 3000000 1413000000 6000000 0 618000000 727000000 1000000 2000000 7000000 1347000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 3000000 4000000 7000000 2000000 2000000 2000000 1000000 1000000 1000000 2000000 6000000 1000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount of hedged item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative amount of fair value hedging adjustment included<br/> in the carrying amount of the hedged item (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) These fair value hedges were terminated in 2018 and earlier periods.</span></div> 99000000 99000000 2000000 2000000 FAIR VALUE MEASUREMENTS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant other<br/>observable inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnifications related to Kidney Care separation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Recorded in connection with the sale of our Kidney Care business and was measured as of January 31, 2025. See Note 2 for additional information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant other<br/>observable inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, cash and cash equivalents of $2.29 billion and $1.76 billion, respectively, included money market fund and other short-term funds of approximately $1.21 billion and $583 million, respectively, that are considered Level 2 in the fair value hierarchy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have contingent payments related related to the Kidney Care separation, which consist of reimbursements to Vantive for certain indemnifications contemplated in the EPA. For additional information on these items see Note 2.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnifications related to Kidney Care separation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair values(a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,398 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments Without Readily Determinable Fair Values</span></div>The carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $37 million as of March 31, 2025 and December 31, 2024. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. These investments are included in Other non-current assets on our condensed consolidated balance sheets. <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant other<br/>observable inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnifications related to Kidney Care separation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Recorded in connection with the sale of our Kidney Care business and was measured as of January 31, 2025. See Note 2 for additional information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant other<br/>observable inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 3000000 0 3000000 0 1000000 0 0 1000000 12000000 12000000 0 0 16000000 12000000 3000000 1000000 4000000 0 4000000 0 12000000 0 0 12000000 37000000 0 0 37000000 53000000 0 4000000 49000000 7000000 0 7000000 0 1000000 0 0 1000000 13000000 13000000 0 0 21000000 13000000 7000000 1000000 2000000 0 2000000 0 12000000 0 0 12000000 14000000 0 2000000 12000000 2290000000 1760000000 1210000000 583000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnifications related to Kidney Care separation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments related to acquisitions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 12000000 1000000 14000000 1000000 37000000 0 0 0 0 37000000 12000000 1000000 14000000 1000000 For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2025 and December 31, 2024.<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair values(a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,398 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)    These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.</span></div> 11000000 2126000000 11000000 2126000000 651000000 626000000 650000000 619000000 9412000000 10374000000 8398000000 9295000000 37000000 37000000 SEGMENT INFORMATION<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is comprised of three segments: Medical Products &amp; Therapies, Healthcare Systems &amp; Technologies, and Pharmaceuticals. The Medical Products &amp; Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems &amp; Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily includes sales to Vantive, pursuant to the Kidney Care MSA, and sales of products and services provided directly through certain of our manufacturing facilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Disaggregation of Net Sales</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our U.S. and International disaggregated net sales.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion Therapies and Technologies</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced Surgery</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care and Connectivity Solutions</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Front Line Care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare Systems &amp; Technologies</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injectables and Anesthesia</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Compounding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Baxter</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Sales Information</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net sales are attributed to the following geographic regions based on the location of the customer. </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Baxter</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Income</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, in conjunction with the change in our Chief Executive Officer, we determined that our chief operating decision maker (CODM) comprises of our Chair and Interim Chief Executive Officer, and the Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products &amp; Therapies, who review the financial information presented for purposes of evaluating the performance of our segments and to make resource allocation decisions. The change in CODM during the first quarter of 2025 did not result in a change in our segments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income is the measure of segment profitability and represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate costs, inclusive of global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment results include net sales, cost of sales, selling, general and administrative expenses, research and development expenses, corporate costs that had previously been allocated to our former Kidney Care segment which did not convey in the related sale, and other segment items which are directly allocated to each segment. Beginning in 2024 annual reporting, we adopted ASU 2023-07 retrospectively. The following table presents our segment information of net sales, significant expense and operating income during the periods presented.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segment operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business optimization items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separation-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medical Devices Regulation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hurricane Helene costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product-related items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional financial information for our segments is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation Expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our CODM does not receive asset or capital expenditure information by reportable segment and, accordingly, we do not report that information for our segments.</span></div> 3 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our U.S. and International disaggregated net sales.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion Therapies and Technologies</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced Surgery</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care and Connectivity Solutions</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Front Line Care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare Systems &amp; Technologies</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injectables and Anesthesia</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Compounding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Baxter</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div>The following table presents our segment information of net sales, significant expense and operating income during the periods presented.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 584000000 410000000 994000000 526000000 440000000 966000000 145000000 123000000 268000000 147000000 116000000 263000000 729000000 533000000 1262000000 673000000 556000000 1229000000 316000000 111000000 427000000 278000000 124000000 402000000 202000000 75000000 277000000 195000000 70000000 265000000 518000000 186000000 704000000 473000000 194000000 667000000 195000000 140000000 335000000 191000000 137000000 328000000 0 246000000 246000000 0 250000000 250000000 195000000 386000000 581000000 191000000 387000000 578000000 48000000 30000000 78000000 11000000 5000000 16000000 1490000000 1135000000 2625000000 1348000000 1142000000 2490000000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net sales are attributed to the following geographic regions based on the location of the customer. </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Baxter</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.</span></div> 1490000000 1348000000 297000000 307000000 838000000 835000000 2625000000 2490000000 1262000000 704000000 581000000 1229000000 667000000 578000000 694000000 356000000 396000000 668000000 346000000 382000000 286000000 217000000 103000000 284000000 207000000 96000000 59000000 45000000 26000000 52000000 47000000 22000000 -21000000 -7000000 -7000000 -2000000 0 0 244000000 93000000 63000000 227000000 67000000 78000000 <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segment operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business optimization items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separation-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medical Devices Regulation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hurricane Helene costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product-related items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional financial information for our segments is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation Expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Products &amp; Therapies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Systems &amp; Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.</span></div> 244000000 227000000 93000000 67000000 63000000 78000000 400000000 372000000 9000000 4000000 -17000000 -69000000 -155000000 -158000000 -11000000 0 -45000000 -22000000 -1000000 -5000000 -13000000 0 -5000000 -7000000 -98000000 0 -6000000 0 58000000 115000000 -64000000 -78000000 3000000 9000000 -3000000 46000000 49000000 58000000 27000000 30000000 16000000 25000000 92000000 113000000 false false false false The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of March 31, 2025, December 31, 2024, and March 31, 2024 (in millions):March 31, 2025December 31, 2024March 31, 2024Cash and cash equivalents$2,294 $1,764 $2,826 Restricted cash included in other non-current assets2 2 4 Cash and cash equivalents of discontinued operations— 648 200 Cash, cash equivalents and restricted cash$2,296 $2,414 $3,030 

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Ñ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น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

    •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end XML 98 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 361 381 1 true 120 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://www.baxter.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited Condensed Consolidated Statements of Loss (unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited Condensed Consolidated Statements of Changes in Equity (unaudited) Statements 7 false false R8.htm 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 8 false false R9.htm 9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) Sheet http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) Statements 9 false false R10.htm 9952159 - Disclosure - BASIS OF PRESENTATION Sheet http://www.baxter.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 10 false false R11.htm 9952160 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.baxter.com/role/DISCONTINUEDOPERATIONS DISCONTINUED OPERATIONS Notes 11 false false R12.htm 9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION SUPPLEMENTAL FINANCIAL INFORMATION Notes 12 false false R13.htm 9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET Sheet http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET GOODWILL AND OTHER INTANGIBLE ASSETS, NET Notes 13 false false R14.htm 9952163 - Disclosure - FINANCING ARRANGEMENTS Sheet http://www.baxter.com/role/FINANCINGARRANGEMENTS FINANCING ARRANGEMENTS Notes 14 false false R15.htm 9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 9952165 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://www.baxter.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS??? EQUITY Notes 16 false false R17.htm 9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Sheet http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Notes 17 false false R18.htm 9952167 - Disclosure - REVENUES Sheet http://www.baxter.com/role/REVENUES REVENUES Notes 18 false false R19.htm 9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGES Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES BUSINESS OPTIMIZATION CHARGES Notes 19 false false R20.htm 9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS Sheet http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS Notes 20 false false R21.htm 9952170 - Disclosure - INCOME TAXES Sheet http://www.baxter.com/role/INCOMETAXES INCOME TAXES Notes 21 false false R22.htm 9952171 - Disclosure - EARNINGS PER SHARE Sheet http://www.baxter.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 22 false false R23.htm 9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Notes 23 false false R24.htm 9952173 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 24 false false R25.htm 9952174 - Disclosure - SEGMENT INFORMATION Sheet http://www.baxter.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 25 false false R26.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 9955511 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.baxter.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 28 false false R29.htm 9955512 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.baxter.com/role/DISCONTINUEDOPERATIONSTables DISCONTINUED OPERATIONS (Tables) Tables http://www.baxter.com/role/DISCONTINUEDOPERATIONS 29 false false R30.htm 9955513 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables SUPPLEMENTAL FINANCIAL INFORMATION (Tables) Tables http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION 30 false false R31.htm 9955514 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) Sheet http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) Tables http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET 31 false false R32.htm 9955515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Sheet http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Tables http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS 32 false false R33.htm 9955516 - Disclosure - REVENUES (Tables) Sheet http://www.baxter.com/role/REVENUESTables REVENUES (Tables) Tables http://www.baxter.com/role/REVENUES 33 false false R34.htm 9955517 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables) Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables BUSINESS OPTIMIZATION CHARGES (Tables) Tables http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES 34 false false R35.htm 9955518 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables) Sheet http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTables PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables) Tables http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS 35 false false R36.htm 9955519 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.baxter.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.baxter.com/role/EARNINGSPERSHARE 36 false false R37.htm 9955520 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) Tables http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES 37 false false R38.htm 9955521 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.baxter.com/role/FAIRVALUEMEASUREMENTS 38 false false R39.htm 9955522 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.baxter.com/role/SEGMENTINFORMATION 39 false false R40.htm 9955523 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://www.baxter.com/role/BASISOFPRESENTATIONDetails BASIS OF PRESENTATION (Details) Details http://www.baxter.com/role/BASISOFPRESENTATIONPolicies 40 false false R41.htm 9955524 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details) Sheet http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails DISCONTINUED OPERATIONS - Narrative (Details) Details 41 false false R42.htm 9955525 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) Sheet http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) Details 42 false false R43.htm 9955526 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) Sheet http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details) Details 43 false false R44.htm 9955527 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details) Details 44 false false R45.htm 9955528 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) Details 45 false false R46.htm 9955529 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) Details 46 false false R47.htm 9955530 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details) Details 47 false false R48.htm 9955531 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details) Details 48 false false R49.htm 9955532 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) Sheet http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details) Details http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables 49 false false R50.htm 9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details) Sheet http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details) Details 50 false false R51.htm 9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) Sheet http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) Details 51 false false R52.htm 9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) Sheet http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetails GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) Details 52 false false R53.htm 9955536 - Disclosure - FINANCING ARRANGEMENTS (Details) Sheet http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails FINANCING ARRANGEMENTS (Details) Details http://www.baxter.com/role/FINANCINGARRANGEMENTS 53 false false R54.htm 9955537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES 54 false false R55.htm 9955538 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 55 false false R56.htm 9955539 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) Sheet http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details) Details http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 56 false false R57.htm 9955540 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) Sheet http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details) Details http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 57 false false R58.htm 9955541 - Disclosure - REVENUES - Additional Information (Details) Sheet http://www.baxter.com/role/REVENUESAdditionalInformationDetails REVENUES - Additional Information (Details) Details 58 false false R59.htm 9955542 - Disclosure - REVENUES - Contract Assets and Contract Liabilities (Details) Sheet http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails REVENUES - Contract Assets and Contract Liabilities (Details) Details 59 false false R60.htm 9955543 - Disclosure - REVENUES - Lease Revenue (Details) Sheet http://www.baxter.com/role/REVENUESLeaseRevenueDetails REVENUES - Lease Revenue (Details) Details 60 false false R61.htm 9955544 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) Details 61 false false R62.htm 9955545 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details) Details 62 false false R63.htm 9955546 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details) Details 63 false false R64.htm 9955547 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) Sheet http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) Details 64 false false R65.htm 9955548 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) Sheet http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) Details 65 false false R66.htm 9955549 - Disclosure - INCOME TAXES (Details) Sheet http://www.baxter.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.baxter.com/role/INCOMETAXES 66 false false R67.htm 9955550 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) Sheet http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) Details 67 false false R68.htm 9955551 - Disclosure - EARNINGS PER SHARE - Additional Information (Details) Sheet http://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetails EARNINGS PER SHARE - Additional Information (Details) Details 68 false false R69.htm 9955552 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details) Details 69 false false R70.htm 9955553 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details) Details 70 false false R71.htm 9955554 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details) Details 71 false false R72.htm 9955555 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) Details 72 false false R73.htm 9955556 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) Sheet http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) Details 73 false false R74.htm 9955557 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Details 74 false false R75.htm 9955558 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details) Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails FAIR VALUE MEASUREMENTS - Additional Information (Details) Details 75 false false R76.htm 9955559 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) Details 76 false false R77.htm 9955560 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) Sheet http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) Details 77 false false R78.htm 9955561 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 78 false false R79.htm 9955562 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) Details 79 false false R80.htm 9955563 - Disclosure - SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details) Details 80 false false R81.htm 9955564 - Disclosure - SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details) Details 81 false false R82.htm 9955565 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) Sheet http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details) Details 82 false false All Reports Book All Reports bax-20250331.htm bax-20250331.xsd bax-20250331_cal.xml bax-20250331_def.xml bax-20250331_lab.xml bax-20250331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 104 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bax-20250331.htm": { "nsprefix": "bax", "nsuri": "http://www.baxter.com/20250331", "dts": { "inline": { "local": [ "bax-20250331.htm" ] }, "schema": { "local": [ "bax-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bax-20250331_cal.xml" ] }, "definitionLink": { "local": [ "bax-20250331_def.xml" ] }, "labelLink": { "local": [ "bax-20250331_lab.xml" ] }, "presentationLink": { "local": [ "bax-20250331_pre.xml" ] } }, "keyStandard": 316, "keyCustom": 65, "axisStandard": 38, "axisCustom": 1, "memberStandard": 69, "memberCustom": 48, "hidden": { "total": 12, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 5, "http://www.baxter.com/20250331": 2 }, "contextCount": 361, "entityCount": 1, "segmentCount": 120, "elementCount": 770, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 997, "http://xbrl.sec.gov/dei/2024": 37, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.baxter.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R3": { "role": "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R5": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R6": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical", "longName": "9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited", "longName": "9952156 - Statement - Condensed Consolidated Statements of Changes in Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R9": { "role": "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical", "longName": "9952158 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R10": { "role": "http://www.baxter.com/role/BASISOFPRESENTATION", "longName": "9952159 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONS", "longName": "9952160 - Disclosure - DISCONTINUED OPERATIONS", "shortName": "DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION", "longName": "9952161 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET", "longName": "9952162 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.baxter.com/role/FINANCINGARRANGEMENTS", "longName": "9952163 - Disclosure - FINANCING ARRANGEMENTS", "shortName": "FINANCING ARRANGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.baxter.com/role/STOCKHOLDERSEQUITY", "longName": "9952165 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "longName": "9952166 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.baxter.com/role/REVENUES", "longName": "9952167 - Disclosure - REVENUES", "shortName": "REVENUES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES", "longName": "9952168 - Disclosure - BUSINESS OPTIMIZATION CHARGES", "shortName": "BUSINESS OPTIMIZATION CHARGES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS", "longName": "9952169 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.baxter.com/role/INCOMETAXES", "longName": "9952170 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.baxter.com/role/EARNINGSPERSHARE", "longName": "9952171 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES", "longName": "9952172 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952173 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.baxter.com/role/SEGMENTINFORMATION", "longName": "9952174 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.baxter.com/role/BASISOFPRESENTATIONPolicies", "longName": "9955511 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSTables", "longName": "9955512 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "shortName": "DISCONTINUED OPERATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables", "longName": "9955513 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables", "longName": "9955514 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "longName": "9955515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.baxter.com/role/REVENUESTables", "longName": "9955516 - Disclosure - REVENUES (Tables)", "shortName": "REVENUES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables", "longName": "9955517 - Disclosure - BUSINESS OPTIMIZATION CHARGES (Tables)", "shortName": "BUSINESS OPTIMIZATION CHARGES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "bax:BusinessOptimizationChargeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:BusinessOptimizationChargeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTables", "longName": "9955518 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.baxter.com/role/EARNINGSPERSHARETables", "longName": "9955519 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables", "longName": "9955520 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9955521 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONTables", "longName": "9955522 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "longName": "9955523 - Disclosure - BASIS OF PRESENTATION (Details)", "shortName": "BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-54", "name": "us-gaap:LossFromCatastrophes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:LossFromCatastrophes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "longName": "9955524 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details)", "shortName": "DISCONTINUED OPERATIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "bax:DisposalGroupIncludingDiscontinuedOperationSeparationCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:DisposalGroupIncludingDiscontinuedOperationSeparationCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "longName": "9955525 - Disclosure - DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R43": { "role": "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "longName": "9955526 - Disclosure - DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Carrying Amounts of the Assets and Liabilities Classified As Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R44": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails", "longName": "9955527 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails", "longName": "9955528 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails", "longName": "9955529 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails", "longName": "9955530 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails", "longName": "9955531 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Interest Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails", "longName": "9955532 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "longName": "9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R51": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails", "longName": "9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bax:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bax:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetails", "longName": "9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "longName": "9955536 - Disclosure - FINANCING ARRANGEMENTS (Details)", "shortName": "FINANCING ARRANGEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R54": { "role": "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9955537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R55": { "role": "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9955538 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "longName": "9955539 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in AOCI by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R57": { "role": "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "longName": "9955540 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Amounts Reclassification from AOCI to Net Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R58": { "role": "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "longName": "9955541 - Disclosure - REVENUES - Additional Information (Details)", "shortName": "REVENUES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails", "longName": "9955542 - Disclosure - REVENUES - Contract Assets and Contract Liabilities (Details)", "shortName": "REVENUES - Contract Assets and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.baxter.com/role/REVENUESLeaseRevenueDetails", "longName": "9955543 - Disclosure - REVENUES - Lease Revenue (Details)", "shortName": "REVENUES - Lease Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "longName": "9955544 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Additional Information (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails", "longName": "9955545 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Summary of Business Optimization Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bax:BusinessOptimizationChargeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R63": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "longName": "9955546 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-184", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R64": { "role": "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "longName": "9955547 - Disclosure - BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details)", "shortName": "BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves Related to Restructuring Initiatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-197", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R65": { "role": "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails", "longName": "9955548 - Disclosure - PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details)", "shortName": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-200", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.baxter.com/role/INCOMETAXESDetails", "longName": "9955549 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails", "longName": "9955550 - Disclosure - EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details)", "shortName": "EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R68": { "role": "http://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetails", "longName": "9955551 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)", "shortName": "EARNINGS PER SHARE - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "longName": "9955552 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "bax:DerivativeNumberOfFairValueHedgesTerminated", "unitRef": "terminate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "bax:DerivativeNumberOfFairValueHedgesTerminated", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:DerivativeNumberOfFairValueHedgesTerminated", "unitRef": "terminate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "bax:DerivativeNumberOfFairValueHedgesTerminated", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails", "longName": "9955553 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "bax:OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bax:OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "longName": "9955554 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R72": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails", "longName": "9955555 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bax:ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R73": { "role": "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails", "longName": "9955556 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-255", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-255", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails", "longName": "9955557 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-257", "name": "us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-257", "name": "us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "longName": "9955558 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-287", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R76": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails", "longName": "9955559 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-277", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-267", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R77": { "role": "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails", "longName": "9955560 - Disclosure - FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-282", "name": "bax:ShortTermDebtCurrentFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-282", "name": "bax:ShortTermDebtCurrentFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9955561 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails", "longName": "9955562 - Disclosure - SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)", "shortName": "SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-349", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R80": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "longName": "9955563 - Disclosure - SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details)", "shortName": "SEGMENT INFORMATION - Revenue rom External Customers by Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-352", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R81": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "longName": "9955564 - Disclosure - SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details)", "shortName": "SEGMENT INFORMATION - Segment Information Of Net Sales And Operating Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-302", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } }, "R82": { "role": "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "longName": "9955565 - Disclosure - SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details)", "shortName": "SEGMENT INFORMATION - Operating Income to Income Before Income Taxes Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bax-20250331.htm", "unique": true } } }, "tag": { "bax_A04SeniorNotesDueMay2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A04SeniorNotesDueMay2024Member", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.4% Senior Notes Due May 2024", "label": "0.4% Senior Notes Due May 2024 [Member]", "documentation": "Zero point four percentage senior notes due May two thousand twenty four." } } }, "auth_ref": [] }, "bax_A130SeniorNotesDueMay2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A130SeniorNotesDueMay2025Member", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.30% Senior Notes Due May 2025", "label": "1.30% Senior Notes Due May 2025 [Member]", "documentation": "1.30% Senior Notes Due May 2025" } } }, "auth_ref": [] }, "bax_A13SeniorNotesDueMay2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A13SeniorNotesDueMay2029Member", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.3% Senior Notes Due May 2029", "label": "1.3% Senior Notes Due May 2029 [Member]", "documentation": "One point three percentage senior notes due May two thousand twenty nine." } } }, "auth_ref": [] }, "bax_A2021AndPriorYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A2021AndPriorYearsMember", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021", "label": "2021 And Prior Years [Member]", "documentation": "2021 And Prior Years" } } }, "auth_ref": [] }, "bax_A2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A2022Member", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "2022 [Member]", "documentation": "2022" } } }, "auth_ref": [] }, "bax_A2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A2023Member", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "2023 [Member]", "documentation": "2023" } } }, "auth_ref": [] }, "bax_A2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A2024Member", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "2024 [Member]", "documentation": "2024" } } }, "auth_ref": [] }, "bax_A2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "A2025Member", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "2025 [Member]", "documentation": "2025" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r114", "r1012" ] }, "bax_AccountsReceivableAllowanceForCreditLossCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AccountsReceivableAllowanceForCreditLossCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Currency translation adjustments", "label": "Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments", "documentation": "Accounts Receivable, Allowance for Credit Loss, Currency Translation Adjustments" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1191" ] }, "bax_AccountsReceivableAllowanceForCreditLossWriteoffAndAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AccountsReceivableAllowanceForCreditLossWriteoffAndAdjustments", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-offs", "label": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments", "documentation": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Adjustments" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net trade accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r871", "r929", "r1033", "r1285", "r1286" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowances of $66 in 2025 and $71 in 2024", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1182" ] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental reserves", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r430", "r969", "r1130", "r1132", "r1224", "r1229" ] }, "bax_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r117" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and OPEB plans", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r5", "r18", "r35", "r139", "r791", "r1152", "r1153", "r1154" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pension and OPEB items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r18", "r35", "r139", "r1152", "r1153", "r1154" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r49", "r218", "r784" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CTA", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r3", "r18", "r35", "r137", "r138", "r246", "r791", "r1153", "r1154" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities", "verboseLabel": "Gains (losses) on hedging activities", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r239", "r247", "r248", "r632", "r950", "r1152" ] }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r234", "r235", "r236", "r239", "r246", "r791", "r1153", "r1154" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246", "r247", "r679", "r681", "r682", "r683", "r684", "r685" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r34", "r35", "r140", "r227", "r780", "r823", "r824" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r246", "r247", "r679", "r681", "r682", "r683", "r684", "r685" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r18", "r35", "r644", "r647", "r702", "r819", "r820", "r1152", "r1153", "r1154", "r1168", "r1169", "r1170", "r1172" ] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionRelatedCostsMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments related to acquisitions", "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1079" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional contributed capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r127" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional contributed capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r837", "r1168", "r1169", "r1170", "r1172", "r1247", "r1324" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1092" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1092" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1092" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1092" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash flows from operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "bax_AdvancedSurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AdvancedSurgeryMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced Surgery", "label": "Advanced Surgery [Member]", "documentation": "Advanced surgery." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1125" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1051", "r1061", "r1071", "r1103" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1054", "r1064", "r1074", "r1106" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1126" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1092" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1099" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1099", "r1107", "r1111", "r1119" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1117" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r228", "r329", "r364", "r367", "r369", "r1286" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for accounts receivable, current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r228", "r329", "r364" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts Receivable [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETAdditionalInformationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r13", "r392", "r399", "r967" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHAREAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computation of EPS (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r285" ] }, "bax_AssetWriteOffsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AssetWriteOffsMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset write offs", "label": "Asset Write Offs [Member]", "documentation": "Asset Write Offs" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r186", "r198", "r222", "r258", "r289", "r298", "r316", "r320", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r628", "r634", "r677", "r777", "r876", "r959", "r960", "r1012", "r1042", "r1238", "r1239", "r1272" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r214", "r230", "r258", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r628", "r634", "r677", "r1012", "r1238", "r1239", "r1272" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r654", "r655", "r999" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164", "r212", "r213" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets of discontinued operations", "totalLabel": "Current assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164", "r212", "r213" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated pre-tax unrealized translation gain in AOCI", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r334" ] }, "bax_AvailableForSaleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "AvailableForSaleDebtSecuritiesMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Available-For-Sale, Debt Securities [Member]", "documentation": "Available-For-Sale, Debt Securities" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r332", "r373", "r654", "r771", "r999", "r1003", "r1183", "r1251", "r1252", "r1253" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1115" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1110" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1110" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1110" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1110" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1110" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1110" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1113" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1111" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1111" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r412", "r1290", "r1291" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r75", "r78", "r412", "r1290", "r1291" ] }, "bax_BridgeFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BridgeFacilityMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Facility", "label": "Bridge Facility [Member]", "documentation": "Bridge Facility" } } }, "auth_ref": [] }, "bax_BundledEquipmentAndConsumableMedicalProductsContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BundledEquipmentAndConsumableMedicalProductsContractsMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bundled equipment and consumable medical products contracts", "label": "Bundled Equipment And Consumable Medical Products Contracts [Member]", "documentation": "Bundled Equipment And Consumable Medical Products Contracts" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent payments related to acquisitions", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r65", "r178", "r624", "r656", "r657", "r658" ] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and integration items", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } }, "auth_ref": [ "r62" ] }, "bax_BusinessGuaranteesRetainedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BusinessGuaranteesRetainedValue", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business guarantees retained", "label": "Business Guarantees Retained, Value", "documentation": "Business Guarantees Retained, Value" } } }, "auth_ref": [] }, "bax_BusinessOptimizationChargeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BusinessOptimizationChargeTableTextBlock", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Business Optimization Charges", "label": "Business Optimization Charge [Table Text Block]", "documentation": "Business optimization charge." } } }, "auth_ref": [] }, "bax_BusinessOptimizationIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BusinessOptimizationIncomeLoss", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business optimization items", "label": "Business Optimization Income (Loss)", "documentation": "Business Optimization Income (Loss)" } } }, "auth_ref": [] }, "bax_BusinessOptimizationProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BusinessOptimizationProgramsMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Programs", "label": "Business Optimization Programs [Member]", "documentation": "Business Optimization Programs" } } }, "auth_ref": [] }, "bax_BusinessSeparationIndemnificationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "BusinessSeparationIndemnificationLiability", "crdr": "credit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnifications related to kidney care separation", "label": "Business Separation, Indemnification, Liability", "documentation": "Business Separation, Indemnification, Liability" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures incurred but not yet paid", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_CapitalizedContractCostAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostAxis", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Axis]", "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer." } } }, "auth_ref": [ "r377" ] }, "us-gaap_CapitalizedContractCostDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostDomain", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Domain]", "documentation": "Cost capitalized in obtaining and fulfilling contract with customer." } } }, "auth_ref": [ "r377" ] }, "bax_CareAndConnectivitySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "CareAndConnectivitySolutionsMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Care and Connectivity Solutions", "label": "Care and Connectivity Solutions [Member]", "documentation": "Care and Connectivity Solutions" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book values", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r87", "r88" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r216", "r946" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Less cash and cash equivalents of discontinued operations", "verboseLabel": "Cash and cash equivalents of discontinued operations", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at start of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r156", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r156" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred, net after-tax gains on derivative instruments", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r86" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r73" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities - discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r108", "r156" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operations \u2013 discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r108", "r156" ] }, "us-gaap_CatastrophicEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CatastrophicEventDomain", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Catastrophic Event [Domain]", "label": "Catastrophic Event [Domain]", "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": [ "r1024" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1090" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1087" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1085" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r207", "r224", "r225", "r226", "r258", "r279", "r280", "r282", "r284", "r292", "r293", "r361", "r436", "r439", "r440", "r441", "r445", "r446", "r474", "r475", "r476", "r477", "r479", "r677", "r829", "r830", "r831", "r832", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r863", "r886", "r904", "r922", "r923", "r924", "r925", "r926", "r1129", "r1165", "r1173" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1091" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1091" ] }, "us-gaap_CommercialPaperAverageOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperAverageOutstanding", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper, outstanding", "label": "Commercial Paper, Average Outstanding", "documentation": "Average amount outstanding of commercial paper." } } }, "auth_ref": [ "r207", "r208" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r171", "r435", "r1034", "r1035", "r1036", "r1039" ] }, "bax_CommercialPaperWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "CommercialPaperWeightedAverageInterestRate", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper, weighted-average interest rate", "label": "Commercial Paper, Weighted-Average Interest Rate", "documentation": "Commercial Paper, Weighted-Average Interest Rate" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r123", "r189", "r778", "r862" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r169", "r425", "r426", "r930", "r1216", "r1228" ] }, "bax_CommonStock100PerValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "CommonStock100PerValueMember", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1.00 par value", "label": "Common Stock, $1.00 per Value [Member]", "documentation": "Common Stock, $1.00 per Value" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r175" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1034", "r1035", "r1036", "r1039", "r1168", "r1169", "r1172", "r1247", "r1322", "r1324" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r126", "r863" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period (in shares)", "periodEndLabel": "Balance, end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r19", "r126", "r863", "r882", "r1324", "r1325" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2025 and 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r126", "r779", "r1012" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1096" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1095" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1097" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1094" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "bax_ComprehensiveIncomeLossFromContinuingAndDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterestNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ComprehensiveIncomeLossFromContinuingAndDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterestNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), From Continuing And Discontinued Operations, Including Portion Attributable To Noncontrolling Interest, Net Of Tax", "documentation": "Comprehensive Income (Loss), From Continuing And Discontinued Operations, Including Portion Attributable To Noncontrolling Interest, Net Of Tax" } } }, "auth_ref": [] }, "bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingAndDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterestNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) from continuing operations", "label": "Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest", "documentation": "Comprehensive Income (Loss) From Continuing Operations Net Of Tax Including Portion Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) attributable to Baxter stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r36", "r243", "r245", "r250", "r773", "r793", "r794" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r136", "r249", "r772", "r791" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r196", "r260", "r289", "r300", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r959", "r960", "r1238", "r1239" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r196", "r260", "r289", "r300", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r959", "r960", "r1238", "r1239" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r69", "r951" ] }, "bax_ConsumableMedicalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ConsumableMedicalProductsMember", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumable Medical Products", "label": "Consumable Medical Products [Member]", "documentation": "Consumable medical products [Member]." } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities, net of tax expense (benefit) of ($1) and $2 for the three months ended March 31, 2025 and 2024, respectively.", "label": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging activities, tax", "label": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Pension and other postretirement benefits, net of tax expense (benefit) of ($4) and $3 for the three months ended March 31, 2025 and 2024, respectively.", "label": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Pension and other postretirement benefits, tax", "label": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Continuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments, net of tax expense (benefit) of $6 and $13 for the three months ended March 31, 2025 and 2024, respectively.", "label": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "auth_ref": [] }, "bax_ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContinuingOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments, tax", "label": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Continuing Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "auth_ref": [] }, "bax_ContractTerminationAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContractTerminationAndOtherCostsMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract termination and other costs", "label": "Contract Termination And Other Costs [Member]", "documentation": "Contract termination and other costs." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.baxter.com/role/REVENUESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Contract Asset", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1241" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r481", "r483", "r495" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r481", "r482", "r495" ] }, "bax_ContractWithCustomerLiabilityCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContractWithCustomerLiabilityCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation", "label": "Contract With Customer, Liability, Currency Translation", "documentation": "Contract With Customer, Liability, Currency Translation" } } }, "auth_ref": [] }, "bax_ContractWithCustomerLiabilityDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContractWithCustomerLiabilityDeferredRevenue", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New revenue deferrals", "label": "Contract With Customer, Liability, Deferred Revenue", "documentation": "Contract With Customer, Liability, Deferred Revenue" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized upon satisfaction of performance obligations", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r496" ] }, "bax_ContractWithCustomerLiabilityTotalRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ContractWithCustomerLiabilityTotalRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue recognized upon satisfaction of performance obligations", "label": "Contract with Customer, Liability, Total Revenue Recognized", "documentation": "Contract with Customer, Liability, Total Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue related to performance obligations", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r490" ] }, "bax_CorporateCostsUnallocated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "CorporateCostsUnallocated", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unallocated corporate costs", "label": "Corporate Costs, Unallocated", "documentation": "Corporate Costs, Unallocated" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r25", "r315", "r316", "r317", "r318", "r321", "r1178" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "negatedTerseLabel": "Costs of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r146", "r147", "r736" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "COGS", "verboseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r435", "r1236" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r435", "r1236", "r1237" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r64", "r1205", "r1206", "r1207", "r1208", "r1210", "r1211", "r1213", "r1214" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ARRANGEMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r170", "r257", "r407", "r408", "r409", "r410", "r411", "r434", "r435", "r447", "r453", "r454", "r455", "r456", "r457", "r458", "r463", "r470", "r471", "r473", "r687" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r31", "r116", "r117", "r187", "r188", "r260", "r448", "r449", "r450", "r451", "r452", "r454", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r971", "r972", "r973", "r974", "r975", "r1010", "r1166", "r1217", "r1218", "r1219", "r1269", "r1270" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate increase following December 31, 2024 milestone", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior notes", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r448", "r687", "r688", "r972", "r973", "r1010" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior notes, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r119", "r449" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r260", "r448", "r449", "r450", "r451", "r452", "r454", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r472", "r971", "r972", "r973", "r974", "r975", "r1010", "r1166", "r1269", "r1270" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r31", "r260", "r448", "r449", "r450", "r451", "r452", "r454", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r971", "r972", "r973", "r974", "r975", "r1010", "r1166", "r1217", "r1218", "r1219", "r1269", "r1270" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r31", "r53", "r54", "r89", "r173", "r174", "r260", "r448", "r449", "r450", "r451", "r452", "r454", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r472", "r971", "r972", "r973", "r974", "r975", "r1010", "r1166", "r1269", "r1270" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r158" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of net losses and prior service costs", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r500", "r538", "r559", "r986", "r987" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r500", "r537", "r558", "r986", "r987" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r500", "r504", "r536", "r557", "r986", "r987" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic pension cost (income)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r534", "r555", "r986", "r987" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r502", "r535", "r556", "r986", "r987" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r13", "r48" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r13", "r289", "r303", "r320", "r959", "r960" ] }, "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, fair value, total", "label": "Derivative Asset, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r232", "r949" ] }, "us-gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsAbstract", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset", "label": "Derivative Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r852", "r854", "r868", "r869", "r870", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r892", "r893", "r894", "r895", "r898", "r899", "r900", "r901", "r914", "r915", "r916", "r919", "r1030", "r1032", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1261", "r1262" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative asset, fair value", "terseLabel": "Gross amounts recognized in the condensed consolidated balance sheets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r27", "r135", "r183", "r184", "r231", "r949" ] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral", "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r23", "r28", "r30", "r83" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, fair value", "verboseLabel": "Gross amounts recognized in the condensed consolidated balance sheets", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r27", "r135", "r183", "r184", "r231", "r949" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral", "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r23", "r28", "r30", "r83" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, fair value, net", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r676" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1245" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r76", "r79", "r82", "r185", "r852", "r854", "r868", "r869", "r870", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r892", "r893", "r894", "r895", "r898", "r899", "r900", "r901", "r914", "r915", "r916", "r919", "r949", "r1030", "r1032", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1261", "r1262" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r182", "r642", "r649" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r20", "r76", "r79" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r20", "r76", "r79", "r82", "r84", "r85", "r639" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r639" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in income, undesignated derivative instruments", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r81", "r1138" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesAbstract", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, fair value, total", "label": "Derivative Liability, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r232", "r949" ] }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivative instruments, liabilities", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset." } } }, "auth_ref": [ "r231", "r917", "r918", "r949" ] }, "us-gaap_DerivativeLiabilityNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotSubjectToMasterNettingArrangement", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, not subject to master netting arrangement, fair value", "label": "Derivative Liability, Not Subject to Master Netting Arrangement", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r949" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1243", "r1244" ] }, "bax_DerivativeNumberOfDeDesignations": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DerivativeNumberOfDeDesignations", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "number of de-designations", "label": "Derivative, Number Of De-designations", "documentation": "Derivative, Number Of De-designations" } } }, "auth_ref": [] }, "bax_DerivativeNumberOfFairValueHedgesTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DerivativeNumberOfFairValueHedgesTerminated", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, fair value, terminated", "label": "Derivative, Number Of Fair Value Hedges Terminated", "documentation": "Derivative, Number Of Fair Value Hedges Terminated" } } }, "auth_ref": [] }, "bax_DerivativeNumberOfNetInvestmentTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DerivativeNumberOfNetInvestmentTerminated", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, net investment terminated", "label": "Derivative, Number Of Net Investment Terminated", "documentation": "Derivative, Number Of Net Investment Terminated" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments designated as hedges", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r20" ] }, "bax_DevelopedTechnologyIncludingPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DevelopedTechnologyIncludingPatentsMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology, including patents", "label": "Developed Technology Including Patents [Member]", "documentation": "Developed technology including patents." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r494", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r494", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "bax_DisclosureBasisOfPresentationDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisclosureBasisOfPresentationDetailsLineItems", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Basis Of Presentation Details [Line Items]", "label": "Disclosure Basis Of Presentation Details [Line Items]", "documentation": "Disclosure Basis Of Presentation Details [Line Items]" } } }, "auth_ref": [] }, "bax_DisclosureBasisOfPresentationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisclosureBasisOfPresentationDetailsTable", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Basis Of Presentation Details [Table]", "label": "Disclosure Basis Of Presentation Details [Table]", "documentation": "Disclosure Basis Of Presentation Details [Table]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from discontinued operations before gain on disposition and income taxes", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r96", "r97", "r98", "r99", "r100", "r106", "r144", "r1287" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from discontinued operations per common share", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income from discontinued operations per common share, basic (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income from discontinued operations per common share, diluted (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "bax_DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Currency translation adjustments, net of tax expense (benefit) of zero and $(2) for the three months ended March\u00a031, 2025 and 2024, respectively.", "label": "Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Discontinued Operations, Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, currency translation adjustments, net of tax", "label": "Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Discontinued Operation, Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r97", "r98", "r99", "r100", "r106", "r111", "r602", "r613", "r615" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingAndDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterestNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) from discontinued operations", "label": "Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax", "documentation": "Discontinued Operations, Comprehensive Income (Loss), Discontinued Operations, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Held-for-Sale", "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r8", "r10", "r212" ] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentAfterTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension and other postretirement benefits, net of tax expense (benefit) of $(3) and zero for the three months ended March 31, 2025 and 2024, respectively.", "label": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, pension and other postretirement benefits, tax", "label": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Discontinued Operations, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax" } } }, "auth_ref": [] }, "bax_DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuedOperationsOtherComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) from discontinued operations", "label": "Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax", "documentation": "Discontinued Operations, Other Comprehensive Income (Loss),Discontinued Operations, Net Of Tax" } } }, "auth_ref": [] }, "bax_DiscontinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DiscontinuingOperationOtherComprehensiveIncomeLossDefinedBenefitPlanAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "label": "Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Discontinuing Operation, Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r212" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "bax_DisposalGroupDiscontinuedOperationGainLossOnDisposalNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupDiscontinuedOperationGainLossOnDisposalNetOfTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain from divestiture of business, net of tax", "label": "Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Net of Tax", "documentation": "Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Net of Tax" } } }, "auth_ref": [] }, "bax_DisposalGroupDiscontinuedOperationGainLossOnDisposalPreTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupDiscontinuedOperationGainLossOnDisposalPreTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax gain from divestiture of business", "label": "Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Pre-Tax", "documentation": "Disposal Group, Discontinued Operation, Gain (Loss) on Disposal, Pre-Tax" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowances", "verboseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets of discontinued operations", "totalLabel": "Non-current assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r164", "r212", "r213" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreed purchase price", "verboseLabel": "Purchase price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107", "r213" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107", "r213" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Disposal Group, Including Discontinued Operation, Inventory", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability" } } }, "auth_ref": [] }, "bax_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Right-Of-Use Assets" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of finance lease obligations", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164" ] }, "bax_DisposalGroupIncludingDiscontinuedOperationOtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net", "documentation": "Disposal Group, Including Discontinued Operation, Other Intangible Assets, Net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r107", "r213" ] }, "bax_DisposalGroupIncludingDiscontinuedOperationSeparationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationSeparationCosts", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Separation costs", "label": "Disposal Group, Including Discontinued Operation, Separation Costs", "documentation": "Disposal Group, Including Discontinued Operation, Separation Costs" } } }, "auth_ref": [] }, "bax_DisposalGroupIncludingDiscontinuedOperationsFinancingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationsFinancingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term finance lease obligations, less current portion", "label": "Disposal Group, Including Discontinued Operations, Financing Lease Liabilities", "documentation": "Disposal Group, Including Discontinued Operations, Financing Lease Liabilities" } } }, "auth_ref": [] }, "bax_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Disposal Group, Including Discontinued Operations, Research And Development Expense", "documentation": "Disposal Group, Including Discontinued Operations, Research And Development Expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "DISCONTINUED OPERATIONS", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r91", "r161" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r988", "r991" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared on common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r175" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r1046" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1078" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1089" ] }, "bax_EarningsFairValueHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "EarningsFairValueHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings, fair value hedge, gain (loss), reclassification, before tax", "label": "Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Earnings, Fair Value Hedge, Gain (Loss), Reclassification, before Tax" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) per common share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r251", "r266", "r267", "r268", "r269", "r270", "r271", "r277", "r279", "r282", "r283", "r284", "r288", "r622", "r626", "r651", "r652", "r774", "r795", "r952" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r251", "r266", "r267", "r268", "r269", "r270", "r271", "r279", "r282", "r283", "r284", "r288", "r622", "r626", "r651", "r652", "r774", "r795", "r952" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r276", "r285", "r286", "r287" ] }, "bax_EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "EasternEuropeMiddleEastAfricaLatinAmericaAsiaMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets", "label": "Eastern Europe, Middle East, Africa, Latin America, Asia [Member]", "documentation": "Eastern Europe, Middle East, Africa, Latin America, Asia" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r678" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.baxter.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r259", "r603", "r611", "r995" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee termination costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1044" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1044" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1044" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1128" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1044" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1044" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1044" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1044" ] }, "bax_EnviromentalCleanUpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "EnviromentalCleanUpMember", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Clean-up", "label": "Enviromental Clean Up [Member]", "documentation": "Enviromental clean-up." } } }, "auth_ref": [] }, "us-gaap_EnvironmentalRemediationContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationContingencyAxis", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Contingency", "label": "Environmental Remediation Contingency [Axis]", "documentation": "Information by type of environmental remediation contingency." } } }, "auth_ref": [ "r1221", "r1222", "r1223", "r1233" ] }, "us-gaap_EnvironmentalRemediationContingencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationContingencyDomain", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Contingency", "label": "Environmental Remediation Contingency [Domain]", "documentation": "Environmental remediation contingency, for example, but not limited to, asbestos, air emissions and mercury emissions." } } }, "auth_ref": [ "r1221", "r1222", "r1223", "r1233" ] }, "us-gaap_EnvironmentalRemediationSiteAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationSiteAxis", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Site", "label": "Environmental Remediation Site [Axis]", "documentation": "Information by location or named area designated for environmental remediation." } } }, "auth_ref": [ "r968", "r969", "r1130", "r1131", "r1132", "r1233", "r1234" ] }, "us-gaap_EnvironmentalRemediationSiteDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalRemediationSiteDomain", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Remediation Site", "label": "Environmental Remediation Site [Domain]", "documentation": "Location or named area designated for environmental remediation." } } }, "auth_ref": [ "r968", "r969", "r1130", "r1131", "r1132", "r1233", "r1234" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1083" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1124" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1124" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1124" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r19", "r209", "r246", "r247", "r248", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r291", "r362", "r363", "r404", "r480", "r609", "r610", "r619", "r620", "r621", "r623", "r625", "r626", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r679", "r681", "r682", "r683", "r684", "r685", "r689", "r691", "r702", "r791", "r819", "r820", "r821", "r837", "r904" ] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment impairment", "label": "Equity Method Investment, Other-than-Temporary Impairment", "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": [ "r1188" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r223", "r675", "r948" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other equity investments without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r360" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1093" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1051", "r1061", "r1071", "r1103" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1048", "r1058", "r1068", "r1100" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair values", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r461", "r676", "r972", "r973" ] }, "bax_EuropeanMedicalDevicesRegulationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "EuropeanMedicalDevicesRegulationExpenses", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Medical Devices Regulation", "label": "European Medical Devices Regulation Expenses", "documentation": "European Medical Devices Regulation Expenses" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1099" ] }, "bax_ExposureToEthyleneOxideMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ExposureToEthyleneOxideMember", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exposure to Ethylene Oxide", "label": "Exposure to Ethylene Oxide [Member]", "documentation": "Exposure to Ethylene Oxide" } } }, "auth_ref": [] }, "bax_FairValueAndCarryingValueByBalanceSheetGroupingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "FairValueAndCarryingValueByBalanceSheetGroupingLineItems", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]", "label": "Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]", "documentation": "Fair value and carrying value by balance sheet grouping." } } }, "auth_ref": [] }, "bax_FairValueAndCarryingValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "FairValueAndCarryingValueByBalanceSheetGroupingTable", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]", "label": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]", "documentation": "Fair Value And Carrying Value By Balance Sheet Grouping [Table]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r654", "r655", "r667", "r999" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r654", "r655", "r667", "r999" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r659", "r663", "r668", "r1001" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Book Values and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r87" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r461", "r525", "r526", "r527", "r528", "r529", "r530", "r653", "r655", "r656", "r657", "r658", "r666", "r667", "r669", "r707", "r708", "r709", "r972", "r973", "r984", "r985", "r986", "r999", "r1003" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r654", "r655", "r656", "r658", "r999", "r1252", "r1263" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "bax_FairValueDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "FairValueDisclosuresLineItems", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Line Items]", "label": "Fair Value Disclosures [Line Items]", "documentation": "Fair value disclosure Line items." } } }, "auth_ref": [] }, "bax_FairValueDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "FairValueDisclosuresTable", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Table]", "label": "Fair Value Disclosures [Table]", "documentation": "Fair value disclosures table." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r662", "r664", "r665", "r666", "r669", "r670", "r671", "r672", "r673", "r769", "r999", "r1004" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value hedges", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r72" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets for identical assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r461", "r525", "r530", "r655", "r667", "r707", "r984", "r985", "r986", "r999" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r461", "r525", "r530", "r655", "r656", "r667", "r708", "r972", "r973", "r984", "r985", "r986", "r999" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r461", "r525", "r526", "r527", "r528", "r529", "r530", "r655", "r656", "r657", "r658", "r667", "r709", "r972", "r973", "r984", "r985", "r986", "r999", "r1003" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments related to acquisitions", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r654", "r655", "r656", "r658", "r999", "r1252", "r1263" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances", "documentation": "Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r661", "r668", "r1001" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value at beginning of period", "periodEndLabel": "Fair value at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r659", "r668", "r1001" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r661", "r668" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value at beginning of period", "periodEndLabel": "Fair value at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r659", "r668" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r461", "r525", "r526", "r527", "r528", "r529", "r530", "r653", "r655", "r656", "r657", "r658", "r666", "r667", "r669", "r707", "r708", "r709", "r972", "r973", "r984", "r985", "r986", "r999", "r1003" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r999", "r1249", "r1250", "r1251", "r1252", "r1253", "r1263" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r75", "r77", "r84" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r365", "r366", "r370", "r371", "r372", "r374", "r375", "r376", "r472", "r478", "r649", "r674", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r792", "r965", "r999", "r1001", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1013", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1184", "r1185", "r1186", "r1187", "r1248", "r1251", "r1252", "r1253", "r1260", "r1263" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r220", "r378", "r398", "r967" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r391", "r393", "r394", "r395", "r397", "r398", "r401", "r402", "r737", "r738", "r942" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross other intangible assets, finite-lived", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r378", "r398", "r738", "r967" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r391", "r393", "r394", "r395", "r397", "r398", "r401", "r402", "r942" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other intangible assets, net, finite-lived", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r737", "r1211" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "crdr": "debit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": [ "r185" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": [ "r185" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange losses, net", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r158", "r884", "r1040", "r1265", "r1266", "r1323" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r949", "r984", "r998", "r999" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1107" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1107" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1107" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1107" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1107" ] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForwardContractsMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Contracts", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": [ "r1246" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1088" ] }, "bax_FrontLineCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "FrontLineCareMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Front Line Care", "label": "Front Line Care [Member]", "documentation": "Front Line Care" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on disposition", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r633", "r1162" ] }, "bax_GlobalNotes13Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "GlobalNotes13Due2025Member", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.3% Global Notes due 2025", "label": "Global Notes 1.3% due 2025 [Member]", "documentation": "Global Notes 1.3% due 2025" } } }, "auth_ref": [] }, "bax_GlobalNotes13Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "GlobalNotes13Due2029Member", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.3% Global Notes due 2029", "label": "Global Notes 1.3% due 2029 [Member]", "documentation": "Global Notes 1.3% due 2029" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r219", "r379", "r770", "r960", "r966", "r1000", "r1012", "r1194", "r1201" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1192", "r1204" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r386" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r966" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r141", "r148", "r197", "r258", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r677", "r954", "r959", "r1175", "r1177", "r1179", "r1180", "r1181", "r1238" ] }, "bax_HealthcareSystemsAndTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "HealthcareSystemsAndTechnologiesMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare Systems & Technologies", "label": "Healthcare Systems and Technologies [Member]", "documentation": "Healthcare Systems and Technologies" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount of hedged item", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r640" ] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r641" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r20", "r639" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r20" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r20" ] }, "us-gaap_HurricaneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HurricaneMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hurricane", "label": "Hurricane [Member]", "documentation": "Tropical windstorm with sustained winds of 74 miles per hour (119 kilometers per hour)." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In process Research and Development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r68", "r143", "r158", "r266", "r267", "r268", "r269", "r270", "r281", "r284", "r626" ] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to noncontrolling interests included in continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r66", "r180", "r270" ] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsAttributableToParentAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from continuing operations per common share", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations before income taxes", "terseLabel": "Income (loss) from continuing operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r142", "r192", "r197", "r775", "r786", "r954", "r959", "r1175", "r1177", "r1179", "r1180", "r1181" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations", "terseLabel": "Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r180", "r197", "r258", "r264", "r270", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r622", "r626", "r652", "r677", "r786", "r954", "r1175", "r1177", "r1179", "r1180", "r1181", "r1238" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations per common share, basic (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r193", "r251", "r264", "r266", "r267", "r268", "r269", "r270", "r279", "r282", "r283", "r622", "r626", "r652", "r774", "r1288" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations per common share, diluted (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r251", "r264", "r266", "r267", "r268", "r269", "r270", "r279", "r282", "r283", "r284", "r626", "r652", "r774", "r1288" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_DiscontinuedOperationsComprehensiveIncomeLossDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from discontinued operations, net of tax", "verboseLabel": "Income (loss) from discontinued operations, net of tax", "netLabel": "Less: Income (loss) from discontinued operations, net of tax", "totalLabel": "Income from discontinued operations, net of tax", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r96", "r97", "r98", "r99", "r100", "r111", "r213", "r616", "r787" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to noncontrolling interests included in discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r66", "r96", "r97", "r98", "r99", "r100", "r106", "r111", "r180" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from discontinued operations attributable to Baxter stockholders", "terseLabel": "Income (loss) from discontinued operations attributable to Baxter stockholders", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r96", "r97", "r98", "r99", "r100", "r106", "r111", "r180" ] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss), before tax", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r145", "r1154" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r988", "r991" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r15", "r22", "r32", "r92", "r101", "r102", "r103", "r104", "r105", "r110", "r112", "r113", "r165" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r405", "r412", "r417", "r660", "r663", "r668", "r816", "r818", "r889", "r942", "r1002", "r1292" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r412", "r417", "r660", "r663", "r668", "r816", "r818", "r889", "r942", "r1002", "r1292" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r259", "r601", "r603", "r604", "r605", "r606", "r607", "r608", "r612", "r614", "r617", "r618", "r834", "r995" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "negatedTerseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r201", "r205", "r273", "r274", "r289", "r306", "r320", "r602", "r603", "r613", "r796", "r995" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r12" ] }, "bax_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities", "documentation": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEquitySecuritiesFvNi", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in fair value of marketable equity securities", "label": "Increase (Decrease) in Equity Securities, FV-NI", "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r200", "r253" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in balance sheet items:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r391", "r396", "r400", "r967" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r378", "r400", "r967" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r391", "r396", "r400", "r967" ] }, "bax_IndemnificationAgreementLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "IndemnificationAgreementLiabilityNet", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification liability, net", "label": "Indemnification Agreement, Liability, Net", "documentation": "Indemnification Agreement, Liability, Net" } } }, "auth_ref": [] }, "us-gaap_IndemnificationGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndemnificationGuaranteeMember", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification Agreement", "label": "Indemnification Agreement [Member]", "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor." } } }, "auth_ref": [ "r1235" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1099", "r1107", "r1111", "r1119" ] }, "bax_InfusionTherapiesAndTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "InfusionTherapiesAndTechnologiesMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infusion Therapies and Technologies", "label": "Infusion Therapies and Technologies [Member]", "documentation": "Infusion Therapies and Technologies" } } }, "auth_ref": [] }, "bax_InjectablesAndAnesthesiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "InjectablesAndAnesthesiaMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Injectables and Anesthesia", "label": "Injectables and Anesthesia [Member]", "documentation": "Injectables and Anesthesia" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1117" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1047", "r1123" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1047", "r1123" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1047", "r1123" ] }, "bax_IntangibleAssetExcludingGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "IntangibleAssetExcludingGoodwillLineItems", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset Excluding Goodwill [Line Items]", "label": "Intangible Asset Excluding Goodwill [Line Items]", "documentation": "Intangible Asset Excluding Goodwill [Line Items]" } } }, "auth_ref": [] }, "bax_IntangibleAssetExcludingGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "IntangibleAssetExcludingGoodwillTable", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset Excluding Goodwill [Table]", "label": "Intangible Asset Excluding Goodwill [Table]", "documentation": "Intangible Asset Excluding Goodwill [Table]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross other intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r219" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "totalLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r391", "r1211", "r1212" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": { "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net of capitalized interest", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r302", "r1155" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense, Net", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNetAbstract", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income Expense Net", "label": "Interest Income (Expense), Operating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 3.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "negatedTerseLabel": "Interest expense, net", "negatedTotalLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r959", "r1155", "r1177" ] }, "bax_InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "InterestIncomeExpenseNonoperatingNetOfCapitalizedInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails": { "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInterestExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating, Net Of Capitalized Interest", "documentation": "Interest Income (Expense), Nonoperating, Net Of Capitalized Interest" } } }, "auth_ref": [] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r943", "r949", "r984", "r999" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r943", "r1037", "r1038" ] }, "us-gaap_InterestRevenueExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRevenueExpenseNet", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Operating and Nonoperating", "documentation": "Amount of interest income (expense) classified as operating and nonoperating." } } }, "auth_ref": [ "r289", "r298", "r320" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1148" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r229", "r947", "r1012" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1150" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1149" ] }, "bax_KidneyCareManufacturingAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "KidneyCareManufacturingAndSupplyAgreementMember", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kidney Care Manufacturing and Supply Agreement", "label": "Kidney Care Manufacturing and Supply Agreement [Member]", "documentation": "Kidney Care Manufacturing and Supply Agreement" } } }, "auth_ref": [] }, "bax_KidneyCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "KidneyCareMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kidney Care", "label": "Kidney Care [Member]", "documentation": "Kidney Care" } } }, "auth_ref": [] }, "bax_KidneyCareTransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "KidneyCareTransitionServicesAgreementMember", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kidney Care Transition Services Agreement", "label": "Kidney Care Transition Services Agreement [Member]", "documentation": "Kidney Care Transition Services Agreement" } } }, "auth_ref": [] }, "us-gaap_LeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseIncome", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/REVENUESLeaseRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease revenue", "label": "Lease Income", "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor." } } }, "auth_ref": [ "r698" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.baxter.com/role/REVENUESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Lease Income", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1271" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r31", "r116", "r117", "r118", "r121", "r122", "r123", "r124", "r258", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r629", "r634", "r635", "r677", "r861", "r953", "r1042", "r1238", "r1272", "r1273" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r131", "r191", "r783", "r1012", "r1167", "r1189", "r1264" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r118", "r215", "r258", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r629", "r634", "r635", "r677", "r1012", "r1238", "r1272", "r1273" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r655", "r1249" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r92", "r109", "r164", "r212", "r213" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r92", "r109", "r162", "r164", "r212", "r213" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities of discontinued operations", "totalLabel": "Non-current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r92", "r109", "r164", "r212", "r213" ] }, "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Catastrophic Event [Axis]", "label": "Catastrophic Event [Axis]", "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": [ "r1024", "r1319" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r31", "r188", "r1283" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r115", "r120" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r115", "r120" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Facility Line Of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation reserve", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r123", "r1229" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal matters", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1139" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and finance lease obligations", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r117" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt obligations", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": [] }, "bax_LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationsCurrentFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and finance lease obligations", "label": "Long-Term Debt and Finance Lease Obligations, Current Fair Value Disclosure", "documentation": "Long-term debt and finance lease obligations, current, fair value disclosure." } } }, "auth_ref": [] }, "bax_LongTermDebtAndFinanceLeaseObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationsNoncurrent", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance lease obligations", "label": "Long -Term Debt and Finance Lease Obligations, Noncurrent", "documentation": "Long-term debt and finance lease obligations noncurrent." } } }, "auth_ref": [] }, "bax_LongTermDebtAndLeaseObligationCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LongTermDebtAndLeaseObligationCurrentMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and finance lease obligations", "label": "Long-Term Debt and Lease Obligation, Current [Member]", "documentation": "Long-Term Debt and Lease Obligation, Current" } } }, "auth_ref": [] }, "bax_LongTermDebtAndLeaseObligationExcludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LongTermDebtAndLeaseObligationExcludingCurrentMaturities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance lease obligations, less current portion", "label": "Long-Term Debt and Lease Obligation, Excluding Current Maturities", "documentation": "Long-Term Debt and Lease Obligation, Excluding Current Maturities" } } }, "auth_ref": [] }, "bax_LongTermDebtAndLeaseObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LongTermDebtAndLeaseObligationMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance lease obligations, less current portion", "label": "Long-Term Debt and Lease Obligation [Member]", "documentation": "Long-Term Debt and Lease Obligation" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTerm", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt term", "label": "Long-Term Debt, Term", "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1251", "r1252", "r1253" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r31", "r1217", "r1218", "r1219" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r52", "r1217", "r1218", "r1219" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r427", "r428", "r429", "r433", "r599", "r825", "r970", "r1230", "r1231" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r427", "r428", "r429", "r433", "r599", "r970", "r1230", "r1231" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r427", "r428", "r429", "r433", "r599", "r970", "r1230", "r1231" ] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": [ "r1229" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r427", "r428", "r429", "r433", "r599", "r825", "r970", "r1230", "r1231" ] }, "bax_LossContingencyNumberOfLawsuits": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "LossContingencyNumberOfLawsuits", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of lawsuits", "label": "Loss Contingency, Number Of Lawsuits", "documentation": "Loss Contingency, Number Of Lawsuits" } } }, "auth_ref": [] }, "us-gaap_LossFromCatastrophes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossFromCatastrophes", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hurricane Helene costs", "label": "Loss from Catastrophes", "documentation": "The charge against earnings in the period for the uninsured portion of a loss from a fire, explosion, or natural disaster (hurricane, earthquake)." } } }, "auth_ref": [ "r153" ] }, "bax_ManufacturingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ManufacturingArrangementsMember", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing services", "label": "Manufacturing Arrangements [Member]", "documentation": "Manufacturing arrangements." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r315", "r318", "r321", "r959", "r960" ] }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum length of time hedge in cash flow hedge", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r17" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r428", "r429", "r431", "r432", "r570", "r599", "r658", "r735", "r815", "r817", "r825", "r853", "r854", "r907", "r909", "r911", "r912", "r920", "r940", "r941", "r964", "r976", "r994", "r1003", "r1004", "r1008", "r1009", "r1023", "r1240", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1091" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1091" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r656", "r657", "r658", "r1003" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r656", "r657", "r658", "r1003" ] }, "bax_MedicalProductsAndTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "MedicalProductsAndTherapiesMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Products & Therapies", "label": "Medical Products And Therapies [Member]", "documentation": "Medical Products And Therapies" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r428", "r429", "r431", "r432", "r570", "r599", "r658", "r735", "r815", "r817", "r825", "r853", "r854", "r907", "r909", "r911", "r912", "r920", "r940", "r941", "r964", "r976", "r994", "r1003", "r1004", "r1008", "r1023", "r1240", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r130", "r190", "r258", "r361", "r436", "r439", "r440", "r441", "r445", "r446", "r677", "r782", "r865" ] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in noncontrolling interests", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": [ "r67" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1110" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds, at carrying value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1118" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1092" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from investing activities - continuing operations", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r1161" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r156", "r157", "r158" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operations", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from operations \u2013 continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r156", "r157", "r158" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Baxter stockholders", "terseLabel": "Net income (loss) attributable to Baxter stockholders", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r149", "r158", "r194", "r213", "r241", "r244", "r248", "r258", "r264", "r266", "r267", "r268", "r269", "r270", "r273", "r274", "r281", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r622", "r626", "r652", "r677", "r790", "r885", "r902", "r903", "r1040", "r1238" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Less: Comprehensive income attributable to noncontrolling interests", "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r71", "r181", "r241", "r244", "r270", "r273", "r274", "r789", "r1154" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net investment hedge", "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r74" ] }, "bax_NewOperatingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "NewOperatingModelMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Operating Model", "label": "New Operating Model [Member]", "documentation": "New Operating Model" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1091" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1055", "r1065", "r1075", "r1099", "r1107" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1082" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1081" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1099" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1118" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1118" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1326", "r1327", "r1328", "r1329" ] }, "bax_NoncontrollingInterestDecreaseFromDistributedRelatedToKidneyCareSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "NoncontrollingInterestDecreaseFromDistributedRelatedToKidneyCareSeparation", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposition of noncontrolling interest associated with the Kidney Care separation", "label": "Noncontrolling Interest, Decrease From Distributed Related To Kidney Care Separation", "documentation": "Noncontrolling Interest, Decrease From Distributed Related To Kidney Care Separation" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r66", "r480", "r1168", "r1169", "r1170", "r1172", "r1324" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undesignated derivative instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r20" ] }, "bax_NumberOfComplaints": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "NumberOfComplaints", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of complaints", "label": "Number of Complaints", "documentation": "Number of Complaints" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r960", "r1176" ] }, "bax_OpelikaAlabamaManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OpelikaAlabamaManufacturingFacilityMember", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opelika, Alabama Manufacturing Facility", "label": "Opelika, Alabama Manufacturing Facility [Member]", "documentation": "Opelika, Alabama Manufacturing Facility" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "terseLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r197", "r954", "r1175", "r1177", "r1179", "r1180", "r1181" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/REVENUESLeaseRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r290", "r696", "r698" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r693" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r692" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r321", "r959", "r960" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r90", "r179", "r826", "r827" ] }, "bax_OriginalWeightedAverageTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OriginalWeightedAverageTerm", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average term", "label": "Original Weighted-Average Term", "documentation": "Original Weighted-Average Term" } } }, "auth_ref": [] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-lived asset impairments", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r1162", "r1215" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r75", "r84" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r221" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r29", "r35", "r247", "r679", "r682", "r685", "r791", "r1152" ] }, "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Fair Value Hedge, And Net Investment Hedge, Gain (Loss), before Reclassification, Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r238" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204", "r237", "r240" ] }, "bax_OtherComprehensiveIncomeLossContinuingOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossContinuingOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "bax_ComprehensiveIncomeLossFromContinuingOperationsNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) from continuing operations, net of tax", "label": "Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax", "documentation": "Other Comprehensive Income (Loss), Continuing Operations, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (income) expense, derivative, excluded component, increase (decrease), adjustments, before tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r233", "r237", "r240", "r636" ] }, "bax_OtherComprehensiveIncomeLossFairValueHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossFairValueHedgeGainLossBeforeReclassificationTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), before Reclassification, Tax" } } }, "auth_ref": [] }, "bax_OtherComprehensiveIncomeLossFromDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossFromDistributions", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation", "label": "Other Comprehensive Income (Loss), From Distributions", "documentation": "Other Comprehensive Income (Loss), From Distributions" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossCashFlowHedgeFairValueHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r637" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r638" ] }, "bax_OtherComprehensiveIncomeLossNetOfDistributionsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossNetOfDistributionsNetOfTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net Of Distributions, Net Of Tax", "documentation": "Other Comprehensive Income (Loss), Net Of Distributions, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r19", "r29", "r242", "r245", "r249", "r270", "r679", "r680", "r685", "r772", "r791", "r1152", "r1153" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) from continuing operations, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Other comprehensive loss attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r11", "r18", "r180", "r242", "r245", "r270" ] }, "bax_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAccumulatedOtherComprehensiveIncomeCashFlowHedgesFairValueHedgesAndNetInvestmentHedgesNetOfTax", "crdr": "debit", "calculation": { "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax", "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from Accumulated Other Comprehensive Income, Cash Flow Hedges, Fair Value Hedges And Net Investment Hedges, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other segment items", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r150", "r151" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortized intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r967", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r158" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingGainsLosses", "crdr": "credit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Nonoperating Gains (Losses)", "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r152", "r153" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 1.0 }, "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSMajorClassesofLineItemsinIncomeFromDiscontinuedOperationsDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r153" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, net", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESSummaryofGainsandLossesonHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other operating income, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1091" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OPEB", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r568", "r569", "r986", "r987", "r988", "r989", "r990" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1053", "r1063", "r1073", "r1105" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1056", "r1066", "r1076", "r1108" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1056", "r1066", "r1076", "r1108" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Baxter stockholders' equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1080" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1135", "r1156" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r416", "r1160" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends on common stock", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r155" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r154" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1090" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1090" ] }, "us-gaap_PensionAndOtherPostretirementBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefit plans", "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)", "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits." } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMS" ], "lang": { "en-us": { "role": { "terseLabel": "PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r498", "r522", "r524", "r530", "r547", "r549", "r550", "r551", "r552", "r553", "r565", "r566", "r567", "r986" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic pension and other postretirement costs", "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash", "documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefits", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r568", "r572", "r986", "r987", "r991", "r992", "r993" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1082" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1099" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1092" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1081" ] }, "bax_PharmaceuticalCompoundingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "PharmaceuticalCompoundingMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drug Compounding", "label": "Pharmaceutical Compounding [Member]", "documentation": "Pharmaceutical Compounding" } } }, "auth_ref": [] }, "bax_PharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "PharmaceuticalsMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceuticals", "label": "Pharmaceuticals [Member]", "documentation": "Pharmaceuticals." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1083" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1127" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1082" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESClassificationandFairValueAmountsofDerivativeInstrumentsDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESDerivativePositionsPresentedOnNetBasisDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of businesses", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r37" ] }, "bax_ProceedsFromDivestitureOfBusinessesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ProceedsFromDivestitureOfBusinessesNetOfTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of businesses, net of tax", "label": "Proceeds From Divestiture Of Businesses, Net Of Tax", "documentation": "Proceeds From Divestiture Of Businesses, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock issued under employee benefit plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r7", "r21" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1136", "r1157" ] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net decreases in debt with original maturities of three months or less", "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less", "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months." } } }, "auth_ref": [ "r1158", "r1159", "r1163" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r323", "r736", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r944", "r977", "r1022", "r1023", "r1025", "r1028", "r1029", "r1232", "r1233", "r1242", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "bax_ProductRelatedIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ProductRelatedIncomeLoss", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product-related items", "label": "Product Related Income (Loss)", "documentation": "Product Related Income (Loss)" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r323", "r736", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r944", "r977", "r1022", "r1023", "r1025", "r1028", "r1029", "r1232", "r1233", "r1242", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net loss", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r213", "r241", "r244", "r254", "r258", "r264", "r270", "r273", "r274", "r361", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r622", "r626", "r627", "r630", "r631", "r652", "r677", "r775", "r788", "r836", "r885", "r902", "r903", "r996", "r997", "r1041", "r1154", "r1238" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r14", "r695" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r163", "r217", "r785" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r695" ] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r14", "r695", "r776", "r785", "r1012" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r163", "r695" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charged to costs and expenses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r252", "r368" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1080" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1080" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r428", "r429", "r431", "r432", "r522", "r570", "r595", "r596", "r597", "r599", "r658", "r710", "r719", "r735", "r815", "r817", "r825", "r853", "r854", "r907", "r909", "r911", "r912", "r920", "r940", "r941", "r964", "r976", "r994", "r1003", "r1004", "r1008", "r1009", "r1023", "r1032", "r1220", "r1240", "r1252", "r1275", "r1276", "r1277", "r1278", "r1279" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONDetails", "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r428", "r429", "r431", "r432", "r522", "r570", "r595", "r596", "r597", "r599", "r658", "r710", "r719", "r735", "r815", "r817", "r825", "r853", "r854", "r907", "r909", "r911", "r912", "r920", "r940", "r941", "r964", "r976", "r994", "r1003", "r1004", "r1008", "r1009", "r1023", "r1032", "r1220", "r1240", "r1252", "r1275", "r1276", "r1277", "r1278", "r1279" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from AOCI", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r29", "r35", "r247", "r679", "r684", "r685", "r791", "r1152" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts reclassified from AOCI", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reclassification from AOCI to Net Income (Loss)", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r46", "r47" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income to Income Before Income Taxes Reconciliation", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r46", "r47" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1048", "r1058", "r1068", "r1100" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of debt", "terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1159" ] }, "bax_ReportableSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ReportableSegmentMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segment", "label": "Reportable Segment [Member]", "documentation": "Reportable Segment" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r600", "r942", "r959", "r1280" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1049", "r1059", "r1069", "r1101" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1050", "r1060", "r1070", "r1102" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1057", "r1067", "r1077", "r1109" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other non-current assets", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1147", "r1164", "r1281", "r1284" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGES" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS OPTIMIZATION CHARGES", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r413", "r414", "r416", "r419", "r424" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected additional pre-tax costs", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r415", "r418", "r421", "r423" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": "us-gaap_RestructuringCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs to implement business optimization programs", "verboseLabel": "Separation-related costs", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r415", "r418", "r421", "r423" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": "us-gaap_RestructuringCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges", "verboseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13", "r420", "r421", "r1225" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r415", "r416", "r421", "r422" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r421", "r422", "r423" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total business optimization charges", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Reserve, beginning balance", "periodEndLabel": "Reserve, ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r416", "r422" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": [ "r1226", "r1227" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r128", "r175", "r781", "r822", "r824", "r833", "r864", "r1012" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r209", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r362", "r363", "r404", "r609", "r610", "r619", "r620", "r621", "r623", "r625", "r626", "r643", "r645", "r646", "r648", "r650", "r689", "r691", "r819", "r821", "r837", "r1324" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r568", "r569", "r572", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r568", "r569", "r572", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r195", "r196", "r289", "r299", "r300", "r314", "r320", "r323", "r325", "r327", "r493", "r494", "r736" ] }, "bax_RevenueFromContractWithCustomerRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "RevenueFromContractWithCustomerRollForward", "presentation": [ "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Contract With Customer [Roll Forward]", "label": "Revenue From Contract With Customer [Roll Forward]", "documentation": "Revenue From Contract With Customer" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.baxter.com/role/REVENUES" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUES", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r206", "r484", "r485", "r486", "r487", "r488", "r489", "r491", "r492", "r497" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r159" ] }, "bax_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global payment terms", "label": "Revenue, Performance Obligation, Payment Terms", "documentation": "Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "bax_RevenueRecognizedContractPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "RevenueRecognizedContractPeriod", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized contract period", "label": "Revenue Recognized Contract Period", "documentation": "Revenue recognized contract period." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price allocated to remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r202" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r203" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r203" ] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining revenue performance obligation, percentage of revenue expected to be recognized", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r1137" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r694", "r1011" ] }, "bax_RisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "RisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://www.baxter.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "label": "Risks and Uncertainties Policy [Policy Text Block]", "documentation": "Risks and Uncertainties Policy" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1118" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1118" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-type leases, receivables", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases." } } }, "auth_ref": [ "r697", "r701" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "presentation": [ "http://www.baxter.com/role/REVENUESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-type Lease, Lease Income", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position." } } }, "auth_ref": [ "r697" ] }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseNetInvestmentInLease", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-type lease, net of investment in lease", "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease." } } }, "auth_ref": [ "r199", "r370", "r701", "r1190" ] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/REVENUESLeaseRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-type lease revenue", "label": "Sales-type Lease, Revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": [ "r290", "r699" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r571", "r1171" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r275", "r571", "r1133", "r1171" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in AOCI Income (Loss) by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r35", "r1267", "r1268" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSNetPeriodicBenefitCostRelatingtoPensionandOtherPostemploymentEmployeeBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r16", "r57", "r58", "r59", "r60" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Gains and Losses on Derivative Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r76", "r79", "r639" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Classification and Fair Values of Derivative Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r77" ] }, "bax_ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ScheduleOfDerivativePositionsPresentedOnNetBasisTableTableTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Positions Presented On Net Basis", "label": "Schedule Of Derivative Positions Presented On Net Basis Table [Table Text Block]", "documentation": "Schedule of derivative positions presented on net basis." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r15", "r22", "r32", "r92", "r101", "r102", "r103", "r104", "r105", "r110", "r112", "r113", "r165" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Income (Loss) attributable to Stockholder", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1174" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Instruments Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1249", "r1250" ] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r80" ] }, "bax_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillTableTextBlock", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets, Net", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill [Table Text Block]", "documentation": "Schedule Of Finite And Indefinite Lived Intangible Assets Excluding Goodwill" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r966" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r966", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r33", "r132", "r133", "r134" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.baxter.com/role/PENSIONANDOTHERPOSTRETIREMENTBENEFITPROGRAMSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense-, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.baxter.com/role/SUPPLEMENTALFINANCIALINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r14", "r695" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofBusinessOptimizationChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r421", "r422", "r423" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Restructuring Charges", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r50", "r166", "r167" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity in Reserves Related to Restructuring Initiatives", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r51", "r168" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Information for Our Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic Shares to Diluted Shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r42" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1043" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1045" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSCarryingAmountsoftheAssetsandLiabilitiesClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r10", "r93", "r94", "r95" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r289", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r327", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r403", "r418", "r423", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r956", "r959", "r960", "r966", "r1027", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r325", "r326", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r849", "r850", "r851", "r908", "r910", "r913", "r921", "r928", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r945", "r978", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1026", "r1032", "r1242", "r1289", "r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r198", "r289", "r294", "r295", "r296", "r297", "r298", "r310", "r312", "r313", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r327", "r955", "r957", "r958", "r959", "r961", "r962", "r963" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Segment Reporting, Other Segment Item, Amount", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r289", "r312", "r313", "r320", "r959" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r150" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SG&A", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "bax_SeniorUnsecuredTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SeniorUnsecuredTermLoansMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Term Loans", "label": "Senior Unsecured Term Loans [Member]", "documentation": "Senior Unsecured Term Loans" } } }, "auth_ref": [] }, "bax_SeparationRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SeparationRelatedCostsMember", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnifications related to Kidney Care separation", "label": "Separation-Related Costs [Member]", "documentation": "Separation-Related Costs" } } }, "auth_ref": [] }, "bax_SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SeveranceContractTerminationAndOtherEmployeeRelatedCostsMember", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance, Contract Termination, And Other Employee Related Costs", "label": "Severance, Contract Termination, And Other Employee Related Costs [Member]", "documentation": "Severance, Contract Termination, And Other Employee Related Costs" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://www.baxter.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r172", "r177" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r114", "r187", "r1012", "r1282" ] }, "bax_ShortTermDebtCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "ShortTermDebtCurrentFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSBookValuesandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "label": "Short-term Debt, Current Fair Value Disclosure", "documentation": "Short-term Debt, Current Fair Value Disclosure" } } }, "auth_ref": [] }, "bax_SiteContingencyNumberOfSites": { "xbrltype": "integerItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SiteContingencyNumberOfSites", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of sites", "label": "Site Contingency Number Of Sites", "documentation": "Site contingency, number of sites." } } }, "auth_ref": [] }, "bax_SoftwareArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SoftwareArrangementsMember", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails", "http://www.baxter.com/role/REVENUESContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software sales", "label": "Software Arrangements [Member]", "documentation": "Software arrangements." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONOperatingIncometoIncomeBeforeIncomeTaxesReconciliationDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSegmentInformationOfNetSalesAndOperatingIncomeDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r211", "r289", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r327", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r403", "r406", "r418", "r423", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r956", "r959", "r960", "r966", "r1027", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r207", "r224", "r225", "r226", "r258", "r279", "r280", "r282", "r284", "r292", "r293", "r361", "r436", "r439", "r440", "r441", "r445", "r446", "r474", "r475", "r476", "r477", "r479", "r677", "r829", "r830", "r831", "r832", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r863", "r886", "r904", "r922", "r923", "r924", "r925", "r926", "r1129", "r1165", "r1173" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofAmountsReclassificationfromAOCItoNetIncomeDetails", "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r19", "r126", "r129", "r130", "r209", "r246", "r247", "r248", "r261", "r262", "r263", "r265", "r270", "r272", "r274", "r291", "r362", "r363", "r404", "r480", "r609", "r610", "r619", "r620", "r621", "r623", "r625", "r626", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r679", "r681", "r682", "r683", "r684", "r685", "r689", "r691", "r702", "r791", "r819", "r820", "r821", "r837", "r904" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r325", "r326", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r849", "r850", "r851", "r908", "r910", "r913", "r921", "r928", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r945", "r978", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1026", "r1032", "r1242", "r1289", "r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1320", "r1321" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r262", "r263", "r291", "r691", "r736", "r828", "r848", "r855", "r856", "r857", "r858", "r859", "r860", "r863", "r866", "r867", "r868", "r869", "r870", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r881", "r883", "r887", "r888", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r904", "r1033" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r275", "r571", "r1133", "r1134", "r1171" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r261", "r262", "r263", "r291", "r328", "r691", "r736", "r828", "r848", "r855", "r856", "r857", "r858", "r859", "r860", "r863", "r866", "r867", "r868", "r869", "r870", "r872", "r873", "r874", "r875", "r877", "r878", "r879", "r880", "r881", "r883", "r887", "r888", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r904", "r1033" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1052", "r1062", "r1072", "r1104" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock issued under employee benefit plans and other (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued under employee benefit plans and other", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r61", "r125", "r126", "r175" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining value available under stock repurchase programs", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Baxter stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r126", "r129", "r130", "r160", "r865", "r882", "r905", "r906", "r1012", "r1042", "r1167", "r1189", "r1264", "r1324" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAOCIbyComponentDetails", "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance, beginning of period (in usd)", "periodEndLabel": "Balance, end of period (in usd)", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r66", "r67", "r70", "r209", "r210", "r247", "r261", "r262", "r263", "r265", "r270", "r272", "r362", "r363", "r404", "r480", "r609", "r610", "r619", "r620", "r621", "r623", "r625", "r626", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r679", "r681", "r685", "r690", "r702", "r820", "r821", "r835", "r865", "r882", "r905", "r906", "r927", "r1041", "r1167", "r1189", "r1264", "r1324" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r686", "r703" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r686", "r703" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r686", "r703" ] }, "bax_SuperfundSitesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "SuperfundSitesMember", "presentation": [ "http://www.baxter.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Superfund Sites", "label": "Superfund Sites [Member]", "documentation": "Superfund sites." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1098" ] }, "bax_TermLoanDueTwoThousandAndTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "TermLoanDueTwoThousandAndTwentySixMember", "presentation": [ "http://www.baxter.com/role/FINANCINGARRANGEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due Two Thousand and Twenty Six", "label": "Term Loan Due Two Thousand and Twenty Six [Member]", "documentation": "Term Loan Due Two Thousand and Twenty Six" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1090" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1097" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.baxter.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r63", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1117" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1119" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "bax_TransactionServiceAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "TransactionServiceAgreementPeriod", "presentation": [ "http://www.baxter.com/role/DISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction service agreement, period", "label": "Transaction Service Agreement, Period", "documentation": "Transaction Service Agreement, Period" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.baxter.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESAmountsRecordedonCondensedConsolidatedBalanceSheetRelatedtoFairValueHedgesDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails", "http://www.baxter.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueMeasurementsthatUseSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r472", "r478", "r649", "r674", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r792", "r999", "r1001", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1013", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1184", "r1185", "r1186", "r1187", "r1248", "r1251", "r1252", "r1253", "r1260", "r1263" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1120" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1121" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1121" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1119" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1119" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1122" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1120" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock in treasury", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://www.baxter.com/role/CondensedConsolidatedStatementsofChangesinEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Balance, treasury, beginning period (in shares)", "periodEndLabel": "Balance, treasury, ending period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock in treasury, at cost, 170,414,885 shares in 2025 and 172,567,636 shares in 2024", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r55", "r56", "r129" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.baxter.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of treasury stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r19", "r126", "r175" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESAdditionalInformationDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESComponentsofRestructuringChargesDetails", "http://www.baxter.com/role/BUSINESSOPTIMIZATIONCHARGESSummaryofActivityinReservesRelatedtoRestructuringInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r415", "r416", "r421", "r422" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails", "http://www.baxter.com/role/SEGMENTINFORMATIONSummaryofFinancialInformationforOurSegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1116" ] }, "us-gaap_VariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseIncome", "crdr": "credit", "calculation": { "http://www.baxter.com/role/REVENUESLeaseRevenueDetails": { "parentTag": "us-gaap_LeaseIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/REVENUESLeaseRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease revenue", "label": "Variable Lease, Income", "documentation": "Amount of variable lease payments from operating, direct financing, and sales-type leases, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r700" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1086" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1174" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r278", "r284" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.baxter.com/role/CondensedConsolidatedStatementsofLossunaudited", "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r277", "r284" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.baxter.com/role/EARNINGSPERSHAREReconciliationofBasicSharestoDilutedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic Shares to Diluted Shares", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "bax_WesternEuropeCanadaJapanAustraliaAndNewZealandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "WesternEuropeCanadaJapanAustraliaAndNewZealandMember", "presentation": [ "http://www.baxter.com/role/SEGMENTINFORMATIONRevenueromExternalCustomersbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Western Europe, Canada, Japan, Australia and New Zealand [Member]", "documentation": "Western Europe, Canada, Japan, Australia and New Zealand" } } }, "auth_ref": [] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XCHI", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NYSE CHICAGO, INC.", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XNYS", "presentation": [ "http://www.baxter.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "New York Stock Exchange", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] }, "bax_YearOfOriginationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "YearOfOriginationAxis", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "YearOf Origination [Axis]", "label": "YearOf Origination [Axis]", "documentation": "YearOf Origination" } } }, "auth_ref": [] }, "bax_YearOfOriginationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.baxter.com/20250331", "localname": "YearOfOriginationDomain", "presentation": [ "http://www.baxter.com/role/REVENUESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "YearOf Origination [Domain]", "label": "YearOf Origination [Domain]", "documentation": "YearOf Origination [Domain]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1084" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-10" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-11" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1043": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1044": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1045": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1046": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r1047": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1048": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1050": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1051": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1052": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1053": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1054": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1055": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1056": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1057": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1058": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1059": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1061": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1062": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1063": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1064": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1065": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1066": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1067": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1068": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1069": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1071": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1072": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1073": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1074": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1075": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1076": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1077": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1078": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1080": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1082": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1083": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1084": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1085": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1086": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1129": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1130": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1131": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1132": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1133": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1134": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 105 0001628280-25-022727-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-25-022727-xbrl.zip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�:O?Z2)11ZY;].*(WENP^D_KG_>ZK9XF)W[5 M;B5_ONE1@]:@-\CK2?WD;Y:>E."9QJ $;4GSOFJ+4_SNT?3NVF4)-F)(S$5: M1?UTGNW$I52:PG433Z+ P@83C3^(JT\D53Y)<;3_\!!>BD[LTCR!%]CC,:XT MK1,JOD>M,!K*A=+V:T.2TOV#AQPV[TIAP>!DK"5:<]MT:L_WT%O?U>W-PZL] M]%ZSN+3RMMKA)VH'])OK3+'S#3[Q'Z8_.0\\D!C4733"/_,\"O\S=BB!D[O8 M[:&KY-4]W&H' M<^.LHT3[%C&<(]JQ6\5)I^0C3M41J#5PCWYU'<^3PK!;(;,K4QF!E6/)+9*8 M0?76=<9F4AVCTFX,\YN%?1B31I! 1JF\A03DQG!0,1+@5 A7PZJ]IZR([D1Z MI#;%Q"J631%C:MJFY[LL]2G1EQGFC831FT741H#]-00K&$!G*T"]#&&:Q()8 M]-K>NQF=L'"+EZ6[XQAK3X4Y6V@KYT/3U1WU*,O)H00UZ!.UG!FFU?<3GWN= MO.&9M;8&NT-H E-=O,+R'8YBS5#*/82SFWE:/]1N#<]F1"UV.%&X0RT7PK+( M5W.WV:K:V.&04&DA(P"2=7HC*(=\%<#;,U/E@=!S".Q&#= M2\1N: D3@W+5MG'LA4^0;.>H[<90U#IP@>DU$9HSIN7&L%=N']_JB,]JQ(-# MK_]#:+=^W%^(5BI.=7/IUZFYHVK?.YEDMP MK_Q80WVH*D>Q?V!:ZC2&VOITNYP;?!U#R*(:-O?50A/$]K;T841M.C;]-0%R MY.99-N$/C!A99E]#<"8Q&P[&+:VI;9WM[MSE;RIT]A)SIZ+JXLBM[B.WL',, M;&RWA7;K@[K.ROT& MZMYG@X11OK4[%R>B%[M$F1%CRSX19Y&QZ W5#II"EXX*!P&X0= /:>B=UN57[5$+UGRE"3?D>P-,]/P>G"QP"0V[1R# M)YF 60\6WCMR\IYS>PF7O^T /S9?J-'\D[I.DE#0&D,V>53Y7'3Y*Q]ET#6D MJ+W#)_E25*>"%,6IKMFMFKJ"&F5#T$649!<4:,D^=>Q]GN_FQO.BI)NO2,V. MH72MQ\9Q\$4+G$KYX_0HA+^0B]0'R+^R<]YBO5]!4TZ03Q95L /YK)/)( =9 M+VS]&H;TUY1!-%C*6QI:MV/D,7FZW#ZLS4.E4OJV^'E"H]("+HM^3!!>G78! M&9&]T)'KP C!-()I]K0*DI@&<_7K]=#5XAD>#()!)F/U+6QXL@AZ^YUWP[F& M<.D4Z):--UPAHISBIEGFO!^:>;\2S]3W"8S41SI75\K>4O<>B?==$T7)GI^! MYS+ZB!X>B>/VJSA6&L-V2^:EL;(@VWJ0[:!HLE61;-M[M^0_KC!QA93:A8G# MPHU]BC=K(!^2=E4+^9"#6HLH9*.$T/)1;#E5!0O"K0?AYJ#8MA%N)Q_55J-R M]O=<70[K7%+[LQM*5W+V:*NG_+-YM$*"5DJ"OJ_Z$RM*4A2=Q#4G6QV'+C,+ M>#D5)HBZ'D3]OEE0.%'WF,FP=R:J1B9#O4*\6;UA$2VKE/0H7"5NO'=C!02 M!&&WC8)0V7M*B=#O@CA3Z_?4Q"DS+9U725@=M'2]HKDBE5OKT%KH9,_GBW;P2TZI!_'I"HJLU MAAUN,I1'C^TMYUWVQG8'L-W.:Y9L'=1*O<)S&[R?5&R5-AY21;;:38@N1_R7 MN2N)L;HH1L6<4$[PO9L8S8+O'N)[[]$<%0XC?6)GY>%?PWP:?H$?\=53XCZ: M=G@0$I![*#)1D$P>)E0BNNY,X8US/+EG.SX8U8!/"9: +5T>76)),^*&+=(G MU*-(.@;.8<&]V^S<)@$JD,:F36P=E@1+AP^FU/:]U@*S;W<=+4-#I3!S/!.I MX=2E%O'-)_KYV33\24S*2W=%9TG;K[>0$:P J'#C+4M4H5/L=7%0 *NK %C^ MB6M$[C!561T0VE%)6],TO:N."-'E=G>LJ>/.B!C:OQ2E$=\T<>-USX 1FR.7 MDI]-,H9MG1+KF6N]WS!).?+3'*_8 WDIW-@/)=.X#H@>BG.G'YGF=,/@4T"PX2; M/G*ZQ0^F+<'#+*R*WKS&)?'67564BR6'7406+,Z.1!;9P6TN^9:='J=L>Q9??$"OO-JKNMT_MKEV68&&%A%-D>*J? MRLAZF+B42E.X;N))%/C=8'+T!W'UB:3*)QO=BC(AO.3 [3CYBQ?P*VW,1VP% M<0VVJ15&225U/MP">D[:7NTZ7BXWL*1.794 G,S9J_2[WNK)E;#=*L[0Z^8R M0V\'7D[ID$=H3)?2%4Q3;Z;A959@-X]9@0?B&=[- [SS,F$>N-/PD+E)7?< M3*G]EP<(GJ:Q1[>!:9O9ON?]7%'(/C/:%^&KP]#(>>"ZU-;GDN_"4RR&?(D8 M_PX\GP5TENE@?90[?O&7'(R($1!9@O1C!+P23EH2F(X+^[#C]3^\+O]LL?KD MT7V]=I(LE(AM9-O+!ME^V+W(C6%"PQ%LFHUQ;?C_6V=>6CCR$KJ:;-OHC)U( MH#IF5,=(M35_$X \7!U&"6+RPUX$[,&JX;>SVU MOS:NL)BL?K(>/UIB69,0O!&+"M)#7A^R5RJU<*K3=[/Z2M'IMT@TJ,9!M#O, M!IPYGN]2WW19ED:*U'<*Y?ZA).U^ 2NPJ?$U7,JM1>PS3 ?>4=TBGF>. <2I MU*/6&*Z'"C[FH.OWY^2\MMAA^5B>#("]:DHX=^@+T/^9"8%]O8$:NM@?OM2" ME.PV0)WIA0?!\1Z]])($9/GDPJD14"''_C=J/&)(!U'Z9/HF+5[;[T_:Y\2; M?+.<9UP\_968-IOSDT3=V(V!@ F<%.SL]4$(%J+UR]Y8XN@BX>Q7R-E/3PCH MSR7*['X[B0J$A\^#=B^5+N3&L-Q#'1SK\B)?S=UF:SFN[<'QB17%,_;/:>US M.";O@8QU4(/ORK:$O/8[4R$4_*< M$@RG&J(&8YW/=](*/$UVYMS^GYRNVE#6%+-S3N5-?>T Y4V']IAJ0%P% M9$M+);,.:IJ$T!*?-,:IIJF!+Y)^L(;P.8HO-D_LV?NNQ=@%=9%7EJQ\?7&< M))*IM#H[B?0:0S6O$95'+>XY[/&\5[GT!D&_4XWT&]ADKI'.=C]79+%G%7WE MRJ1S\K,2!5DNM<5CQYT2_Y>&^>*?CLT7:C3_I*Z3)!K[C2%^M:&$.G>;O[@M MKV\M,<'Z<6N&-50+HJ0J[ZA"+JC?N3QVT,;B^G*[1->_FHI/>;$[T[,AWBK$.2B2I':E!IP&V9%^1E<^B M;*NH[$%(W2J7$:=,)4U9XTXB8ERL%LD:41ZPHSEY308468>J>: Y4U,O'S=3 MI"9JHDNV%C_EJ3_J4Z%2J/[(C=GQ0%,_K]K^\E5'?' MCEIKU*!^Z1UE(?R)@Y7#GME&,@?O4JZXF>N5-N:Q!GD=\RY??=2'VLJICST8 MW;'F9 G9 3Y)CE-U4YGZJ>_4\TZE1-5"E@A)\AW)7B$E-I(%:6DO9Z0R3)]C M'2PPWRN3IRMJ3QN=5MH*S]'I8R6(+56O.Q#$.N+5I"*H\E'.J7S>LY#QT/(Y MJS6< .4E"/>\Z+&8O0-9Q),9^ M .%1-.:H21-DX7O1AVXN4:]\.;_ &3*"EVK/2X68&1FYJH%'3O-BBY(P8EUW-0\H38C\!OIBU=_A&8_KPVXY&3UGC@>ZDLZF]I3VRMF+?[P$?17L-,W,YP3@>\C4IY)33T5XDR MY9;74.L\YG\OGE'WF>/I$ DN()!^B#7)FX#]GZJ=28UV?63;C9&,=C\8=#[X M$5[@YL:B58&":3,('-'VSV"%D:!F*2(,ZZ,G3V:F3ZPC , =]0D>[)0H<6U8 MZS$(NC-=#Z:!Q3S0A,.&C MFF8$$^$>A<,]>\!-X'L^L1$621F1/D[I/2K!O(?W[)8T8AJ3SZ9RMM =58A(A0;=(T"V%&@^10\7(*1*GT8/6*$/& MPTF]JE"&$)]U$Y_9^E!MZ\66MR!=KO6U@VG3$CP4!$\U"TI/"OC M0+1U%2-X1/ (;SS2YU+-]!K#WDE;J82:V9(E+_(HE+BJE&8DH9Q36DJ'1UEW M3?WHP'FU6XNDVVW4D$/TWQ P%3 5,!4P%3#E#J:9?-;>^P;YK>N,31][%B79 MS?T\9V((; H.X9%#MKBL[W/(0' (7]C<+T>?,@9UZK M9"5E8)I-OXIF'TT/MCG* H-[JAN M$<\SQ[ *AGAGG&+X.M9D.-C)$QLE3:CT-].PZ5PZQRZY'IV1<'::*%T0 4D! M4P%3 5,!4P%3 =,ZP72_V,+K<-KW;&2<4'MA>F%I-C873S*6.]C>H,-)4DT@ M>V-E0R[([@ID"VE909CF-$%^;_[I\<0_XLQ)9:XZBF*1^[#_L^<%U .-:@K MT>G,4C(MPL8,H'3#>'\),;%BI;:OF8.+AB MTN BSG5^)1 ]4QZ&(6\/WFN&.*DYJ2=&^_,5SO:"AR8B6X MH[LA_N_$"F@RWI/0S6JTE9S._@JLYU#AL-9>[KVF/OOB7\46IO(Z_@7#"PTJ M8'H\,,WS4% ^@@E/(>35UD4@73 2CXQT"#Y2..*CHRC5N3"?3(/:AH?(M0!- MA@1TH*>9V%:C4+((SPN8"I@*F J8"ICR"M-LU=1;FH4LU/[2#*YSXDV2;#*U M,>SO4SDMT"I8A6=6V1(@R,(JFF 5P2J5@NE^9W1VYY0.'YQR%#48%^Q@C1F? MQ+&39]9*Q/,R=M/NR4)>"*>O!E-G4Y5K]2,'J[I2XCZ8= MOK<-B(W>UD1N.AW,?$ DNW6QO7"=L#6+S#QZ&O_R.2YN,6U&"^RFS]'3HSWC ML:$WRV3;"+_^_&P:_N1TT&NIR@ )**J,B5X:NLG?Q$^**LKB+R.!K(9LG%AD M%DN7-LJ6S:5KXK+#7E9(%2?WI:'<+U!<)5!5N:L$JBISE4!59:X2J*K,50)5 ME;E*H*HR5PE45>8J@:K*7"5059FKL@76EP+V.L64A(BLBR=5YTDBLOZN7'X_ MSMM>NRXA?QU*A?(3M]\V&%0S0:0 M+=F%;,_8B])K@\CSI=D04GC:,B]L56371[;=",F2:4M^=$SVV"!P7%L_@Q5& M II5"X5M?R2=S$R?6$< @#OJ$_C0D"AQ;5CK,0BX,UT/I@'K[!2.889-+LU$ MERS'.P8P/#A XE)DK.QHF51@F]?)/:#38+@"NPN1F("OG-I]\U=[EV5NQRLX27!2@8:(PN/)MT[8S*B_=S,CP4."AXKG M(95+'L+>0]T36=[[^*A@(L%$!S#I^&YXV6&M@CH)A[&%12<8B2=MQ&5[R@X. M(CW1VNN=MH0R$CS$'0\=J)OD.IMTP?$1,3C!(Q7@$2Y[YG1Z3,_LWW#U$#PD MCEI4YJI=)V55:H#Y-?4E$[AP2G\BL]MN#/<.#0M)UA*46N^GRG$;>"Y@*F J8"I@*F J8"ICR M6V.FI3TVP$RJ\V6+ZHH95&CS7E/_9OQ 7I)L7P5K+M=SCYE+Q 2R-L>0$11)) '3*L!T MLXY-[BV@I3D9>L6DP47@8E4G+,LQPOX"[.=7XE$#%3!H7]:)\IOCCJGI4R-) M[7:3,D"9YXX*Y.^?R-L-\7\G5D"3\9Z$[AY86>WUX_&"Y4OSH-9.L;YW_FYO M_/<;P\X^W1$$YH4"%3"M.DSSK!;*1RX-$N620+I@)*YAFF-U3RY\U&MSQ$=' M405T83Z9!K4-#Y%K 9H,">A 3]-/O4:19)%B%3 5,!4P%3 5,.45IMFJ&+8< M(EJH_:5NV>?$FR399-B54N.L8&&_KO"<8'2? W"U)MXMKD86XE4X)-X:X54( M>M[*6G9G%9435CF*LHCS";$?\<"-9&<=]E*C^).(Z0F8"I@*F J8"I@*F J8 M"I@*F/($TV(.D_PP;<=EG2U#4S_,E%[9.LY=HAXP/6N2?"H VKXH%,5WFPXP#QY58J8\F4I(<2'%*^%RK',25Z.N>@,V MO53.<7JI8$W!FMRIN23./-#@GVP,V6^S<:C[=]443"F8LH),R>6DH;[,YJNV MVS7PB@17"J[,;L6N529S9<7V%1S8VE-RZ.0D.%-P9I7T99H#GH?G1Q4G\\D] MH2X%4QXA4W:VC,[939^CAT5;Q',@;U;%5AU^_?G9-/S)Z:#74I4!$DQ4]!*]./Q6;@$M?5K_ M7%%;?;F7^%6[)2=^ONE1W9;2T<23*OFD7DM6%<[6U&T-9#6O-763OXF?%!6+ MQ5]& E@-V3BQ?BP6)FT4)7M,N13WB_MSN;^0]MG<]^3F?H'B*H&JRETE4%69 MJP2J*G.50%5EKA*HJLQ5 E65N4J@JC)7"515YBJ!JLIJ$WN.[9QLQZ>>1%SXV&:]G1Y=8DDSXOIX?-2?4(]B M]LF@MD=Q\S;+M! ?_AB;-K%U6!.L'3Z84MOW6HLLS]MM1\O0<)TSQS,Q,W3J M4HOXYA.-DAM1*FSIKB@UTGZ]A8Q@!8&_^9:E3(].,9>5#X015RD W%D%P/)/ M7"/FRDQ55@>$=E32UC1-[ZHC0G2YW1UKZK@S(H;V+Z7?B&^:+*+5,_)(FR.7 MDI]-,H9MG1+KF4N^'S!-.?+3'._8!7D+VQU)WVSG&=/^A#8)#!P MC-1'3G?TP;0E>)@%H/<6:SQP]G/0DM5>UNQG3VEUE'QR3++2:O?[^3UJD"9? MM4GOO)M2NF$C3E018Z8B MQJXSE9P9=9GZV]R [7'25W&=^A=IB_B2]K5UM*L0V\G2RG>EDJ\6]<9FSZ.YFXD%,QU&T-9Z98Z M30AA^TE08@TH<8QVXOQ*/&N=+($RB9\RQK3?\ M%088=P98>I3VL,DZ#R@] HL+"QAF;"20J4N(E=B5=/P)=:69X_DNF,HN*VD$ M(.PZ%[:^RCJM/78; A<4] V"]G8%LE^I3<>@L2]?$ ?TC@($/&+=C*,/,(Z6 M/#5YT&\,R];G@@C26FQ%$<&@,5R7F,*HRYDD&,XDR[$?FY;Y!&XJ\3PL )O. MB.FRL*DP\C(8>0R<9PC"JP4$S\%*>$R:O:*VVXUA0E=<8>EQ9^F]B]?EGG-C M\X4:S3^IZR3A6UZ,%.4!Z24>SQ.O%J^NDF,F(9$0\_$6\H5ZH'K8I*0 M!<5%EG!/&18!.B[QB3S!.''$HJN)7-#'BE21#ZR:;-L5W8/&L&QLU]TP6[B< M,S)GS9#J;YX5*MEB>-Z&X$R@:KF-,VIYR/H(4D2I=L8 M#M9]P\R6468R+\I.K@'EY!@OR)]>>HUA=^_#8H4339ZV-I+EYNY(WT 2.L"8&48HTFD06FL;IY]97EI6=A)-)3+X=WH6K:3]1# M7$ID@OBN47G"L,UH:;P?@J!O'[1BJ>U!*Q'7 M;GB'"NMP*033."$'S5)6A*D.&?M)8*B4*2>%G1_+H>I>Q(/*-ZH/1C1X.JV= M@]7-6:"HJL'V#2+Y:%.5.5JM*1EG4ZYJN4&8'4R;AN,WH](1I3(S1=V/P$;)4;JFMTRRBE*UC:)4 MZ>;5[4.8M]R*WRQ$M$XG+/&YC[#ETY2M32 T@!%6A)P/R!&X9V0*+Z$Y=2:0I/GL#?KF11 M[P@".\7,,EE*3RUSX_W$$_ \&^!OW.X ]B6,U\#[V M"I"*"$[Q%9/[(SYU_W^U4Z7^_S6P/YD;89CH$=H&2$@;]CD%<0EO=_2?PA;= MI7(##)08H.<,F&PN8!*U=QO#?MDC? 1:4Q;=I4BD,@#"! M)9F>AUD\V!9U)3J=6@I(X-5>!#*P*Z77% & MORX^5]&%RMG"81ES4B#]2*9-%!XV6"IV9<#^%L/ZW=R3UA;MC3E >.J*YOT1 MCLG&LN?;YIY1K'@]6WVGI M2*EHSV*/E/(7$VE[M2HMG$P*+[OC31Q?CL=4]S&E!4P/7]@2?='9C#K))3Z5 M]&A>'49P ?$G[*=$_PC,)\ NUA=@&VCPS7S7U'UJA-]7HVO>R/%]9\JMH[PE MA!)B#@>ZASBZ W3=V,B=^/_+5PS=+9"#7X#7O/K!TI5)/(NIM+S&LQ7 MQ$. MN>BE5P(]%2+D#T19V.\UA[**0HGJZ.K_XN;DTH>X(.(C%D2DE_V%V.YU-+FR M].C;F>]N82..L=YQ/HJ-+G-XR/5)C(IG%/?RF[,R13FF?1V)+,L9FG*)#).; M77Z)+*F) KF_0/8N4Z&\_A+FS<%B( M@0O3 Z01ZU> Z0SNR.?,IH8S"D\T>3V.+R9('YZ0U%Z%*6F 84QYL*Z#*C2@ M.HLS5 -=1'$$V9%IH?I$J+-(E@H+E@[FF4^4W%IDBR1).2382=&K@EL:E%&Y MM=6\"IWXR\!P'E?# PN1VK*-=?V&AS1S;!=36P.S2#6PPGG+_+B5_]X]>])1 M)(-? K(\ M5?;[$)!,9%D>X/F74J!1:<%5I.[+;$]JA?@T^TJ-S*I0\*#@06Z,A\Q,V&%- M1O)VZ@[+A,S.^.03>$\<#H,?\5JGQ'TT[?"E@,U\Z**_C2P4EF>5/TH2TL;8 M<7S;\6D(=AL3]PMK[LP//\(/X^ON'%S;Q/=GIY\^/3\_MUY&KM5RW,=/8-JI MGUSX^E-\;6/X,*%PIV4YSV@M,#A(L["\$LP+,"[@7;IIFDO$FSC/ MMD1&SA.5?$?RX55D"HB'RUTZP MX&F4^A)ASNH/XNJ3D,I4^412VDKG1+J@.IV.J+ORN7;"EK9^@R9]@/<"MBPT MCCZ>,B*.X3*,:1<^BX = B#& 0 <:)I!*R;KD#Z!)BPR\^AI_,OG^,21:3,D MLYL^1X05T7I"N):1;_CUYV?3\"EL^CM):L#/);5>_=1VUQ)E*V_GK'1< C@=0MLB!OJ]!@ ME,'(7(I9(D6CM KL*6;K>%M:/;:U@JK5/1TH!IGGG@?I#]\D!2"+:;>8VO(] M/"32V[[9=GS0(N%T6\W9QP0+]HW=>N:?$]>= PS^3JR 9C9CNZ$OF5<)1]Z& MZDJ)N6",XV2,%"52^3,&UD2>]+J",01C<,L8:2(B^7-&/VRO6OC!I-(.D'!O M2MZ]B368+-D%?X%3[[".%X"6IAZX+N!;(FR"Y.%;)/'-.UNLK=5 81(;#)(F M\AVR=4WVXWE M5["JJLM)5=7.Y\_K2$=%GB/:L[*JJS:&7:WE?6[WAZMYO3\73!N8)SJ\>Y M53XRV>T5Q:C7J*PR7>SY\P-I%MU:/W2]M.EJ&AH6@ MZX?Z%_6?_Z>Q$R_;K+60$*PC\S;>L%<(=%,#=-WT'EG[B&I'R3556!X1V M5-+6-$WOJB-"=+G='6OJN#,BAO8OG-D;W31Q7PO^'FESY%+RLTG&L*U38CV3 MN8<$N$Q;0%C+H'X+I1 6PR\C]],P::G)9/JFRW4);XMF.=^P3S2A\ F(&_A^X_KVTI).EKC?53F M5^2_!HE> B1"L@$=X(1*XI0-^ F[=,@M*5)UU\$4'JZO]^];568W[B.QS3_9 M@UZA"7^ 2KIU0539/OOS9KP [RMT46=9CA>X] %>\=5B(Z!B3=1_>^( /\,% M4-!:,Z0F-X 5?SV[O[J7;KY)MW>7]Y?7#VC_E$!9 <0M_*;/$S8X2'C98'V#AR>:S7IJP0Q,+[GF-(LB0NVU46:P )@) M%WG!R#,-D[@X=/3#,SV1G,#%::/AK1^E"7G"(534EF8N!:T(;YL%+L[,\>/S M'FY@T3BD]AA8H2D4*4_IGNKQ3%.\(F[4)^$<,M/SD" ^W%^>?T3+:;'-U_V$ M9TA 3[>D,]#:+IHIUOQ$TL$4(28J[-#BPN?@\]DA&F-!Z!Y\ %];UGRE>"01 M7HO]P06$O8L=26$C6G]OW;>D1VJ#H8?/@J_I# &/UP5(5(]P.[S!G"$H/K#+ M?ST[NV6-31$,O]L,CXP9O26@OB(4MN],31^N:DD/S.K8#_W>Q DL ]X","1L M4W#/OP,[M*C9KJ(#.5L>%(/56ZV_ 3(YLX&G+>F.X0C;=W\#8$MRN_DWADU\ M_)P2%ULHP4W)1W>D#^SGRJ,^OM%I;\4+)RRZ4;*A6!E>A8AW9J8=G:J:$ALL M& 3J"?MJ/_RZ=&QA6W4@2(D8_PX\/_S>S7O']/ADT,C+@$+<9CU"P,7P1K6Z#$9&+( !<*3?X8%SI(V68)E<71I2[(?+V[./H<"*I3X9C]EQQ7!0]CEQ+=B( MQ'SS4+U]B#[[B'#T*, ,Z>1OIF'3.5X/TC?P8*D>0R]V'(W^A+5-3"!A$S7' ML_339J<;/>GOA,V#DWZCQ(*%?/]^+GV(/ON(%Z-#Z9I,CH_9NU MT=57>O21 M;0@Y:G'\4I^XC@TV#GY(](!I+V+-@? 0WRZ9Q9H3P/]DZCC0RXR#$HS.?,>& M-2WN.@'.FCJO?T44X@0H,>Q0HUI$#T&[>$-X@#*LJ730Q@1&GC&IOKBD)0$F M_YL L8%H>3V0^4S9WBV*5(H4ZA&+QD!( CAS"2*,,0D%\'T$9#_B*(A9C'X MILX>\Y=,L2!E)1;4>VLI9LC9HE$)" K_6(1N!@M[LM=N#-56?SUR(XW"XZ:O M+$S *,L0@>$%SX[[,_QK9OJ (L0%&P^_)$A!O*+/*SV:3W@I M#6=J+#UR1>@^HUC1*5 G4-4,B.T%8.)3D#_9X*F^#\_E>5D7\#+/-U%DWXR_ M1LA>FM&R!#IL%-;JR9M!!]*YZ9.74._,XEFIP*8QW"+1Z;L@F,@;B\;&$\0, M5OB(Q=VH9/*'Q(B\I('"-?5OQ@_D)5V < E4./>HI6X(#T;@2J0PH'._&8-K MA8X>]E'_[S#VLF!"/#SB,G <=R00_&4YRYX;:C^++ J\%\B*B3>T#Q8'R4$0 M;RBWB^WLE=!>!G,J$H"P-9 \()4B#1[#Y-5@#T&)LLY9F& ;UM0"YX=*& >1 ME%#4&889.6%+?LOF $YY:ON]H,5O:)[IQ$9E:(%+Q.'RF?5]CRX:.U0<&AUO MUQVK^A$H [B1M:TWQWB%+[E,H@)% !B @E#S _T[(6T[TC^ Q\&C!MRZ('2 M"X"V;()U)@%2FT&F8.@O8AM#!@_KCX\ M5 JFYP;,\5SF4#]DK?@90'8F.J[ #C;3!(QXV>0[%'NH;**>#&"W>KX#9HIW M$KONCNLMF0+ 'S_IQ+$ ]TQOAQX,+/()>,8!.P OG8*#,P74Q*M#40K7SF!Y M:&/H++3NX4*B5_O.,W$9DWO!E$GS56# 6P+8#,C057N\)?UC8H(L829'R&[X M(C,>)P*>D*.'GIA%8:^P$]UU0-;\!%%E@E1@EC3(&", IL4$RLP+/;$%^)]A MH6ABSU]?"\PZFK.KHD[ H?OD@D'[!]A"J&?@0S2&6E+D\R5^&RME3,(8&96/ M]GZ*ZSML$I7/.?&)Y[O.;))]PEY/;0PW]J6..FBP/LB1:D8M"Z::BX.[8AG. M1.*4&F$C$1"IX'F.7<:62T2E@V;RD")()%YCH(9LX\5B^ >+./1T\57X+ZJ@A8K8H!56(V= 5, 8"[?+GX W(DT!*Y-8-81! MC80F)2UI+?ZY/9:)=L2=Z?WTSFSC=SL2&Q@U"^.9FZ*:/6T]JMG3>(AJ)H7" M&T.V148+*YODT7-]3P7>@W,$,@)]!!]5!=H/#R"VQ^-P<[]:S@CDQB6@QID" MTC$%8JX>"^!GHXWA/R(=@=$&%X2VCNRPI V!SRU@O\0@5%AV)-$1H+3*Y;<02 9W<":@!)@2 !UWR+*&MCAN, M#-$% )%1R-=$0V/70;$,R5,A-&G,%OU^OI-QD4DRYA6B V(R!A(4/^P M0+C[B82QK;&UJLQB$(+QP08GPHI?5:ZW:OR[H1C36720A1;TR/?V)N9LQI#$ M+B*LCH M$-2S980*$10TBLO??R)UTY-8;HY!"OFQ'/UA&@9HXTM0.4O2_9$Z M,Q!6K$X@@M.2WF9DYJ$=#3!V8>NAP(V-]R=B6F04JF(FOE?1S2 0WF>P" %N M ^Y=)Q0T01)1[*%4?\WKOQ(V6BF+:!N *32:0,T]AL&ZD";PP8B[9%\IVL8X M"..65_;"XF=AS3#V8P.\]44,]Y&PE,9B!B8"'9,'L'J#2@A)/0X S9A.?A,! MPO>9&'[Y_]E[T^;$D6QA^*\HB)E[JR*PFWVIGH<(E\M5[9DJVV_9/1W/\V5" M0&+4)21&BUWTKW_/.9FI!4F 0(# &7%OCPM$*O/DV=>9#/WAG@1Y>A&6!% # M4P^M']^ABY)?1I!X#J8*\&.T"D&RS_01\_D]BF??5V7B-%P+6+6<0/B]_PG: MFCLV1H*X^46'I(-!$W)9Q.PO8'H_F+A8)IGE*&"6$<3!ZQ'@)2/1Y5):GAQW M[Q+=P\<34K)1=*,XIL6EAP75Q3$^/UEHJV,,R2R6,J9R9&8"[5=@=+-S/ Z= MKI$=76YD1VA(12J-^(VX!6;PQ[,@8_*_HEE@<+X0(/.0+8!$N.N5!QZ NCCO MXI9@E$.]@NJ.D00AVZ)T&*'\)6V]!'%7/$::0 2<$=(B"MD5L]-8@-*,^ M$*ZM6($&*\(#0EL)8EV;P&3#+*ONZ619-?)F6<7"1.Z:VKY5657==HIYWDZ: MYY]N'Z_O[YYN[WZ_^:3=/]Q\I[2JQZWRJOCZ*6]ME$?B7<7=-/!:E!?H_HQT MC07^F^7LY^&=&6.>U(%'CD&L@-2^*3/'%_#'!84>1J;NNJ2& 82"'TI#'@F\MNJ5*0+:!^]#0A56D7 MT1A3*;TF*AP>#51V5#A\VW!X=P_A<#"=N6<<+/"_\-3!(C(L&T7.7:#0B;JP M8QB5BDA?X/48K[BWY+,/(#DQ,IX,2?0J@WH_!2XR'/'NJ/L.8_K)G?=QG/F* MG6/T!"]-__G^Z'PY4R_%KO \WS.P*E,YV(QY<1G,<]>DW.61F;A,-H*D,(S- M$K+J8(8M_A)<\[^87VQX7.]'^H,4H[H?AN57 L ,;, ML"3X/##36-2(0VZ_D2R?ZF.>>P" !K[G4I)E=;#I"RW(>":X=+$AK+I JRB77'07^-S.''M$H\ U(719,ND QEI(K' M@@'*,D0EB!70 8LD3$0WS$,'20YHYD7.?XG0CUW*$CQBE[#\_9BT ?3F(%LS MF-PI7),^FHJ3Q%)<90;GA0RNAQOF3X?_EAD-@4TE3 [?G("X(;#)Y%$"BS_' M(ZPTB=OMJ'1\"O4*<5D!6!Z(CF/)!D JHP]CW\$LY4 B]FH@$6O+!BUE,KOQ M7+5W,3"(_!LTTI"J1*@ ]67XRO""3P. $NPQM?S]!C>&')_G!L 3DG!T)Z8Y M&5Q:;YU"P*7%ZLT\I:!/@"G$IRG3(< B7LQAL:7,QUBR,3*9=VOQ\'T*(E8I M)]X*LMDI#3XLN?$"FD?.GA>Q.KLC%J5AA)B%V:1)S**']H5:Y')CYAS B(Z? M4(K*.@*/IT;1,RGY44&Q0M2W.M&&-J:7Z YG$)&=7X9,,M@+.;C2,$F6Z<1J MHSPVFEH@Z9X7: "9PADB@NX\U;L:"^>G<-J1[3=X)WB) 0HY])*"JT,7R$IYTL&!J ::C1=$R$=AP,*Z^?116NA^H:N(4Q\VX$1E%)/N4W6O)'B\7 522%$VASS ME+LQFUD8X)%,$\D_J,F#L\>#U/I/Y)TS'H!&I[00=N(>TEAB@E-5Z1UHQ4IR MIO1N7H;$+YLC"M^:=/>9AHPU1*9*!0X;2OC+9T5F]'A"=G8;?W? R[[*/8#) MF#7F7VF<>8ZJFU2X&]R@$3)@O)]C5,VH((9P(S/J"HR]IX<9L MZ&-4(7K99)!-%E$_#1')F%P>+AE2Z'7@>CYINYA"%PI\DE"!%S2YC?U>5S1U M\EJ^?K2X&HT<.%BL<3R71+6/9O?[KO!4+T2"K2/E8U6+\HZ9/@Z2=GA.5*@,8!)OQ'#+$ZU]Z\DWO=(G MWU"P,2T$V2Q1)G+H)AU+: +=LM-_:I>IJ)U3&K7Y M1%3XC5/A34B%J )N,$ST9&[J",TK-[N V*3E#2"^<3?",F+;AI-W3_V,FXSA M/3[E') *\T]W6W/9^Z;=]>H4W?6=C'"#8]^%C,7-SQK+G_%FI;8.9+' MOF,=&+HQDIX*3!MK[SR03 T?592P1TKH%T\).1UZ-*6W7CL)0BFE7#^JCG#\ M83D;4L5UM%_":4]2+;=$1$"[]Y,OMCUV'VUSG$;S.'^X5M0XEC^_3+RXU+9?7HX/*QP4^;]0=R3N*=YE7ND.JN])\H'BY #=P(-C M3PP/,Q%2V$ ?$R=;Y1]"KU#F0*)C Y3!F="-TT*9,LF!$[05#BTY'AGE>%9E M3_RTC%"1$Z+LB'W*#PY^BO-'@7_#89_&'!I8FE9&M?+-HD.!LB$_.C3!RLSL M^ZBLC!)(A/01SV63"-^9RRC>SFL?7YAISZGT:"%[1!?=&T6%-6;8AJC0 MK0RZ.X?I#XH*96+ARM!:B].WL@5X4'-E,4\95VL9.W;[@;^6R5J"DU.U4);O M;"LH0Z>:W22=8V^JK&I.9425CWUO=L_1M*R)\9.-+_YBCIUV__T*7':O46_\ M6D(D*!,;+H.&7W*6?D^-+]YQ)?[][HS]K+WEFS)V FJ4P&.4GR1IV!HUMB^= M(_S-WG2"HQ=VT_7*H"@=7;%ME5B5HJ-O6E*L#1GH'.&PS&A;:CZF@%:B#CIO M/$7KW5[$1*HK/33Q>2O?E$<^TKWQ!U.;P+9JC.?*D7_S-E"HX+#\ MOA"G"8I(5O>6H.P% M%1S)3P9?P;[]H-V% [9TCT_ZH6:GGJT!9*@MN$TUAGP,"28\19NV9DBD-QXB M.984NHKVCK"#(GZP<7"$!Q:06U[-'/Z:V">=SMY%^AP#L>30T+!(@)\^S M]Z88?*?YH@"H&YJ2GL:L&\7;KKORC4*;A2K*4Y1W!&UI \IK5@;-@L/-QZ"\ M4FH^A6M1O]"]1L'L2SZYYS1FA[0O^_7TP1ZY!W[4+IO]@L:0X%)M-3ND MT-DAJ8^=T'&/OT%UV)-Y2H%7@?=TGU+@5> ]W:<4>!5X3_ ]W:<4>!5X3_8"W6:]J.-.:>H[@X.>JYN88\:&]>_SR/_IL M_NO5>YFGY&I_RQ/ZKA?2 ON1S?7(@+6<8S9;]=:*HBHQVYS D.MH!;7WWO5L M[E/ -1TCB K;O:/\RQA9;:->ZP[2AJ'"^U(*D@B"&+0Y-KXL1D,#H%H:B M95N"#[0?V&D8@<;H<^17(GY="W^B#UW;]+WLGR3&L"_1:F;&PWZ)N+\$J\A_ MIX[!#_ .^1J9@&OK0, '1X!MZPI@80!^ZFUT^ M)TG*LS/II(H$1ENR@6D#LT4"M"AGAGXZU$W=&L$!IHPV0KOZQ$9L-F1.C+FW M/L3O<^5MG$3V2*]U6:^MS1[93,AO],)Z\[+3[Z]\X89)$T=(W>MMUF4+T$V( M@Q6=Y//J2RN.S?GL\0\N:4:3Y!([?.%56ELDJ!]C(+3N\HD^(_R#_=8*]P4J =!SP =%3!47;;D)<%3;[4_;H$D)>_ISO:8"[3U MU=9QG)2\L]06^*UZ%PR35EGZZ!ZH[=(1<.+6>@$&9SO&7BGEG)OR%$@I\C(6 M]32*Z%4&O<;.110%=>4Y7['RX+"Y#M(W<#^BAFI3$WUR2EF>L,N59#DVO8BK M IE"7=JOZ%JN^26E45"_,FC4=NY]>V29DD]5[%YVVZ4DL^L8+:'.EN'(VK]8 M>F-M$]81("'<@(6_DS>4FTGIE4*^V=Q_JO/>& M7N=KI7VQ[?&K89K*1#LV6C8PDLAUR .) MI#=%(3G32.AF;H.+X9IDNH.OT<2QQCO[SY6#;^,QWB;37:81("[LR87OLOT[ M,MZB5,E+,_*"ON+]?,?-W$]^=P7QI%%."]T8.T\$5V)F(S$#$+Y0?K]R*6%R M)J.XEVQ*:5<&S4Y9QFX>R.%72EJZ2U"1\OB=).D)E2Z@O=S>A ZZ_-J[>^%/ MW^7'L:M92GJ]V@^-[M'=5Q+ ;=N;\*VG:&T1=,C->KJ50;M:WSW:4%I'9F1' MRVT14WE/V6.#<+F^PW/>@1--#(N2T;D=:P]A=WOA1?F >1[,*.>9SYT;Y;5% M!,)^#8LTTOA/KS+80Z1S$TH_@D%?;@X3Y([.]04F(2J;_MAT)&_D@5](&OW@ M6*'6SGZOQLN&8-U.'>J4-XQU3231K]1:AINZ2X).G5*X-^LZA$U%+;H2>7]?;5MIXO/.;,LNW- M*GSDNH$$I.$'MJ6\UN6,K[J?Z1YE@'6UC=9L%#CYN$2$>3I!UZ5TA<.HEV_1 M1MLI34%24=JPER9F]G2+FO]:$CNMC*22R$]0MEB);+&E)(4U+\BZ62/6+*Z.%3$TK:=+"USV2ZR' >XZA MQ+<],MW9,;_:(D#":]69?9^VF7FNU M6J-.$2TRZ\]GV[EV&)P6QYD^T932Y)EZR[O/ M:# I3IIR_D9VV\GF0=&D,@B.CIQ!^P34Z$U\4Y,PRM&<\2"<-+-5IN%JNNB7 MN9!],4=3W7IFV!66&EGJL:..Y5%U&=*?;->4^/+<&EBJ\:=%-3#/.8QTXSZ4 M,V,\-MDA^U ^$4U\XS1Q$]($]J4LK!_GEM ]FZZEV[;E+ N2(%M\&\=L[0WG M"Z&,X-2G;D3WUE0.1)1^ MJ?CQZ.S<9_5 5% N\7S\R4!' MU45.)J?D>@HV-Q^$P4[[(NYVF);FP:_AKF>4\./:+X<)J M*2PGC='4*X.D_SEA3^T['T1=,5QQ8FA405?<2*MP.NH5EY1WGDR2T1^.X;$+ M>S+9CE&>6J[0;HPR3*S;-#9!X 7H7EGCJ_&?ONO-,L9-M)J505)+VYRT"LH, M4O>>QCWW>>^8&%:N>R\I2ST==91RD$8+S7-@%9.'&O40"]Z$1EJD0IJ'\"3P MGT+8KR' =@%5VTIW+17WS8\$G=VD[YM3; M*$"HA]X[$+A@60^\8M5 )@RIA M,,+<]N;E[58&G9T[N!\Y^T]1E:*JK:BJG6&I[TY6O%C,3>5C^1V%N2 M)-W(L$5-PE*EDNXSE?2MI1Z>P"CT,-\46T]O.:UIC\ 8B'Y#HF\2A%$6\C;+J2V[.Z=5OZ@U=_O9L QWRL;:LVV/WT8ZUSX8E00C3@)U\S9B M:+>P$4,!?$SE\*VM\\U_?F&,693(LVT[V6RI)6%8>HJK1 M,:@\,#A(50.,4=%:%:U5T5H5K3UTM!86.:C #3GA/."$+.2$ND<%U,>/X1X: M+L>,91WZK 5:-IG:P1?'=O.[4+!?2[75+''+%KRK8X5X%4V4@R;6&"+%TD2G MAC31:?5*3Q,'B@ ?&C.N1B-_YINZQ\9P[7,';DI?.0UJ;]'"0Y\\5]'>NKJ6 M$(J?(D"$OTU&U7G6^&J&8[;^HL\S:2@W^6!/DFJW?K2^)*' >.,(LJ[)V[$0 MI$$(TDWRU\,BR('K,$_?5+'8MF;*P;S+IZ*P[=^U7&9U;EL39PL_6 M>#;]Z.;AJDI_1'^AA["(3IPSX+UPYSK^+Y8B4]D@/@]K#1GO M'C1A ,XQ.F9U#;5C1QO#?VD$1C#Q2C>KFL.>47NV<:@&?$57X3#=M2WWDH:$ M.(B"YH)OCDII<5G:&&A8#E"1 _!$0+B&ZXE^W<'(#27F28QMIEN^1.X7M]!N,%?-/07@0H891H_]*IV M9>I#?:83S\F'U8W"L/H:"6Z\Y7"T#J9WK*'QJN;ZPS]!!$A&[L*KW(DX)8#Y M!?BC[;L:CM"2*$9-!H"_/B58*J'_R(1_&!.#/M6FS!Q?P,8O2*YL3R)[P'?M MCZEA,CZ*21S/83.02^[V4"&4%%L'N8+$C,M,A5P32V#'9O@IPU,%PYKP(3#O MM:%M_X WF#Z3@Z(D<,.3:.&8I_GXPJ^P6H]ZP,*"Q/6,@FN0'-YR+18:OI3T:>1!-'H809E2]S MB'R9TO6#V]>@K,/GAYS!H*S"+/U3F))UX,,>9436X<^HYF,=WF$6R%,FY:G0 M2T#X&Q[LZ2_@189X2*5BJ;23E5,J*(2Q%7,197P<35J@Q2$JU/CKB.H5\4 M6-(?]ENGC*WHO<4N-"-0V6V7-5#)$]#>\4.\5^%*%:Y4X4H5KE3ARO,YHPI7 M'EZ!_&P[\$\+;/G15+>>F6;:KHM)L-O;]&_0L#AWTV%-=%(@46PN)U_UBVY8 M.++S=\MAW,,83^^<&#_9^.(OYMAI%D6G N9#KU%O_'H*D1U%'F^5/#:UK//1 M29(>NI5!2JU["4FA[(+[-(*<#V#@R@(5GBP^MUW/89[A\+S_(;/8Q/"HA/H( MHPM*'17;U)4L@'QEC7[K!%S8\X-#5=<^/.L+2);CAAV0VOZ2.W*7;?\!::RT:^$Z_F M/=B(B3+K>)N')D=8FF6PB_PH^G9+P5*/S_/5897=%>45G)JU&?.F-M9JO##7(WO+F,U! M>N*?YV]L%>@>Y/#\1N"\#:!)&O@3Z"5/;#:W'=U9W ;@3>.=CY[8U=PKUF82[ALS3&3M4^(?1(#3J]<55T#6M-Y/B@(]G]2C&\-/+! MMEDE4D#?YIVN8:!Y[[2=ULSGC1L510_O.0G^J;TS1'+<5IGY!4+H#"*814+C MM-E57A$42S--8UB=W;P@Q5)R<6'^(TVY.U<2.C,JRBOTUU)1-\T>/A05G6J2 MP$FT6@4TN+C6W:EV+Y&!4@"X,8W_NH++?BEOQ]7O^/>%/;GP7:8%"*V9C+H6 M\B9O]A [HU(KE##W$'L0\J?L(2 +M0-TZ5/J^$9)TC.>),W").EXNSL"%2:3 M:J_,8?E:&JZ1='2N^\GO+J/VM_?B"+?6C3C 9]L)KNPKGD/VQEVD$7"O,DB6 MT\JD9CI&KLVO83 [;3Y?1\8>QLFSIFT&'1D=YF+30..%F8N@)V<12-K8"$FU M(E^Y&5TL=2!$^(A>F(3I,?H5/VQA)!!M8:EYYGS5 M= WLF6'Z8\Y[E[L;9_<1W86Q=IJKF9/H0$#:SMCP?. -H/]@FN3XH^_=V=[_ M9=Z#;J0E1?9K8$TD%:'M^6BGM;^]8OPWF^.(R@]"2XAY7-IKU9E]G[:9> M:[5:HTYSJ.NC>JTS:34G[:$^;OVG!0AR+&1.TW&XE@A0MGG/WP_ 7IB#3U4& MK4LM7\7C%]L>OP($>5M6$&4&X#%O4!_IRYJH=.PW^,U3*^(K3WR&R\?K'[_< MWW_ZX_;K5^WJ[I-V__3;S7?M]N[IZN[+[<>O-]K5X^/-TV-5N[MY2JB3R_UF MTXB7OS%E'XWLRLO#WA5 0 !XAP:Z856J7"SE0IH;E)X*"=>!C4= TC\P*\:6 MT!/;-.U75&P-5].QA[YM87]M779/?A8GU8:85?6,K#?0J6L M5"ULJ7YG[0$WLT WWWM'#=$^K6'3W]@8WZ\]./;8'X&N]#_Z;/XK]H5W0!=8 MD2AY4J?\C>FF-QUAV_K'A>NQ67!.-II:\.;GLSGJPU0'>W;$?-K&)H?:S.5T M D=_LD%W+=V@]"+AT-\(#A_%\ 1N[D3'R6MIE,,W/IOJ[:OTUYM#DI] M-J^3K-^J#.K5>B]KJ0S:K9/ [UP6KJ*"-T<%:P:[;BT#ND AU4:W_"J0JNHITP;58=5A MSZ\X;3._A>P=P^WOFMNU6NH(DY,H)7R3V+ F17,W9*A7!IV=AT@5 M@0P''CI2G;:-<:&-YI- J>25>> M:B=%3XJ>TNBIL2=Z:O)XT9$'C"AZ4O1T6'I:DSF?'8!JUUJ50;N]LW%S9((I M-#:ER$J1%2>K/4FI-D:TFKL["(])=%L5RHHM]N-Y^0!],(R@#$24F\8; M86Q>OH S5,/2A<\&8!2C,I,QF] _OAHO+%%UJURTZOL.EG12V%D%I=4K++*+(R/W928])"OGMA(N--\I\< M]0D!.%3%3>DN^MIWX8T@8'C%.QQL:LS/I/CD$WMAICT'[/5D8B:'?7+T,2-EZDP.Q!5,?6;#/O[:D@-M%8A)'_76PD8*(^:Z MVG?F,HH[83L!0<$K^T 7C=0%'RW6Z^*TB\^6K.(MPIE%8M9&OHI5[0_6EJ(5 M#Z8U^J-:7:V>O?JII5ENZ$S\XMC ]C.\'+OD@IR!%SGM5*?M#5[3\N=SMJ^/ M\"2WF[B+PE\%?A+^+OFB+C]?B; M1-%^9=#?/5M$(:A"4$30-?'B+1"T7JL,>EE-4A5^*OS,A9]K2I[R!JS3\!63 MXWL[E[,KA%4(BPB[=L3F[@B+&=@U96(IA#U "X14J9^"I?GLK'H3=(1JLU6* MN8=G.GGN:C3R9[ZI>VPLPWKDDU=SZ(IRD44@?!4!#+WM[/D>.RNV!) M)CT?ZJYWOFLQ&7F[6@,%3@7.\G"B-?;6 300'N-J')M1[3CHMI#VW(?&E(VJ M>/(-.'P372ES'[ET/.) )ND=\W+S@SY:).U:4;Z8PS1TW:!'T&X$44?5D"W7 MD*UND7FRI49J]7-<7160J>RP4W=%]M;T*"^Z *?1X05DI4@,4_A[^OB[I@MR MX?A+!9#U=DOAK\+?(O!W3=?A+>IS&CTL("O%- "%H*>/H&O:^&Z#H#BA1A4X M*OPL!#_7Q-(+\$0V:ZJ 3"%L80B[)HQ?!,+650&90M@#=1S?3P%9LT$%9-U2 M-.I0!61O.J%W>Q?9YJ4%S288;I)=[BZ[ -?]O9^CAR7W0%+4MVUJGA2X'Q3X,Q7RGIT#81B M7(W^L360'0O(3F:6\/%JR][Z5+DBH5$ZIG,@&W>+VJ)F#TV N XJ*%!65FXKVGW_4:NRA9%81EB*LD[)P=9_TX'PDFJ5L_ MN.'(CPZ*J=T43%W5&Z!]J?TC1F])=(M?WR_0AO MJ\OQ <#(QE>>^ S787"S?;NZN[Z]N[+]K5]^]7=U]NOMW/KSH*(O:J],B#SN6[D9&*]>(>W[C(9?(97IKOL?@CBF;#4O;6$AG+M.PX<]9ON^8[A&6S# M_(:?MXVDZ6 M,UB>=B4GZJT\!?YO;%> 0:,/8]]Y!;W%95:PE7:M,I@ Q[]8,-U99C>:!\MH MI@WH.M%'A@EHKLWHU-:S9EB(4IT4L5 ",KUVV-CPM,]\UW!%6BGI\][2_NF; M"ZW>K0H9#/1)8^]!6!N69VNZ-N)'T9]!FB.%:7/?<7WD/_#UZ]083>$AU&#G MFCW1AKKUP]7FCOUBH,#W70UNVP"-P ?U:N3CNL&ENGB'<%3]&=8&)&?P.\,: M&7/=1.W,AU? BK NO"@?O?76T!L XG["[TA*;_M.8^;./MN/8KTAD^AR^ M\19Y::M=KPP:E[6D!A>GK7<55)&&CC%^9@%R5]Y?:L$&7,%M4IZ#6W) C7W1 M#1,U=00CAQ)7N<:.SA> 3R:PB/9.?T_+..A,T '"0#X 6>1CF6"%DPZ9DX!L M3)MLIVDCMY8+*@5BRBTADNM]AZM]]#!CZX$Y(_A"?V8!Y%#D2M#A3+#+9B-9 M(?!W[9%CT9WM 2V-?09_O3#TV('02G7.OWR\=+S=-_:J:A#R7YZX[AXE(3QYXA M93'' BQWF.T\ZY:T0CP'B((?V87O>-4*72O37("6O+1_&6.++;1K';!@Z,.Z MS'4WQ!PX*./OAXO1=/@_S4%(#4'6C#78 ZYO B>_H$./4<5P"*)$K6PR 0V= MG\(S9HQVA_^+\,#W!4O3JF2O+*+0M7W/!1,#Q9@V9 L;?O:)C?C5").@I;W: MOHG\!U@/;$L;+O*B:3^6ZM-:C:8?===P'^?PKO&]]6^X**0I1)]Z*I*",EB[ M;"3I^^^!)"J"?S#JHA8T @SQC](-QF=.. ?," M++B2VIW4Z[#_^H;#7^N[C-:TF*>-='>*8GC$V%B\ M3O*G&)=Y9TBM,MS3.E;S'E^&6OR"J-O."3!QA4M01 *&W<%)A(Q")0 @P7MT MC0 >\"EF@H8;UNFD)GMA#DB4)0UKI9M*8'2K#2@_MUV"ZP=BN*"*_OIJC+VI M=#I&?B5<<;7P)_K0M4W?R_Y)Q.TV(KUJ2;W+]/[MEXCKC25@1?X[=>3FY@#5 MBR'PQ1\7^@3V_D$W7P%YT4\8U5]!>8W"25SC3G\@,/>@M6A6W&G@.^2*)FC,Q+? M,R'.H<\!J*"7 UL$*R47L-K-=& -]9\?'@1?_ P<[Q-0/&AYR+#O)Q\%AV,8 M$;B?/.D_<\.Q71DT+]>"<4*LBZCJ E7%%':]"2<.&3$^71YDZFR-3 G!4$7= M@9N9I > *8J$$XKQRVU-ZR/QWBNB#=X$-D#_J8[83Y;#)]LT=0>@:]E240GM M#V&,A\#AD,&?VQ8CT0Z*")%/:&5'X%SE;TE[B<->;/.%%*GX2XBYZ=J-[]B; M_0!U*"?S,-GOF<*]ZMJ(>[> )+@!#H)&(Q+6QQ"3E MYF4DKD3W?:G=Z,"GA%B?A&Y14![23"?IW)6J$O[G\%>>BP?$](W;N\^;"]2) M\9.-+_YBCAU<BE2#6I^ATAY!0)4(S"CMT?G"'++:Y_H&7?,"'\%!@:( MV@VR^@.?4?BK@-F'_M@L^8"WAC87AA)XV$!'MX#N>AJ\#78$;\+?1W$@>[_H M28WZJ*21!SLR1UAX3'Z3;"PA;>Z%A0> M^/A.I%!T>PE@7'@PO)G$= M)0W*A7?^@'>>PV&4W':VVZ*5ZK9H']0S$7H8XWL""%( +SBGK>(QW2M M0 FUETXC5: D*3-*MIED=ZE=K? Y!#96/AI<,U;N,&'[",2:E4$S4].?A;Z% ME2!\-3R,V'+T@>O1A?MT*7(SR1USZ:3&7-#?LH0V?XA7"_2)A@G3(BZ=5F70 MNNPF,\[^SBU3.+)C '4BHT>C-]QZ>N9"OQW=V[WX[=*F,A,8QOHBW!D0=:N= MR%I #_^E=IN=A50"F;V"?\&AK$AL B2HX_'PQ7(*3WZGTYJ\W(-35&<3BAKJ MIFZ-6 HC2H:/DK>MI?BG-DQ<[)].XF(G;^+B=1BMPYLFB#TS:P2WN"J?L9.2 MS]A)R6>\OO_V[?:)DABUJ[M/VO7]W=/MW9>;N^O;F[QIC9W4M,;.J:0U=E+3 M&CM'2FO,CBJ3V8\:/N4>H3=\[(^\((MB405AYC&,MH3RK:JQV=RT>0Y&&"XT MV3-( V $P+C T)AB^-DQ7/(K4(04N80)Z_B.&SC8PTR*/Y## 9:CVS-XO?8Z M919^@).##!$K83HYP(!U,KV+\8S]K>. MP^R=LY Y#K@'.&BXTRAF4*16I$4(WZ1$@C$((=]%/\"0F?8K,05D48C5A.: M2!'J"F@>5N2D@T0,]$;4$'W/*"KJZ!L1W2*3C4A+;I (*TC[")>2>]1-3%I: MR,>!>/Z8&DB/F%H34A>]TV(<98@8A._+U(U9E%0#^@P8&:R,"0X&3V5Q&!S* MX'P$5$",U8(J!!J]86/W,DS:(ECKFAM)4S=FH7,'XF+@KVS^E81$UYXA!G3%C-,Q*Y"R' M#DL:B$B@X?)J#(1 \)6%!] 1L,]L+X]J2OYT7'\JLQFV 1 MD2M9J+PFK#:"$P'<"96JFAG0'N[8L!"REF>BKTM@";_ ;,8SA3,.347"@6/[ M:S*K!R3VRRS(@#I!VW.,H:1.892@.U%S_>&?@M$3!AON#SSHQ*? @CY&<>=Z M#J7Z$""%.. )47#32]+BV88+D"("GW?8,[H!;63*!,_+E4 M8T LZ:9)^4M_PC73@]6(RH(6,.BB? &!E1$"B>1IX3>2ME&:Z;#<5+/8JWR7 M^Y[6G=D6\S#) NY OB]<)4JA(^/%,!%A *8S,J3G#/Y+GKP$/-!/8)KP#Y\3 M'^S1XPEI>&SD(C^!;#CQ15\207J@-L!SBU)K,HEZ. GJN V)J[QZ^/[PG@1)7]D9PQ]:%/X<;=WF":J9R!3* )3P9O0Q7 M*?J4'N$'H46[N"-_V?T$/W:33B7+GP55,8FP6[=6&;C&SZ0.]N@#-E%V/V[/ M3H%. '()?U5R /.#JBN^T0[D_UO^ ]MN^B4QJ><1DO(-%1T0)^H1/_ M 2:Y&)F:BX6;%71""1Q"=L1@V01[*U*0/&\*=MD*#&$[N4>(H_BNP1W\$Q MBE0ERBU[YA4)7';,0%7A_R;61P!^E)-8WGP/AZSJ;.]FZ;.].ZG9WITC97NGJT=?N)#00L])*74DL)J" MY-):-5NK0<'G8PK0DJ.^5ENAV<293:#9?.5KY59NFI6!]YH2 Q9[$ZZXB8') M8?HS""77P\P185_?H4T-=H3VR>"V$[*(6^!HEHTYZ2#,3+]F5U,O#IQ2=[4<,9+0<0Z3]>A7;G2 MDR)\:X&($$D[H4P0\8J7$"94@]6X$H<(X8%L2.*?ST.I?B6"/-7@Q0B+E?//!- MI@<6X1CWEG8_\FPJ"JO1APW,YA;PIER/+$+Y@R$&QNDDP,\X92QRT,7R<6F/ MP<[K';G)UX"$M9DMO3F@W*4U_->(^9:R 0>@:U"EEGPO?2Y%YD4&+LQUHI0TR -Y7H2 ,PI-G_ M10<;T+$IX0JB<&890]BG8 WX$CP)F.TO! 9@R8'8#)P9)%:GF#6*]5+H\@NX MZ05?66)$%#H?]9^(',OQP/Q(G95CO252M]/#;&3X\UL0P"&R99;!:9:@C!DY M(L5-R#, Q9]PWA'CU6$ #CS[###,F)MR*5=#_H7 =3#,@!Z7&6*GPUMY\)SI MB? ]<.5 @IYN.*2E>F#G<]\'DL.SHY/='EXBTEHVH$>2[R9!G956CZ"6L W8 M=FX%M%,9V!9+@CZ!3L$.)4H*7"+Z#6!#LHK\.FR$K0T2N5/SI/0*1>(+6)<@ M38%2%X%X%*\AS2,_GK:*Q=-NNA=!5G5P0"'&1.62Q(4A+U(D?GFIQ60I<=M4 M@4IY(-03QA3H3-J;B$UBO(?4\.B;=6PJP&E[2,[9$O>DU8J =Q/H!D$FFD0E1L4#*?C(-KGX$X "VY MMG\U\H+8]Q70QL6_C-$/=-O007Q/])\(CHL('ED_5,>'#K?@PKI6N##-TV?< MP^SR,-\D=0?\':0K"*\L%V$LT.]0A.IQML1WP0]I4<01" "5]:!.BJ46PNO\G M7)[K<\*4H85KBO'>AA&)%X3JC/H87=]^>B]5 8[($1H_/(7%3]5*.Y6D/^(% M!+E'\='[:JQ!6;U'0:OK2ZW9:X%"&IZ-4UGLM\3H/%T&$S'P;^IS-SP) $J$ M<0@J;E2RA.#AKF7TF@(LY(UX4G(HR'9>"5T@' 'O0BF0)E!3[ M;$QL7)QI1$$[X(+'CG%G=KP+3=I>5<@_K*8B+P"83GH@0NG3]X&B%O)::0UF M"-]0GI)#0;<6@5RU(A);"C3Q.L':XW(S\-AP,U.*RI6>SRJ6GN$5P3*I!WNY MS-KYKQD[_S5SU_P%'#N$*R\0#X0J>!8FTEKJO-DO;A;Q\A&.@)(=V8#G^"XU M,\4OZ[U^K2I_IC4EI@$'67CP 3P5"J[ THZO MJF0%GTKUG/NC"[-:3N"W*B M>MQM*L4E?B>0G.>&2-,9WJ0[8SCO]>_TUJ'AH"-W5 :!@8M]R])VARE MNI0XYC6X]RMN"(RFN V+]ALHL"3XQ,:57OAOY$LBOEQ:JOZG;S'I&(7C?6DJYGP2UT<:F>@]EYD37@YFFEIE#+;1B#J5 C6YC*>@/(HW MACCQ$5[$W\__@N]_@:U]E!OYC"2YVS ,_NLQZ':(_CXS0H.98=ZGE&WG2 MHUA9PX2V1OU7GNS*0YV4/XL_(AU.H4H>HFZHTG,_!8XN#X)I]9#1(:E8.Q'Q\ HT#/),.)SC)N4 M2VW#I K ?8Z4GZ6C&DH4*IHO"J%J!T'QMJP7CKA50;S-F>Q).L$P5+#L1GDF MFY7S87O;,B5\KBKGZ^8MYWN<@MX_!5$)S/;FO[[A+:ZL,7U(S10>1'?V9$%? MMY?,^^CVD@5]CT_WU__Z[?[KIYOOCS(S^.;_^_WVZ?]F5?.M)!7^BI07-\J3 M<'*-!1&?#,Q'M,9N*14OVN)8;E%D$&!%' @;%V]_VVD@&^3Z/3"'$&SE2)9& M6MVI;3UZ@(,!:.5*G\3VTWS??6S[6T_.T5J?YY>US_X^]MFK47OBI)=^*<>O ME GH=%I0W:7>ICTX]K.CS]R=.G4H,GQ7ZT41W%= _2 M5S%56O>]J>W .\G-113DA/"8*[HC 4I"HNX_1K B@!4E3R#[%1$]VKJ[DC13^HL\.90$O"!$ M(%1WKT2D(T>KJEY]1N".GJ*>V$>DUJZY\2X):=A,)(7CC3( R< M+"%W9@>8(ELO8&N],O'&5;I:;XO6"W-0UIB%Y86W%B9QXZ"$I&[62VEEU&LE M=;.KZ^O?O_W^]>KIYI-V__3;S7?M^O[;P_>;WV[N'F__?:/=WL&_;[1W7^\? M']]OI:[QMZ;LY2CJ6H8N% 4K,EO, !21.TK]0=>>)7)G7*0PH2]+=9:1WLS] M.&.;5QI3UP(>5(VV;:>80'2-JO0JN(8H/D&_K-C$.ZQ<>U_51O[,Y_8Z7\T4 M)#7^TW=%X_QWUT]7^*1P/)(SC%=)VM@6F6\%$U!EB0.O7@3KWG.89S@\(L:; M,C!,H;+ E/.T=_5,H"-,IGG K*6347B:8 M%)05CI(.H-HQD?B)L@=-DS?A\_AX&9>WVK^P)]2LVO5G,Y$+0'9RB-5Z"*>@ M<7\*47!\U-Y=W5_?OD>7(CYE6X@Y6YH+P37S'0?.)QJ2.<(FQ'.7?9!__(HU M9Z:^^&!8! 'ZT:_QBT"WS/*,3.3!_.O08W-9XUX;')P93O447U_"5[\D/V\W M+ON-1NI78&.D?IZU5/>RWT[_1=Z5^I?U6C$K]2YK_79!I^MT6H6MU%VY$HT^ M%;<(B(+H]'\JS4KHV.-C56LX5%6L$SQ6;R>>2YDES+V9RUC%$:H8(N]M-$CW M"W'2=YR-OH_-I=T0"!L.2C[\T=X!$Q)%;4LG2S_0QF-TRWB/(*K/_8@/$4T# M50BN09S[J7\##8BL(3[;$]289ORT1?W)&C1Z4&,\<^Z[M<4^=K[>5> =BH!OY*]>3%XG)!]]0' M/FOIRO,<8^B3#?1DW]D6OLJQ,:WJ6;;FS=M7M8=]5:NM%)]?0BDKDL"US:_V M%T5";YV$$MV]]TQ"22KI5@:M;G*2J*(112,EH9%$8].#TTBO,JC7DFUV%(TH M&MG76?.1R)H.4_NCC#[H6!F=ZQ5Q*.(HA0!IE=I,Z== :O6ZJ4V4W)[1D0V M=-I+NX?UV6^(4O=K(X4B*]=A5+1!_5@I#I[I%&SD@T\J9TF]E". )Z?*EN@B MF$%RJP+9'PG>WY?!'0Y%3I)2O3)H)[,C-Z>C%5B[GE3$K?QRODB0"P?JM=4Z M2<%7W^#%$;MI(NK^"[S_^A[O?^,!;_TF#0H MH?K02$B.PV@/V $K: